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Abstract 
Recent advances in the fast growing area of therapeutic/diagnostic proteins and 
antibodies - novel and highly specific drugs - as well as the progress in the field of 
functional proteomics regarding the correlation between the aggregation of damaged 
proteins and (immuno) senescence or aging-related pathologies, underline the need 
for adequate analytical methods for the detection, separation, characterization and 
quantification of protein aggregates, regardless of the their origin or formation 
mechanism.  
Hollow fiber flow field-flow fractionation (HF5), the miniaturized version of 
FlowFFF and integral part of the Eclipse DUALTEC FFF separation system, was the 
focus of this research; this flow-based separation technique proved to be uniquely 
suited for the hydrodynamic size-based separation of proteins and protein 
aggregates in a very broad size and molecular weight (MW) range, often present at 
trace levels. HF5 has shown to be (a) highly selective in terms of protein diffusion 
coefficients, (b) versatile in terms of bio-compatible carrier solution choice, (c) able to 
preserve the biophysical properties/molecular conformation of the proteins/protein 
aggregates and (d) able to discriminate between different types of protein aggregates.   
Thanks to the miniaturization advantages and the online coupling with highly 
sensitive detection techniques (UV/Vis, intrinsic fluorescence and multi-angle light 
scattering), HF5 had very low detection/quantification limits for protein aggregates. 
Compared to size-exclusion chromatography (SEC), HF5 demonstrated superior 
selectivity and potential as orthogonal analytical method in the extended 
characterization assays, often required by therapeutic protein formulations. In 
addition, the developed HF5 methods have proven to be rapid, highly selective, 
sensitive and repeatable. HF5 was ideally suitable as first dimension of separation of 
aging-related protein aggregates from whole cell lysates (proteome pre-fractionation 
method) and, by HF5-(UV)-MALS online coupling, important biophysical 
information on the fractionated proteins and protein aggregates was gathered: size 
(rms radius and hydrodynamic radius), absolute MW and conformation (shape and 
mass distribution about the gravity center). 
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This dissertation addresses two major aspects regarding the aggregation phenomena 
occurring in complex protein samples: the first regards the emerging field of protein 
therapeutics and the current need for adequate characterization methods for protein 
formulations; while the second one regards the study of aggregation phenomena 
occurring in living organisms as a consequence of the natural process of aging, as 
well as the cause of notorious neurodegenerative disorders.  
 
Therapeutic proteins and, in particular, antibodies, are the compounds most used as 
biopharmaceuticals. However, the biggest problem is their instability which often 
leads to aggregation. While aggregation is necessary in particular cases for the 
proteins to perform their biological activity, the presence of aggregated proteins for 
therapeutic use is undesirable. Even at very low levels, the aggregates of any kind 
may not preserve or, even worse, it may impede the desired biological functionality 
and above all, may represent a potential immunogenic risk. Hence the need to 
carefully evaluate their clinical relevance [Cromwell et al. 2006].  
In order to ensure the efficacy and safety of biopharmaceuticals it is essential to 
employ suitable analytical methods to monitor/evaluate efficiently and accurately the 
phenomenon of aggregation during development, production and storage of 
products. Usually, the various aggregation mechanisms are acting simultaneously 
and have not been fully elucidated [Mahler et al. 2009, Philo and Arakawa 2009, 
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Engelsman et al. 2011]. Moreover, the formed aggregates have sizes in a very wide 
dimensional range (few nm-mm). The limitations of currently employed analytical 
methods in terms of sensitivity, speed of analysis, robustness, range of application 
(Figure 1) or sample complexity and recovery, together with the fact that the term 
“aggregate” is constantly redefined as a consequence of continuous new findings in 
the clinical field, have created a “gap”[Philo 2006]. 
 
Biological aging, also known as senescence, is a fundamental process which is the 
main risk factor regarding the development of cancer, cardiovascular and 
neurodegenerative diseases (Alzheimer, Parkinson and Huntington disease) in 
vertebrates. In particular, immunosenescence represents the progressive 
deterioration of the immune system caused by the natural aging process. Inside any 
living organism, damaged cells are constantly being replaced and proteins are 
degraded to their constituting amino-acids (proteasome degradation or chaperone-
mediated autophagy by lysosome) and re-synthesized. Following senescence, the 
body gradually loses its ability to repair itself. This is due to loss of equilibrium 
between the oxidizing species (in particular, the reactive oxygen species) and 
antioxidants, leading to a pathological condition called oxidative stress 
[Bandyopadhyay et al. 1999, Squier 2001]. Upon oxidation (most frequently resulting 
in the carbonylation of particular side chains), the proteins lose their native 
conformation, becoming thermodynamically unstable, and have a high propensity to 
form larger assemblies. Moreover, since the degradation mechanisms no longer work 
efficiently, the aggregates accumulate in the endosomal compartments, increasing in 
size with advancing age [Cannizzo et al. 2011, Cannizzo et al. 2012]. An appropriate 
proteomics technology platform, based on a separation technique capable of 
separating protein aggregates based on their biophysical properties, would allow 
further analysis on how protein sequence/structure determine their tendency to 
aggregate, how different post-translational modifications affect unfolding and 
aggregation and the proteomic machinery associated with their degradation. 
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Moreover, it would open a world of possibilities towards the discovery of novel drug 
targets and early disease markers [Garbis et al. 2005]. 
Figure 1 [Zölls et al. 2012] depicts the size range of application of the currently 
employed analytical methods for the characterization of protein particles. As 
therapeutic proteins, as well as aging proteins can form different types and sizes of 
aggregates and particles, a case-by-case selection of the appropriate analytical 
characterization methods is required, since there is no “general solution” to fit all. 
 
 
Figure 1 – Approximate size range of current analytical methods for the size characterization of 
sub-visible and visible (protein) particles [Zölls et al. 2012] 
 
The figure shows that no single method is capable of providing a complete 
characterization, which would cover the whole nm-mm aggregates size range, 
therefore making the combination of several methods (usually based on different 
measurement/separation principles) mandatory for an extensive characterization 
[Philo 2006, Zölls et al. 2012]. The second challenge lies within the data 
interpretation; since different measurement/separation principle are applied, results 
may not always be directly comparable and need to be evaluated case-by-case 
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considering the underlying theory. The possibility of applying several orthogonal 
characterization methods has been proposed as means to bridge this “gap”, by 
selecting one or more methods for sample-to-sample comparison and searching for 
trends rather than concentrate on actual numbers. [Carpenter et al. 2010, Carpenter et 
al. 2012, Zölls et al. 2012]. 
  
Both protein aggregation topics were faced with the help of field-flow fractionation 
(FFF), a chromatographic – like flow-based separation technique [Giddings 1966], 
which is particularly suited for the separation of macromolecules (proteins and 
protein complexes/aggregates) in a very broad MW range [Zattoni et al. 2007]. FFF 
and liquid chromatography (LC) employ almost the same instrumental setup, but, 
since the separation in based on a different principle, the separation device in FFF is 
an empty channel instead of a chromatographic column. In FFF, the retention does 
not rely on interaction of the analytes with a stationary phase, but with an external 
field that is applied perpendicularly to direction of the mobile phase flow. Hence the 
field-flow dualism required for the separation [Giddings 1973, Giddings 2000].  
In flow FFF (Fl FFF or F4), the applied field consists in a second stream of mobile 
phase applied through the channel section, therefore called cross-flow [Reschiglian 
and Moon 2008]. This is the FFF variant of choice for the studies reported in this 
Thesis because of its ability to separate macromolecules and particles in a very wide 
size (few nm - µm) and MW range. Moreover, the flow field offers intrinsic 
advantages for the separation of proteins and protein aggregates: (i) the gentle 
separation mechanism and the lack of a stationary phase; (ii) bio-friendly, and 
virtually any type of mobile phase can be used; (iii) offers high selectivity in terms of 
diffusion coefficient differences. Features (i) and (ii) imply that interactions between 
the proteins and the separation device are negligible. This makes it possible to 
preserve the native molecular conformation, a fundamental bio-physical property. 
Feature (iii) is correlated to the separation principle in F4, based on differences in 
diffusion coefficients.  
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The diffusion coefficient (D) is a key parameter which relates to the protein size, shape 
and surface properties. [Reschiglian and Moon 2008]. 
 
In particular, this dissertation is centered on the applications in the bioanalytical field 
of the miniaturized version of F4, called hollow fiber flow field-flow fractionation (hollow 
fiber F4 or HF5), which is characterized by a symmetrical channel geometry 
represented by a cylindrical channel with porous walls. [Johann et al. 2010].  
 
Many efforts have been employed over the years by the Analytical Chemistry 
research team of the “G. Ciamician” Chemistry Department into developing the HF5 
separation device prototype. Thanks to the successful collaboration between the 
Analytical Chemistry team and Wyatt Technology Europe (Dernbach, Germany), 
once the HF5 separation device achieved its ready-to-market phase, it was 
implemented in the Eclipse® DUALTECTM FFF separation system. This novel 
implementation made “the first commercial FFF system using both HF5 and AF4 
technique integrated into one instrument”, which was launched on the market in 
2012. The commercial HF5 channel is equipped with an Enhanced Sealing 
Technology (EST, patented) facilitating the channel assembly and is also leakage-
proof. 
In addition to the key advantages offered by F4, HF5 distinguishes itself through 
unique features, such as: (i) low channel volume, which reduces sample dilution with 
fractionation, (ii) low flow rates, which makes it possible to be successfully coupled 
on-line with MS; (iii) disposable usage, which eliminates sample carry-over and 
possible sample contamination. Features (i) and (ii) also lead to a higher sensitivity 
by increasing the limit of detection/quantification for protein aggregates. Thanks to 
all these key advantages, which have led to the promising results described in the 
literature [Reschiglian et al. 2002, Reschiglian et al. 2004, Reschiglian et al. 2005, 
Silveira et al. 2005, Roda et al. 2006, Rambaldi et al. 2007, Kang et al. 2008, Kim et al. 
2008, Lee et al. 2009, Kang et al. 2010, Lee et al. 2010], HF5 offers unparalleled 
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performances that are fundamental for the characterization of proteins and protein 
aggregates. 
The analytical information was enhanced by HF5 on-line coupled with highly 
sensitive spectroscopic detection methods, such as UV absorbance and fluorescence 
emission detection, or with optical detection methods, like multi-angle light 
scattering (MALS), which measures the light scattered at multiple angles by the 
proteins and protein aggregates fractionated through HF5.  
Combined with a concentration detector (like a UV detector), MALS is able to 
provide directly the size (root mean square radius or rms radius, the mass-average 
distance between each point in the macromolecule and the center of mass), and the 
absolute molar weight (MW) of the fractionated proteins and protein aggregates as a 
function of their elution time. Comparing the rms radius values obtained from the 
MALS measurements with the hydrodynamic radius (rH) values, which are readily 
obtained from the experimental retention time, HF5-MALS allows obtaining 
information regarding the shape and mass distribution inside the protein aggregates 
[Reschiglian and Moon 2008].  
 
In Part 1 of this dissertation (Chapter 4, sub-chapter 4.1), HF5 coupled online with 
MALS, UV-Vis and/or fluorescence detection was proposed to bridge the "gap" of 
suitable techniques for the characterization of the sub-µm particles. A fast method is 
proposed for the characterization of a standard protein mixture, with particular 
regard to the repeatability, resolution, sensitivity, selectivity and robustness. The 
superior performance of HF5 is demonstrated, especially from the selectivity point of 
view, when compared to size-exclusion chromatography (SEC) – the benchmark in 
quality control (QC) of therapeutic proteins. Exploratory methods are proposed for 
the separation and characterization of self-associated immunoglobulins (IgGs) under 
different experimental conditions, showing the versatility and the sensitivity of HF5 
when coupled with fluorescence detection (FLD) and MALS. The advantages of 
miniaturization are explored further, sensitivity is improved even more when 
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employing a hollow fiber with a smaller inner diameter for the separation of an IgG 
with low aggregates levels. A fast method is proposed to compare HF5 and SEC 
performance, employing an IgG1 monoclonal antibody, once again demonstrating 
the HF5 superiority in terms of selectivity. Finally, a highly repeatable and sensitive 
HF5-MALS method, providing insight on the biophysical nature of aggregates, was 
developed employing an avidin derivate as sample model (AvidinOX®, provided by 
Sigma Tau).  
 
The aging-related protein aggregation topic, occurring under the effects of oxidative 
stress, was addressed in collaboration with the Laboratory of Pathology, 
Microbiology and Immunology, Albert Einstein College of Medicine of Yeshiva 
University (New York, USA), and the analytical information was enhanced or 
corroborated by complementary assays performed by the above-mentioned 
laboratory. In Part 2 of the dissertation (Chapter 4, sub-chapter 4.2), it is demonstrated 
that HF5 can be used as a first dimension of separation of aging-related protein 
aggregates from whole cell lysates and, by coupling HF5 with MALS, important 
biophysical information on the separated aggregates can be gathered (size, molecular 
weight and conformation). The effectiveness of the separation method was confirmed 
by both native-PAGE and proteomic analysis of the high molecular weight 
aggregates.  It is shown how, under the effect of the oxidative stress (either induced 
or naturally occurring in aging organism), protein aggregates are modified and have 
a smaller size when compared to native aggregates of same molecular weight. 
Moreover it is shown that oxidative stress-related proteins aggregate and have a 
different, more compact, molecular conformation. The ability to separate cell lysates 
under both physiological and denaturing conditions confirmed what previously 
reported: most of aging-related aggregates are urea-insoluble. Moreover, offline 
coupling of HF5 with Mass Spectrometry confirmed the presence of several proteins 
previously reported to be insoluble or with increased tendency to aggregate during 
aging. 
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1.1. INTRODUCTION TO THE ANALYTICAL PROBLEM: 
 PROTEIN AGGREGATION 
 
Aggregation is a general term that surrounds several types of protein-protein 
interactions or characteristics; protein aggregates may emerge from several 
mechanisms [Philo and Arakawa 2009, Wang et al. 2010] and may be classified in 
numerous ways, including soluble/insoluble, covalent/non-covalent, 
reversible/irreversible, and native/denatured. [Cromwell et al. 2006]. In order to 
address protein aggregation as an issue, an accurate definition of “protein aggregate” 
is required, even though not often available and definitely, not general. 
 
Protein aggregates sizes cover a very wide size spectrum, from small oligomers to 
visible “snow” or “flakes” and precipitates, and, as a rule of thumb, only the smaller 
species have a reversible character. Furthermore, even though less acknowledged, 
aggregates also display an ample range of life spans, and this aspect impacts greatly 
on the choice of appropriate detection methods. In addition, the measurement itself may 
destroy or create aggregates, hence impact on aggregates levels; this aspect 
represents a major analytical challenge and is decisive as well for appropriate method 
selection [Philo 2006]. 
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Consequently, there is no “general solution to fit all”, since no single analytical method 
or approach is able to provide a complete answer and, at the same time, able to work 
in all situations and on all different samples. Despite all the efforts to define the 
analytical challenge at stake and all the information currently available on the 
protein aggregation topic, many pharmaceutical scientists fail to acknowledge 
protein aggregation as an encompassing phenomenon and its implications on the 
measurement approach and on the data interpretation. In fact, the case-by-case use of 
complementary (orthogonal) characterization methods is recommended, as well as 
identifying trends in the obtained results instead on concentrating on raw numbers 
[Philo 2006, Carpenter et al. 2010, Carpenter et al. 2012, Zölls et al. 2012]. 
 
 
1.1.1. THE PROTEIN AGGREGATES HAVE A WIDE SIZE RANGE 
 
Due to the complexity of the protein aggregation phenomenon, there is no universal 
terminology to describe the numerous aggregate sizes or types; however, some of the 
commonly occurring aggregates are classified by [Philo 2006] as follows: (1) rapidly 
reversible, non-covalent small oligomers (dimer, trimer, tetramer, and so forth); (2) 
irreversible, non-covalent oligomers; (3) covalent oligomers (for instance, linked 
through Schiff bases or disulfide bonds); (4) “large” aggregates ( ≥ decamer); (5) “very 
large” aggregates (diameter ~50 nm - 3 µm); and (6) visible particulates ( “snow”, 
“flakes” or “floaters”), which are, most likely, irreversible. Except for the visible 
particulates, there is a chance that the large and very large protein aggregates have a 
reversible character, if associated through non-covalent bonds. 
In addition, protein aggregates are characterized by the tendency to “evolve” over 
time, typically into larger and less reversible/irreversible species; moreover, it is 
highly likely for a protein sample to contain more than one of these types or classes 
[Philo 2006, Philo and Arakawa 2009]. 
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1.1.2. MOST PROTEIN AGGREGATES ARE REVERSIBLE 
 
Despite the common tendency to make a black vs. white distinction, which usually is 
interpreted as a permanent and irrevocable classification of aggregates into 
“reversible” and “irreversible”, in reality, though, an aggregate that is irreversible in 
one context can become reversible in another, indicating the existence of a continuum 
of aggregation states between reversible and irreversible [Philo 2006]. 
 
1.1.3. THE LIFE SPAN OF PROTEIN AGGREGATES IS VARIABLE 
 
The ample range of life spans feature of reversible protein aggregates (their 
permanence in time) is probably their most neglected; the rates of 
association/dissociation phenomena between oligomers vary greatly, ranging from 
ms to several days. Many analytical methods, more in particular, separation 
techniques, allow only the detection the longer life span species; proteins displaying 
dynamic self-association (rapid and reversible protein self-assembly), under the 
effects of the separation method, find themselves under a constant struggle between 
separation and re-equilibration, because of the law of mass action. Consequently, the 
separation results often depend on the rates of the association/dissociation process, as 
well as the equilibrium constants [Philo 2006]. 
Although either SEC and SV-AUC or Flow FFF methods may successfully resolve 
multiple peaks, in fact, neither of those peaks represents a pure, individual oligomer, 
but more likely a dynamic mixture of multiple oligomers; however, if the 
association/dissociation reactions occur very slowly compared to the duration of the 
separation, the self-associated protein system behaves like a true mixture, therefore 
individual oligomers can be resolved. Such reversible, but extremely slow 
association/dissociation reactions, responsible for the existence of so-called 
“metastable oligomers”, are rather common [Philo 2006, Philo and Arakawa 2009]. 
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1.1.3. THE SEPARATION IS INTRINSICALLY DISTRESSING FOR PROTEIN AGGREGATES 
 
When analyzing protein aggregates, one of the fundamental problems is represented 
by the simple fact that most characterization techniques and, in particular, separation 
techniques, have a chance of perturbing the distribution of protein species in the 
sample to be analyzed; not only the measurement itself may destroy or cause the loss 
of some aggregates, but new aggregates can also be created by or during the 
measurement[Philo 2006, Engelsman et al. 2011].  
For instance, both SEC and FFF (AF4 or HF5) produce a high sample dilution of the 
sample during the separation, which potentially induces the dissociation of the 
reversible aggregates. Moreover, SEC is also infamous for filtration effects and poor 
sample recovery, which makes the use of an elution buffer containing high levels of 
salts and/or organic modifiers mandatory; these carrier solution additives may 
modify the distribution of non-covalent aggregates. Generally less problematic that 
SEC, the protein recovery in FFF (AF4 and HF5) may also suffer from non-specific 
adsorption of proteins to the channel wall, therefore some adjustments of the carrier 
solution are in order. As for the creation of new aggregates, the major impacting 
factor is the composition of the carrier solution (and changes thereof); however, in 
both SEC and FFF, protein aggregates may also arise from pre-dilution of the sample 
with the separation buffer, whose composition is usually different than the protein 
formulation buffer [Arakawa et al. 2010, Carpenter et al. 2012, Zölls et al. 2012].  
 
1.1.5. IS IT POSSIBLE TO REPLACE SEC? 
 
Despite its notoriety, it is very likely that SEC (and its macro-column version, fast 
protein chromatography, FPLC) will continue to be the workhorse tool for protein 
aggregates characterization in the near future. Alternative analytical platforms, such 
as SV-AUC and FFF (AF4 and HF5) with or without multi-angle scattering (MALS) 
detection, still have one or more of the following drawbacks: (1) they are not robust 
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enough (do not provide repeatable results) or/and easy to use as routine QC 
procedures, therefore difficult to validate for lot release, (2) they have low 
throughput, (3) they require expensive equipment (SV-AUC) or extensive method 
development (FFF), therefore highly trained personnel, and (4) the software may be 
very far from being 21 CFR part 11 compliant [FDA 1997]. 
Despite these shortcomings, the above mentioned analytical methodologies proved 
themselves to be invaluable as orthogonal methods for SEC, whose purpose is to 
help determining the reliability of the results provided by SEC. Such cross-validation 
practices are usually time and resources-efficient, and they can be implemented fairly 
easily at all stages of drug development, as well as technological platforms in 
functional and structural proteomics. In addition, these complementary methods can 
help guiding the development and the improvement of SEC methods [Philo 2006, 
Arakawa et al. 2010, Carpenter et al. 2010, Engelsman et al. 2011, Carpenter et al. 
2012, Zölls et al. 2012]. 
For all the reasons described in the previous paragraphs, the protein aggregation 
phenomenon needs a targeted approach; two main fields of research and their 
applications are explored in this dissertation, and various aspects are described in 
order to obtain a wholesome understanding of the protein aggregation issue.  
Moreover, a critical evaluation of the most frequently employed analytical 
methodologies, which are currently dedicated to the study of protein aggregation, is 
due in order to find the best course of action in each described case. 
 
In this dissertation, the miniaturized variant of Flow FFF (hollow fiber FFF or HF5) online 
coupled with spectroscopic and/or optical detection methods, is employed for the study of 
protein aggregation phenomena. Various aspects, ranging from instrumental and method 
robustness (and validation), to detection sensitivity and instrumental/method versatility, in 
terms of aggregates size-range and MW range, as well as versatility in terms of carrier 
solution choice (enabling the discrimination of different types of protein aggregates), are 
explored. 
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1.2. PROTEIN AGGREGATION PHENOMENA RELATED  
TO BIOLOGICAL AGING (SENESCENCE) 
 
From the pathological and immunological point of view, protein aggregation is a 
general terminology which describes the association of proteins into larger assembly, 
following loss of the secondary, tertiary or quaternary protein structure and often 
leading to loss of biological activity. Protein aggregation is a common biological 
phenomenon associated to the cellular inability to maintain the homeostasis of their 
proteome (proteostasis). In physiological conditions, the tendency to aggregate of de 
novo synthesized unfolded proteins is balanced by the several chaperones that aid 
their folding [Kopito 2000]. Soluble aggregation is also commonly observed in 
ubiquitinated unfolded proteins before proteasome degradation or in oxidatively 
damaged proteins before translocation into the lysosomes by chaperone-mediated 
autophagy [Kiffin et al. 2004]. Additionally, temporal changes to the cellular 
homeostasis (temperature, pH, water content and salt/ions concentration) can induce 
transitory protein unfolding and soluble aggregation. Lately, it has been reported 
that, during physiological aging, proteostasis becomes gradually compromised and 
several hundred proteins tend to become more insoluble and aggregate. These 
proteins have been shown to have common biochemical and biological properties, 
such as a primary structure with amino acids stretches often found in proteins 
associated with neurodegenerative diseases and secondary structure with increased 
beta-sheets [David et al. 2010] or present extensive oxidative post-translational 
modifications [Cannizzo et al. 2012]. 
During pathological conditions, protein aggregation is also a very common occurrence 
giving rise to the group of diseases collectively known as protein conformational 
diseases. In many degenerative diseases of the CNS, such as Alzheimer’s, Parkinson’s 
and Huntington’s disease, protein aggregation is a common pathological hallmark 
[Rubinsztein et al. 2005]. Protein aggregates can be classified according to their 
biochemical and biophysical characteristics. Biochemically, aggregates can be formed 
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by covalent bonds, through Schiff-base formation, or non covalent bonds, mainly 
mediated by hydrogen bonds, hydrophobic and electrostatic interactions. The former 
are irreversible aggregates whereas the latter can be, at least partially, reversed by 
cellular molecular chaperones. Size-wise aggregates can range considerably, from 
protein oligomers up to visible cytosolic inclusions, known as the aggresome [Kopito 
2000]. The sub cellular location of these aggregates can also vary, from perinuclear to 
peri-ER or intra-endosomal. 
Recently, there has been a strong interest in analyzing protein aggregates for 
different reasons: (i) to determine how protein primary and secondary structure 
influence their tendency to aggregate during physiological or pathological 
conditions; (ii) to map the post-translational modifications observed in chronic 
inflammatory, metabolic and degenerative diseases that induce protein aggregation, 
and (iii) to analyze the machinery recruited to the aggregate to aid its disaggregation 
or to dispose them through proteasomal or autophagy-mediated endosomal 
degradation. 
Consequently, several methods have been employed to separate protein aggregates, 
including filter assay, analytical ultracentrifugation (AUC), gel electrophoresis and 
size exclusion chromatography (SEC) [Stegemann et al. 2005, Ishii et al. 2007, 
Linetsky et al. 2008, Scharf et al. 2013]. However, the first two methods separate the 
aggregates as a total, thus, making it impossible to analyze the biochemical 
composition of the aggregates with different MW, shape and biophysical properties. 
SEC is limited by the pores size of the column used for fractionation (therefore allow 
for a specific size range of aggregates to be separated), and by the amount of 
detergent that can be used during the run (which can, in turn, affect the size and 
composition of the aggregates). Gel electrophoresis does not allow for an accurate 
analysis of their MW, nor does provide any additional information on the 
biophysical properties of the aggregates.  
Therefore, an analytical methodology with the ability to separate soluble aggregates 
from terminal aggregates or aggregates with different biophysical properties would 
Chapter 1: Protein Aggregation Phenomena 
8 
 
allow for a more functional analysis. Indeed, in prion disease, a correlation between 
the size and the infectivity of the protein’s aggregate was reported [Silveira et al. 
2005]. 
 
1.3. PROTEIN AGGREGATION PHENOMENA IN  
THERAPEUTIC PROTEIN FORMULATIONS 
 
Antibodies, the most developed therapeutic proteins, are large multi-domain 
proteins. In particular, human monoclonal antibodies (mAbs) display poor biophysical 
properties characterized by low stability and unfavorable tendency towards 
aggregation. Among the factors that lead to these shortcomings, protein formulation 
plays an important role, even though the core of problem is the primary sequence of 
the protein itself; moreover, since mAb therapeutic action is so specific, there are 
significant differences among them (related to Fab differences and the particular 
antigen specificity of the monoclonal), which explains the differences in stability and 
aggregation propensity between antibodies [Lowe et al. 2011]. 
The final formulation of a therapeutic mAb therefore must be carefully chosen; not 
only to ensure drug quality (stability and purity), but also to allow drug manufacture 
at an appropriate scale. Moreover, an effective therapeutic drug requires high-
concentration liquid formulations, e.g higher than 100 mg/mL. The mAbs can lose 
stability and aggregate also, as a result of conformational changes [Schwegman et al. 
2009] which can occur upon storage (usually freezing in high-volume vessels [Singh 
et al. 2009]. Moreover, the constituting amino acids may undergo post-translational 
modifications during expression, purification, or storage, leading to loss of stability 
and eventually aggregation [Jenkins et al. 2008]. 
Known effects of aggregation among therapeutic proteins are: lower in vivo efficacy, 
increased variability among batches, and perhaps most importantly, immunogenicity 
in patients [Cordoba-Rodriguez 2008]. Therefore, it is vitally important that for each 
of the steps of expression, purification, concentration, formulation, storage, and final 
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filling of the mAb, protein degradation, such s aggregation, must be minimized 
[Lowe et al. 2011]. 
In the biopharmaceutical field, the aggregates are defined as high molecular weight 
(MW) protein assemblies; formed either spontaneously, through 
electrostatic/hydrophobic/hydrogen bonds interactions between native-state 
monomeric units (also known as protein self-association), or by association between 
denatured (damaged) monomers. Both types represent a concern from the 
immunological point a view, and their capacity to enhance immune responses to the 
monomeric form has been known for over a half a century [Rosenberg 2006]. While 
large aggregates are more easily identified and separated (eliminated through 
filtration; for example), as their presence is rigorously regulated by FDA [Zölls et al. 
2012], little is known about the immunological effects of protein self-association 
phenomenon, which may impede the effectiveness of the therapeutic protein by 
neutralizing the monomer action. 
Although it was initially believed that protein-protein favorable interactions can only 
occur if  hydrophobic surfaces are exposed upon denaturation (intended as 
irreversible damage), leading to aggregation and often causing severe precipitation, 
an increasing concern regarding the native protein interactions has recently emerged 
[Cromwell et al. 2006]. In fact, recent literature indicates that even small 
perturbations in the protein structure may cause the exposure of hydrophobic 
surface: it is belied that the formation of self-associated antibody species is mediated 
by electrostatic interactions [Liu et al. 2005], while dipole-dipole interactions are 
believed to be the cause of fibrillogenic association of b–sheets [Fernández 2005].  
Comprehension on how to control the aggregation phenomenon, through 
thermodynamic and kinetic studies, helps assessing the danger correlated to the 
presence of associated species during the formulation development of therapeutic 
proteins. The main rising concerns of the biopharmaceutical industry, which impacts 
on the safety and efficacy of therapeutic proteins, is represented by protein 
aggregation and particulate formation in protein formulations, with their very wide 
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size range (nm-µm) being the most pressing issue since no single analytical method 
is able to resolve it. In fact, many efforts have been employed to fill the “gap” of 
techniques able to identify, separate and characterize the presence of undesired 
protein aggregates in the sub-µm size range [Cao et al. 2009, Zölls et al. 2012].  
Moreover, many efforts have been developing in order to optimize the time and 
resources required for protein formulations by means of high-throughput techniques 
for formulation screening [Capelle et al. 2007, Goldberg et al. 2011], as well as of 
simplification and customization of the protein formulation process through FDA 
regulations based on Design of Experiments [Hinz 2006, Feng et al. 2012].  
 
 
1.4. THE NEED FOR APPROPRIATE 
 ANALYTICAL METHODOLOGIES 
 
 
The need for adequate analytical methods for the detection, separation and 
characterization of protein aggregates, regardless of their origin or formation 
mechanism, justifies the sudden growth of new analysis methods. Since therapeutic 
proteins, as well as aging proteins, can form different types and sizes of aggregates 
and particles, a case-by-case selection of the appropriate analytical characterization 
methods is required: there is no “general solution” to fit all.  
No single method is indeed capable to cover the nm-mm aggregates size range, 
therefore making the combination of several methods (usually based on different 
measurement/separation principles, therefore orthogonal) mandatory for an extensive 
characterization, as means to bridge this “gap”[Philo 2006, Zölls et al. 2012].  
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CHAPTER 2:                               
FIELD-FLOW FRACTIONATION 
(FFF) 
 
 
2.1. THE PROPOSED ANALYTICAL SOLUTION: 
FIELD-FLOW FRACTIONATION 
 
Albeit a little slower and less visible, but in parallel with traditional techniques such 
as electrophoresis (gel, GE or capillary, CZE), liquid chromatography (LC) and flow 
cytometry (FC)  [Reschiglian et al. 2005], the development and improvement of field-
flow fractionation (FFF) were motivated by the potential of FFF to fulfill many of the 
needs described in the previous Chapters. Since early stages of FFF “the great 
application range, resolution and versatility for macromolecular and supra-molecular 
samples, by providing high selectivity and speed, simultaneous measurement, simplified 
coupling to other measurement devices (…) and applicability to diverse samples over a broad 
mass‐size range, gentleness in separating delicate species, and flexibility in targeting specific 
problem areas”  make it the ideal candidate for the study of protein aggregation 
phenomena [Giddings 1993].  
 
Although LC and electrophoresis are still the most employed (traditional) methods 
for the separation and characterization of biological samples, field-flow fractionation 
arises as a highly selective, chromatographic-like flow-based separation technique 
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particularly suited for processing macromolecular and supra-molecular samples that 
range over 15 orders of magnitude in molecular weight [Giddings 2000] – 
incidentally, proteins and protein complexes/aggregates – under gentle instrumental 
conditions [Zattoni et al. 2007, Roda et al. 2009].  
 
The major strength of FFF is its versatility, because of the numerous field types which 
can be applied (Table 1), the instrumental setup, channel design and modes of 
operation, and not to mention the wide choice of experimental conditions. FFF is 
therefore suitable for the separation-characterization of a very wide selection of 
macromolecular and particulate samples [Giddings 2000]. 
 
Table 1 – Field types and corresponding FFF techniques  
Field FFF technique 
Cross-flow (Fl) Flow FFF (FlFFF) 
Sedimentation (Sd) Sedimentation FFF (SdFFF) 
Gravitational (Gr) Gravitational FFF (GrFFF) 
Thermal (Th) Thermal FFF (ThFFF) 
Electrical (El) Electrical FFF (ElFFF) 
Magnetic (Mg) Magnetic FFF (MgFFF) 
Dielectric (Dl) Dielectric FFF (DlFFF) 
 
Many types of fields have been employed for the FFF separation (displayed in order 
of their relevance in Table 1) in order to explore its versatility trait and motivated by 
the fact that they have different size ranges and areas of applicability. 
Its greatest strength it is also its major flaw; the wide choice of options (in terms of 
field, instrumentation or experimental conditions), as well as the broad applications 
range, have led the way to dispersive efforts being spent exploring the limits of FFF. 
Exploring the FFF “maze”, even though showing the resolution of topical issues and  
highlighting the particular FFF features [Reschiglian et al. 2005, Roda et al. 2009] , has 
left a relevant gap between potential and realization, therefore made this technique 
generally “good at everything” but, unfortunately, “not specific enough for a particular 
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purpose” and, more importantly, not yet able to replace any of the above-mentioned 
reference techniques [Giddings 2000].  
 
2.1.1. PRINCIPLES OF FFF  
 
The FFF concept and separation principle was described for the first time in 1966 by 
Calvin Giddings [Giddings 1966]; together with his research team, has contributed 
significantly during the four stages of FFF development described by [Wahlund and 
Nilsson 2012]. FFF is a flow-based separation family of techniques which, thanks to 
the “flow” concept, belongs to the wider chromatographic category; FFF and liquid 
LC employ almost the same instrumental setup. 
The typical FFF operation mode consists in injecting the sample in a narrow band 
into a stream flowing through a thin/capillary flow chamber, where the sample is 
separated into components and which are eventually flushed out towards a detection 
and /or collection system. As the sample components are driven through the length 
of the flow chamber, they get separated according to their biophysical features, 
therefore eluted at different times and sequentially detected and/or collected 
[Giddings 2000].  
Similar to the chromatographic column concept, in FFF, the flow chamber that makes 
sample separation possible is called channel. Since the FFF separation principle is not 
based on differential retention of sample components by the stationary phase as 
occurring in LC, the FFF channel is empty (no stationary phase required) and is 
usually made of inert and/or biocompatible material. In FFF, the retention relies on 
the analytes interaction with an external field, applied perpendicularly to direction of 
the mobile phase flow. Hence the field-flow duality required for the separation 
[Giddings 2000]. The lack of a stationary phase reduces considerably unwanted 
interaction between the analytes and the separation device, therefore makes FFF an 
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intrinsically “soft” separation method, ideally suited to macromolecular and supra-
molecular systems, such as protein aggregates.  
 
2.1.3. MECHANISM OF FFF 
 
In order to understand why FFF is valid candidate for the described problematic, the 
retention mechanism which lies behind the soft separation must be examined.  
First, the stream flowing through the thin/capillary empty FFF channel is a laminar 
flow (made of very thin streamlines also called layers or laminae), governed by an 
ideally parabolic flow profile (Figure 1a); the velocity of the parabolic flow is null in 
proximity of the channel wall and it gradually increases towards the channel center, 
where it reaches the maximum value, according to the law of Poiseuille. 
 
 
Figure 1 – Separation principle in FFF (a) parabolic flow profile, where vmax represents the 
maximum flow velocity at the center of the parabolic flow profile and (b) differential elution 
driven by the applied field 
 
In the absence of the applied field, if any particle (macromolecules, supra-molecular 
species etc.) is set free in the mobile phase flowing through the FFF channel, it will be 
driven randomly over the short distance between the walls of the channel by the 
Brownian motion, while being carried downstream by the flow. This random motion 
of the particle will carry it through stream lines of different velocity (reported in 
Figure 1a as arrows of different length, proportional to the stream velocity), 
following a movement called random walk. The particle will move downstream very 
slowly when found near the wall and very fast when near the parabolic flow center; 
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the average velocity <v> will be the same for particles of any size (but small enough 
to be driven by Brownian motion), therefore will reach the channel exit at the same 
time [Giddings 2000]. 
However, when the field is applied perpendicularly to the stream of mobile phase, it 
will drive the different particles in specific zones of the parabolic profile, between the 
channel walls; under the effect of the field, particles found in a certain region of the 
parabolic flow profile, will be moved downstream at a velocity equal to the mean 
flow velocity in that region, therefore carried toward the channel exit at different 
speeds. An example of differential elution of two analytes (A and B), under the effect 
of the field, is reported in Figure 1b; A is forced by the field in a stream line 
characterized by higher flow velocity compared to B, therefore will elute faster. 
The field itself must meet three requirements, in order to be effective and actually 
make the analytes separation possible. Firstly, it needs to be strong enough in order to 
drive forcefully the analytes into specific, highly localized regions of the parabolic 
flow profile. Secondly, it needs to be selective enough, in order to drive the analytes 
into different streamlines of the parabolic flow profile. Thirdly, it needs to be easily 
implemented, in order to make instrument development practical and possibly 
economical and, more importantly, easy to use and reliable [Giddings 2000].  
Many field types have been proposed in FFF over its 50 years of existence (Table 1), 
however their relevance and frequency of usage have changed over time, thanks to 
the development and improvement of adequate and affordable FFF instrumentation, 
not to mention their ability to meet the above-described criteria. 
 
2.1.3. FFF MODES OF OPERATION 
 
As the analytes are driven into different localized region within the parabolic flow 
profile, their relative distribution over the flow streamlines or laminae (ideally, only a 
few µm thick, meaning that the particles would be held essentially at a fixed position 
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within the parabolic flow profile) dictates their order of elution, selectivity, band 
broadening or other separation parameters.  
There are several types of distributions, also called operating modes; their variety adds 
flexibility to the intrinsically versatile FFF [Giddings 2000]. The most commonly used 
modes of operation, are: (a) normal (Brownian) mode; (b) steric mode and (c) lift-
hyperlayer mode; the normal mode will be examined in the following paragraphs. In 
order to understand how each mode operations, it is fundamental to examine how 
these distributions are formed. 
When a homogeneous population of sample particles enters into an FFF channel, the 
particles are distributed rather evenly over the channel cross section, at first. When 
the field begins to act by driving the particles toward the channel wall (or 
accumulation wall), in a process called sample relaxation, the particles will respond with 
forces of transport opposing the external field (whose origin will be discussed further 
on in this Chapter).  
Consequently, even though the field continues to act, the sample relation is 
completed after a short while because the opposing forces balance themselves and 
the sample components reach a steady state, therefore a corresponding equilibrium 
distribution. The nature of the opposing transport forces exerted by the particles 
themselves determines the form of the particles distribution, therefore the FFF 
operating mode and all separation parameters: order of elution, selectivity, 
resolution etc. [Giddings 2000]. 
 
2.1.3.1. NORMAL (BROWNIAN) MODE 
 
The normal (Brownian) mode governs the equilibrium distribution and subsequent 
elution of most sub-µm particles and virtually all macromolecules (proteins and 
protein aggregates included); it is the most widely implemented mode, therefore 
called “normal”. As the analytes are driven by the field against the accumulation 
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wall, their concentration builds up, creating a concentration gradient and causing the 
analytes to diffuse in the opposite direction (Figure 2a); this transport mechanism 
holds true until the analytes diffusion force balances the field force [Giddings 2000].   
When the Brownian diffusive and the field transport forces reach an equilibrium, the 
analyte concentration c (relative to the accumulation wall concentration, c0) 
approaches an exponential function of elevation x, above the accumulation wall, as 
reported in Equation 1 [Giddings 1973, Giddings et al. 1991, Schure et al. 2000] and 
reported in the enlarged view of Figure 2c, where l is the characteristic elevation of 
the analyte cloud from the accumulation wall and x is the distance to the channel 
wall.  
 
          
 
    
 Equation 1 
 
The separation is achieved in normal mode because different analytes form 
exponential distributions / layers of different thickness, as depicted in Figures 2b and 
2c; the greater the thickness of the layer, the higher flow velocity streamlines the 
analyte will reach and, consequently, the faster it will elute.  
 
 
Figure 2 – Normal operative mode: (a) balance between (Brownian) diffusive and field forces; (b) 
separation of analytes A and B (c) equilibrium distribution analytes A and B in normal mode, 
enlarged view of the exponential distribution 
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The thickest layers migrate fastest (analyte A) as opposed to the most compressed 
distributions (analyte B), which migrate slowest. The sequence of smaller particles 
eluting faster than larger particles is the characteristic elution order in normal mode 
[Giddings 2000].  
The characteristic elevation, l for each analyte represents the ratio between the 
analyte diffusion coefficient D and the field‐induced velocity U (Equation 2); the 
separation is therefore achieved because of differences in diffusion coefficient, since 
the field force is uniformly exerted.  
 
        
 Equation 2 
The diffusion coefficient, D is described by Stokes-Einstein equation (Equation 3), 
where k is the Boltzmann constant, T is the absolute temperature, η represents the 
viscosity of the mobile phase, rH is the hydrodynamic radius and dH is the 
hydrodynamic diameter of the diffusing particle: 
 
  
  
     
 
  
     
 
                                                                                                        Equation 3 
The field-induced velocity, U is described by Equation 4, where f represents the 
friction coefficient: 
                         
                                                                                                        Equation 4 
At the stationary state, the relationship between l and the force F exerted by the field 
on a single particle is described by Equation 5 [Giddings et al. 1991], where k is the 
Boltzmann constant and T, the absolute temperature: 
 
         
                                                                                                                  Equation 5  
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The distribution thickness (l) is, therefore, inversely related to the primary field force 
exerted on the particles. In order to achieve optimal levels, the values of l can be 
controlled by varying the field strength, to which F is directly correlated. Assuming 
that the sample particles are non‐interacting point masses, the velocity V of a cloud of 
such particles is the average velocity of an exponential distribution within the 
parabolic flow profile.  
The parabolic flow profile is therefore described by Equation 6 [Schure et al. 2000], 
where x represents the distance from the wall and x represents the channel thickness 
(height): 
       
 
 
 
  
  
  
Equation 6 
 The retention time of the particles is described by Equation 7 [Giddings et al. 1991], 
where L is the channel length.  
 
   
 
   
                                                                                                                     Equation 7 
If w is the channel thickness (w>x) and w >> l, as it should be for efficient operation, 
the ratio between a retained and an unretained analyte is given by Equation 8 [Schure 
et al. 2000], where t0 is the void time (the elution time of an unretained component), R 
is the retention ratio and represents the delay of a retained analyte caused by its 
compression by the field. Both t0 and R have the same meaning as in 
chromatography. 
 
  
  
  
 
 
  
 
    
  
 
Equation 8 
Equation 8 shows how the retention time of an analyte, tR is directly proportional to F 
and represents the fundamental expression that relates retention time to sample 
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properties in normal FFF; for instance, F (therefore tR) usually increases with particle 
size or molecular weight. 
 
2.1.4. FFF TECHNIQUES: FLOW FFF 
 
In Flow FFF (Fl FFF or F4), the applied field consists in a second, independent, stream 
of mobile phase applied across the channel section, therefore called cross-flow; the 
flow field permeates the channel walls and is applied perpendicularly to the to the 
primary flow stream.  
Flow FFF is the most universal of all FFF techniques, the flow itself, acting as an 
universal field (a moving fluid), is able to displace any unattached object [Giddings 
2000]; this is the FFF variant of choice in this dissertation, because of its versatility, 
being able to separate macromolecules and particles in a very wide size (few nm - 
µm) and MW range. The lower MW/size limit is determined by the MW cut‐off of the 
accumulation wall, which is usually constituted of an ultra filtration membrane able 
to retain the macromolecular and supra-molecular analytes inside the channel. 
Flow FFF became the most frequently employed FFF sub-technique thanks to the 
rapid growth in the 1990s and 2000s, growth which is motivated by the instrumental 
and application advancements and its commercialization [Wahlund and Nilsson 
2012].  
The flow field offers intrinsic advantages for the separation of proteins and protein 
aggregates, which are of interest in this dissertation. Firstly, like all other FFF sub-
techniques, Fl FFF has the gentle separation mechanism and does not require a 
stationary phase for separation. Secondly, its universality implies that virtually any 
type of mobile phase can be used; in particular, a bio-friendly mobile phase is 
appropriate for the separation of biological samples. Therefore, due to the lack of 
stationary phase, the interactions between the proteins and the separation device are 
negligible and since the separation can be performed in a bio-compatible carrier 
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solution, make it possible for the proteins and protein aggregates to preserve the 
native molecular conformation, a fundamental bio-physical property.  
Thirdly, it offers high selectivity in terms of diffusion coefficient differences; this 
feature is correlated to the separation principle in F4, based on differences in 
diffusion coefficients, where the diffusion coefficient (D) is a key parameter which 
determines the protein size, shape and surface properties, therefore unique 
[Reschiglian and Moon 2008]. 
Moreover, Fl FFF is also flexible in channel design, which led to the development and 
improvement of its sub-techniques: symmetrical Fl FFF (F4), asymmetrical Fl FFF (AF4), 
and hollow‐fiber Fl FFF (HF5). Over the past 20 years, AF4 was of particular interest in 
the FFF community; however, thanks to its particular features, HF5 gained terrain in 
the last decade, culminating with its commercialization in 2012. 
 
2.2. FLOW FFF SUB-TECHNIQUES:  
HOLLOW FIBER FLOW FIELD-FLOW FRACTIONATION (HF5) 
 
HF5 is the miniaturized version of Fl FFF, distinguishing itself through the 
symmetrical channel geometry and employing a channel with porous walls, 
represented by a cylindrical ultra-filtration membrane [Johann et al. 2010, 
Reschiglian et al. 2012]. The idea of hollow fiber membranes as tubular, micro-column 
channels for FFF was proposed initially in the 1970s and complete theories were 
worked out; however, it never turned into experimentally useful separations (Lee 
H.L., 1974 and Doshi M.R., 1979). In the late 1980s, HF5 regained interest in the FFF 
community and a much improved experimental design of the separation device was 
proposed (Jonsson J.A. and Carlshaf A., 1989-1993); however, technical problems 
caused by the quality and stability of the hollow fibers impeded further 
advancements [Wahlund and Nilsson 2012]. HF5 was reborn in the early 2000s [Lee 
et al. 1999, Kang and Moon 2005, Park et al. 2005, Reschiglian et al. 2005] and, later 
on, excellent results demonstrated the HF5 potential as pre-fractionation tool for 
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proteomics analysis [Lee et al. 2010]. Moreover, recent advancements suggest that, in 
the near future, HF5 can potentially replace AF4 as an extended characterization tool for 
protein therapeutics [Reschiglian et al. 2013], therefore complement SEC. 
Many efforts have been employed over the years by the Analytical Chemistry 
research team of the “G. Ciamician” Chemistry Department into developing the HF5 
separation device prototype, which was employed during the most experimental 
work presented in this dissertation. Thanks to the successful collaboration between 
the Analytical Chemistry team and Wyatt Technology Europe (Dernbach, Germany), 
once the HF5 separation device achieved its ready-to-market phase, it was 
implemented in the Eclipse® DUALTECTM FFF separation system, “the first 
commercial FFF system using both HF5 and AF4 technique integrated into one 
instrument” , which was launched on the market in 2011 [Johann et al. 2010]. The 
commercial HF5 channel is equipped with an Enhanced Sealing Technology (EST, 
patented) facilitating the channel assembly and is also leakage-proof. The commercial 
HF5 separation device consists in a 17 cm long PES hollow fiber, with a MWCO of 10 
kDa. 
In works reported in literature over the past 15 years [Reschiglian et al. 2002, 
Reschiglian et al. 2003, Roda et al. 2006, Kang et al. 2008, Kim et al. 2008, Lee et al. 
2009], the porous membrane was made of a an inert polymeric material, PES 
(polyethersulfone), CPVC (coated polyvinyl chloride) or PAN (polyacrylonitrile), 
usually with an internal diameter of 0.8 mm, an optimal length of ~24 cm and a 
membrane porosity (cut-off) of approximately between 10 and 100 kDa of MW.  
 
In addition to the key advantages offered by F4, the channel miniaturization in HF5 
distinguishes itself through unique features. Firstly, the low channel volume (~1/10 of 
the commercial AF4 channel) reduces considerably the sample dilution. Secondly, 
due to the reduced size of the separation device, HF5 employs low flow rates, which 
made it possible to be successfully coupled on-line with Mass Spectrometry 
[Reschiglian et al. 2005, Lee et al. 2010]. These first two features highlight the 
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advantages of miniaturization, in particular, the higher sensitivity which is achieved 
thanks to the increased limit of detection/quantification; this is of particular interest 
for very low levels of protein aggregates which may be present in therapeutic protein 
formulations, but also present in the proteome of whole cell lysates. Thirdly, the 
disposable usage eliminates sample carry-over and possible sample contamination, 
therefore ideal for biological samples; disposable channels can be particularly 
appealing for analytical and micro‐preparative scale bio‐separations, for which either 
sterility or inter‐run reproducibility are critical [Reschiglian and Moon 2008]. HF5 
disposable devices have been successfully employed for the fractionation of whole 
bacteria, yeast and red blood cells [Reschiglian et al. 2002, Reschiglian et al. 2003, 
Reschiglian et al. 2004] 
Because of the promising advancements described in the literature so far [Silveira et 
al. 2005, Roda et al. 2006, Kang et al. 2008, Kim et al. 2008, Zattoni et al. 2008, Lee et 
al. 2009, Kang et al. 2010], HF5 had to offer unequalled performances which were 
fundamental for the purpose of this dissertation. 
 
2.2.1. SEPARATION PRINCIPLES IN HF5 APPLIED TO  
PROTEINS AND PROTEIN AGGREGATES 
 
The principle of HF5 separation relies on differences in diffusion coefficient (D), 
specific for each protein, correlated to its size (hydrodynamic radius or diameter) 
through Equation 3 and molecular weight (MW) [Reschiglian et al. 2013].  Since in 
HF5 the radial flow, which acts as the separation field, cannot be controlled 
independently of the longitudinal one, the process of sample relaxation / focus is 
then performed by simultaneously pumping a stream of mobile phase through the 
entry and exit of the fiber (Figure 3a); this action results in the focusing of the sample 
in a narrow band. This aspect is of particular interest in HF5, considering the reduced 
volume of the fiber compared to that of traditional AF4 channels; if the sample band 
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is not narrow enough compared to the length of the fiber, it would compromise the 
separation efficiency.  
Therefore, a typical HF5 separation begins by injecting the sample into the hollow 
fiber, and initially subjecting it to the action of two longitudinal flows entering the 
channel from opposite sides (Flow in and Flow out), with a typical inlet to outlet flow 
ratio of 20:80 (Figure 3a).  The purpose of this step, called sample focus step, is the 
sample relaxation, which allows the sample components to reach their equilibrium 
distributions when the diffusive forces balance the force exerted by the cross-flow; a 
simultaneous result of this action is the sample concentration in a narrow band, at the 
focus position, where the resulting longitudinal flow is null.  
During the sample focus phase, the flow exiting in a radial direction through the 
hollow fiber pores, called focus flow, represents the sum between Flow in and Flow 
and has the same meaning as the cross-flow during the sample elution phase; it 
continues to push the sample components towards the fiber membrane (Figure 3a, 
black arrows), while being opposed by the proteins diffusive force (Figure 3a, white 
arrows). Since D is specific for each protein, each component will reach a steady state 
at a specific distance from the channel wall, where the diffusive force and the radial 
field force are in equilibrium.  
 
 
Figure 3 – HF5 separation principles: (a) sample focus/relaxation and (b) sample separation during 
elution 
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Once the sample components have reached their steady state and have been 
distributed in laminae embedded in the parabolic flow profile, the elution step begins: 
the Flow out is switched off, thus, the Flow in can push the sample components 
towards the channel exit, while the radial flow continues to push them towards the 
membrane (Figure 3b), allowing the sample components to maintain their specific 
distance from the fiber wall. 
As described previously in this Chapter, the longitudinal flow has a parabolic profile, 
characterized by a maximum flow velocity at the center of the hollow fiber and an 
almost null velocity near the channel wall (Figure 1 and 3b); larger proteins and 
protein aggregates (with smaller D) will find themselves closer to the fiber 
membrane, into slower velocity stream lines and will be more retained by the radial 
flow field, while smaller proteins will elute faster (Figure 3b).  
This represents the elution order in normal mode, as mentioned previously in this 
Chapter, and applies to proteins and protein aggregates with 5 nm up to ~ 500 nm in 
diameter [Schure et al. 2000]; when the protein aggregate size exceeds this limit, the 
elution will be switched into the so-called steric mode, when the diffusive forces 
become negligible and characterized by an inverted elution order with respect to the 
normal one (larger particles, with diameters up to 50 µm, being the first to elute) 
[Caldwell 2000]. 
Once the sample run is complete and the components of interest have been 
separated, the radial flow is switched off (procedure also called “field release”), 
allowing the cleaning of the injection line and flushing away all non-separated 
sample components, which have been retained for too long in the separation device 
(if their size exceeds the limits of either normal or steric mode, they have a virtually 
infinite retention time). The purpose of this phase is to clean the separation device, in 
order to avoid sample carry-over when the replacement of the hollow fiber is 
unnecessary. 
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2.2.2. HF5 RETENTION THEORY IN NORMAL MODE 
 
Assuming a uniform radial flow velocity along the hollow fiber length, through a 
series of approximations, the retention time of an unretained analyte, t0 (a.k.a. void 
time) is expressed by Equations 9, where Flowout = Flowin – Flowradial represents the 
longitudinal flow velocity during elution, V0 represents the channel void volume, 
calculated based on Rf, the hollow fiber inner radius and L, the hollow fiber length:  
 
   
  
          
   
      
       
               
  
Equations 9 
Based on a series of approximations [Wijnhoven et al. 1996, Lee et al. 1999], which 
include an ideal Gaussian concentration profile, the retention time of a separated 
component, tR is expressed by Equation 10, where D is the diffusion coefficient of the 
separated component and Rf is the fiber inner radius. 
 
   
  
 
  
   
      
       
  
Equation 10 
Taking into consideration the sample focusing/relaxation process [Lee et al. 1999], 
which occurs at a certain distance from the hollow fiber inlet, called focus position 
(L0), the expression of the retention time can be rewritten as Equation 11:  
 
   
  
 
  
  
 
  
 
        
  
             
       
 
  
 
 
Equation 11 
Correlating Equation 11 with the Stokes-Einstein expression for the diffusion 
coefficient, D (Equation 3), the relationship between the retention time and the 
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hydrodynamic diameter, dH is described by Equation 12, cited in [Zattoni et al. 2007, 
Reschiglian et al. 2012]: 
 
   
   
     
   
 
  
 
        
  
             
       
 
  
 
  
  
 
Equation 12 
Through Equation 12 is, then, possible to convert the retention times in the value of 
the hydrodynamic diameter of the particles and obtain the size distribution of the 
samples (particle size distribution). 
Moreover, the HF5 separation performance can be expressed in terms of number of 
theoretical plates per unit of time, N directly related to the analyte limit 
concentration which does not induce overloading, c* and the analyte limit of 
detection (minimum detectable concentration), cLOD expressed through Equation 13, 
cited in [Zattoni et al. 2007, Reschiglian et al. 2012]: 
 
 
 
  
 
   
  
   
  
     
 
Equation 13 
Equation 13 shows how the maximum separation efficiency is determined by the 
analytes biophysical and chemical properties, more specific, by their detectability 
and tendency towards overloading, a key aspect regarding HF5 applications. A 
performance decrease is, therefore, expected with increasing MW because of the 
consequent D decrease (D is inversely proportional to MW), but also because of the 
consequent c* decrease with increasing MW (c* is also inversely proportional to MW) 
[Moon and Myers 2000]. 
 
Equally important, Equation 13 shows how miniaturization enhances HF5 
performance; by further reducing the fiber inner radius the sample dilution is 
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decreased since the separation would require a lower longitudinal flow rate and by 
applying higher cross-flow rates, the separation performance improves. 
 
The relationship between D and MW is described by Equations 14, where A is a 
parameter correlated to the nature of the analyte and b is an empirical parameter, 
whose value can be calculated based on the shape of the particle; for a rigid sphere, 
the theoretical value of b is 0.33 [Wijnhoven et al. 1996, Valencia and González 2011]: 
  
                     
  
                   
Equations 14 
 
 
 
2.3. HF5 FOR PARTICLE SIZE-CHARACTERIZATION 
 
Typically, the HF5 separation is monitored by UV/Vis detection and occasionally by 
fluorescence (FLD) and multi-angle light scattering detection (MALS), which are 
usually set at a specific wavelength in order to facilitate the detection of the sample 
components on interest (for proteins, UV detection at 210, 215 and 280 nm is used, 
while, for florescence detection, an excitation/emission combination of 280 nm/340 
nm is usually employed).  
The output of such detectors, the sample elution profile, representing the sample 
concentration signal, reported as a function of time and is called fractogram, by 
analogy with the chromatogram. A typical HF5 elution profile/fractogram is reported 
in Figure 4b. 
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Figure 4 – Retention in HF5: (a) Separation occurring inside the hollow fiber, sample components 
A, B and C are eluted towards the detector; (b) typical elution profile, depicting the separated 
components A, B and C as seen by the detector (concentration over time) 
 
As previously stated in this Chapter, the steps of a typical HF5 separation are: (a) 
sample focus or relaxation, (b) sample separation or elution and (c) field release, all 
three depicted in figure 4b. Figure 4b also depicts the void time, t0 which can be 
determined applying Equations 9 and the specific retention time for each separated 
component tR, from which the size of components A, B and C can be determined 
though Equation 12. Moreover, the experimental retention time value can be used to 
determine the diffusion coefficient, D through Equations 3 and 11 and, through a 
series of approximations and applying Equation 14, the MW.  
HF5 is, therefore, able not only to separate, but also to characterize the analytes. The 
particle‐size distribution (PSD) can be obtained from the fractogram by means of a 
numerical conversion of the retention scale. Particle size distribution (PSD) analysis 
is considered one of the most remarkable trends in analytical science. In fact, many 
samples of topical analytical interest are found in dispersed form, and information 
regarding their size distribution is as fundamental as knowledge of their MW.  
For instance, in industrial applications, the size characterization of sample particles is 
routine procedure and is an essential part of the overall quality control (QC) 
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practices. In the pharmaceutical field, for particles used in drug delivery, the size is a 
critical factor because it has a strong influence on the particle bio-distribution, hence 
their performance as carriers, as well as their ability to bind to the active drug. From 
the hydrodynamic size, the analyte MW can be also derived; however, in this case, 
assumptions on analyte shape or conformation are required and not always accurate. 
 
2.4. HF5 SEPARATION PERFORMANCE EVALUATION:  
CRITICAL PARAMETERS 
 
Since FFF (therefore, HF5) is a chromatographic-like technique, many parameters 
which help evaluate the separation performance can be applied, parameters which 
will prove useful through this dissertation, especially when HF5 methods are being 
developed or when the HF5 performance is compared to the one obtained employing 
other separation techniques. 
Figure 5 depicts another typical HF5 elution profile, which will serve as example, 
used to facilitate the definition of the various separation parameters. 
 
 
Figure 5 – HF5-UV separation profile depicting the separation of two species and the correlated 
separation parameters (retention time and peak width at half height) 
 
The extent of peak broadening and the efficiency of the separation device can be 
evaluated by means of number of theoretical plates, N expressed through Equation 15, 
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and the height equivalent to a theoretical plate, H (plate height) reported in Equation 16, 
where σt2 represents the variance of the eluted peak and L is the length of the 
separation device [Podzimek 2011]: 
 
   
  
  
 
 
      
  
  
  
 
 
 
Equation 15  
  
  
 
 
 
   
  
 
    
 
Equation 16 
 
Unlike what occurs in chromatography, where the analyte occupies the carrier only 
for a time equal to t0, in FFF the analyte occupies the solute at all times, therefore the 
axial diffusion in FFF is inversely proportional to Rs; axial diffusion occurs in FFF as a 
response to the axial concentration gradients, which cannot be eliminated in FFF. 
However, this phenomenon is counteracted by the fact that high MW analytes have 
small D, therefore diffuse little. Another source of band broadening in FFF, the main 
one, is the non-equilibrium, which arises because individual components of the 
analyte cloud (distribution) are carried downstream at different velocities and 
resulting in the sample could dispersion along the axial coordinate. Other band 
broadening effects emerge, for example, from the sample relaxation process or even 
the sample polydispersity itself  [Davis 2000]. 
 
Peak symmetry is another parameter which characterizes the quality of a separation 
device, and is usually software-calculated; peak symmetry is a measure of peak 
tailing, which usually has a negative impact on resolution; a symmetry > 1.2 indicates 
the fact that the separation device is compromised and is no longer working properly 
[Podzimek 2011].  
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Resolution, Rs is a measure of separation between two bands and, for can be 
calculated employing Equation 17, where tR,A and tR,B represent the experimental 
retention time values of species A and B (B eluting after A, Figure 5) and w1/2 
represents the peak width at half peak height of peak A and B, respectively. 
 
   
    
 
         
   
   
   
   
 
 
Equation 17 
 
The difference in retention time reflects the selectivity of the separation process, 
whereas w represents the zone spreading that is correlated to the efficiency of the 
process. At a resolution of 1, peaks A and B are not completely separated, but the 
peak areas overlap is only 2%; complete separation (baseline separation) is achieved 
at a resolution of 1.25 [Podzimek 2011]. Equation 17 also shows how resolution is 
controlled by selectivity and efficiency, meaning that if the separation is not selective 
enough, a satisfactory resolution cannot be achieved. 
 
In order to achieve a better characterization, the specific resolution, Rsp can be 
employed in HF5 similarly to SEC, which takes into account the MW values of the 
two species, A and B [Podzimek 2011]; the expression for the specific resolution in 
reported in Equation 18: 
 
    
    
 
         
   
   
   
   
                
 
Equation 18 
Selectivity is the defined as the inherent ability of a technique to separate two 
components; is FFF can be defined in terms of size, Sd or MW, SMW – Equations 19 
[Schure et al. 2000, Podzimek 2011]: 
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Equations 19 
 
High selectivity is a fundamental FFF feature, which makes it an appealing 
separation tool; high selectivity means a significant change in retention time 
corresponding to a small change in particle size or MW. Selectivity depends on the 
retention characteristics and is independent from band broadening (efficiency); the 
limit of maximum selectivity is approached as the retention levels increase. 
Maximum selectivity in Flow FFF varies between 0.5 – 0.7, comparable to SEC 
selectivity values of ~ 0.1, even though the SEC efficiency is much higher [Schure et 
al. 2000]. 
 
On the other hand, the SEC selectivity is related to the slope of the calibration curve, 
meaning that SEC columns which are highly efficient do not necessarily provide a 
good resolution, unless the calibration curve is low enough. The SEC calibration 
curves, although slightly curved, can be approximated by a linear function in a 
certain range of tR, Equation 20 [Podzimek 2011]: 
 
                         
                 
       
 
Equation 20 
The separation (selectivity) in SEC increases inversely to the slope value and depends 
also on the pore size of the column packing material; however, the calibration curves 
and, consequently, the slope b can be different for different MW regions separated on 
the same SEC column [Podzimek 2011].  
Finally, the fractionating power is even more specific for a technique than selectivity, 
because it defines the relative increment in particle diameter of MW which can be 
separated with unit resolution (Rs = 1). Similarly to selectivity, it can be defined as 
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size-based fractionating power, Fd or MW-based fractionating power, FMW – Equations 
21 [Schimpf 2000]: 
 
   
  
  
  
 
  
   
                
  
   
   
 
  
   
    
Equations 21 
 
Substituting Equation 13 in either of the Equations 21, the fractionating power can be 
rewritten as a function of efficiency and selectivity – Equation 22: 
 
      
 
     
 
        
Equation 22 
 
Consequently, the choice of working at high retention levels is motivated by higher 
selectivity values, as well as increased N [Schimpf 2000]. Equation 22 justifies the fact 
that SEC is given an advantage at lower MWs (< 100 kDa), while FFF quickly 
overtakes SEC at higher MW values (FFF is superior starting from MWs of few 
hundreds of kDa). Moreover, a uniform fractionating power can be achieved in FFF 
(HF5) by gradually decreasing the field strength during the experiments [Schure et 
al. 2000] 
Similar to the SEC capacity factor, k (or chromatographic partition coefficient), the 
retention level, RL in FFF (HF5) is defined through Equations 23 [Wahlund 2013]: 
 
   
     
  
                       
  
  
 
Equations 23 
The recommended RL differs from sample to sample, as observed by [Litzen et al. 
1993, Wahlund 2013]; however, they should be kept below a value of 50. Therefore, 
both selectivity and fractionating power can increase only up to a certain point. 
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On the other hand, in SEC, contrary to other types of chromatography, resolution can 
be controlled only through selectivity and column efficiency, since the capacity 
factor, k does not play a role [Podzimek 2011]. 
 
Most separation parameters are software-calculated (for example, by ChemStation – 
the chromatography software for the Agilent Technologies HPLC instrumentation); 
however, the software does not have the ability to correct the HF5 retention time by 
subtracting the focus time. 
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3.1. HF5 INSTRUMENTAL SETUP 
 
The HF5 instrumentation required for samples separation and characterization 
adopts the same components of a HPLC system (automated autosampler, pump, 
degasser and detection systems), but a hollow fiber FFF channel as a separation 
device instead of the HPLC or SEC column. The HF5 channel (also called cartridge) is 
implemented in the Eclipse® DUALTECTM FFF separation system (provided Wyatt 
Technology Europe, Germany). The FFF module, also automated, is controlled by a 
specific driver, implemented in the software which controls the HPLC 
instrumentation; in this dissertation, a 1200 Agilent HPLC system (Agilent 
Technologies, Santa Clara, USA) was used in all experiments, together with its 
correlated software, ChemStation®.  
The main purpose of the detector in an FFF system is to determine quantitatively the 
number of particles, and the volume or mass concentrations of the separated 
fractions through FFF according to size. Consequently, the sample concentration can 
be derived employing appropriate detection systems, which are able to correlate the 
signal intensity with the sample concentration through the Lambert-Beer law; for 
example, UV-Vis and refractive index detectors are also called concentration detectors. 
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Moreover, online detectors such as multi-angle light scattering (MALS) or quasi-
elastic light scattering (QELS) detectors, are able to provide further information on 
the size, as well as on the MW distribution of the sample. 
An analytical separation technique requires a detection method which is able to 
respond to some or all of the components that elute from the separation system. The 
choice of the detector is, therefore, usually determined by sample requirements. In 
the FFF family of techniques, many of the detection systems have evolved from those 
used in LC. The detection can be performed either online, with a detector coupled to 
the stream of mobile phase, or by collecting sample fractions followed by subsequent 
analysis. For example, mass spectrometry and gel electrophoresis were used during 
the experimental work described in this dissertation as offline methods to 
characterize the HF5 fractions. 
When choosing a detector and designing the experimental setup, one needs to 
consider the concentration of the analyte, the sensitivity of the detector, the level of 
the background noise, as well as the detection limit. The maximum sample amount 
that can be injected is usually limited by the sample overloading limit [Moon and 
Myers 2000], which is a main limitation of FFF, resulting in inter-particle interactions 
that disturb separation. Therefore, a limit of detection well below the sample 
overloading concentration is required in order to be able to quantify the analytes 
without excessive background noise. 
 
3.2. DETECTION SYSTEMS 
 
It is a widely known fact that, since conformation of protein molecules affects their 
biological activity, their tendency towards aggregation, and consequently the 
immune responses directed towards such aggregates, are tightly correlated to 
conformational changes endured by the native form. Conformational studies of the 
protein molecules in soluble aggregates (native-form aggregates) may be performed 
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either directly in the protein formulation or after the isolation of the aggregate 
population of interest. Methods such as: fluorescence spectroscopy (intrinsic, with 
fluorescence dyes or quenching), UV absorbance and near-UV circular dichroism 
spectroscopy, binding to conformationally-dependent antibodies for tertiary 
structure investigations  and infrared and far-UV circular dichroism spectroscopy are 
usually employed for the analysis of the protein structure (tertiary, quaternary). 
Some native-state aggregated proteins may also lead to the loss of their active 
property. In some cases, large and insoluble protein aggregates can be separated 
from their formulation and studied with these same spectroscopic methods 
[Carpenter et al. 2012] (and references therein). 
 
Just like liquid chromatography (LC, SEC), FFF systems (therefore HF5), may employ 
standard concentration detectors, such as refractive index (RI), UV absorbance, 
fluorescence detectors and/or light scattering detectors, in order to monitor the 
elution process. [Qureshi and Kok 2011] (and references therein) 
HF5 separates according to the hydrodynamic size of the sample components. In the 
previous Chapter was shown how HF5-UV coupling can provide additional sample 
information, such as PSD. FFF is not only used in combination with UV or 
fluorescence detectors, but also with light scattering detectors (e.g., multi-angle light 
scattering, MALS), which enhance the analytical information by accurately 
determining the MW of the protein aggregates, either soluble or insoluble [Mahler et 
al. 2009] (and references therein).  
Static light scattering detection, usually in the multi-angle light scattering (MALS) 
version, is often used in a multitude of application fields. MALS detection can 
provide the absolute MW of proteins and protein aggregates, and the size (rms 
radius) can be obtained without any approximation on particle shape. Another 
interesting possibility is the recently developed online coupling of HF5 with dynamic 
light scattering (DLS), which is now commercially available. Online DLS provides 
immediate information regarding the hydrodynamic size or the diffusion coefficient 
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of the separated proteins and aggregate populations [Qureshi and Kok 2011] (and 
reference therein). 
 
FFF coupled with appropriate detection methods can be particularly suitable for the 
separation and characterization of soluble aggregates with sizes above 100 nm, where 
SEC or SDS-PAGE fail because of their operational range limitation. FFF is therefore 
able to fill the “gap” of suitable separation methods in this range [Mahler et al. 2009, 
Zölls et al. 2012] (and references therein). In SEC, the upper size limit of detectable 
protein aggregate is dictated by the column characteristics; larger aggregates can be 
filtered out by frits in the system or by the column itself, therefore large protein 
aggregates may be disrupted and be overlooked in the analysis [Engelsman et al. 
2011] (and references therein). 
In addition, since the FFF operational size range is wide enough, it makes it also 
suitable for the separation and characterization of insoluble aggregates, up to the sub-
visible size region (~500 nm – 50µm) [Mahler et al. 2009, Zölls et al. 2012] (and 
references therein). 
 
 
In a recent review, [Engelsman et al. 2011] critically analyzed the current analytical 
methods employed for the study of protein aggregation phenomena. For the purpose 
of this dissertation, only some of them – reported in Table 1 – will be discussed. 
 
Table 1 - Typical use of analytical techniques in the biopharmaceutical industry with respect to 
aggregate analysis [Engelsman et al. 2011] 
Method Validation Quantification Robustness Sensitivity 
Sample 
throughput 
QC 
method 
AUC No Yes Low Medium Low No 
SEC Yes Yes High Medium High Yes 
AF4 Yes Yes Medium Medium High No 
SEC-MALS No 
No 
(MALS part) 
Medium High High No 
UV-VIS 
spectroscopy 
No No Medium Medium High No 
Fluorescence 
spectroscopy 
No No Medium N/A High No 
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Table 1 (full table in [Engelsman et al. 2011]) helps classify and suggest the 
appropriate use of an analytical technique in the industry as analytical quality 
control (QC) and extended characterization assays (EC) particularly suited when the 
routine QC methods provide atypical/inconsistent results.  
For example, SEC robustness combined with sample throughput makes it the ideal 
candidate for QC assays, for which it has been routinely employed in the 
biopharmaceutical industry, despite its known shortcomings. On the other hand, 
even though FFF operates in a wider size range and has many advantages over SEC, 
it is not yet employed during QC of therapeutic proteins because it is less robust than 
SEC, less mature as a technique, and it often requires time-consuming method 
development.  
Nonetheless, FFF is extremely valuable during the extended characterization (EC) 
assays that are applied during all stages of therapeutic protein formulation 
development. Implementing the EC assays early in the product development can 
mitigate the presence of undesired protein aggregates in formulations during 
production. Since in vitro or in vitro tests for immunogenic reactions are not 
currently available, some effects of protein aggregation is only observed during the 
human trials or even only after commercialization [Engelsman et al. 2011] (and 
references therein).  
Implementing the FFF technology in the biopharmaceutical industry as EC assay has 
been suggested also by [Pollastrini et al. 2012], who highlight the FFF versatility at all 
stages of drug development, from the identification of the lead product candidate, to 
process scale-up, formulation development and process control maintenance 
(strongly recommended by FDA, [Hinz 2006, DiMasi and Grabowski 2007]), pre-
clinical and clinical development (drug stability tests) and last, but not least, to 
commercial product investigations.  
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3.2.1. SPECTROSCOPIC DETECTION SYSTEMS 
 
3.2.1.1. UV/VIS SPECTROMETRY 
 
UV-Vis spectrophotometers are the most commonly used detectors in FFF 
applications, mainly due to their availability, simplicity and low cost. Coupled with 
an FFF system, they have a dual purpose: monitor the separation process and allow 
the sample quantification (concentration detectors).  
For homogeneous samples (i.e. proteins), which absorb specific wavelengths, the 
relationship between sample absorption and concentration is straightforward, 
described by the Lambert-Beer law. However, when dealing with particulate samples 
(very large particles, usually > 1µm), their signal is a combination of light scattering 
and absorption. Therefore it needs to be corrected for scattering contributions 
[Sharpe 2012]. Consequently, the quantification of the separated particles is not 
straightforward, since the UV signal is actually a turbidimetric measure. The UV/Vis 
detector might be “blinded” by the light scattered in the forward direction. This leads 
to underestimating the fraction of the largest particles in a sample, especially when 
the particle size is close to the wavelength of the incident beam [Reschiglian et al. 
1997].  
However, for chromatographic applications, UV/Vis spectrophotometers have been 
designed for use as absorption detectors. They have a very low internal volume, 
which helps minimizing the sample band broadening.  
The simplest detectors operate at a single, yet variable, wavelength (variable 
wavelength detector, VWD), while more complex instruments allow for the 
simultaneous detection of different wavelengths to match the spectral properties of 
the analyte (diode array detectors, DAD). Moreover, DAD allows registering the 
entire UV/Vis spectra of eluting samples. UV/Vis spectra are particularly useful for 
monitoring (chemical or physical) changes in sample composition during separation. 
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The detection wavelength is generally chosen with the intent to maximize the 
sensitivity to the analyte while avoiding interferences, such as absorption by the 
carrier liquid. For instance, high concentration acetate buffer, succinate, citrate buffer, 
phthalate and barbiturate are known to absorb strongly at 215 nm [Aitken and 
Learmonth 2002], which is also one of the main protein absorption bands.  
In particular, protein quantification is usually made possible thanks to the specific 
protein absorption in the near UV region (280 nm), which depends on the amino acid 
(AA) content; tyrosine (Tyr) and tryptophan (Trp) are the major contributors, 
although a very small contribution to the UV absorption is also due to phenylalanine 
(Phe), and to the presence of disulfide bonds [Aitken and Learmonth 2002]. 
Since the AA sequence and content varies greatly from protein to protein, leading to 
different absorption intensities among proteins, a specific absorption for each protein 
must be determined. The extinction coefficient Ɛ relates the protein concentration with 
its absorption intensity. For protein solutions at 1 mg/mL, most Ɛ0.1%280nm values are 
between 0.5 and 1.5 (average 1.0). Moreover, the protein absorption at 280 nm can be 
employed to determine the protein AA composition, and the Trp, Thy and Phe %. 
Absorption interferences at 280 nm may exist, due to nucleic acids contamination. 
However, DNA contamination can be confirmed and quantified by detection at 260 
nm [Aitken and Learmonth 2002]. 
The protein peptide bond has a very strong, specific absorbance in the far UV 
(maximum at 190 nm, but usually detected between 205 and 215 nm), which can be 
exploited for protein quantification. However, due to oxygen interference at 190 nm, 
measurements are more convenient at 205 nm, where the absorbance is ~ half than 
that at 190 nm. As previously mentioned, at these wavelengths (205-215 nm) possible 
interference from the mobile phase composition (especially highly concentrated salts) 
may hinder detection, therefore protein quantification. Since protein absorption in 
the far UV region is not due to AA side chains, it does not distinguish among 
proteins, and it can be employed as an absolute method for protein quantification [Aitken 
and Learmonth 2002].  
Chapter 3: HF5 Instrumental Setup and Detection Systems 
49 
 
Protein quantification by spectrometric methods  is based on the Lambert-Beer law, 
which can be expressed as Equation 1, where A represents the absorption intensity, Ɛ 
represents the molar extinction coefficient (a proportionality constant which 
correlates the absorption intensity and the sample concentration), c represents the 
sample concentration (molarity, M) and l represents the path length [IUPAC 2014]: 
 
A = Ɛ · c · l 
Equation 1 
 
 A particular version Equation 1 is its adapted version for flow systems, expressed by 
Equation 2, where F represents the volumetric flow rate: 
 
A · F = Ɛ · c · l 
Equation 2  
 
Equation 2 describes the inverse proportionality between sample absorbance and 
elution flow rate; this relationship can be exploited to increase detection sensitivity in 
flow systems. According to Equation 2, a smaller flow rate implies a larger area under 
the peak, therefore decreased sample limit of detection (LOD) and quantification 
(LOQ), leading to higher detection sensitivity. By further reducing the fiber inner 
radius, both efficiency and sensitivity (cLOD) increase, according to Equation 13 in sub-
chapter 2.2.2 (Chapter 2).  Thanks to a smaller fiber inner radius, the separation 
would require a lower longitudinal flow rate, thus decreasing sample dilution and, 
by applying higher cross-flow rates, the separation performance improves (higher 
efficiency).  
Other methods for protein quantification are represented by offline, specific tests, 
like the Bradford assay or the BCA assay, which involve protein binding to an 
absorbing molecule (chromophores).  
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3.2.1.2. FLUORESCENCE SPECTROSCOPY 
 
Fluorescence spectroscopy is classified by [Engelsman et al. 2011] as an indirect 
method for assessing protein folding state, by detection of fluorescence emission 
(intrinsic or extrinsic) which aids observing the protein tertiary/quaternary structure. 
Its advantages comprise the non-destructive nature, the multiple fluorescence 
techniques, the possibility of combining fluorescence with microscopic tools, as well 
as the online detection possibility, which is one of the most appealing features when 
coupling with a separation technique is considered. 
 
Protein fluorescence is analyzed to monitor changes in the tertiary structure and the 
environment of the fluorescent amino acids, mainly tryptophan.  Intrinsic protein 
fluorescence is attributed to tryptophan (Trp or W), tyrosine (Tyr or Y)), and 
phenylalanine (Phe or F), with fluorescence intensities decreasing in this order. The 
absorption/emission maxima in aqueous solution are: 280 nm/350 nm for Trp, 275 
nm/304 nm for Tyr and 258 nm/282 nm for Phe. Trp is the mostly monitored 
fluorophore, since it exhibits the strongest fluorescence and is selectively excitable at 
wavelengths between 295 and 300 nm. However, Trp is usually very poorly 
represented in the AA structure of proteins. Moreover, its presence highly varies 
from protein to protein (i.e., Bovine Serum Albumin contains 2 Trp residues in the 
AA sequence, while Thyroglobulin contains 40 – [SwissPDB 2014]). Therefore the Trp 
fluorescence emission cannot be used as a method  of identification or quantification 
[Zölls et al. 2012] (and references therein). 
The Trp fluorescence intensity changes dependent on the polarity of the 
environment. For this reason the Trp property is used to monitor changes in the 
protein structure and the consequent formation of aggregates. However, fluorescence 
is only suitable to detect relative structural changes (qualitative information) and not 
to determine the absolute tertiary structure [Zölls et al. 2012] (and references therein). 
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Optical detectors are available for online coupling with separation techniques, such 
as UV/Vis absorbance and fluorescence detectors, that are highly sensitive in 
detecting chromophores. This allows characterizing proteins with a good S/N ratio 
for protein concentrations as low as 10 µg/mL [Mahler et al. 2009] (and references 
therein). 
 
In addition to intrinsic fluorescence, fluorescent dyes (extrinsic fluorescence) can also be 
used to examine the conformation and other properties of protein aggregates. 
Fluorescent dyes can be covalently or non-covalently attached to the protein of 
interest. Covalently attached fluorescent dyes can be used to analyze protein 
aggregates and particles in complex buffers or directly in serum. Non-covalent 
fluorescent dyes, bound by hydrophobic or electrostatic interactions, are usually 
more interesting for the study of therapeutic protein aggregates and particles because 
their fluorescence intensity changes with the polarity of the environment (behavior 
similar to intrinsic Trp). The fluorescence intensity of non-covalent dyes such as ANS 
(8-anilino-1-naphthalenesulfonate), bis-ANS (4,4-dianilino-1,1-binaphthyl-5,5-
disulfonate), SYPRO orange, or Nile Red can be employed to study the exposure of 
hydrophobic protein regions by unfolding and aggregation. Extrinsic dyes can 
provide information about structural changes and/or the formation of aggregates, as 
well as the properties of the formed aggregates, just like intrinsic fluorophores. 
However, the formation or suppression of protein aggregation should be carefully 
considered, known to be caused by the organic solvent in which they are prepared or 
caused by the fluorescent dye itself. [Zölls et al. 2012] (and references therein) 
Extrinsic fluorescence detection allows the characterization of very dilute samples 
employing fluorescent labels. However, careful consideration of protein label (dye) is 
due, because the extrinsic dye might alter the protein sample (protein-protein 
interactions), thus creating artifacts (for instance, protein aggregates). The addition of 
the dye itself may indeed induce artifacts by shifting the equilibrium between 
different conformational states of the protein [Mahler et al. 2009] (and references 
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therein). For the study of larger/insoluble aggregates, fluorescent dyes are mostly 
employed for visualization in fluorescence microscopy or for Fluorescence activated 
Particle Sorting, FAPS [Zölls et al. 2012] (and references therein). 
 
Intrinsic fluorescence proved to be extremely valuable in evaluating the 
structural/molecular conformational changes which occur as a consequence of 
changes in the environmental conditions, responsible for different degrees of protein 
aggregation [Song et al. 1999] (and references therein). 
Intrinsic fluorescence of tryptophan was employed to highlight differences between 
lyophilized and non lyophilized antibodies and to study the effects of sample 
lyophilization on antibody stability, leading to aggregation [Wang et al. 2007] (and 
references therein). IgG aggregation by means of fluorescence emission was also 
studied by [Demeule et al. 2007]. 
A recent study, where a fluorescent dye was added to the carrier solution or the 
sample, showed that SEC performed better for the separation of monomers and 
dimers, but AF4 was able to provide a higher recovery for larger aggregates. The 
increased fluorescence intensity observed upon heating an IgG antibody was 
correlated to IgG aggregates formation, as well as to structural changes in the IgG 
conformation [Qureshi and Kok 2011].  
Intrinsic Trp fluorescence spectroscopy (emission wavelengths of 300-450nm, using 
an excitation wavelength of 295nm) was employed successfully for the study of 
antibody conformational changes leading to non-native aggregation, which occurred 
during the denaturation process; the unfolding/refolding process of the antibody was  
induced by either treatment with concentrated GuHCl or at elevated temperature 
[Brummitt et al. 2011] (and references therein). 
Finally, intrinsic and extrinsic fluorescence spectroscopy coupled to an AF4 system, 
together with Differential Scanning Calorimetry (DSC), circular dichroism (CD) and 
FTIR were employed for the determination of the melting temperature and onset 
temperature of unfolding of an antibody during its formulation development; a 
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progressive destabilization of the native protein structure is usually observed as the 
temperature is increased, often leading to (irreversible) aggregation. This qualitative 
study of the conformational changes by means of sensitive and fast fluorescence 
detection, related to the degradation of the tertiary structure during formulation 
development, demonstrated the role of conformational stability, as well as colloidal 
stability on the final protein formulations [Hawe et al. 2012] (and references therein). 
 
3.2.2. OPTICAL DETECTION SYSTEMS:  
 
LIGHT SCATTERING 
 
Many analytical methods for the study of colloids are based on the interaction of 
particles with light; therefore light scattering techniques play a central role in protein 
particle characterization, as well [Zölls et al. 2012]. Since the intensity of light 
scattering increases with the sixth power of the aggregate radius, the sensitivity of 
light scattering detectors for large aggregates is considerably higher than UV, FLD or 
RI detection. However, when protein aggregates are present at low levels and only 
the light scattering signal is detected, the determination of MW and the 
quantification of the aggregates (as mass fraction) cannot be made performed, but 
light scattering can still provide a qualitative tool for monitoring the presence of 
aggregates [Carpenter et al. 2010]. 
 
Upon sample illumination, the light scattering phenomenon can be observed as a 
very fast sequence of photon absorption followed by an almost instantaneous 
emission of another photon. The absorbed energy can be released from the virtual 
state as photons in two different ways:  (1) if the scattered photon has the same 
energy/frequency as the absorbed photon, the phenomenon is called elastic light 
scattering, characteristic for scatterers smaller than the wavelength of the incident 
light (or Rayleigh scattering) and for scatterers in the range of the wavelength of the 
incident light and above (Mie scattering); (2) if the scattered photon has an 
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energy/frequency different from that of the absorbed photon, the phenomenon is 
called inelastic or Raman scattering and occurs only for 10−3 of all scattered photons.  
Rayleigh/Mie scattering (1) is employed for dynamic light scattering (DLS) or quasi-
elastic light scattering (QELS), nanoparticles tracking analysis (NTA), and static light 
scattering (SLS), while Raman scattering (2) is the basis for Raman spectroscopy 
[Zölls et al. 2012]. 
The most used light scattering techniques for the characterization of protein 
aggregates are dynamic light scattering and static light scattering (multi-angle light 
scattering); both can be used either as standalone (batch) techniques, or on-line 
coupled with FFF, although the on-line coupling is more advantageous. A quick 
review of the two techniques is reported in Table 2, adapted from [Engelsman et al. 
2011].  
Since DLS was not employed during the experimental part described in this 
dissertation, the focus will be directed towards MALS.  
Table 2 - Light scattering techniques for the analysis of protein aggregates [Engelsman et al. 2011] 
Method 
Static light scattering 
MALS 
Dynamic light scattering 
DLS 
Principle 
Time-averaged light scattering 
intensity of particles, detected at 
multiple angles 
Fluctuations in scattered light intensity 
due to Brownian motion 
Observable 
Molar mass, size  
(rms radius) 
Hydrodynamic size 
 
Size range 103Da – 109 Da 1 nm – 5 μm 
Advantages 
High sensitivity; absolute 
determination of size; commonly 
used as online detector 
Easy to perform (batch mode); non-
destructive; high sensitivity; low sample 
consumption 
Disadvantages 
Solute concentration must be known; 
complicated data analysis; not 
quantitative; limited use in batch 
mode; very sensitive to sample 
contamination 
Complicated data analysis; not 
quantitative; low resolution (weak 
differentiation between particle 
species); less suitable for 
polydisperse samples; very 
sensitive to contamination 
(e.g. dust) 
 
Although other methods, such as Mass Spectrometry, membrane osmometry or 
sedimentation equilibrium allow the determination of the absolute MW, MALS  is 
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non-destructive and the determination of the MW and size of the particles is 
performed without any calibration; therefore can be considered an absolute technique.  
These characteristics, combined with a relatively short analysis times, make MALS a 
fast and accurate analysis method, optimal for the characterization of 
macromolecules in solution. 
 
3.2.2.1. MULTI-ANGLE LIGHT SCATTERING (MALS) 
 
The analytical information provided by HF5-UV or HF5-FLD detection can be 
enhanced even further by online coupling with optical detection methods, like multi-
angle light scattering (MALS), which measures the light scattered at multiple angles by 
the proteins and protein aggregates, previously fractionated by means of HF5. 
Combined with a concentration detector (like a UV detector), MALS is able to 
provide directly the size (root mean square radius or rms radius, the mass-average 
distance between each point in the macromolecule and the center of mass) the 
absolute molar weight (MW) of the fractionated proteins and protein aggregates as a 
function of their elution time. Comparing the rms radius values obtained from the 
MALS measurements with the hydrodynamic radius (rh), which is readily obtained 
from the experimental retention time, HF5-MALS allows obtaining information 
regarding the shape (conformation) and mass distribution inside the protein 
aggregates [Reschiglian and Moon 2008] 
The coupling between a miniaturized separation device (HF5) and a highly sensitive 
detection method such as light scattering has a synergetic effect on decreasing the 
limit of detection, which proves particularly useful for the characterization of protein 
samples containing low levels of aggregates. Therefore, the HF5-(UV/FLD)-MALS 
coupling appears to be the ideal solution for the characterization of the widely-sized 
protein aggregates present in therapeutic formulations, as well as a possible new 
technological platform in functional and structural proteomics.  
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As previously mentioned, static light scattering can provide information about the size 
and MW of the proteins and protein aggregates in the measured solution. In SLS, the 
excess Rayleigh’s ratio is measured, this excess ratio represents the time-averaged 
intensity of scattered light by the particles at a certain angle, compared with the 
scattering intensity of the solvent. SLS is suitable for molecules which scatter light 
roughly isotropically, with a radius of gyration smaller than 1/20 of the incident 
wavelength (up to ~ 30 nm, as laser wavelengths in the range of 600–700 nm are 
mostly used). 
MALS is a particular case of static light scattering, where the scattered light is 
measured at multiple angles; MALS is necessary to obtain more detailed information 
about molecules whose scattering type is no longer isotropic (such as high MW 
protein aggregates) [Zölls et al. 2012] 
Parallel to Mass Spectrometry, the development of multi‐angle light scattering 
instruments represented a breakthrough in particle sizing [Wyatt 1968]. In a typical 
light scattering measurement, the MALS detector and a concentration detector 
(UV/Vis or a DRI detector) are connected in series after the fractionation device; 
MALS detection is applicable in a size range from 1 nm to over 1 μm, and its 
sensitivity increases proportionally to the particle size. 
The Zimm equation [Zimm 1948, Wyatt 1993] is used to calculate the size (rms 
radius, which represents the mass-averaged distance from each scattering point in 
the particle from its center of gravity) and the MW of the analyzed species from the 
angle-dependent light scattering intensities, which are  also correlated to the sample 
concentration and the refractive index difference between analyte and solution. The 
dependence of the radius on MW yields information on the molecular conformation 
of the species in dispersion. 
As previously mentioned, MALS can also be employed as a stand-alone technique, 
for batch measurements; however when applied to heterogeneous samples, like 
aggregated protein formulations, only a Z-average value for the MW of all species 
present in the solution is provided. Consequently, in protein aggregation analytics, 
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MALS is mostly used as a detector for SEC or FFF (AF4 or HF5), in combination with 
UV and/or refractive index detection (to measure the concentration that is needed to 
calculate the molecular weight).  The available MALS software, although powerful in 
most situations, is limited for the characterization of highly dispersed samples with 
very broad MW distributions are obtained and especially when the sample 
components characteristics (e.g. shape/conformation) vary over time [Wahlund 
2013]. 
The major advantage of MALS hyphenation with separation techniques is the 
possibility to calculate the MW and size of the individually eluting species; this 
makes the use of MW standards obsolete (i.e. standards for SEC column calibration); 
therefore, misinterpretation of aggregate sizes based on different elution behavior of 
standards can be avoided [Zölls et al. 2012].  
Consequently, the combination of MALLS with SEC or AF4 is the method of choice 
for the analysis of protein aggregates and particles as shown by numerous 
publications; moreover SEC and FFF complement each other, since FFF can pick up 
aggregates characterization when SEC fails to provide reliable results. 
SEC, as standalone technique, has been the workhorse in the biopharmaceutical 
industry for QC practices and batch release; however, cross-validation of SEC 
methods for aggregate analysis is nearly always required, by means of orthogonal 
methods, such as AUC, batch-mode SLS or DLS and FFF [Philo 2006, Arakawa et al. 
2010, Carpenter et al. 2010, Carpenter et al. 2012, Liu et al. 2012]. 
AF4 and SV-AUC were employed as orthogonal methods for the characterization 
and quantification of soluble aggregates of acid stressed/unstressed recombinant 
humanized monoclonal antibody, initially measured by SEC and analyzed by 
SEDFIT/c(s); SV-AUC and AF4 were able to detect markedly higher total aggregate 
levels than SEC in equivalent antibody samples. Moreover, SEC failed to detect 
higher MW soluble aggregates due to probable antibody physical adsorption to 
column matrix, which were apparent in SV-AUC and AF4 analyses, leading to 
incomplete mass recovery. An aggregation model, based on nearly linear end-to-end 
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assembly of monomeric subunits, is proposed and corroborated by SV-AUC, SEC, 
AF4, and DLS measurements [Gabrielson et al. 2007].  
SEC-MALS is very useful throughout product development as EC assay; however, 
due to MALS shortcomings, it is not recommended as a routine QC method. One of 
the major disadvantages of MALS in general is its sensitivity biased towards large-
sized particulate (including non-protein particulates, such as contaminations) and 
consequent prolonged equilibration times to obtain a stable baseline. Moreover, since 
data evaluation is so time consuming, its robustness is, therefore, significantly 
compromised [Engelsman et al. 2011].  
 
This hyphenation between separation and detection techniques, like FFF (HF5)-
UV/FLD/RI-MALS, has contributed greatly to the development of Flow FFF as an 
analytical separation method; this coupling has become a very popular instrumental 
setup for the determination of absolute MW, MW distribution and size-
characterization (z-average rms radius) of separated sample populations [Wahlund 
2013]. Here below, some of the most recent applications are briefly described. 
The aggregation of a monoclonal IgG1 type antibody, induced by freeze–thawing and 
elevated temperature, and the protein aggregates structural properties were studied 
by AF4 with UV and MALLS detection, and HP-SEC with UV and online fluorescent 
dye detection; the study demonstrated that thermal stress led to an increased 
formation of dimers and soluble oligomers, observed by both HP-SEC and AF4 
[Hawe et al. 2008]. 
A combination of spectroscopic techniques (UV-absorption, CD, ATR-FTIR and 
fluorescence), light obscuration, dynamic light scattering, SDS-PAGE, AF4 with UV 
and MALLS detection, and HP-SEC with UV and online fluorescent dye detection 
was employed in a study aimed to characterize the structural properties of 
aggregates formed after freeze–thawing and thermal stressing (typical stress factors 
during development, production and storage) of a humanized monoclonal IgG1 
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antibody; an increased formation of dimers and soluble oligomers was observed by 
both HP-SEC and AF4 [Hawe et al. 2009]. 
Like many other protein misfolding diseases, Prion diseases are notoriously known 
through the formation of abnormal protein aggregates, whose size ranges from 
oligomers to large amyloid fibrils and plaques; among the many approaches which 
were considered for the task of fractionating and characterizing abnormal prion 
protein particles, only AF4-MALS was effective. AF4-MALS was employed 
successfully by [Barton et al. 2012] in order to assess the infectivity associated with 
the widely-sized PrPres in a study which showed that, even though large amyloid 
fibrils of PrPres are still able to transmit disease, the most infectious J-particles, 
identified by [Silveira et al. 2005], are smaller oligomeric species. 
The time-dependent Aβ1-42 aggregation pattern, representing the  self-assembly of the 
42-amino-acid-long amyloid peptide Aβ1-42 into insoluble fibrillar deposits in the 
brain and a crucial event in the pathogenesis of Alzheimer's disease, was studied by 
AF4 with on-line multi-angle light scattering detection; the fibril deposition occurs 
through an aggregation process involving transient and metastable oligomeric 
intermediates, which are intrinsically difficult to be accurately monitored and 
characterized by traditional methods. On-line AF4-MALS coupling allowed the 
separation and the determination of the MW and size distribution of both the early-
forming soluble aggregates and the late pre-fibrillar and fibrillar species, 
demonstrating unique information on the dynamic aggregation kinetics [Rambaldi et 
al. 2009]. 
Using different analytical methods, which included visual inspection, turbidity, light 
obscuration, size exclusion chromatography, and dynamic light scattering, the 
aggregation behavior of an IgG1 stressed by shaking or heat following static storage 
was investigated, to determine whether protein aggregates exist in equilibrium; the 
study demonstrated obvious differences between shaken and heated samples upon 
storage [Kiese et al. 2010]. 
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A combination of intrinsic/extrinsic fluorescence (FL), circular dichroism, 
calorimetry, chromatography, capillary electrophoresis, and laser light scattering was 
used for the study of an IgG1 antibody under acidic conditions, as a function of 
solution pH; protein unfolding, refolding, native colloidal interactions, aggregate 
structure and morphology, and aggregate dissociation were observed [Brummitt et 
al. 2011]. 
A combination of dynamic light scattering, size exclusion chromatography (SEC) and 
field flow fractionation (FFF) was employed to study the effect of pH and salt 
concentration, on the stability and aggregation kinetics of IgG solutions under the 
conditions typically encountered in downstream processing. The oligomer 
distributions provided by SEC and FFF are consistent, demonstrating that, for the 
given antibody, low pH and presence of salt induce conformational changes that are 
responsible for progressive, but reversible aggregation, proportional to the salt 
concentration [Arosio et al. 2011]. 
A recent HF5-MALS-based application, consisting in a customized, fast and accurate 
method for characterization of therapeutic proteins, using as a model sample an 
oxidized form of Avidin (AvidinOX®), showed the boost in detection sensitivity 
obtained by combining a miniaturized separation device (HF5) and a highly sensitive 
detection method (MALS); the first application developed employing the commercial 
hollow fiber FFF miniaturized channel [Reschiglian et al. 2013]. 
A wide range of opportunities for inspiration and exploitation of the distinct 
characteristics of AF4-MALS throughout the long, winding and multifaceted 
therapeutic proteins development process are proposed by [Pollastrini et al. 2012] 
AF4-MALS was used to study the aggregation properties of antibodies, two different 
proteins and a protein-polysaccharide conjugate (PPC); the AF4 method was found 
to be less destructive on the aggregates, but at the expense of separation. Loose 
protein and antibody aggregates were detected by MALS and their presence was 
corroborated by complementary spectroscopic and microscopic techniques; the 
aggregates readily reversed to monomers during AF4 separation. The results 
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obtained by [Palais et al. 2012] demonstrate the importance of AF4 versatility in 
terms of experimental conditions (flow combinations), able to characterize the 
complexity of protein aggregation. 
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INTRODUCTION 
 
Therapeutic and diagnostic proteins represent the fastest growing area of 
biopharmaceutical applications [Daugherty and Mrsny 2006] and, among them, 
antibodies are the major player, controlling many types of diseases such as cancer, 
infectious diseases, allergy, autoimmune diseases, and inflammation [Wang et al. 
2007]. A fast keyword search on [ClinicalTrials.gov 2013] reports almost 3000 clinical 
trials involving monoclonal antibodies in 2013, spread globally (Figure 1). 
 
 
Figure 1 - Clinical studies involving monoclonal antibodies in 2013.  
Source: [ClinicalTrials.gov 2013] 
 
Therapeutic protein drugs, antibodies in particular, (a) have a very specific action, 
therefore lead to less side effects compared to small molecule drugs; (b) may be used 
for drug delivery, namely conjugated to another therapeutic drug for efficient 
delivery of this entity to a target site, therefore reducing potential side effects and (c) 
may be conjugated to radioisotopes for specific diagnostic purposes [Wang et al. 
2007]. All these reasons explain why this category of therapeutics is gaining 
extraordinary drive, as well as widespread recognition. Since the approval of the first 
monoclonal antibody product in 1986 (-OKT-3) [Wang et al. 2007], the booming 
increase in protein drugs development (30-fold increase over 7 years, 2006-2013) 
reflects the relevance of bio-therapeutics and the advances made in antibody 
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engineering. Most of the FDA-approved drugs target cancer or inflammation, 
pathologies which have not been previously treated effectively with traditional, 
small molecule drugs [Daugherty and Mrsny 2006]. 
Antibody therapeutics are large (MW>150 kDa), complex molecules and must be 
administered at high levels in order for them to be effective (~1g/dose). Their 
production and purification scale has reached unpredicted industrial levels, 
previously assumed impossible. Development of stable and high concentration 
formulations, as well as effective delivery strategies of large amounts of complex 
molecules progressively became pressing issues for the biopharmaceutical industry. 
Product stability soon became a critical aspect, since tightly related to its effectiveness, 
as well as its potential toxicity [Daugherty and Mrsny 2006].  
Consequently, the need for (improved) high throughput methods to optimize the 
development of protein formulation, the need for sensitive and accurate methods to 
determine and to monitor over time the composition of the protein formulation, as 
well as the need for robust QC protocols for batch release have emerged [Capelle et 
al. 2007, Carpenter et al. 2012].  
These needs justify the sudden growth of new analysis methods, aimed at the 
development of sensitive and selective separation techniques, with a wide range of 
applications, appropriate resolution and versatility regarding the analysis of complex 
samples. Among them, albeit a little slower and less visible, the development and 
improvement of field-flow fractionation (FFF) has progressed in parallel to the 
development of electrophoresis (gel, GE or capillary, CZE), liquid chromatography 
(LC) and flow cytometry (FC) [Reschiglian et al. 2005].  
The development of befitting technologies and scientific understanding of their 
manufacture and formulation have sustained the consequent booming 
commercialization of monoclonal antibodies therapeutics (mAbs). [Lowe et al. 2011] 
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SYNOPSIS: ANTIBODY INSTABILITY 
 
Antibodies are large multi-domain proteins with similar tertiary structures. The 
multitude of disulfide bonds and tight domain–domain interactions in antibodies 
make render them relatively stable and more resistant to moderate thermal stress 
compared to other proteins [Wang et al. 2007]. However, similar to most proteins, 
many human monoclonal antibodies display poor biophysical properties, such as low 
stability and a propensity to aggregate. The factors which contribute to instability and 
tendency towards aggregation are complex, act simultaneously and are not fully 
understood [Lowe et al. 2011]. 
Examples of physical and chemical instabilities regard phenomena such as: 
denaturation, aggregation, surface adsorption, deamidation, oxidation, isomerization 
or fragmentation. Due to their highly specific action, there is a significant difference 
in the primary sequence among different antibodies; therefore, the relative severity 
of these degradation pathways needs to be studied case-by-case. The most frequent 
manifestations of antibody instability include: aggregation, deamidation, and 
isomerization [Wang et al. 2007, Singh et al. 2009]. 
Due to differences in their stability, some antibody products are formulated in a 
liquid form, while others are lyophilized. Commercial antibody formulations are 
either neutral or weakly acidic, indicating the optimal pH range for most antibodies. 
Among the additives employed to suppress antibody aggregation, surfactants have 
been used in most of these antibody products. As for the excipients, aimed to assure 
the product stability over time, the two most commonly used are sucrose and NaCl; 
they have been equally successful in liquid formulations, while sucrose is preferable 
to NaCl for lyophilized formulations [Ohtake et al. 2011]. Nonetheless, a case-by-case 
study of appropriate formulation excipients and buffering agents is due, since 
antibodies differ at structural level.  
Major issues, regarding the antibody formulation challenging task, have emerged: (1) 
Chapter 4, Part 1: Study of protein aggregation phenomena in therapeutic formulations 
71 
 
the development of stable high-concentration formulations and (2) the management 
of the high-concentration associated viscosity of these formulations. However, the 
available stability data found in the literature and the information on the commercial 
antibody products suggest that antibody formulation, compared to other protein 
drugs, although challenging, is relatively manageable [Wang et al. 2007, Lowe et al. 
2011, Zölls et al. 2012]. 
 
Although more stable than other proteins, antibodies are subjected to a variety of 
physical and chemical degradation pathways, which can be observed in liquid, 
frozen, and lyophilized states. For instance, the glycosylation state of an antibody can 
significantly affect its degradation; however, in many cases, multiple degradation 
pathways can occur simultaneously and the degradation mechanism may change 
depending on the stress conditions. These degradation pathways are divided into 
two major categories: (A) physical and (B) chemical instabilities [Wang 2005, Wang et 
al. 2007, Wang et al. 2010] (and references therein).  
 
 
Understanding how these mechanisms act (and probably interact) is fundamental knowledge 
because it aids data interpretation, from protein formulation development, industrial process 
scale-up and manufacturing, choosing the most appropriate analytical tools for stability 
testing, to ensuring the adequacy of the procedures for stability tests or batch release tests 
and, ultimately, to ensuring the quality (purity and stability) of the finished drug product. 
Moreover, the development and the implementation of a Process Analytical Technology 
(PAT) [Hinz 2006] working side-by-side with Design of Experiments (DOE), is strongly 
suggested by the FDA, aimed to make the therapeutic drugs development more manageable, 
more time – efficient and more cost-effective [DiMasi and Grabowski 2007].  
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A. PHYSICAL INSTABILITY OF ANTIBODIES 
 
There are two major, correlated, pathways through which antibodies display 
physical instability: denaturation and aggregation. Protein denaturation leads to 
aggregation, but aggregation is not necessarily dependent upon antibody 
denaturation, since it can occur even among native antibody molecules [Cromwell et 
al. 2006] 
 
DENATURATION 
Antibodies can denature under a variety of conditions, including temperature 
change, shear, and various processing steps; however, antibodies appear to be more 
resistant to thermal stress compared to other proteins. Shear stress, as well as the 
lyophilization process, may cause antibody denaturation [Wang et al. 2007]. An 
example of forced antibody degradation which occurs during lyophilization was 
illustrated by [Hawe et al. 2008], employing AF4 and SEC coupled with tryptophan 
intrinsic fluorescence to demonstrate the various extents of protein denaturation.  
 
AGGREGATION 
Antibody aggregation is the most common manifestation of physical instability and 
was extensively discussed in the dedicated Chapter 1 of this dissertation. One of the 
greatest challenges in therapeutic protein formulation development is the 
concentration dependent antibody aggregation because, in order to be effective, the 
antibody formulations require high concentrations (>100 mg/mL in liquid 
formulations) [Lowe et al. 2011].  
Increasing the antibody concentration increases the aggregation propensity. Protein 
aggregates generally have reduced activity and, more worrisome, greater 
immunogenicity potential because of the multiplicity of epitopes and/or 
conformational changes [Wang et al. 2007] compared to the native monomeric form.  
Antibody aggregates can easily form both in liquid and solid states, under a variety 
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of conditions. The protein–protein interactions, which ultimately lead to protein 
aggregation, are influenced by both diffusion rate and geometric constraints of the 
interaction sites, therefore are tightly correlated to protein concentration changes, 
viscosity, ionic strength, pH, and temperature [Saluja and Kalonia 2008, Mahler et al. 
2009]. These factors impact greatly on the aggregation extent. Other conditions 
known to induce protein aggregation include: shaking (can accelerate antibody 
precipitation), long-term storage, freeze-thaw process [Hawe et al. 2009] and 
lyophilization process [Hawe et al. 2008]. 
Lyophilization may induce different extents of antibody aggregation, as well as 
different aggregate types (from non covalent- linked monomers and/or even disulfide 
linked aggregates). Furthermore, antibody aggregation is a common phenomenon 
during storage in a lyophilized state [Wang 2005].  
Thermal treatment (high temperature) is known to accelerate the aggregation process 
in antibodies, nevertheless, low temperature storage is believed by [Wang et al. 2007] 
to reduce the hydrophobic interaction (the major force in protein folding) therefore 
leads to  the formation of high molecular weight species. For instance, a well known 
example is the case of reversible aggregation in serum Cryoglobulins, which 
precipitate at temperatures below normal body temperature (37°C) and dissolve 
again if the blood is heated.  
Closely related to the low-temperature effect, the freeze-thaw process often induces 
protein aggregation; nonetheless, it does not pose a threat, partly due to the 
reversibility of antibody aggregates [Wang et al. 2007]. 
In this dissertation, the reversible freeze/thaw-induced aggregation phenomenon of an IgG1 
type antibody was monitored by HF5-UV in sub-chapter 4.1.3 and, employing the same self-
associated antibody, the performance of HF5-UV-MALS was compared to SEC, the 
benchmark in QC of antibodies, in sub-chapter 4.1.6. In the latter sub-chapter, a wide MW 
and size range of antibody aggregates was monitored over time and MW-characterized by 
online MALS detection. 
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Several protein aggregation mechanisms have been proposed by [Philo and Arakawa 
2009] and will be discussed in a separated sub-section, further on in this chapter. 
 
B. CHEMICAL INSTABILITY OF ANTIBODIES 
 
There are several types of chemical degradation pathways which cause antibody 
instability, which – based on the site of changes – may or may not lead to the loss of 
antibody activity [Wang et al. 2007]. 
DISULFIDE FORMATION/EXCHANGE 
Disulfide bond formation/exchange is likely the most frequent cross-linking pathway 
causing chemical aggregation during the various processing steps of antibody 
formulation development. Furthermore, storage often leads to disulfide-based 
aggregation [Wang et al. 2007]. 
DEAMIDATION 
This chemical degradation pathway has been widely reported in literature and is so 
frequent that purified antibody formulations may contain many deamidated forms 
[Wang 2005]. 
ISOMERIZATION 
Similar to deamidation, the relative rate of isomerization can be influenced strongly 
by steric effect; the most common isomerization pathway in antibodies is the 
formation of iso-aspartic acid, from direct isomerization of aspartic acid (Asp), as 
well as from hydrolysis of the pH-dependent succinimide intermediate [Wang et al. 
2007].  
OXIDATION 
Although not as prevalent as deamidation and isomerization in antibodies, oxidation 
of amino acid (AA) residues (such as: Met, Tyr, Trp, His, and Cys) can easily occur 
during storage. 
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FRAGMENTATION 
Fragmentation is a chemical degradation pathway that can easily occur in antibodies 
even during production processes. A variety of process conditions may accelerate it, 
for instance: acidic or basic treatment, thermal treatment, freeze/thaw, and storage. 
The most probable sequences leading to fragmentation in proteins are Asp-Gly and 
Asp-Pro; however, there are other sequences which can also experience cleavages, 
like Asn-Ser. Fragments types include monomer species that have lost a light chain 
(M-LC), a Fab arm (M-Fab), a heavy chain (HC) and the light-chain (LC). Though less 
commonly, fragments can also be represented by antibody subunits resulting from 
both peptide and/or disulfide bond cleavage. Furthermore, antibodies are also prone 
to (UV) radiation-induced cleavages [Wang et al. 2007] (and references therein). 
In this dissertation, the presence of fragments of IgG1 type of antibodies was observed during 
the exploratory study described in sub-chapter 4.1.4, probably caused by either processing or 
storage conditions (freeze/thaw). Furthermore, in the same study, it was shown how the 
specific but undesired UV absorption of the mobile phase (phosphate buffer) can hinder the 
detection of antibody fragments. 
 
SYNOPSIS: THERAPEUTIC DRUGS FORMULATION 
 
The most obvious and common solution to the antibody instability (ultimately 
leading to antibody aggregation) is to increase conformational and colloidal stability 
by changing the drug product formulation. The antibody formulation development 
involves simultaneous variation of multiple parameters (like ionic strength and pH) 
and the addition of excipients (such as amino acids, sugars, and detergents) [Lowe et 
al. 2011] (and references therein). Since antibodies are typically prepared in a wide 
range of formulations, high-throughput methods for structural and colloidal stability 
analyses, as well as accelerated stability studies are currently required during 
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therapeutic drug formulation, aimed to explore the optimal combination of 
parameters. The formulation development can take a significant toll on time, product 
and expenses. Nonetheless, these current needs led to the development of higher-
throughput methods for analysis [Lowe et al. 2011] (and references therein) and more 
efficient approaches, like the Design of Experiments implementation in the 
formulation development. 
 
A. LIQUID ANTIBODY FORMULATIONS 
 
Given that the antibody structure itself allows it, liquid dosage form is generally 
preferable to lyophilized products because it is easier to administer and less 
expensive to manufacture. Half of the commercial antibodies are stable enough to be 
formulated in a liquid form [Wang et al. 2007]. 
 
EFFECT OF PROTEIN CONCENTRATION 
A previously mentioned, the concentration-dependent protein aggregation is the 
greatest challenge to developing high-concentration protein formulations, since a 
relatively large amount of antibodies needs to be dosed to achieve any therapeutic 
effect (otherwise, a large volume of antibody preparation has to be infused). The 
solubility of antibodies does not pose issues, since it seems to be relatively high and 
excipients such as surfactants have been effective in increasing it even further. The 
decrease in antibody solution viscosity is achieved by adding sufficient amounts of 
NaCl, though even adjusting the formulation pH could produce a similar effect 
[Wang et al. 2007] (and references therein). 
From the analytical point of view, high protein concentration is a problem, as well. In 
SEC and FFF, both chromatographic flow-based separation systems, the 
quantification of aggregates levels usually involves not only sample dilution prior to 
analysis (because high volumes are required in order to provide robust results), but 
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also a high dilution during the separation itself. Since the sample dilution may 
induce the disruption of high MW species, it also leads to potential inaccurate 
aggregates quantification, as reported by [Gabrielson et al. 2007, Arakawa et al. 2010, 
Carpenter et al. 2010], therefore requiring orthogonal methods for results validation. 
In this dissertation, a phenomenon similar to the concentration effect was observed (though in 
a concentration range much lower than typical antibody formulation) during the study 
discussed in sub-chapter 4.1.5, where an IgG1 type antibody displayed decreasing aggregates 
levels, proportional to the injected amount. Other sample loading tests have been performed in 
order to establish the HF5 overloading limit, a critical parameter given the fact that HF5 is a 
miniaturized separation device, discussed in sub-chapters 4.1.3 and 4.1.4.   
 
 
EFFECT OF FORMULATION pH 
The determination of a stable formulation pH is often the starting point of 
formulation development. The pH has a known effect on the antibody stability, 
depending on the formulation composition, stress conditions and even antibody 
concentration, just like for other proteins. Formulation pH may have an effect of the 
(a) physical stability of antibodies, because it alters the number and distribution of 
charges on the protein surface, as well as on (b) chemical stability, playing a critical 
role in controlling many degradation pathways (such as disulfide bond 
formation/exchange, deamidation, fragmentation and isomerization). Oxidation may 
even be inhibited by adjusting the pH  [Wang et al. 2007] (and references therein).  
The formulation pH has to be adjusted in order to balance all the potential antibody 
pathways leading to degradation/aggregation. The optimum pH value depends on 
the AA sequence of the antibody; nonetheless, an acidic pH appears to be optimum 
for the antibody majority. The pH value appears to be an issue even when 
performing antibody stability tests, therefore depends on the analytical method 
chosen for these tests [Wang 2005, Wang et al. 2007], which will be discussed further 
on. 
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EFFECT OF BUFFERING AGENTS 
Both the type and concentration of a buffering agent may affect the stability of 
proteins; therefore, their combination needs to be carefully considered. Choosing the 
optimal buffering agent can potentially achieve both pH control and stabilization of 
antibodies [Arakawa et al. 2010]. Seldom, a buffering agent optimal for one antibody 
may be harmful to another [Wang et al. 2007]. The role of the buffering agent, aside 
from maintaining the pH stable, is to shield proteins by charge, therefore suppress 
aggregation. Moreover, as states before, the addition of salts (the most common, 
NaCl) with the purpose of decreasing the formulation viscosity, also has a shielding 
effect. The effects of the buffering agents and salts and their concentration on the 
separation process and antibody aggregates quantification will be discussed further 
on. 
 
EFFECT OF FORMULATION EXCIPIENTS 
One of the most convenient and effective methods employed to achieve antibody 
stability (and suppress/reduce aggregation) in solution is the use of formulation 
excipients. A plethora of formulation excipients have proven to be effective in 
protecting the physical and chemical stability of antibodies under different 
processing conditions and storage, including sugars, polyols, amino acids (arginine), 
surfactants and polymers [Wang et al. 2007] (and references therein). 
Among them, sugars and surfactants are the most commonly used. While they have 
proven to be useful in reducing shaking/stirring-induced aggregation, surfactants 
may have negative effects during long-term storage due to the presence of residual 
level of peroxides (which have been shown to cause protein oxidation), therefore 
should be carefully considered [Wang et al. 2007]. The addition of common antibody 
formulation excipients in the carrier solutions employed during the characterization 
of antibody formulations will be discussed further on. 
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B. LYOPHILIZED ANTIBODY FORMULATIONS 
 
Lyophilized formulations share common traits with the liquid formulations 
(previously described). However, they pose some particular issues, as well, since the 
lyophilization process itself can promote degradation pathways and lead to protein 
aggregation. 
 
 
EFFECT OF FORMULATION pH 
Although a pH of the solid state could not be defined for lyophilized formulations, 
the pH of the liquid formulation which is freeze-dried can have a potential effect on 
the stability of the lyophilized formulation. Therefore, the same precautions need to 
be taken (in fact, even more) in adjusting the formulation pH by employing various 
buffering agents, which, consequently, may have an effect on the antibody stability 
both during lyophilization and storage of the lyophilized products [Wang et al. 
2007]. 
 
 
EFFECT OF PROTEIN CONCENTRATION 
Often, increasing the protein concentration tends to increase the stability of the 
protein during lyophilization. However, antibodies do not seem to follow this trend 
and many of them have shown decreased stability both during lyophilization and 
storage at high concentrations [Wang et al. 2007] (and references therein). 
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PRODUCT QUALITY ASSURANCE: PURITY 
 
ANALYTICAL METHODS EMPLOYED FOR ANTIBODY 
FORMULATION CHARACTERIZATION: SEPARATION AND 
PROTEIN AGGREGATES LEVELS QUANTIFICATION 
 
SEC has been the benchmark analytical system for determining the composition of 
protein samples, thanks to the robustness of the data, the wide range of both HPLC 
systems and commercially available SEC columns and the time-efficient data 
generation [Arakawa et al. 2010]. Many published examples over the past 20 years, 
showing the use of SEC for the characterization of mAb formulations and detection 
of mAb aggregates, as well as the effects of changing buffer composition, pH, use of 
excipients, and mutations to the antibody sequence, have led to SEC implementation 
in the QC protocols for antibody formulations batch release [Lowe et al. 2011] (and 
references therein). 
Although a very robust system, which is the main reason for SEC implementation in 
QC assays, some of the drawbacks of SEC include: compromising between the 
dynamic range of analysis and the resolution, the possible loss of large aggregates 
(physically filtered out of the sample, either via the column frits or interaction with 
the column matrix) and possible sample interactions with the column matrix 
[Arakawa et al. 2010, Engelsman et al. 2011]. Moreover, when analyzing by SEC, 
protein samples are often diluted in a buffer which usually is quite different from the 
final formulation that has been chosen for antibody production and storage [Zölls et 
al. 2012].  
Data interpretation, choosing the most appropriate column matrix and the adequate 
mobile phase, together with employing appropriate known standard samples require 
a careful consideration [Carpenter et al. 2010, Lowe et al. 2011, Carpenter et al. 2012]. 
Incomplete sample recovery, compromised selectivity and resolution and inaccurate 
estimation of aggregates levels are the main reasons why complementary analyses 
are required when SEC fails. 
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It is a generally acknowledged fact that, in order to accurately characterize a protein 
formulation (identification, quantitation, as well as size- and MW-characterization 
of all present species), it is absolutely vital to employ analytical methods which 
allow such analyses in an environment as close as possible to the antibody 
formulation buffer. 
First of all, the dynamic ranges in HF5 in virtually unlimited, thanks to the opposite 
elution order with respect to SEC. This feature is very appealing for the separation of 
antibody aggregates in a very wide size and MW range (see Chapter 1). 
In this dissertation, the possibility to validate an HF5-UV method for the separation of 
protein mixtures was discussed in sub-chapter 4.1.1. Parameters like: results repeatability 
(first level of precision), resolution, efficiency, selectivity and robustness show the 
advancements achieved with a commercial instrumentation when compared to data found in 
literature on hollow fiber prototypes.  
SEC and HF5 performance was compared in the studies described in sub-chapters 4.1.2 
(standard protein mixture) and 4.1.6 (IgG1 type antibody). In both sub-chapters, HF5 
superiority in terms of selectivity is another appealing feature worth considering for this type 
of application. Moreover, it was shown how online coupling with MALS can enhance the 
analytical information. 
It is a known fact that the SEC columns offer a limited operational range in terms of 
pH, as well as aggregates sizes and MW (depending on the material and the size of 
the pores of the column packing). Even though the choice of commercial hollow 
fibers is more limited (as material type and MWCO), the same HF5 membrane type 
(for instance, PES material) can be employed for a wide spectrum of applications 
(protein aggregates separation included) because they operate in the whole pH range 
and are highly resistant. Furthermore, since the stationary phase is eliminated in 
HF5, one does not have to consider possible column packing-mobile phase 
interactions, which are another SEC limiting factor. In addition, hollow fibers are not 
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only less expensive than SEC columns, but can also be employed as disposable 
devices, thus avoiding sample carry-over or contamination.  
In order to maintain the sample integrity, thus the aggregates levels, it is highly 
important to separate in a mobile phase whose composition is as close as possible to 
the formulation of a given antibody and the FFF (HF5) versatility in terms of carrier 
solution composition allows doing so.  
In this dissertation, the effect of the pH of the carrier solution on the antibody stability and on 
the separation HF5 performance was discussed in sub-chapter 4.1.4, which describes an 
exploratory study performed on an IgG1 type antibody.  
Next, since the buffering agent and the (salts) concentrations have shown a great 
influence on antibody stability during formulation, it is expected for them to 
influence the antibody behavior during their characterization (and separation), as 
well. 
In this dissertation, an exploratory study employing HF5 coupled with UV detection for the 
separation of different IgG1 type antibodies is described in sub-chapter 4.1.4, showing the 
influence of the buffering agent and its concentration on the separation process, as well as on 
the sample stability.  
The carrier solution ionic strength is another important separation feature in HF5 
because it controls (by charge shielding) the protein interactions during separation, 
therefore influences protein stability and consequently the sample recovery (proteins 
interacting with the separation device) and the aggregates levels (protein-protein 
interactions).  
In this dissertation, different buffering agents and concentrations thereof, therefore having 
different ionic strengths, were explored in sub-chapter 4.1.4 with the purpose of observing 
their influence on antibody stability during HF5 separation and identifying the optimal 
combination for the aggregates levels quantification of an IgG1 type antibody. 
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SEC and HF5 performance is compared for the separation of an IgG1 type antibody in sub-
chapter 4.1.6, including aspects like sample recovery, identification of different types of high 
MW antibody aggregates and the reversibility of the aggregation process (which was 
monitored by UV-MALS detection).     
Seldom, the optimal a buffering agent for one antibody, may be harmful to another. 
In this dissertation, an exploratory study involving different buffering agents (phosphate 
buffer, citrate buffer and a combination of the two), different concentrations and different IgG1 
type antibodies was described in sub-chapter 4.1.4; the study shows differences among 
antibodies behavior during their separation.   
While the addition of salts (NaCl is the most common) is required for a complete 
sample recovery, it is not a guarantee. In fact, SEC requires very high NaCl 
concentrations (300-500 mM) [Arakawa et al. 2010] (and references therein), with the 
risk of disturbing the aggregates levels and achieving the opposite effect: incomplete 
sample recovery. On the other hand, HF5 can achieve complete sample recovery 
even at lower salt concentrations, added to carrier solutions whose composition is 
much closer to the antibody formulation (with a better chance of reflecting the true 
sample composition). 
In this dissertation, the HF5 performance for the separation of an IgG1 type antibody was 
compared to SEC when employing carrier solutions containing different amounts of NaCl 
and discussed in sub-chapter 4.1.6. In the same sub-chapter, two carrier solutions with a 
composition similar to the antibody formulation buffer were employed for the HF5 separation 
and characterization of IgG1 type antibodies. 
Moreover, the influence of different types of salt (NaCl and MgCl2, both known chaotropic 
agents) was observed during the HF5 separation of different IgG1 type antibodies and 
discussed in sub-chapter 4.1.4. 
The addition of excipients (such as sugars or surfactants) to the carrier solution in HF5, in 
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order to render it more sample-compatible (similar to the formulation buffer), was explored, 
although results are not shown in the experimental section of this dissertation. Sugars tend to 
modify the rheological properties of the carrier solution, causing instrumental setbacks and 
clogs in the HPLC capillaries, while surfactants, as they pass through the FFF system 
components, have a tendency to foam, therefore can only be employed at very low 
concentrations (with the risk of not being effective enough to suppress antibody aggregation). 
The use of low foaming surfactants may be a temporary solution, however, it may have 
unexpected effects on the antibody stability if they are different from the one used in the 
original formulation. High concentrations of surfactants (if provided in the original antibody 
formulation) may lead to the formation on micelles, which impede the aggregates detection 
and quantification by MALS, since MALS detection does not discriminate them from protein 
aggregates. 
 
PRODUCT QUALITY ASSURANCE: STABILITY 
 
ANALYTICAL METHODS EMPLOYED FOR THERAPEUTIC 
PROTEIN STABILITY TESTS 
 
Typically, therapeutic proteins (mAbs as well) are stored over several months 
between manufacture, filling, and clinical administration. As detailed previously, 
they are typically formulated at high concentrations (mAb formulations exceed 100 
mg/mL, for subcutaneous administration). In order to understand the stability and 
aggregation tendency of particular mAb in a given formulation, accelerated stability 
studies are conducted during development, although stability tests are conducted on 
the finished products, before and even after commercialization [Lowe et al. 2011] 
(and reference therein). In fact, the FDA regulates the quality of biopharmaceutical 
drugs (in terms of product purity and stability), from development to 
commercialization. 
The stability tests, although rigorously regulated by the FDA, are developed 
according to the ICH guidelines [ICH 2014] that are somewhat flexible (hence 
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guidelines, not rules), considering the particularities of antibodies, meaning that each 
test is antibody-customized. The short-term, as well as long-term stability of 
therapeutic proteins being at stake, suitable analytical tests are required on both 
liquid and lyophilized protein formulations, in order to monitor the behavior, 
identify and quantify (possibly discern between various types of) protein  
aggregates.  
The accelerated stability tests, also called stress tests, whose purpose is to simulate harsh 
and inappropriate storage conditions, as well as deliberately induce the accelerated 
formation of aggregates (in order to understand the underlying causes, as well as 
simulate long-term storage), typically involve the incubation of the antibody 
formulation at defined temperatures, usually 4 and 40°C over several months. At 
defined time intervals, samples are removed and subjected to stability analyses. The 
presence of low MW fragments (degradation products) and high MW aggregates 
levels, as well as aggregation/degradation rates are measured against previously 
defined values and used to determine whether the antibody is appropriately stable 
over long periods of time [Lowe et al. 2011] (and references therein). 
Nevertheless, the accelerated stability tests performed on therapeutic proteins (at 
room temperature or 5-8°C), may or may not be possible or accurate because the  
presence of complex and multiple degradation pathways – which may have different 
degree of temperature dependencies – are unpredictable, therefore may not be able 
to simulate the long-term behavior [Wang et al. 2010] (and reference therein).  
In this dissertation, a short-term accelerated stability study conducted by HF5 coupled with 
UV and MALS detection on a modified protein, stored in lyophilized form (AvidinOX®), was 
discussed in sub-chapter 4.1.7. The protein aggregates, present at trace levels, were 
successfully quantified and their MW values were calculated by MALS. The same study also 
highlighted the miniaturization advantages regarding the decreased limit of detection of 
protein aggregates and the HF5 versatility regarding the carrier solution composition (the 
possibility of working in denaturing vs. native mobile phase), which made possible the 
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distinction and quantification of different types of protein aggregates (covalent vs. non-
covalent). 
The advantages of miniaturization of the HF5 separation device (employing a hollow fiber 
with a smaller inner diameter), coupled online with highly sensitive detection methods 
(intrinsic fluorescence detection and peptide bond absorption) were explored and discussed in 
sub-chapter 4.1.5. The study showed how the detection limit of antibody aggregates can be 
decreased to ng of injected sample, even in antibody formulations where the aggregates levels 
represented only a 2% (mass fraction) of the injected sample. 
 
PROTEIN AGGREGATION MECHANISMS 
 
As thoroughly discussed in Chapter 1, therapeutic proteins (mAbs included) exhibit 
a wide spectrum of aggregation phenomena, making it virtually impossible to find a 
single analytical method able to work well in all cases. Moreover, though less 
recognized, aggregates also exhibit highly different life spans, and their lifetime has 
important consequences for detection methods. Another major analytical challenge 
resides in the fact that the measurement itself may destroy or create aggregates and is 
a key determinant for appropriate method selection [Philo 2006]. Lastly, SEC 
capabilities are limited, though routinely employed as benchmark analytical method 
in QC practices, therefore the use of orthogonal techniques is vital for an accurate 
estimation of the aggregation extent. For this purpose, MALS and (intrinsic) 
fluorescence are often employed as detection methods during the extended 
characterization assays, although their implementation as QC methods is currently 
not possible [Gabrielson et al. 2007, Engelsman et al. 2011, Zölls et al. 2012]. 
A general understanding of the underlying aggregation mechanisms which occur during 
formulation development may actually help finding solutions for the aggregation issue, but is 
just as important in choosing the appropriate characterization methods and data 
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interpretation. An accurate determination of the extent and type of aggregates contributes 
ultimately to assuring the quality of the therapeutic drug. 
Protein aggregation can occur through a number of distinct mechanisms or 
pathways, which are not mutually exclusive, therefore can act simultaneously on the 
same product, although usually one is dominant. A general understanding of the 
most frequent aggregation mechanisms may point development into the right 
direction (finding a good formulation, or a method to suppress and remove 
aggregates) or at least avoiding excipients and processes that are likely to make 
things worse. The following aggregation mechanisms were proposed by [Philo and 
Arakawa 2009, Wang et al. 2010] and reviewed by [Amani and Naeem 2013]. 
 
MECHANISM 1: REVERSIBLE ASSOCIATION OF THE NATIVE MONOMER 
 
Mechanism 1 describes the intrinsic tendency of the native form of the protein to 
reversibly associate (aggregate). As the surface of the native protein monomer is self-
complementary, it will readily self-associate to form reversible small oligomers. 
There may be multiple “sticky” or complementary zones on the monomer surface 
and, when the protein concentration rises (or, generally, when the monomers find 
themselves closer to each other), progressively larger oligomers form, driven by the 
law of mass action. Over time and as their size increases, these larger aggregates 
often become irreversible. Due to multiple mechanisms acting at the same time, these 
irreversible aggregates may be formed through covalent bonds, like disulfide 
linkages. Every known protein has an intrinsic tendency to self-associate; however, the 
aggregation propensity differs from one protein to another.  
For instance, insulin is the most commonly known example of a therapeutic protein 
which readily (and normally) associates to form reversible oligomers. Although the 
reversible insulin aggregates do not pose a threat due to their reversible nature, such 
association can have important consequences for bioactivity, information which led 
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to the development of important new therapeutic products [Philo and Arakawa 2009] 
(and references therein).  
 
MECHANISM 2: AGGREGATION OF CONFORMATIONALLY-ALTERED 
MONOMER 
 
Mechanism 2 is similar to Mechanism 1, but applies to native monomers with a very 
low propensity to reversibly associate. The first step of Mechanism 2 is a transient 
conformational change/partial unfolding of the monomer to a non-native state, 
characterized by a strong tendency to associate. At any given time, the non-native 
(aggregation-prone) fraction of protein will usually be quite small. Conformational 
changes and aggregation through Mechanism 2 will be promoted by stress (such as 
thermal, heat or freeze/thaw or shear stress), which may trigger the initial 
conformational change. Consequently, the aggregates formation will be suppressed 
by conditions that stabilize the native conformation. This aggregation mechanism 
does appear to be the dominant one for many proteins [Philo and Arakawa 2009] 
(and references therein).  
In this dissertation, the reversibility of the self-association process between IgG1 type antibody 
monomers, which have (most likely) suffered a conformational change due to freeze/thaw 
process and/or due to the fact that the sample was diluted in a buffer with a composition 
different from the formulation buffer, was monitored by HF5-UV-MALS (and SEC-UV-
MALS) and discussed in sub-chapters 4.1.3 and 4.1.6. 
 
MECHANISM 3: AGGREGATION OF CHEMICALLY- MODIFIED PRODUCT 
 
As discussed previously in this Chapter, the chemical instability of proteins leads to a 
series of degradation pathways. Mechanism 3 is, in fact, a version of Mechanism 2, 
where the change in protein conformation is caused by modifications in the covalent 
structure, which lead to aggregation. Chemical changes may include degradation 
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pathways like oxidation, deamidation, or proteolysis and may induce the formation 
of new “sticky” patches on the surface, or even change the electric charge leading to 
reduced electrostatic repulsion between monomers.  
A particular feature of this type of aggregation is that the aggregates will be enriched 
in the modified form. Nonetheless, improving the chemical stability of the monomer 
will reduce the aggregation extent. Importantly (and intuitively), chemically-altered 
aggregates can be particularly immunogenic [Philo and Arakawa 2009] (and 
references therein). 
In this dissertation, the self-association process between monomeric units of an oxidized 
protein (AvidinOX®), which have (most likely) suffered a conformational change due to 
chemical instability, and/or promoted by the presence of degradation products, was monitored 
by HF5-UV-MALS and discussed in sub-chapter 4.1.7. The study showed that the 
AvidinOX® oligomeric species are stable over time and, thanks to the HF5 versatility, non-
covalent, as well as covalent aggregates were discriminated, quantified and monitored over 
time.  
 
MECHANISM 4: NUCLEATION-CONTROLLED AGGREGATION 
 
Mechanism 4 is common mechanism for the formation of visible particulates or 
precipitates, a process which is similar to growing large crystals by adding micro-
crystal “seeds” to a saturated solution. The critical nuclei are also sometimes called 
the “seeds” or “templates” for aggregate growth. When the native monomer has a low 
tendency to form small and moderately-sized oligomers (because is not 
thermodynamically favored), but an aggregate of sufficient size still manages to 
form, afterwards the growth of this “seed”/critical nucleus through addition of 
monomers is highly favored and the formation of much larger species is very fast. A 
special feature of Mechanism 4 is that the rate of formation of the large particles or 
precipitates usually exhibits a lag phase (whose length can vary from vial to vial 
within the same lot), that is, no particles or precipitates can be observed for a long 
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period of time, but then, all of a sudden, the large species appear and accumulate 
[Philo and Arakawa 2009] (and references therein).  
 
The main advantage in understanding of the mechanism of aggregation is that it can 
help guide either upstream or downstream process development. For instance, when 
proteins are prone to conformational changes (partial or complete unfolding), 
mechanical stress and exposure to air or solid surfaces, which may lead to 
adsorption-induced unfolding, must be avoided at all costs. While the addition of 
“generic protein stabilizers”(sucrose, polyols and certain amino acids and salts), may 
aid against various environmental stresses that cause unfolding by suppressing 
aggregation via Mechanism 2,  in fact will usually significantly increase aggregation 
via Mechanisms 1 and 4 [Philo and Arakawa 2009] (and references therein). 
 
Some forms of aggregates may be worse than others. High order (high MW) native-
like oligomers formed via Mechanism 1are more likely to cross-react with the native 
monomer, potentially neutralizing it, rather than induce an immune response. On the 
other hand, non-native aggregated monomers formed via Mechanisms 2-4 are more 
likely to have altered potency, as well as altered immunogenicity.  
 
Understanding aggregation mechanisms is also important from the analytical point 
of view, because it may aid in choosing an optimal chromatographic purification step 
in order to remove aggregates during production or by applying pressure-induced 
aggregates disruption, provided that the chosen purification method does not 
generate new aggregates. Furthermore, knowing the type of aggregates may even 
help design a better chromatography method for aggregate removal [Philo and 
Arakawa 2009] (and references therein). 
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4.1.1. HF5 – UV PERFORMANCE EVALUATION FOR THE 
SEPARATION OF A STANDARD PROTEIN MIXTURE.  
HF5-UV METHOD VALIDATION TENTATIVE: SPECIFICITY, 
REPEATABILITY / FIRST LEVEL OF PRECISION, SELECTIVITY AND 
ROBUSTNESS. 
 
 
 
 
 
This chapter is aimed towards deepening the understanding of the critical 
parameters which affect HF5 performance during the separation of protein 
formulations and to establish whether HF5 is a valid candidate for the QA (quality 
assurance) and QC (quality control) of biopharmaceutical products.  
In particular, the following characteristics of the proposed HF5 method were 
investigated: method specificity, method repeatability / first level of precision, method 
selectivity and method robustness. All the experimental work described in this chapter 
is aimed on evaluating the HF5 separation performance of a mixture consisting in 
four standard proteins, with molecular weights (MW) ranging from 29 kDa to 670 
kDa. 
The method specificity was tested by comparing the separation profiles obtained 
during single proteins injections with the separation profile of the protein mixture 
containing the same proteins. The retention time value was the comparison/matching 
criteria.   
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Following the ICH guidelines [ICH 2014] regarding the validation of analytical 
procedures (Q2 (R1)), aimed to evaluate the quality of biopharmaceutical products, 
the method repeatability was studied employing a sequence of injections of the same 
sample (in terms of composition, amount and volume), performed under identical 
experimental conditions. The variability and the trends of the well known separation 
parameters (retention time, peak width at half height, peak symmetry and sample 
recovery) were monitored during subsequent analyses, as well as separation 
resolution and efficiency. The definitions and formulas of all analytical parameters 
employed for the method validation tentative in this sub-chapter were previously 
discussed in sub-chapter 2.4 (Chapter2). 
The method molecular weight-based selectivity (SMW) was calculated using the average 
values of the retention times, determined during the repeatability study, and the 
declared MW values.  
Finally, the method robustness was evaluated by varying simultaneously two critical 
parameters: channel flow rate and cross-flow rate, therefore by varying of the ratio 
between them, vc/vx. 
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4.1.1.1. EXPERIMENTAL SETUP 
 
HF5 was performed using an Agilent 1200 system (Agilent Technologies, Santa 
Clara, CA, USA) consisting in a 1200 Agilent degasser, a 1200 Agilent isocratic pump, 
a 1200 Agilent auto sampler, and a 1200 Agilent variable wavelength detector 
combined with an Eclipse® DUALTECTM prototype FFF separation system (Wyatt 
Technology Europe, Dernbach, Germany). The software package Wyatt Eclipse @ 
ChemStation Version B.04.02 [98] (Wyatt Technology Europe) was used to control the 
FFF separation system.  
The hollow-fiber was a 17 cm long polyether-sulfone (PES) fiber, type FUS 0181 
available from Microdyn-Nadir (Wiesbaden, Germany) with the following 
characteristics according to the manufacturer: 0.8mm ID, 1.3mm OD and a molecular 
weight cut-off (MWCO) of 10 kDa, corresponding to an average pore size of 5 nm. 
The UV detector response at 215 nm was used to monitor the separation process. 
 
4.1.1.2. SAMPLES AND REAGENTS 
 
The carrier solution (mobile phase) was 50mM NH4HCO3 (Fluka) with a pH ~ 8.0. 
The carrier solution was prepared using water purified by an Elix 3 UV Water 
Purification System (Millipore, Billerica, USA) and filtered through a 0.1 µm-pore 
membrane.  
The protein mixture stock solution contained 1 mg/mL of each of the following 
proteins: carbonic anhydrase (CAH), bovine serum albumin (BSA), apoferritin (Ferr) 
and thyroglobulin (Thy), all obtained from Sigma Aldrich (St. Louis, MO, USA) 
dissolved in the carrier solution, resulting in a total protein concentration of 4 
mg/mL. The standard protein characteristics are summarized in Table 1. The same 
mixture has been used as a benchmark in various publications [Kang and Moon 2005, 
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Lee et al. 2009]. The stock solution was diluted 1:10 in carrier solution before injection 
in HF5.  
Table 1 – Standard protein characteristics 
Proteins Abbreviation 
Product code    
(Sigma Aldrich) MW (kDa) pI 
Carbonic anhydrase 
(bovine erythrocytes) 
CAH C3934 29.0 5.9 
Bovine serum albumin (bovine; 
fatty acid free, and essentially 
globulin free) 
BSA A3782 66.7 4.7 
Apoferritin (equine spleen) Ferr A3641 481.2 4.4 
Thyroglobulin (bovine thyroid) Thy T1001 660.0 – 690.0 4.5 
 
Single protein samples were solutions of CAH, BSA, Ferr and Thy prepared at a 
concentration of 1 mg/mL (0.1%) in the carrier solution.  
 
4.1.1.3. METHODS 
 
The “step gradient” HF5 method evaluated in this chapter was developed as an 
improvement of a similar fractionation method proposed in a recent study [Johann et 
al. 2010] on the same standard protein mixture and using the same separation 
system. The radial field was reduced as the MW of the proteins increased by placing 
two steep flow field gradients to reduce as much as possible the time required for the 
fractionation, while considering the optimal retention factor for each protein. The 
radial field/cross flow rate (vx) was maintained constant at 0.85 mL/min for 13.5 min, 
linearly decreased to 0.5 mL/min in 0.5 min and maintained constant at this value for 
7 min. After the 7 min, the flow was linearly reduced to 0.4 mL/min in 0.2 min and 
maintained constant until the end of the run. The focus-inject step was performed for 
4 min at a focus flow rate of 0.85 mL/min. The sample was focused at a distance of 
approximately 15% fiber length from the channel inlet.   
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4.1.1.4. RESULTS AND DISCUSSION 
 
A. METHOD SPECIFICITY: PEAK IDENTIFICATION 
 
The specificity of an analytical method is defined in the ICH guidelines as “the ability 
to assess unequivocally the analyte in the presence of components which may be expected to be 
present. Typically these might include impurities, degradants, matrix, etc”. This definition 
implies that the proposed method, in order to be specific, it should be able to ensure 
the identity of an analyte, its purity (regarding the presence of possible contaminants 
such as related substance test) and the accurate composition of the sample 
(quantitation of active substance and known impurities) [ICH 2014]. 
An amount of 2 µg of standard protein mixture (0.5 µg of each protein) was injected 
and the separation was monitored by a UV detector set at 215 nm for more 
sensitivity. The choice of two steep field gradients in the method (depicted in Figure 
1, black trace) was made not only to speed up the fractionation process, but also in 
regard to the optimal retention factor for each protein. A field that is too strong not 
only has a negative effect on the performance of the separation itself, but also on the 
peak characteristics (shape and width) and on sample recovery. The radial flow was 
reduced as the MW of the proteins increased.  
 
 
Figure 1 – Separation profile of the standard protein mixture (blue) at 215 nm. The black trace 
above the fractogram represents the cross-flow rate during the separation. 
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The fractionations performed on the single proteins (0.5 µg each) simplified the peak 
identification for the protein mixture and also ensured that there are no interactions 
between the proteins in the mix. The fractograms reported in Figure 2 show that the 
retentions times of the proteins in the mixture and the corresponding peaks in the 
single protein are almost a perfect match.  
 
 
Figure 2 – Separation profiles at 215 nm corresponding to the standard protein mixture (a) and 
single standard proteins: carbonic anhydrase (b), bovine serum albumin (c) and apoferritin (d). The 
correspondence between the retention time values for specific proteins and their oligomers is 
traced in red 
 
Comparing the separation profiles (retention time values) of the single proteins with 
the profile of the protein mixture, (0.5 µg each), the BSA monomer shoulder was 
identified as the CAH trimer (peak 3). Moreover, the CAH dimer is completely 
covered by the BSA monomer (peak 2) and, similarly, the Ferr dimer is covered by 
the Thy monomer (peak 6). There is little separation between the Thy dimer and the 
Ferr trimer (peak 7) because of the small difference in MW (about 100 kDa) and 
because the width of the peaks tends to increase with the MW. 
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B. METHOD REPEATABILITY (A.K.A. INTRA-ASSAY PRECISION OR  
THE FIRST LEVEL OF PRECISION) 
 
The precision of an analytical method is defined in the ICH guideline as “the closeness 
of agreement (degree of scatter) between a series of measurements obtained from multiple 
sampling of the same homogeneous sample under the prescribed conditions. Precision may be 
considered at three levels: repeatability, intermediate precision and reproducibility”. 
The precision of an analytical procedure is usually expressed as the variance, 
standard deviation or coefficient of variation of a series of measurements. 
Repeatability, also called intra-assay precision, expresses the precision under the same 
operating conditions over a short interval of time [ICH 2014]. 
A total amount of 2 µg of protein (0.5 µg each protein) was injected repeatedly (in a 
series of 13 subsequent injections) in order to assess the first level of precision of the 
method and the results are reported in Figure 3. As it is evident from Figure 3, 
baseline separation for all proteins in the mixture was obtained in less than 30 min 
with a good peak shape. A high repeatability is also evident for the overlay of 
repeated runs, as further analyzed in the next paragraphs. 
 
 
Figure 3 – Separation profiles of the standard protein mixture recorded at 215 nm, representing 13 
subsequent injections. Separated species in eluting order: (1) CAH monomer; (2) BSA monomer; (3) 
BSA dimer, (4) Ferr monomer; (5) Thy monomer and (6) Ferr trimer 
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Only the completely separated species were considered, therefore the CAH trimer – 
which eluted as a shoulder of the BSA monomer – was not included in the 
repeatability study. 
The repeatability of the method was evaluated by calculating the average values (mean 
values) of the following parameters: retention time, peak width, peak shape, 
resolution between eluting species, efficiency (in terms of plate height and number 
of plates per minute) and assessing the standard deviation (STDEV) and the relative 
standard deviation (RSD%) values.   
 
C. RETENTION TIME AND PEAK WIDTH 
 
Table 2 and 3 summarize the average values, the standard deviation and the relative 
standard deviation (RSD %) of the retention time and peak width over 13 subsequent 
runs. Peak widths at half height values were considered for the statistical analysis. 
 
Table 2 – Retention time: average values, standard deviation and relative standard deviation over 
13 subsequent sample runs 
Retention time, tR (min) Average STDEV RSD (%) 
CAH monomer 6.34 0.053 0.843 
BSA monomer 8.99 0.082 0.912 
BSA dimer 12.40 0.134 1.084 
Ferr monomer 15.87 0.112 0.707 
Thy monomer 19.78 0.171 0.867 
Ferr trimer 25.17 0.287 1.141 
 
Table 3 – Peak width at half height: average values, standard deviation and relative standard 
deviation over 13 subsequent sample runs 
Peak width (min)  Average  STDEV  RSD (%)  
CAH monomer 0.667  0.007  1.032  
BSA monomer 0.773  0.013  1.747  
BSA dimer  1.189  0.034  2.878  
Ferr monomer 0.966  0.036  3.694  
Thy monomer 1.549  0.066  4.254  
Ferr trimer 3.029  0.316  10.444  
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As the MW of the eluted proteins increases, there is a slight but distinct increase in 
peak width with increasing number of injections. Since there is no significant shift in 
the retention time (retention time RSD <2% for all the proteins), it suggests that this 
variation is more likely due to the protein stability over time and consequently to 
different carry-over effect related to non-specific interaction with channel walls, 
rather than loss of performance due to the device itself. In fact, the peak width RSD 
exceeds 4% only above the MW of Thy (the largest and less stable protein in the 
mixture). 
 
D. SAMPLE RECOVERY  
 
The sample relative recovery was calculated considering the largest peak area as 
having a 100% sample recovery (for each protein). Table 4 summarizes the average 
values, the standard deviation and the relative standard deviation (RSD %) of the sample 
recovery over 13 subsequent runs. 
The sample relative recovery has a low variability for three of the eluted species 
(monomers of BSA, Ferr and Thy) with an RSD < 2%. From the fractograms reported 
in Figure 3 we can notice that the peaks become wider over time and their height 
decreases, even though the lowest recovery over 13 runs is about 89%, which is still 
relatively high for a biological sample. The recovery loss is most probably related to 
the protein stability over time.  
 
Table 4 – Sample relative recovery: average values, standard deviation and relative standard 
deviation over 13 subsequent sample runs 
Relative recovery* (%) Average STDEV RSD (%) 
CAH monomer 93.327 3.853 4.129 
BSA monomer 98.518 0.670 0.680 
BSA dimer 93.558 3.568 3.814 
Ferr monomer 98.587 0.999 1.013 
Thy monomer 97.047 1.538 1.585 
Ferr trimer 88.963 7.402 8.320 
* The largest area corresponds to 100%  sample recovery 
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E. PEAK SYMMETRY (SHAPE) 
 
Even under optimal experimental conditions, the peak shape in FFF can appear 
skewed. The peak shape can be easily altered as a consequence of an overloading 
effect. This effect is present if: (a) a high amount of sample is loaded in the channel 
and the sample does not have enough physical space for the relaxation step; (b) the 
radial field is too strong and the sample is pushed too forcefully towards the channel 
wall causing peak tailing or (c) the channel flow rate is too slow and the sample band 
is left for too long inside the channel causing peak tailing. Even the MW of the 
protein appears to have an overloading effect, therefore a smaller amount of sample 
is required for proteins with high MW values [Moon and Myers 2000, Podzimek 
2011]. 
The peak symmetry measures the peak tailing, which has a negative effect on the 
resolution. Some peak tailing is normal (symmetry <1.2), but a larger value is an 
indication of a damaged separation device or the presence of interactions between 
the analytes and the separation device [Podzimek 2011].  
Table 5 summarizes the average values, the standard deviation and the relative standard 
deviation (RSD %) of the peak symmetry over 13 subsequent runs. 
 
Table 5 – Peak symmetry: average values, standard deviation and relative standard deviation over 
13 subsequent sample runs 
Peak symmetry  Average  STDEV  RSD (%)  
CAH monomer 0.773  0.014  1.858  
BSA monomer 0.925  0.005  0.561  
BSA dimer  0.804  0.059  7.387  
Ferr monomer 0.917  0.018  2.010  
Thy monomer 0.794  0.045  5.870  
Ferr trimer 1.437  0.145  10.111  
 
BSA and Ferr monomers show an almost Gaussian peak, with symmetry close to 1. 
CAH monomer, BSA dimer and Thy monomer peaks are slightly fronted (symmetry 
< 1) and the Ferr trimer peak is tailed (symmetry > 1). The peaks corresponding to 
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CAH, BSA and Ferr monomers have low peak shape variability (RSD% < 2), but the 
variability tends to increase for the higher MW species. This effect can be attributed 
to the instability of Thy, the standard protein with the highest MW, instability which 
can ultimately lead to non-specific interactions inside the separation device. 
 
F. RESOLUTION 
 
Resolution is a measure of the separation between two zones. The difference in the 
retention times of two components reflects the selectivity of the separation, while peak 
width (w) represents the zone spreading that is related to the efficiency of the process. 
Therefore, resolution is controlled by both selectivity and efficiency. A resolution 
value of 1 indicates that a 2% of the peak areas overlap; therefore the peaks are not 
completely separated. The complete separation is achieved at a resolution of 1.25. A 
better evaluation of the separation process can be achieved by calculating the specific 
resolution (Rsp), which takes into account the MW values of the separated species, as 
well as retention time and peak width [Podzimek 2011]. 
Table 6 summarizes the average values, the standard deviation and the relative standard 
deviation (RSD %) of resolution between eluting species over 13 subsequent runs. 
 
Table 6 - Resolution: average values, standard deviation and relative standard deviation over 13 
subsequent sample runs 
 
All calculated resolution values exceed the 1.25 value, meaning that all considered 
peaks are completely separated. Figure 4 reports the resolution average values 
between eluting species. 
Resolution  Average  STDEV  RSD (%)  
CAH – BSA monomers 2.163  0.015  0.716  
BSA monomer– BSA dimer  1.757  0.030  1.698  
BSA dimer – Ferr monomer 1.899  0.066  3.489  
Ferr – Thy monomers 1.829  0.049  2.673  
Thy monomer – Ferr trimer  1.379  0.085  6.184  
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Resolution is influenced by both retention time and peak width but, since the 
retention time variability is not significant (RSD% < 2% for all proteins), we can only 
assume a great influence from the peak width on the corresponding resolution RSD% 
values.  
 
 
Figure 4 – Average resolution values between eluting species in the standard protein mixure 
 
The resolution average values are always higher than 1.25, with peak symmetry very 
close to unity, which implies a baseline separation between the eluted species. 
 
G. EFFICIENCY 
 
The efficiency of a separation device is affected by the amount of sample band 
broadening during the separation process. It is known that, the longer the time an 
analyte spends inside the separation device, the greater its band broadening will be. 
Band broadening (also called zone broadening, zone spreading, zone dispersion or 
axial dispersion) is expressed in terms of plate height (H) or number of theoretical plates 
(N) [Schimpf 2000]. High efficiency is characterized by a large plate count, N and a 
small plate height, H. High selectivity means high resolution only if band broadening 
is minimal, since high selectivity can be ruined by excessive band broadening 
[Podzimek 2011]. 
Table 7 summarizes the average values, the standard deviation and the relative standard 
deviation (RSD %) of efficiency over 13 subsequent runs, expressed as plate height. 
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Table 7 – Separation efficiency (plate height, cm): average values, standard deviation and relative 
standard deviation over 13 subsequent sample runs 
Plate height, H (cm) Average STDEV RSD (%) 
CAH 0.034 0.001 1.839 
BSA 0.023 0.001 2.577 
BSA dimer 0.028 0.001 4.536 
Ferr 0.011 0.001 6.131 
Thy 0.019 0.001 6.945 
Ferr trimer 0.045 0.010 22.014 
 
The separation efficiency for the standard protein mixture is also reported in Figure 
5, expressed as number of plates/minute. These values were obtained by dividing the 
number of plates calculated for each peak by the corresponding retention time. 
 
 
Figure 5 – Average efficiency values expressed as number of plates/minute 
 
A significant increase in efficiency is observed with respect to previous HF5 methods 
reported in the literature [Park et al. 2005], the plate height values obtained in this 
study are about 10 times lower than the values reported for the same protein 
mixture. 
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H. METHOD SELECTIVITY 
 
Selectivity is a parameter that quantifies the selective dispersion of the sample and 
represents the difference in retention time with MW of size. High selectivity means 
that there is a significant change in retention time with a small change in MW or size; 
therefore, selectivity can be expressed in terms of size (particle diameter, Sd) or MW 
(SMW). Resolution is the decisive parameter when it comes to evaluate the separation 
performance, because it takes into account both selectivity and efficiency [Davis 2000, 
Podzimek 2011]. 
The FFF selectivity calculated for this study was the MW-based selectivity (SMW), 
defined as the slope of the log (tR) against the log (MW) plot, derived from the 
experimental retention time values for the eluted species and standard MW values 
for proteins reported in Table 1. 
If a radial field gradient is to be used in the method, the relationship between the two 
logarithms is no longer linear. Therefore, when the “step gradient” method is 
employed (Figure 1 and Figure 6a), we can only calculate the selectivity for the first 
three eluting species, when a constant cross flow rate of 0.85 mL/min was applied.  
In Figure 6b, a method, which uses a constant cross-flow rate, was employed to 
separate the same standard protein mixture, in order to calculate the selectivity for 
more than 3 separated species.  
At a first glance, it can be noted that the peaks corresponding to proteins with higher 
MW (Ferr and Thy) are much wider, as a consequence of the stronger field (0.85 
mL/min). Moreover, if the method in Figure 6b is to be applied, the elution time 
should be increased in order for the Ferr and Thy oligomers to be eluted.  
 
Chapter 4, Part 1, 4.1.1. HF5-UV performance evaluation (standard protein mixture) 
108 
 
 
Figure 6 – Separation profiles of the standard protein mixture obtained employing the "step 
gradient" method (a) and the constant field method (b). The cross-flow rate is represented as a black 
line. 
 
The separation performances of the HF5 methods illustrated in Figure 6 were 
compared and the results are summarized in Tables 8 (“step gradient” method) and 9 
(constant field method). 
The retention level, RL (or level of retention) of each analyte was calculated, as 
proposed by [Wahlund 2013], a parameter similar to the capacity factor, k in column 
liquid chromatography, as well as the specific resolution, Rsp – a parameter which 
takes in consideration the MW of each species [Podzimek 2011] – previously 
discussed in sub-chapter 2.4 (Chapter 2) and in the Resolution section of this study, 
which can easily be applied to FFF separation methods. 
As expected, employing a stronger (and constant) field for the whole duration of the 
separation, the method depicted in Figure 6b offers a higher RL for all analytes, even 
though the maximum retention level should be kept, in general, in the range 5 – 50 to 
avoid band broadening and peak tailing [Litzen et al. 1993, Wahlund and Nilsson 
2012]. In fact, at constant strong field, the peaks are broader (Figure 6b), but the 
specific resolution is very similar to the one offered by “step gradient” method 
(Figure 6a) because of the analytes eluting at retention times further apart from each 
other. 
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Table 8 – Separation performance of the “step gradient” HF5 method (Figure 6a), evaluated through 
the following parameters: analytes retention level, resolution and specific resolution 
Peak  Species  
MW  
(g/mol)  
t
R (min) 
Retention 
level (R
L
)  
Resolution 
(R
s
)  
Specific 
resolution 
(R
sp
)  
1  CAH monomer  29000 6.34  14.1    
2  BSA monomer  66700 8.99  20.0  2.163  6.0  
3  BSA dimer  133400 12.40  27.6  1.757  5.8  
4  Ferr monomer  481200 15.87  35.3  1.899  3.4  
5  Thy monomer  670000 19.78  44.0  1.829  12.7  
6  Ferr trimer  1443600 25.17  55.9  1.379  4.1  
 
Table 9 – Separation performance of the constant field HF5 method (Figure 6b), evaluated through 
the following parameters: analytes retention level, resolution and specific resolution 
Peak  Species  
MW  
(g/mol)  
t
R 
 
Retention 
level (R
L
)  
Resolution 
(R
s
)  
Specific 
resolution 
(R
sp
)  
1  CAH monomer 29000 6.6  14.7    
2  BSA monomer  66700 9.5  21.2  2.16  6.0  
3  BSA dimer  133400 13.8  30.6  1.93  6.4  
4  Ferr monomer  481200 19.3  43.0  1.78  3.2  
5  Thy monomer  670000 27.5  61.2  1.89  13.1  
 
This comparison proves that an excessive retention level leads to compromising the 
separation performance, while the “step gradient” method is optimal for the 
separation of proteins in a wide MW range because it takes into consideration the 
optimal retention level for each protein in the standard mixture.  
 
The selectivity plots corresponding to both methods are reported in Figure 7. 
The equation for the log (tR) vs log (MW) plot was: y=0.42x-1.05, where the slope 
(0.42) represents the selectivity of the “step gradient” method for the first 3 eluted 
species. From the calculated MW-based selectivity value and considering a globular 
shaped protein (dH proportional to MW1/3), the diameter-based selectivity was 
estimated. A high value of 1.23 was obtained.  
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The constant field method still provides a good selectivity (slope: 0.34) for the 
separation of 5 species, although band broadening is much more evident, 
compromising the separation performance. 
 
 
Figure 7 - Selectivity plots: log (tR) plotted against the corresponding log (MW). The slope 
represents the selectivity value 
 
I.  METHOD ROBUSTNESS 
 
As defined in the ICH guidelines, the method robustness is “a measure of the analytical 
method to remain unaffected by small but deliberate variations in method parameters and 
provides an indication of its reliability during normal usage”. Experiment design 
(fractional factorial design or Plackett-Burmann design) is common and useful to 
investigate multiple parameters simultaneously [Feng et al. 2012]. This result will 
help identify critical parameters that will affect the performance of the method [ICH 
2014]. 
As an example, in this study we chose to vary the ratio between the channel flow rate 
(vc) and the cross-flow rate (vx), therefore changing two parameters simultaneously. 
Moreover, different operators were assigned to perform the required sample 
injections. Since the obtained results (fractograms) were not significantly different 
between the two operators, only one set of results is depicted in Figure 8.  
Chapter 4, Part 1, 4.1.1. HF5-UV performance evaluation (standard protein mixture) 
111 
 
 
Figure 8 - Robustness of the method, evaluated by varying the ratio between the channel flow rate 
and the cross-flow rate 
 
It can be noted that, as the ratio between the channel flow rate and the cross-flow 
increases, the peaks shape and width remain almost constant, for all species. The 
only differences between the graphs consist, as expected, in the retention time values 
because as the vc/vx ratio increases, the proteins elute faster. Moreover, the CAH 
trimer can be observed up to a ratio of 0.31 as a shoulder to the BSA monomer, after 
which it disappears into the peak tail. 
 
4.1.1.4. CONCLUSIONS 
 
The work presented in this chapter shows an improvement of the fractionation 
performance for protein analysis of an HF5 method, accomplished employing the 
Eclipse® DUALTECTM FFF separation system prototype. The “step gradient” HF5 
method proposed for the fractionation of the standard protein mixture has proved to 
be effective, reproducible, efficient and highly selective, showing promise as a 
candidate for the separation of complex protein mixtures.  
The use of steep field gradients during sample elution served not only to reduce as 
much as possible the analysis time, but also considered the optimal retention factor 
for each protein in the mixture. By comparing the performance of the “step gradient” 
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HF5 method proposed for validation in this sub-chapter with an HF5 method which 
consists in applying a constant strong field thought the whole elution process of 
proteins in a wide MW range, it is proved that the first is superior to the latter. The 
“step gradient” method is faster and provides an optimal separation of even more 
protein species than the constant field method. 
The method also proved to be robust, when the flow rates affecting the separation 
performance were simultaneously varied.  
The work presented in this chapter represents a promising step towards the 
validation of an FFF method for the implementation as QA and/or QC method of 
biopharmaceutical products, even though many efforts have been and are currently 
employed towards this topic. 
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4.1.2. HF5 – MALS AND SEC – MALS PERFORMANCE 
COMPARISON FOR THE SEPARATION OF A STANDARD PROTEIN 
MIXTURE.  
FFF SELECTIVITY FEATURE 
 
 
 
 
In this chapter, the performance of an HF5 developed for the separation of the 
standard protein mixture is compared to size exclusion chromatography (SEC), the 
benchmark for the QA and QC of therapeutic proteins. The performance comparison 
was made under two different experimental conditions: (a) employing a high ionic 
strength (optimal/recommended for SEC) mobile phase and (b) employing a low 
ionic strength mobile phase. 
The identification of the separated species was possible due to HF5 and SEC online 
coupling with UV and MALS detection. This coupling allowed the determination of 
the absolute MW of the separated species, as well as the calculation of the sample 
recovery at all times. The separation performance was evaluated in terms of 
efficiency (N), resolution (Rs) and MW-based selectivity (SMW), as well as sample 
recovery. In particular, specific separation parameters like retention level (RL) for 
HF5 and capacity factor (k) for SEC and specific resolution (Rsp) values were 
compared under each experimental condition. The definitions and formulas of all 
analytical parameters employed for the comparison in this sub-chapter were 
previously discussed in sub-chapter 2.4 (Chapter 2).  
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This study shows the potential of HF5-UV-MALS as orthogonal method for the 
validation of SEC results during the characterization of protein formulations. 
Furthermore, the HF5 device employed in this study (having double the length of a 
commercial, standard device) allowed the scale-up of the injection amount to levels 
comparable to the SEC requirements, in order to provide reliable and robust results 
(absolute MW). 
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4.1.2.1. EXPERIMENTAL SETUP 
 
SEC and HF5 analyses were performed using an Agilent 1200 HPLC system (Agilent 
Technologies, Santa Clara, CA, USA) consisting in a degasser, an isocratic pump, an 
auto sampler and a variable wavelength UV detector, combined with an Eclipse® 
DUALTEC prototype separation system (Wyatt Technology Europe, Dernbach, 
Germany). The ChemStation version B.04.02 (Agilent Technologies) data system for 
Agilent instrumentation was used to set and control the instrumentation and for the 
computation of various separation parameters. The software package Wyatt Eclipse 
@ ChemStation version 3.5.02 (Wyatt Technology Europe) was used to set and 
control the FFF separation system. An Agilent 1100 UV-Vis variable wavelength 
detector operating at a wavelength of 280 nm was used as a concentration detector at 
all times. 
An 18-angle MALS detector model DAWN® HELEOSTM light scattering detector 
(Wyatt Technology Corporation, Santa Barbara, CA, USA), employing a laser 
operating at a wavelength of 658 nm, was used in all experiments.  
ASTRA® software version 5.3.2.14 (Wyatt Technology Corporation) was used to 
handle signals from the detectors (MALS and UV) and to compute the proteins MW 
and concentration values. 
The SEC column was a WTC-0305S (Wyatt SEC protein column for MALS, 5µm 
coated silica beads 300Å, size 7.8x300mm), operating in the MW range from 5.000 to 
1.250.000 g/mol. 
The HF5 separation device was a 34 cm long cartridge assembled from two 
commercial (17 cm long) cartridges connected with a union piece, thus called “double 
length” HF5 cartridge. A separation device this size should allow the scale-up of the 
injection amount to levels comparable to the SEC requirements and provide reliable 
and robust results (absolute MW). 
The hollow-fiber was a 34 cm long polyether-sulfone (PES) fiber, type FUS 0181 
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available from Microdyn-Nadir (Wiesbaden, Germany) with the following 
characteristics according to the manufacturer: 0.8mm ID, 1.3mm OD and a molecular 
weight cut-off of 10 kDa corresponding to an average pore size of 5 nm. 
 
4.1.2.2. SAMPLES AND REAGENTS 
 
The carrier solution/mobile phase was phosphate buffered saline (PBS) prepared at 
two concentrations, with different ionic strength values:  
(A) High/optimal ionic strength PBS, recommended for SEC column by the 
manufacturer: 50 mM phosphate buffer supplemented with 50 mM NaCl at pH 6.8 
(IS = 200 mM). 
(B) Low ionic strength PBS: 10 mM PB supplemented with 25 mM NaCl at pH 
7.0 (IS = 55 mM). 
Both carrier solutions employed during this study were prepared using MilliQ water 
purified by an Elix 3 UV Water Purification System (Millipore, Billerica, USA) and 
filtered through 0.2 µm pore membrane sterile filter units (Millipore), at all times. 
The protein mixture and the BSA solution at 1.0 mg/mL (0.1%) used for this study 
were prepared as described in the Samples and Reagents section of sub-chapter 
4.1.1.2 (Chapter 4), but the dilutions were prepared in the PBS mobile phase.  
 
4.1.2.3. METHODS 
 
An amount of 40 µg of total protein (10µg of each of the following proteins: CAH, 
BSA, Ferr and Thy) was injected in the SEC column and the separations were 
performed at 0.5 mL/min flow rate at all times. 
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The HF5 methods evaluated in this chapter are similar to the “step gradient” HF5 
method described in sub-chapter 4.1.1 (Chapter 4), but modified according to the 
mobile phase ionic strength, which is a known critical parameter in FFF.  
 
The same protein amount (40 µg) was injected in the HF5 separation device during 
the focus-inject step, which was performed for 4 min at a focus flow rate of 0.85 
mL/min. The sample was focused at a distance of approximately 15% fiber length 
from the channel inlet an eluted afterwards at a channel flow rate of 0.2 mL/min. The 
cross-flow rate was reduced as the MW of the proteins increased, by placing a steep 
field gradient to reduce as much as possible the time required for the fractionation, 
while considering the optimal retention factor for each protein. The HF5 methods for 
(A) and (B) mobile phases are summarized in Table 1. 
 
 
Table 1 – HF5 flow rates timetable for the protein mix separations in high IS mobile phase (Method 
A) and low IS mobile phase (Method B) 
Channel flow rate (vc): 0.2 mL/min 
Focus flow rate (vfoc): 0.85 mL/min 
Focus – Inject duration: 3.5 min (0.5 min focus time before focus-inject step) 
Method 
vx start 
(mL/min) 
vx end 
(mL/min) 
Duration 
(min) 
A (high IS) 
0.85 0.85 17.5 
0.85 0.40 0.5 
0.40 0.40 20.5 
0.00 0.00 2.0 
Total analysis time: 42.5 min    
B (low IS) 
0.85 0.85 15.5 
0.85 0.40 0.5 
0.40 0.40 20.5 
0.00 0.00 2.0 
Total analysis time: 40.5 min    
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4.1.2.4. RESULTS AND DISCUSSION 
 
A. SEC AND HF5-UV-MALS 
 IN HIGH IONIC STRENGTH MOBILE PHASE (200 mM) 
 
The standard proteins mixture was first injected in SEC and HF5 and separated 
employing the mobile phase recommended for SEC column (IS = 200 mM). The BSA 
sample was separated by both SEC and HF5 under the same conditions as the 
protein mixture in order to check the correspondence between the retention times 
and to confirm that there are not interactions between the proteins in the mixture 
which might lead to difficulties in the peaks assignment. 
The SEC separation profiles at 280 nm of the protein mixture and the BSA sample, 
confirming the identity of the BSA peak are reported in Figure 1 (a) standard protein 
mixture and (b) BSA sample and, respectively in Figure 2 for the HF5 separations. 
 
 
Figure 1 – SEC separation profiles at 280 nm for (a) standard protein mixture and (b) BSA sample. 
BSA oligomers identification based on the retention times and order of elution 
 
Figure 1b shows that the SEC separation under optimal conditions allows the 
identification of 3 BSA oligomers. In Figure 1a, when the BSA is mixed with other 
standard proteins, only the BSA monomer and dimer are visible, while the BSA 
trimer elutes under the peak of a different species in the mixture (most probably the 
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Ferr monomer), even though the MW difference is considerable (MW 200 kDa for the 
BSA trimer vs. MW 481 kDa for the Ferr monomer). This indicates low separation 
selectivity, topic which would be discussed in the following paragraphs. 
 
 
Figure 2 – HF5 separation profiles at 280 nm for (a) standard protein mixture and (b) BSA sample. 
BSA oligomers identification based on the retention times and order of elution. The black trace 
represents the cross-flow rates variation during the separation. 
 
Figure 2b allowed the identification of 3 BSA oligomers, just as in SEC, only in 
reversed elution order. Figure 2a shows that in HF5, when the BSA is mixed with 
other proteins, the BSA trimer elutes right before the Ferr monomer. This indicates 
that the HF5 method is more selective compared to the SEC method. 
Next, SEC and HF5 were coupled online with a MALS detector for the determination 
of the absolute MW. The separation profiles, as well as the calculated MW for each 
separated peak are reported in Figure 3 (SEC) and Figure 4 (HF5). 
In both cases the peak assignment was based on the elution order and confirmed 
afterwards by the absolute MW values derived from MALS data. Both SEC and HF5 
separation profiles show the presence of 7 separated species.  
The peak identification, as well as other fundamental separation parameters 
computed by Astra® and ChemStation – with the purpose of comparing the SEC and 
HF5 performance – is reported in Table 2 for the SEC separation and Table 3 for the 
HF5 separation. 
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Figure 3 – SEC-UV-MALS elution profile of the standard protein mixture at 200 mM ionic strength. 
Rayleigh ratio at 90° represented as a thick line and UV signal at 280 nm represented as a dotted 
thin line.  
 
All SEC peaks are slightly fronted, except for the first one, which represents a 
polydisperse population of Ferr and Thy oligomers. The complete separation is 
achieved in less than 30 minutes and the efficiency, expressed as number of plates, is 
very high. The SEC separation profile shows the presence of unidentified species 
eluting between the CAH and BSA monomers, which could be attributed to 
fragments of larger proteins broken or carrier over during the separation. These 
unidentified peaks may also indicate the malfunction of the SEC column. 
 
Table 2 – SEC separation performance evaluation: separation parameters derived from data at 
optimal ionic strength (200 mM). Peak assignment in agreement with the calculated MW 
Peak 
# 
tR 
(min) 
Calculated 
MW (kDa) 
Peak 
assignment 
w1/2 
(min) 
Peak 
symmetry 
Plates 
number 
Resolution 
(Rs) 
1 11.75 >3000.0 
Thy and Ferr 
oligomers 
0.4311 5.81 4115  
2 12.06 1358.2 Thy 2mer 0.7001 0.21 1644 0.32 
3 13.27 679.4 Thy 1mer 0.6673 0.78 2189 1.04 
4 15.06 485.1 Ferr 1mer 0.6455 0.93 3016 1.61 
5 16.52 137.0 BSA 2mer 0.8954 0.73 1886 1.11 
6 18.25 68.2 BSA 1mer 0.415 0.9 10714 1.55 
7 20.62 30.1 CAH 1mer 0.4174 0.62 13523 1.0 
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Figure 4 – HF5-UV-MALS elution profile of the standard protein mixture at 200 mM ionic strength. 
Rayleigh ratio at 90° represented as a thick red line and UV signal at 280 nm represented as a dotted 
thin red line.  
 
Most HF5 peaks are symmetrical, while the others are slightly tailed. The complete 
separation is achieved in approximately 40 minutes. The HF5 efficiency, expressed as 
number of plates, is very low compared to SEC because the HF5 peaks are very 
broad (it is a known fact that the peaks in FFF are much broader compared to 
chromatographic peaks). The resolution between species is comparable to SEC. The 
HF5 separation profile does not contain unidentified species, which confirms that the 
separation is very gentle and may confirm undesired sample-column matrix 
interactions observed previously in the SEC elution profile. 
 
Table 3 – HF5 separation performance evaluation: separation parameters derived from data at SEC 
optimal ionic strength (200 mM). Peak assignment in agreement with the calculated MW 
Peak 
# 
tR 
(min) 
Calculated 
MW (kDa) 
Peak 
assignment 
w1/2 
(min) 
Peak 
symmetry 
Plates 
number 
Resolution 
(Rs) 
1 7.66 29.9 CAH 1mer 0.8736 0.85 426  
2 10.71 68.8 BSA 1mer 1.2765 0.9 390 1.66 
3 14.54 135.6 BSA 2mer 2.8455 0.72 144 1.09 
4 20.52 483.5 Ferr 1mer 1.9365 1.35 622 1.47 
5 24.8 677.2 Thy 2mer 3.2275 1.15 327 0.97 
6 27.65 1356.3 Thy 2mer 4.8566 0 179 0.41 
7 34.64 > 2000.0 
Thy and Ferr 
oligomers 
2.8656 0.96 809 1.06 
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SPECIFIC SEPARATION PARAMETERS  
FOR PERFORMANCE EVALUATION 
 
Selectivity is a fundamental parameter in analyses of mixtures, because it is important 
to avoid co-elution of species. The selectivity was calculated as the MW-based 
selectivity (SMW), defined as the slope of the log (tR) against the corresponding log 
(MW) plot, where the retention times, as well as MW values, were derived from the 
experimental data. The selectivity plots obtained at high/optimal ionic strength are 
displayed in Figure 5a for the SEC separation and 5b for the HF5 separation. 
 
 
Figure 5 – Selectivity plots obtained at 200 mM ionic strength for (a) SEC and (b) HF5. The numbers 
near the data points represent the peak numbers in their elution order. 
 
Since the HF5 separation was performed employing two different cross-flow rates 
(see Figure 2), the selectivity was calculated by dividing the separated species into 2 
groups: the ones separated at a constant cross-flow rate of 0.85 mL/min and the ones 
separated at 0.4 mL/min. 
The SEC selectivity is related to the slope of the calibration curve, meaning that SEC 
columns that are highly efficient do not necessarily provide a good resolution, unless 
the calibration curve is low enough (optimal b value: 0.1). Since the separation, 
therefore the selectivity in SEC, increases inversely to the slope value and depends 
also on the pore size of the column packing material, a slope value of b = 0.15 for the 
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SEC WTC column indicates a lower selectivity when compared to the separation of 
polystyrene standards in the same MW range, reported by [Podzimek 2011]. 
Furthermore, the SEC selectivity decreases with the MW range of the proteins 
separated on the same column (b = 0.2 for peaks 2-4). 
On the other hand, maximum selectivity achievable in Flow FFF (therefore HF5) 
varies between 0.5 – 0.7, comparable to SEC selectivity values of ~ 0.1, even though 
the SEC efficiency is much higher [Schure et al. 2000]. Flow FFF selectivity also 
depends on the sample conformation and the carrier solution employed for the 
separation and varies in the range 0.3-0.7. Generally, the FFF selectivity is higher 
than SEC selectivity [Podzimek 2011]. 
As expected, the HF5 selectivity for both small and large proteins is higher compared 
to SEC, meaning that HF5 is potentially able to detect more species. These species 
may be overlooked by SEC analysis because they co-elute with proteins with similar 
MW value. The HF5 selectivity should increase with the MW of the separated 
species, but this applies to methods which use a constant cross-flow rate during 
elution (not the case described in this study).  
The specific resolution (Rsp) is another fundamental separation parameter and was 
calculated for both SEC and HF5 separations, as well as the retention levels (RL) and 
the corresponding retention factor (k) for the SEC separations. The obtained values 
are reported in Table 4. Peak 1 (SEC) and peak 7 (HF5) were excluded from the 
calculations because they represent polydisperse populations.  
The dead volume of the SEC column was calculated as the volume of the cylinder 
with the same size characteristics and was found to be 14.33 mL. Therefore, the dead 
time (t0) at 0.5 mL/min flow rate was 28.67 min (shown in Figure 1). The t0 was 
related to the retention time through capacity factor (k) for the analytes separated by 
SEC, instead of the retention level calculated for the analytes separated by HF5. 
In HF5, the RL for the protein with the highest MW is, as expected, the highest of all 
and above the recommended value (>50) [Litzen et al. 1993, Wahlund 2013].  SEC and 
HF5 present similar specific resolution values and, except for the high MW proteins 
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and oligomers, a baseline resolution is achieved with both techniques.  
 
Table 4 – Capacity factor (SEC), retention level (HF5), specific resolution and selectivity for SEC 
and HF5 at high ionic strength, 200 mM 
Peak Species 
Calculated 
MW 
(kDa) 
t
R (min) Retention 
Specific 
resolution 
(R
sp
) 
Selectivity 
SEC  Capacity factor (k)  
2 Thy dimer 1358.2 12.06 0.58  
0.2 3 Thy monomer 679.4 13.27 0.54 3.5 
4 Ferr monomer 485.1 15.06 0.47 11.0 
5 BSA dimer 137.0 16.52 0.42 2.0 
0.15 6 BSA monomer 68.2 18.25 0.36 5.1 
7 CAH monomer 30.1 20.62 0.28 2.8 
HF5  
Retention level 
(R
L
)  
1 CAH monomer 29.9 7.66 20.2  
0.36 2 BSA monomer 68.8 10.71 28.2 4.6 
3 BSA dimer 135.6 14.54 38.3 3.7 
4 Ferr monomer 483.5 20.52 54.0 2.7 
0.27 5 Thy monomer 677.2 24.8 65.3 6.6 
6 Thy dimer 1356.3 27.65 72.8 1.4 
 
 
A net distinction in the favor of HF5 is made by selectivity; the selectivity of both 
small and large proteins (and their oligomers) is always higher for HF5. The values 
reported in Table 4 will also be discussed by comparison with the ones obtained at 
low ionic strength. 
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B. SEC AND HF5-UV-MALS 
IN LOW IONIC STRENGTH MOBILE PHASE (55 mM) 
 
Next, the standard proteins mixture was injected in SEC and HF5 and separated 
employing the low ionic strength mobile phase (IS = 55 mM). The purpose of 
employing this mobile phase during the separations was to demonstrate the 
versatility of HF5 in regard to the wide choice of carrier solutions. SEC and HF5 were 
coupled online with a MALS detector for the determination of the absolute MW. The 
separation profiles, as well as the calculated MW for each separated peak are 
reported in Figure 6 (SEC) and Figure 7 (HF5). 
 
In both cases the peak assignment was based on the elution order and confirmed 
afterwards by the absolute MW values derived from MALS data. At low ionic 
strength, both SEC and HF5 separation profiles show the presence of 7 separated 
species. The peak identification, as well as other fundamental separation parameters 
computed by Astra® and ChemStation – with the purpose of comparing the SEC and 
HF5 performance – is reported in Table 5 for the SEC separation and Table 6 for the 
HF5 separation. 
 
Figure 6 - SEC-UV-MALS elution profile of the standard protein mixture at 55 mM ionic strength. 
Rayleigh ratio at 90° represented as a thick blue line and UV signal at 280 nm represented as a 
dotted thin blue line. 
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Table 5 – SEC separation performance evaluation: separation parameters derived from data at low 
ionic strength (55 mM). Peak assignment in agreement with the calculated MW 
Peak 
# 
tR 
(min) 
Calculated 
MW (kDa) 
Peak 
assignment 
w1/2 
(min) 
Peak 
symmetry 
Plates 
number 
Resolution 
(Rs) 
1 11.44 >2000.0 
Thy and Ferr 
oligomers 
0.5854 0 2123  
2 11.80 1358.2 Thy 2mer 0.6928 0.60 1608 0.33 
3 12.78 679.4 Thy 1mer 0.7183 0.91 1755 0.82 
4 13.98 485.1 Ferr 1mer 0.6115 0.83 2898 1.06 
5 15.56 137.0 BSA 2mer 0.8243 0.67 1976 1.29 
6 17.25 68.2 BSA 1mer 0.4125 0.65 9685 1.60 
7 20.34 30.1 CAH 1mer 0.5048 0.63 9001 0.99 
 
The peaks are broader compared to the separation at optimal IS, and the consequent 
decrease in efficiency is significant for the separation of CAH, BSA and Thy 
monomers. The resolution is not compromised as much as the efficiency when the 
analysis is performed in a carrier solution with lower salt content. The presence of 
unidentified species eluting between the CAH and BSA monomers persists, as 
expected, since the purpose of a high salt content in the carrier solution is to 
prevent/minimize analyte – matrix interactions. The specific resolution of the species 
separated by SEC, as well as the capacity factor and the selectivity will be discussed 
further on.  
 
 
Figure 7 – HF5-UV-MALS elution profile of the standard protein mixture at 55 mM ionic strength. 
Rayleigh ratio at 90° represented as a thick blue line and UV signal at 280 nm represented as a 
dotted thin blue line. The black line represents the cross-flow rate trend during the separation 
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Table 6 – HF5 separation performance evaluation: separation parameters derived from data at low 
ionic strength (55 mM). Peak assignment in agreement with the calculated MW 
Peak 
# 
tR 
(min) 
Calculated 
MW (kDa) 
Peak 
assignment 
w1/2 
(min) 
Peak 
symmetry 
Plates 
number 
Resolution 
(Rs) 
1 7.48 29.9 CAH 1mer 0.9658 0.86 332  
2 10.22 68.8 BSA 1mer 1.3881 0.73 300 1.37 
3 14.13 135.6 BSA 2mer 2.9284 0.84 129 1.06 
4 17.82 483.5 Ferr 1mer 1.1939 0.73 1234 1.05 
5 21.32 677.2 Thy 2mer 2.3879 0.82 442 1.15 
6 24.27 1356.3 Thy 2mer 4.5949 0 155 0.50 
7 29.57 > 2000.0 
Thy and Ferr 
oligomers 
3.7661 0 342 0.75 
 
In HF5, the separation of 7 species at low ionic strength is achieved in less than 40 
min. The peaks become broader compared to the separation at high ionic strength 
and the separation efficiency consequently decreases. A slight decrease in resolution 
is also observed. Compared to the SEC separation at low ionic strength, the HF5 
separation profile does not show any unidentified peaks. The specific resolution of 
the species separated by HF5, as well as the retention level and the method 
selectivity will be discussed separately. 
 
SPECIFIC SEPARATION PARAMETERS 
 FOR PERFORMANCE EVALUATION 
 
The MW-based selectivity (SMW) plots obtained at low ionic strength are displayed in 
Figure 8 (a) for the SEC separation and (b) for the HF5 separation. Peak 1 (SEC) and 
peak 7 (HF5) were excluded from the calculations because they represent 
polydisperse populations (not resolved).  
The HF5 selectivity was calculated by dividing the separated species into 2 groups: 
the ones separated at a constant cross-flow rate of 0.85 mL/min and the ones 
separated at 0.4 mL/min.  
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Figure 8 – Selectivity plots obtained at 55 mM ionic strength for (a) SEC and (b) HF5. The numbers 
near the data points represent the peak numbers in their elution order. 
 
The HF5 selectivity is always higher than SEC selectivity, shown by the 
corresponding selectivity slope trends for small MW proteins (b = 0.32 in HF5, vs. b = 
0.17 in SEC), as well as for high MW proteins (b = 0.28 in HF5, vs. b = 0.16 in SEC). 
Furthermore, at low IS, the SEC selectivity slope trend does not change significantly 
between lower and higher MW proteins (b = 0.16-0.17, Table 7), as previously 
observed at high IS (b = 0.15-0.2, Table 4). 
 
The superior HF5 selectivity indicates that the HF5 method is potentially able to 
separate more species. These species may be overlooked by SEC analysis because 
they co-elute with proteins with similar MW value. Employing this “step gradient” 
method, the HF5 selectivity does not increase with the MW, as it would normally do 
at constant cross-flow rate. The HF5 selectivity for high MW proteins at low ionic 
strength is slightly higher compared to the value obtained at high ionic strength 
(Figure 8b and Figure 5b). 
 
The specific resolution (Rsp) was calculated for both SEC and HF5 separations, as well 
as the retention levels (RL) and the corresponding capacity factor (k) for the SEC 
separations and the results are reported in Table 7. 
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Table 7 – Capacity factor (SEC), retention level (HF5), specific resolution and selectivity for SEC 
and HF5 at low ionic strength, 55 mM 
Peak Species 
Calculated 
MW 
(kDa) 
t
R (min) Retention 
Specific 
resolution 
(R
sp
) 
Selectivity 
SEC  
Capacity factor 
(k) 
 
2 Thy dimer 1358.2 11.8 0.59  
0.16 3 Thy monomer 679.4 12.78 0.55 2.7 
4 Ferr monomer 485.1 13.98 0.51 7.2 
5 BSA dimer 137.0 15.56 0.46 2.3 
0.17 6 BSA monomer 68.2 17.25 0.40 5.3 
7 CAH monomer 30.1 20.34 0.29 2.8 
HF5  
Retention level 
(R
L
)  
1 CAH monomer 29.9 7.48 18.7  
0.32 2 BSA monomer 68.8 10.22 25.6 3.8 
3 BSA dimer 135.6 14.13 35.3 3.6 
4 Ferr monomer 483.5 17.82 44.6 1.9 
0.28 5 Thy monomer 677.2 21.32 53.3 7.9 
6 Thy dimer 1356.3 24.27 60.7 1.7 
 
At low ionic strength, the SEC capacity factor, k shows only a slight increase for all 
species (2-9% increase), while the retention level, RL for all species separated by HF5 
decreases (7 – 18% decrease), especially for the high MW proteins. The specific 
resolution Rsp obtained in SEC and HF5 is comparable. Even at low ionic strength, 
HF5 presents a higher selectivity when compared to SEC, for all MW in the protein 
mixture. 
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C. SAMPLE RECOVERY AT HIGH AND LOW IONIC STRENGTH 
 
While an accurate MW characterization, as well as effective separation of all existing 
species in a protein formulation is important, the sample recovery is another 
fundamental parameter worthwhile taking into consideration. If the sample 
recovery, usually determined by MALS measurements or estimating the area under 
the peak at 280 nm (or any other protein specific wavelength), is not complete (100%) 
during QA or QC protocols based on SEC, a secondary separation/characterization 
technique is required to understand the reason. 
In this study, the sample recovery was calculated by Astra® for both SEC and HF5 
separations, and investigated when employing both low and high ionic strength 
mobile phases. The results are reported in Table 8. 
 
Table 8 – Sample relative recovery in SEC and HF5 in high (200 mM) and low (55 mM) ionic 
strength mobile phase 
Species 
SEC  
200 mM 
(µg) 
SEC  
55 mM 
(µg) 
HF5  
200 mM 
(µg) 
HF5  
55 mM 
(µg) 
CAH monomer 4,59 3,98 2,99 3,04 
BSA monomer 6,59 7,06 11,09 9,47 
BSA dimer 2,84 2,27 1,78 1,32 
Ferr monomer 13,39 14,78 15,28 12,34 
Thy monomer 6,39 6,62 6,58 6,09 
Thy dimer 3,34 2,35 1,94 1,52 
Total sample recovery (µg) 37,14 37,06 39,66 33,78 
Total sample recovery (%) 94.3 94.1 99.3 87.6 
 
First of all, it can be noted that the proteins proportion is no longer in balance 
(1:1:1:1), shown by both SEC and HF5 results. However, since the total recovered 
protein is close to the injected amount (40 µg), it may indicate the lack of sample 
homogeneity during injection. 
The SEC results indicate that, in this study, the recovered protein amount was not 
affected by the change in the salt composition of the mobile phase, as it would be 
Chapter 4, Part 1, 4.1.2: HF5-MALS and SEC-MALS performance comparison (standard protein mixture) 
132 
 
expected. It is a known fact that SEC requires a high salt content to supress sample-
matrix interactions which lead to loss of sample during the separation. However, 
even under high/optimal ionic strength conditions, SEC does not offer a complete 
recovery for all proteins. 
The highest recovery is observed when HF5 is performed in high ionic strength 
mobile phase. When the ionic strength is decreased in HF5, it is followed by a 
decrease in sample recovery, suggesting the presence of non-specific interactions 
between the proteins and the separation device. The ionic strength in HF5 is as 
important as it is in SEC when the sample recovery is at stake. 
 
4.1.2.5. CONCLUSIONS 
 
The scale-up of the HF5 separation device allowed a rather high sample amount 
(40µg) to be separated, detected reliably and, most importantly, recovered. 
While the separation efficiency is always higher for SEC thanks to the reduced band 
broadening, the resolution (Rs and Rsp) of SEC and HF5 is comparable and selectivity 
is always higher in HF5.  
However, as suggested by [Zölls et al. 2012], the comparison between results 
obtained employing techniques which are based on different principles should be 
done looking for data trends instead on focusing on numbers.  
In fact, this study shows that the SEC selectivity trend, even under optimal 
conditions (recommended by the column manufacturer), is lower than previously 
reported by [Podzimek 2011] on polystyrene standards with MWs in the same range 
(b = 0.13 – 0.14 for the protein mix in this study vs. b = 0.09 for the polystyrene 
standards, much closer to the optimal value of 0.1).  
The selectivity in HF5, on the other hand, displays an opposite trend, meaning that 
the slope values are higher than reported by [Podzimek 2011], on the polystyrene 
standards mentioned before (b = 0.27 – 0.28 for the protein mixture in this study vs. b 
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= 0.2 for the polystyrene standards). 
This is an appealing (HF5) feature for the separation of complex protein samples, 
because it allows the detection and quantification of species that otherwise would be 
overlooked. It was shown that, in SEC, the co-elution of species is very common, 
even if the MW difference between the separated species is considerable. The 
possibility to use mobile phases at low ionic strength is another appealing possibility, 
even though reducing the salt concentration should be considered carefully due to its 
correlation with sample recovery. 
Even if SEC compensates with higher efficiency, it does not earn any extra points if 
the species are co-eluting. A second SEC column with a different porosity may be 
coupled online with the first one, in order to ensure the required selectivity. 
However, placing a second SEC column, in series with the first one, could 
compromise further the sample recovery. 
The SEC sample recovery is incomplete, but still high and it does not change 
significantly upon ionic strength variation, indicating the robustness of the 
separation device. 
The highest sample recovery is obtained when the separation is performed in HF5 in 
high ionic strength carrier solution, and a direct correlation between the recovered 
sample amount and the ionic strength is shown. 
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4.1.3. FREEZE-THAW INDUCED ANTIBODY SELF-
ASSOCIATION MONITORING BY HF5 – UV AND 
MALS CHARACTERIZATION 
 
 
 
 
In this sub-chapter, the reversible self-association between antibody monomers was 
observed and monitored over time by HF5 and UV detection. The possible causes for 
this aggregation phenomenon were identified as freeze/thaw stress on the antibody, 
as well as sample dilution (previous to separation by HF5) in a buffer with a different 
composition than the formulation buffer.  
One of the main concerns in therapeutic proteins quality control (QC) and quality 
assurance (QA) is represented by the possible changes that the protein composition 
may undergo upon sample dilution, especially if the dilution is not performed in the 
formulation buffer. If the QC tests employ flow-based methods (either SEC or FFF), 
sample dilution is inevitable during the separation and is often required even before 
the separation [Arakawa et al. 2010]. 
In FFF, the sample concentration changes drastically during a normal separation 
because first, the sample needs to be focused (concentrated in a narrow band) and 
afterwards, the sample is inevitably diluted during elution. Upon dilution, and 
especially when the dilution is performed in a buffer different from the formulation 
buffer (which is usually the case), weakly-bound and/or associated protein species 
with rapid association/dissociation conversion rates, are likely to be disrupted [Philo 
2006, Arakawa et al. 2010, Engelsman et al. 2011].  
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In this study, the sample dilution was controlled to some extent during elution by 
adjusting the flow rates and employing a miniaturized separation device (HF5). Since 
the dissociation occurred very slowly compared to the duration of the separation, the 
self-associated protein system behaved like a true mixture, therefore individual 
oligomers could be resolved. Such reversible, but extremely slow 
association/dissociation reactions, responsible for the existence of so-called 
“metastable oligomers”, are rather common [Philo 2006, Philo and Arakawa 2009] and, 
due to their reversible nature, pose less threat from the immunogenic point of view. 
HF5 coupled with UV detection (absorption wavelength of the peptide bond, 215 
nm) proved to be rather sensitive in detecting changes in the sample composition, 
which occurred faster at first and experienced a deceleration over time. 
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4.1.3.1. INSTRUMENTAL SETUP 
 
HF5 analyses were performed using an Agilent 1200 HPLC system (Agilent 
Technologies, Santa Clara, CA, USA) consisting in a degasser, an isocratic pump, an 
auto sampler and a variable wavelength UV detector, combined with an Eclipse® 
DUALTEC prototype separation system (Wyatt Technology Europe, Dernbach, 
Germany). The ChemStation version B.04.02 (Agilent Technologies) data system for 
Agilent instrumentation was used to set and control the instrumentation and for the 
computation of various separation parameters. The software package Wyatt Eclipse 
@ ChemStation version 3.5.02 (Wyatt Technology Europe) was used to set and 
control the FFF separation system. An Agilent 1100 UV-Vis variable wavelength 
detector operating at a wavelength of 215 nm was used as a concentration detector at 
all times. 
An 18-angle MALS detector model DAWN® HELEOSTM light scattering detector 
(Wyatt Technology Corporation, Santa Barbara, CA, USA), employing a laser 
operating at a wavelength of 658 nm, was used in all experiments.  
ASTRA® software version 5.3.2.14 (Wyatt Technology Corporation) was used to 
handle signals from the detectors (MALS and UV) and to compute the proteins MW 
and concentration values. The hollow fiber was 17 cm long a polyether-sulfone (PES) 
fiber, type FUS 0181 available from Microdyn-Nadir (Wiesbaden, Germany) with the 
following characteristics according to the manufacturer: 0.8mm ID, 1.3mm OD and a 
molecular weight cut-off of 10 kDa corresponding to an average pore size of 5 nm. 
 
4.1.3.2. SAMPLES AND REAGENTS 
 
The mobile phase was 10 mM phosphate buffer supplemented with 25 mM NaCl, at 
a final pH of 7.2 (total ionic strength: 55 mM), prepared using MilliQ water purified 
by an Elix 3 UV Water Purification System (Millipore, Billerica, USA) and filtered 
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through 0.2 µm pore membrane sterile filter units (Millipore). 
The sample used in the study was an IgG1 type antibody, for simplicity named 
mAb1. The sample was diluted 1:100 in the mobile phase, at a final concentration of 
0.385 mg/mL and divided in two aliquots: Vial §1 and Vial §2. Vial §1 was used for 
analyses immediately after the sample dilution, while Vial §2 was stored at -20°C and 
thawed before the analyses. Both vials were stored at room temperature during the 
working days and at 4°C during the night and/or over the week-end.     
 
4.1.3.3. METHODS 
 
An amount of 2 µg of mAb1 (5.2 µL) was injected at all times, unless otherwise 
specified. The mAb1 sample was injected in the HF5 separation device during the 
focus-inject step, which was performed at a focus flow rate of 0.85 mL/min for 4 min. 
The sample was focused at a distance of approximately 15% fiber length from the 
channel inlet an eluted afterwards at a channel flow rate of 0.35 mL/min under the 
effect of a constant cross-flow rate of 0.35 mL/min.  
The separation was monitored by UV detection at 215 nm and, when specified, by a 
multi-angle scattering detector. The sample was injected at different time intervals 
and the oligomers distribution was observed. 
 
4.1.3.4. RESULTS AND DISCUSSION 
 
The purpose of the study presented in this sub-chapter was to observe by HF5-UV 
the changes that occur in therapeutic protein samples due to dilution, handling and 
different storage conditions.  
First, 2 µg of mAb1, taken from Vial §1, were injected and separated by HF5. The 
separation was repeated after 6 hours and after 3 days since the first injection. The 
separation profiles are reported in Figure 1. 
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Figure 1 – HF5-UV separation profiles at 215 nm of mAb1 in Vial §1 
 
Figure 1 shows the elution of two species, most likely mAb1 monomer and dimer. 
Even though the sample was diluted 1:100 in a buffer different than the formulation 
buffer, the composition of mAb1 in Vial §1 is stable over time. It is very likely that 
the phosphate buffer employed as carrier solution, as well as dispersion media, 
stabilizes mAb1. The retention times shift slightly, but this change is very likely due 
to the hollow fiber usage. 
Table 1 reports the exact composition of the sample immediately after dilution, after 
6h and 3 days after dilution and overnight storage at 4°C. 
 
Table 1 – mAb1 composition in Vial §1 at different time intervals 
Time point Peak 1 (%) Peak 2 (%) 
t0 97.95 2.05 
6h 97.76 2.24 
3 days 97.48 2.52 
 
Based on the retention time value, it was assumed that the first peak corresponded to 
the mAb1 monomer and the second to the dimer. Their amounts, which are reported 
in Table 1, confirm the fact that the sample composition did not change significantly 
over time. The monomer amount decreases slightly over time, suggesting the 
presence of mAb1 species which self-associate very slowly into dimer. 
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Next, the stability of mAb1 in Vial §2 was monitored. After dilution, Vial §2 was 
stored at -20°C to avoid mAb1 composition changes, while the study on Vial §1 was 
conducted immediately after the sample dilution. The same amount of mAb1 (2 µg), 
taken from Vial §2, was injected and separated by HF5 at all times. The separation 
was repeated after 6 hours and after 3 days since the first injection. The separation 
profiles are reported in Figure 2. 
 
 
Figure 2 – HF5 separation profiles at 215 nm of mAb1 in Vial §2 
 
Figure 2 shows the elution of two additional mAb1 species (four species in total), 
whose amounts vary greatly over time. It is very likely that peak 1 corresponds to the 
monomer and the following peaks (2 – 4) correspond to mAb1 oligomers. The exact 
sample composition is reported in Table 2. 
 
Table 2 – mAb1 composition in Vial §2 at different time intervals 
Time point Peak 1 (%) Peak 2 (%) Peak 3 (%) Peak 4 (%) 
t0 63.20 25.32 8.80 2.58 
6h 77.89 17.22 3.66 1.21 
3 days 93.98 5.75 0.25 - 
7 days 97.93 2.07 - - 
 
The mAb1 oligomers amounts reported in Table 2 show the increase of monomer 
amount over time at the expense of larger oligomers. This situation is opposite to the 
one observed for mAb1 in Vial §1. After only 6h, approximately 50% of all larger 
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oligomers have spontaneously dissociated into monomeric units.  
The mAb1 oligomers distribution in Vial §2 was assessed after one week (7 days) and 
the elution profiles are reported in Figure 3. The distribution of mAb1 species in Vial 
§2 after 7 days is very similar to the one reported for Vial §1 at t0 (Table 2).  
 
 
Figure 3 – HF5 separation profiles at 215 nm of mAb1 in Vial §2 immediately after dilution and 
after 7 days 
 
Figure 3 and the values reported in Table 2 suggest that mAb1 in Vial §2 reaches the 
species distribution of mAb1 in Vial §1 at t0 after a week. It is expected that, from this 
point forward, the oligomers distribution of mAb1 in Vial §2 will follow the trend 
which was observed for Vial §1. 
These findings suggest that mAb1 in Vial §2 experiences two aggregation 
phenomena. The first is depicted in Figure 2, showing the monomer in dynamic 
equilibrium with its larger oligomers. The mAb1 oligomers, which are self-
assemblies of the monomer, slowly dissociate into monomer over approximately 3 
days. The second aggregation phenomenon is the exact opposite, seen for mAb1 in 
Vial §1 in Figure 1, which is the slow self-association of monomeric units into larger 
assemblies.  
The self-association phenomenon was investigated by coupling the FFF separation 
system with a DAWN HELEOS multi-angle light scattering detector. The absolute 
MW values of mAb1 oligomeric species in both Vial §1 and Vial §2 are reported in 
Figure 4.  
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Figure 4 – HF5-MALS elution profiles of mAb1 in Vial §1 and Vial §2 at t0 
 
Figures 4a confirms the monomer assignment to the first peak, but the MW of the 
second peak does not correspond to the dimer. In fact, peak 2 appears to correspond 
to very high MW species (2×106 – 5×106 g/mol) that are present at trace levels and are 
very compact as size, since they elute very close to the monomer. Figure 4b, on the 
other hand, shows that mAb1 contains different levels of monomer (peak 1), dimer 
(peak 2), trimer and tetramer (peak 3). Therefore, it is very likely that peak 4 (which 
is shown in Figures 2 and 3) corresponds to high MW aggregates, whose MW could 
not be determined during the separations reported in Figure 4a. These HMW 
aggregates found in Vial §2 are larger in size than the ones found to co-exist with the 
monomer in Vial §1, since they elute later than the trimer or tetramer of mAb1. 
 
Finally, increasing amounts of mAb1 from Vial §2 were separated by HF5-UV in 
order to determine the sample overloading limit, which is topic closely related to the 
sample dilution requirement. Since the HF5 cartridge is a miniaturized device, the 
protein amount which can be injected into the channel and separated under optimal 
conditions without the risk of overcrowding is limited by the hollow fiber’s internal 
area (4.27 cm2) and/or the internal volume (85 µL).  
Figure 5 reports the separation profiles of increasing amounts of mAb1 from Vial §2, 
which were separated subsequently and under identical experimental conditions.   
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Figure 5 – HF5 separation profiles at 215 nm of different amounts (0.5 – 10.0) of mAb1 from Vial §2 
 
The enlarged view of the baseline for 0.5 µg of mAb1 (Figure 5, far right graph) 
shows that, when coupled with UV detection at 215 nm, HF5 is very sensitive in 
detecting and quantifying very low amounts of mAb1 aggregates. The trimer and 
tetramer amount below peak 3 represent roughly 44 ng of mAb1 (8.8% of the sample 
at t0). Since its detection and quantitation limit appear to be very low, there is no 
need for large amounts of sample, which are usually required for data 
reproducibility for batch release or sample complete workup.  
Figure 6 reports the separation profiles of even higher amounts of mAb1 from Vial 
§2, separated subsequently and under identical experimental conditions. 
 
 
Figure 6 - Separation profiles at 215 nm of different amounts (10.0 – 15.0) of mAb1 from Vial §2 
 
As expected, when the injected amount exceeds the overloading limit, not only the 
separation is no longer achieved properly because there is not enough physical space 
for the sample to relax properly during the focus step (at 15 µg, the peaks appear as 
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if they were “split”), but also the larger peaks actually cover below their tail smaller 
peaks, corresponding to species which are less abundant. For mAb1, the overloading 
limit appears to be around 10 µg. This amount should be sufficient for the MALS 
detector to provide reliable MW values for the species separated by HF5. 
 
4.1.3.5. CONCLUSIONS 
 
The HF5 true potential resides in the detection sensibility, especially when coupled 
with detection techniques which are intrinsically sensitive (such as UV absorption of 
the protein peptide bond at 215 nm or multi-angle light scattering), therefore it does 
not require large sample amounts to provide reliable results. 
However, a detection method which is too sensitive (like MALS) has its downsides, 
such as being also very sensitive to large-sized particles, without having the ability to 
discriminate between protein particles and impurities like dust particles [Zölls et al. 
2012].  
This is where hyphenated techniques come to the rescue. By online coupling a 
separation technique such as HF5, which brings its own miniaturization advantages, 
with a specific sample property (such as protein specific UV absorption and/or 
fluorescence emission), the analytical information provided by the MALS detector is 
enhanced. In the absence of specific UV signal, MALS cannot provide information 
regarding the nature of the sample or its absolute MW, even though it can provide 
accurate information about the size regardless of the nature of the sample. 
In this study was shown how HF5-UV can be employed to monitor antibody 
composition following dilution, how the freeze/thaw process – following sample 
dilution – induced dynamic aggregation (probably facilitated by the reduced volume 
of the sample when in frozen state) and how, once the sample was thawed, HF5-UV 
was able to monitor the slow dissociation into antibody monomeric units.  
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“LESS IS MORE” 
It is also shown that, when coupled with intrinsically sensitive detection methods 
(UV at 215 nm and MALS), HF5 reduces considerably the need for large sample 
amounts in order to detect the presence and quantify trace amounts of antibody 
aggregates. Moreover, if the sample amount exceeds certain limits (overloading 
limit), not only has a negative impact on the separation process, but even impedes 
the detection of low abundant species. 
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4.1.4. CARRIER SOLUTION SCREENING EXPLORATORY 
STUDY BY HF5-UV: 
INFLUENCE OF PH, SALT TYPE AND CONCENTRATION, IONIC 
STRENGTH AND BUFFERING AGENT ON THE 
IMMUNOGLOBULINS (IgGS) STABILITY DURING SEPARATION 
 
 
 
 
 
In this sub-chapter, the influence of parameters like pH, buffering agent and 
concentration, salt type and concentration, as well as carrier solution ionic strength 
(IS) on the stability of antibodies (immunoglobulins, IgGs) during their separation by 
HF5 was monitored by UV detection.  
The same parameters which impact greatly on the antibody stability also play a 
major role during the HF5 separation. For instance, the ionic strength value of the 
carrier solution influences the protein interactions during separation, shielding the 
proteins by charge and the same role (shield by charge) is played by the solution pH 
and the salt concentration.  
A universal buffer cannot be employed for all antibodies, since their structure varies 
substantially (hence their specific biological function), an optimal buffer for one 
antibody may be harmful to another. The same effect was observed when the salt 
type is changed (from NaCl to MgCl2). 
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Furthermore, the HF5 versatility in terms of carrier solution composition is shown, as 
well as the wide pH range (allowed by the PES hollow fibers) of carrier solutions that 
can be employed for the separation. The study also shows how the carrier solution 
components specific absorption can interfere with detection (in this study, the 
phosphate buffer absorption interfered with the detection of antibody degradation 
products/fragments, buy may also interfere with the detection of antibody 
aggregates), therefore need to be considered carefully.  
The phenomenon of nonspecific protein adsobtion to the hollow fiber inner wall leading 
to incomplete recovery, abnormal elution position, loss of peak symmetry and poor 
resolution is an issue which HF5 (FFF) and SEC have in common. The sample 
interaction with the column matrix is a known SEC limitation. In this study, this 
issue was addressed by performing a series of injections of the same sample (make-up 
runs) in order to improve sample recovery. This is a common practice in SEC and 
recommended by SEC columns manufacturers, therefore was adopted in HF5 as 
well.  
Finally, two mobile phases, with a composition similar to the antibody formulation 
buffer were employed during the HF5 separation. Nonetheless, even though the 
sample stability may be maintained, it appears that the low ionic strength leads to 
poor separation performance, as well as compromised sample recovery (even after 
make-up runs), therefore not optimal for sample characterization. 
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4.1.4.1. INSTRUMENTAL SETUP 
 
HF5 analyses were performed using an Agilent 1200 HPLC system (Agilent 
Technologies, Santa Clara, CA, USA) consisting in a degasser, an isocratic pump, an 
auto sampler and a variable wavelength UV detector, combined with an Eclipse® 
DUALTEC prototype separation system (Wyatt Technology Europe, Dernbach, 
Germany). The ChemStation version B.04.02 (Agilent Technologies) data system for 
Agilent instrumentation was used to set and control the instrumentation and for the 
computation of various separation parameters. The software package Wyatt Eclipse 
@ ChemStation version 3.5.02 (Wyatt Technology Europe) was used to set and 
control the FFF separation system. An Agilent 1100 UV/Vis variable wavelength 
detector operating at a wavelength of 280 nm was used as a concentration detector at 
all times. 
The hollow-fiber was a 17 cm long polyether-sulfone (PES) fiber, type FUS 0181 
available from Microdyn-Nadir (Wiesbaden, Germany) with the following 
characteristics according to the manufacturer: 0.8 mm ID, 1.3 mm OD and a 
molecular weight cut-off of 10 kDa corresponding to an average pore size of 5 nm. 
 
4.1.4.2. SAMPLES AND REAGENTS 
 
The reagents required to prepare the carrier solutions/mobile phases were supplied 
by Sigma and are reported in Table 1. All carrier solutions were prepared according 
to the schematic reported in Figure 1, using MilliQ water purified by an Elix 3 UV 
Water Purification System (Millipore, Billerica, USA) and filtered through 0.2 µm 
pore membrane sterile filter units (Millipore), at all times. 
The samples used in the study were three IgG1 type monoclonal antibodies, for 
simplicity named mAb1, mAb2 and mAb3. All the available information regarding 
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the antibodies is reported in Table 2. The sample aliquots were stored at room 
temperature during the working days and at 4°C during the night and/or over the 
week-end.     
Table 1 – Reagents used for the preparation of the mobile phases 
Reagent Buffer type Product code from Sigma 
Na2HPO4 · 2 H2O 
Phosphate buffer 
342483 
NaH2PO4 · 2 H2O S5136 
Na citrate 
Citrate buffer 
W302600 
Citric acid C0759 
NaCl - S5886 
MgCl2 - M2393 
 
Table 2 – Available information regarding the monoclonal antibodies (mAbs) used in this study 
Antibody 
short name 
IgG isotype pI 
MW 
(kDa) 
Initial concentration (mg/mL) 
mAb1 IgG1 8.73 142.2 38.5, in ammonium acetate, pH 5.0 
mAb2 IgG1 N/A 150.0 2.0, formulation N/A 
mAb3 IgG1 8.25 144.2 40.0, in phosphate/citrate buffer, pH 5.0 
 
 
Figure 1 – Carrier solutions preparation (a) phosphate buffer; (b) citrate buffer and (c) 
phosphate/citrate buffer similar to the formulation buffer for mAb3 
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4.1.4.3. METHODS 
 
The same amount of each mAb was injected at all times (2 µg of mAb1 and mAb2 
and 0.6 µg of mAb3), unless otherwise specified. The samples were injected in the 
HF5 separation device during the focus-inject step, which was performed at a focus 
flow rate of 0.85 mL/min for 4 min. The sample was focused at a distance of 
approximately 15% fiber length from the channel inlet an eluted afterwards at a 
channel flow rate of 0.35 mL/min under the effect of a constant cross-flow rate of 0.35 
mL/min.  The separation process was monitored by UV detection at 280 nm 
 
4.1.4.4. RESULTS AND DISCUSSION 
 
The factors which induce aggregation in therapeutic protein formulations were 
divided in: (a) sample variables (sample concentration) and (b) carrier solution/buffer 
variables. In the latter category we included: solution pH, buffer composition, 
solution ionic strength, salt type and salt concentration.  
Once the carrier solution variables were identified, their influence on the antibody 
stability and/or HF5 separation performance was observed under different 
experimental conditions, reported in Figure 1. The carrier solution variables that 
were taken into consideration are summarized in Table 3. One parameter was 
changed at a time, while all the others remained constant.  
Two buffer types were used in this study: phosphate buffer, which operates between 
a pH value of 5.7 and 8.0 and citrate buffer, which operates in the pH range between 
3.0 and 6.2 [Dawson et al. 1986, www.sigmaaldrich.com 2014]. A third buffer, which 
consisted in a mixture containing both phosphate and citrate buffers (whose 
composition was very similar to the mAb3 formulation buffer), was employed as 
carrier solution as well.  
Two salts were employed in the study: NaCl and MgCl2, both chaotropic agents 
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(protein stabilizers) according to the Hofmeister series, which divides tested 
reagents/substances into protein denaturants and protein stabilizers, according to the 
same principle on which protein salting in/salting out is based. NaCl was also used 
to adjust the mobile phase ionic strength, which has a known impact on the FFF 
separation performance, as well as on protein stability. 
The solution pH is another parameter that has a great impact on protein stability and 
therefore on FFF performance of protein samples. The pH extreme values (4.9 and 
10.5) were chosen below and above the reliable pH buffering range of the phosphate 
buffer, avoiding the proximity to the pI of IgGs, which is approximately 7.3 ± 1.2. 
Considering that no acids/bases were added to the mobile phase during the 
separations, the buffers maintained their set pH, although sometimes outside their 
operating range. 
 
Table 3 – Carrier solution variables and values employed in this study 
# Variable Values Buffer type Constant parameters 
1 pH 
4.9 
6.9 
10.5 
Phosphate 
Buffer composition (50 mM) 
Buffer salt: NaCl (150 mM) 
Solution ionic strength (300 mM) 
2 Salt I 
NaCl 
MgCl2 
Phosphate 
Buffer composition (50 mM) 
Solution ionic strength (300 mM) 
pH: 4.9 
3 Ionic strength I 
150 mM (A) 
75 mM (B) 
150 mM (C) 
300 mM (D) 
350 mM (E) 
Phosphate 
Buffer type 
Buffer salt: NaCl 
pH: 6.9 
4 Ionic strength II 
150 mM (F) 
150 mM (G) 
300 mM (H) 
350 mM (I) 
Citrate 
Buffer type 
Buffer salt: NaCl 
pH: 4.9 
5 Salt II 
NaCl 
MgCl2 
Citrate 
Buffer composition, 50 mM 
Solution ionic strength, 300 mM 
pH: 4.2 
6 Ionic strength III 
141 mM (J) 
216 mM (K) 
Phosphate / 
citrate 
Formulation 
Buffer salt: NaCl 
pH: 4.9 
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A. CARRIER SOLUTION PH VALUE – PHOSPHATE BUFFER 
 
The first carrier solution variable observed during this study was the pH value. To 
this purpose, three phosphate buffer solutions were prepared (Figure 1a), each one at 
a different pH, by adjusting the salts concentration (the ratio between the amounts of 
Na2HPO4 · 2 H2O and NaH2PO4 · 2 H2O) in order to meet as much as possible the 
desired final pH value. The final pH adjustment (to 4.9, 6.9 and 10.5) was performed 
by adding concentrated HCl or NaOH. 
Once the carrier solutions were prepared and the HF5-HPLC system was 
“conditioned” by fluxing the chosen carrier solution through the separation-detection 
system until the UV baseline was stable, a series of blank injections were performed. 
Their purpose was to establish the UV baseline variations during a normal HF5 run.  
It is a known fact that the phosphate buffer has a specific absorption in the UV range 
if its concentration exceeds a certain value [Aitken and Learmonth 2002] (sub-chapter 
3.2.1.1). Furthermore, the UV signal responds to pressure changes in the system that 
usually occur during a normal FFF run. The blank injections performed in phosphate 
buffer carrier solutions are reported in Figure 2. 
 
Figure 2 – Blank injections performed in phosphate buffer carrier solutions at different pH 
 
The blank runs reported in Figure 2 show that higher pH values (6.9 and 10.5) of the 
phosphate buffer have a significant impact on the UV baseline, especially 
immediately after the elution step begins, which represents the chromatographic 
Chapter 4, Part 1, 4.1.4. Carrier solution screening exploratory study by HF5-UV and IgGs stability 
155 
 
space for the elution of small proteins and/or protein fragments. A UV signal 
variation in this region could impede the detection of mAb fragments or degradation 
products. 
In order to verify if the above statement applies to mAb1, mAb2 and mAb3, each of 
them (2 µg of mAb1 and mAb2 and 0.6 µg of mAb3) was separated by HF5-UV and 
the elution profiles are reported in Figure 3, 4 and 5. 
 
 
Figure 3 – HF5 separation profiles of mAb1 at 280 nm in phosphate buffer solutions at different pH 
values. The false baseline signal marked with “F”, possible mAb1 fragments marked as “f” 
 
Figure 3 shows the presence of three species corresponding to mAb1, detected by UV 
at 280 nm. The mAb1 monomer is the predominant species and its peak partly covers 
the aggregates peak (peak 2). At pH 4.9, peak 2 is not even visible, but it is the only 
experimental condition which allows the detection of species eluting before the 
monomer (“f”, very likely mAb1 fragments/degradation products). At pH 6.9 and 
10.5, the UV baseline false peak “F” impedes the detection of mAb1 fragments. 
 
Figure 4 – HF5 separation profiles of mAb2 at 280 nm in phosphate buffer solutions at different pH 
values. The false baseline signal marked with “F”, possible mAb1 fragments marked as “f” 
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Figure 4 shows the elution profiles of mAb2, which are similar to the ones observed 
for mAb1. Just as for mAb1, at pH 4.9, peak 2 is not even visible, but it is the only 
experimental condition which allows the detection of species eluting before the 
monomer because, at higher pH values, the UV baseline false peak “F” impedes the 
detection of mAb1 fragments “f”. 
 
Figure 5 – HF5 separation profiles of mAb3 at 280 nm in phosphate buffer solutions at different pH 
values. The false baseline signal is marked with “F” 
Finally, Figure 5 shows the elution profiles corresponding to mAb3 under different 
experimental conditions. The UV signal at 280 nm does not detect the presence of 
fragments eluting before the monomer in any of them.  Even though the mAb3 
sample amount was the same in every experimental condition, the elution profile at 
pH 6.9 shows a sample overloading effect consisting in a broad and tailed monomer 
peak, with delayed retention time. This result indicates that the separation in 
phosphate buffer at this pH value is not suitable. It is very likely that mAb3 is 
unstable and interacts (non-specifically) with the hollow fiber. 
Peak 2, corresponding to mAb3 aggregates, is detected only at low and high pH. 
Under these experimental conditions the peaks are symmetrical and the highest 
sample recovery is obtained at high pH. 
 
These experiments have shown how the pH of the carrier solution influences the antibody 
stability in a very short time (equal to the duration of the HF5 run) and how the instability of 
an antibody leads to poor/lack of separation and/or interactions with the separation device. 
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Moreover, the results indicate a correlation between the phosphate buffer pH and the 
phosphate UV absorption. This specific absorption impedes the detection of antibody 
fragments/degradation products. 
 
B. CARRIER SOLUTION SALT (I) – PHOSPHATE BUFFER 
 
Next, the salt type was considered as variable and the two salts chosen for this study 
were NaCl and MgCl2. To this purpose, a phosphate buffer solution was prepared at 
pH 4.9 (Figure 1a) and divided in two containers which were supplemented with the 
necessary amount of each salt in order to reach a final solution ionic strength of 300 
mM. A concentration of 150 mM of NaCl added the same ionic strength to the final 
mobile phase as 50 mM MgCl2. The final pH adjustment to the desired values (4.9, 6.9 
and 10.5) was performed by adding concentrated HCl or NaOH. 
As soon as the system was “conditioned”, a series of blank injections were performed 
in order to check the UV baseline for variations caused by pressure changes. Since, in 
this case, there were no UV false peaks; each mAb (2 µg of mAb1 and mAb2 and 0.6 
µg of mAb3) was separated under both experimental conditions. The elution profiles 
are reported in Figures 6, 7 and 8. 
 
 
Figure 6 – HF5 separation profile of mAb1 and blank injection at 280 nm in phosphate buffer 
solutions supplemented with different salts. The mAb1 fragments are marked as “f” 
 
The separation profiles of mAb1 at 280 nm reported in Figure 6 show the elution of 3 
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peaks, corresponding to mAb1 fragments, monomer and aggregates. Since the 
monomer is the dominant species, its peak partly covers the aggregates peak. The 
sample recovery is slightly higher when NaCl is added to the phosphate buffer and 
the separation performance improves, the band broadening is reduced and the 
monomer symmetry is closer to a Gaussian peak.   
 
 
Figure 7 – HF5 separation profiles of mAb2 and blank injection at 280 nm in phosphate buffer 
solutions supplemented with different salts. The mAb2 fragments are marked as “f” 
 
The separation profiles of mAb2 reported in Figure 7 are very similar to the ones of 
mAb1 in Figure 6: the aggregates peak (peak 2) is separated better when MgCl2 is 
added to the carrier solution, but at the expense of sample recovery, peak symmetry 
and band broadening (separation efficiency).  
 
 
Figure 8 – HF5 separation of mAb3 and blank injection at 280 nm in phosphate buffer solutions 
supplemented with different salts. 
 
The separation profiles of mAb3 reported in Figure 8 show the presence of two 
eluting species: mAb3 monomer and aggregates. The resolution between species is 
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improved visibly when MgCl2 is added to the mobile phase and the sample recovery 
remains constant. There are no significant differences in terms of peak symmetry or 
band broadening. 
 
These experiments have shown the importance of choosing the appropriate salt to be added to 
the carrier solution. The purpose of supplementing the buffer/mobile phase with salt is to 
improve sample recovery.  The ions in solution (in this study, [Na+] + [Cl-] and [Mg2+] + 2[Cl-
]) surround the protein surface and create an electrostatic shield which suppresses protein 
interactions (protein-protein or protein-separation device interactions). While the separation 
of mAb1 and mAb2 is improved in carrier solution containing NaCl, the same effect is 
observed for mAb3 when adding MgCl2.  
 
C. CARRIER SOLUTION IONIC STRENGTH (I) – PHOSPHATE BUFFER 
 
The third variable considered for this study was the ionic strength of the carrier 
solution. To this purpose, different phosphate buffer solutions at pH 6.9 were 
prepared from a stock solution of 50 mM phosphate buffer supplemented with 150 
mM NaCl (IS 300 mM) that was subsequently diluted 1:2 (IS 150 mM) and 1:4 (IS 75 
mM). Part of the phosphate buffer solution was left as such (without NaCl 
supplement, IS 150 mM). The exact composition of the carrier solutions is reported in 
Table 4. 
Table 4 – Composition of phosphate buffer carrier solutions of different ionic strength (pH 6.9) 
Carrier Composition Ionic strength (mM) 
A 50 mM phosphate buffer 150 
B 50 mM phosphate buffer + 150 mM NaCl 300 
C 25 mM phosphate buffer + 75 mM NaCl 150 
D 12.5 mM phosphate buffer + 37.5 mM NaCl 75 
E 50 mM phosphate buffer + 200 mM NaCl 350 
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A series of blank injections was performed under each experimental condition to 
monitor the behavior of the UV baseline in response to the increasing ionic strength 
(NaCl amount) and the results are reported in Figure 9. 
 
 
Figure 9 – Blank injections at 280 nm in phosphate buffer solutions with increasing ionic strength. 
 
Figure 9 shows how the UV baseline suffers variations as the ionic strength of the 
mobile phase in increased, a situation which is similar to the one observed when the 
pH was varied (Figure 2). 
Next, an amount of 2 µg of mAb2 was separated by HF5-UV employing phosphate 
buffer carrier solutions B, C and D (Table 4) and the elution profiles are reported in 
Figure 10. 
 
Figure 10 – HF5 separation profiles of mAb2 and blank injection at 280 nm in phosphate buffer 
solutions of different ionic strength (pH 6.9). The false UV baseline signal is marked with “F” 
 
Figure 10 shows how the separation worsens as the ionic strength is decreased (B > C 
> D), not only the mAb2 fragments are completely covered by the false peak “F”, but 
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mAb2 starts interacting with the separation device when carrier D is employed (the 
monomer peak is a broad and highly tailed). 
 
D. CARRIER SOLUTION IONIC STRENGTH (II) – CITRATE BUFFER 
 
In order to determine whether the UV signal variations (that impede the detection of 
mAb2 fragments) could be avoided, a different type of buffer (citrate buffer) was 
employed as carrier solution for the separation of the antibodies. Four citrate buffer 
solutions were prepared at different ionic strength values according to the scheme in 
Figure 1b, at pH 4.9 and their exact composition is reported in Table 5.  
 
Table 5 – Composition of citrate buffer carrier solutions of different ionic strength (pH 4.9) 
Carrier Composition Ionic strength (mM) 
F 50 mM citrate buffer 150 
G 25 mM citrate buffer + 75 mM NaCl  150 
H 50 mM citrate buffer + 150 mM NaCl 300 
I 50 mM citrate buffer + 200 mM NaCl 350 
 
An amount of 2 µg of mAb2 and 0.6 µg of mAb 3 were separated by HF5-UV 
employing citrate buffer carrier solutions G, H and I (Table 5) and the corresponding 
elution profiles are reported in Figure 11. 
 
Figure 11 – HF5 separation profiles at 280 nm of (a) mAb2 and (b) mAb3 in citrate buffer solutions 
of different ionic strength (pH 4.9). Fragments/degradation products of mAb2 are marked as “f”. 
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Figure 11a shows that when citrate buffer is used as carrier solution, instead of 
phosphate buffer, it allows the detection of mAb2 fragments. Both Figures 11 show 
that, as the ionic strength is increased (G < H < I), the resolution between peaks 1 and 
2 improves. The highest sample recovery for both antibodies is achieved when 
carrier H is employed. Carrier solution G (IS 75 mM) does not allow the separation of 
the tested mAbs. 
Next, mAb2 and mAb3 separations were performed in buffers (phosphate and 
citrate) either containing a high NaCl content (200 mM) or not at all. The elution 
profiles corresponding to mAb2 and mAb3 are reported in Figure 12 and Figure 13, 
respectively. 
Figure 12a reports the separation of mAb2 in carrier solutions which do not contain 
NaCl. The presence of mAb2 fragments is detected (peak “f”), but the aggregates 
peak is absent. On the other hand, Figure 12b shows that the presence of high 
amounts of NaCl in the phosphate buffer leads to the UV false peak “F”, which 
covers the mAb2 fragments. However, the addition on NaCl allowed the separation 
of the aggregates peak (peak 2) in both phosphate and citrate buffers. 
 
 
Figure 12 – HF5 separation profiles at 280 nm of mAb2 in (a) carrier solutions without NaCl, A – 
phosphate and F – citrate and (b) carrier solutions containing a high amount of NaCl, E – phosphate 
and I – citrate. 
 
The best separation performance and the highest sample recovery were obtained (at 
both low and high IS) in citrate buffer. It is also very likely that the carrier solution 
pH had a contribution to improving the separation performance, since the citrate and 
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the phosphate were employed at different pH values. 
 
 
Figure 13 – HF5 separation profiles of mAb2 at 280 nm in (a) carrier solutions without NaCl, A – 
phosphate and F – citrate and (b) carrier solutions containing a high amount of NaCl, E – phosphate 
and I – citrate. 
 
Figure 13a reports the separation of mAb2 in carrier solutions which do not contain 
NaCl. The false UV peak “F” is visible in phosphate buffer, but neither buffer allows 
detecting the presence of mAb3 aggregates. Figure 13b shows that the presence of 
NaCl in the phosphate buffer leads to an increased UV false peak “F” that covers the 
mAb2 fragments, therefore, both phosphate salts and NaCl amounts contribute to its 
appearance. Furthermore, the separation performance worsens visibly in carrier E. 
Antibody mAb3 appears to interact with the separation device resulting in a broad, 
tailed peak. The best separation performance and the highest sample recovery were 
obtained in citrate carrier I.  
 
These experiments demonstrated how the carrier solution ionic strength affects both mAbs 
stability and HF5 separation performance. If the ionic strength is too low, the separation does 
not take place, whereas employing a higher ionic strength can consequently improve sample 
recovery, as well as aggregates peak separation from the monomer. However, employing 
phosphate buffer resulted to be problematic, especially at higher salts concentration, leading to 
system false peak “F” that covered mAb2 fragments. Replacing the buffer type, the UV system 
peak was eliminated and the separation performance was improved. It is very likely that a 
lower pH value played a role into improving the mAbs separation.  
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E. CARRIER SOLUTION SALT (II) – CITRATE BUFFER  
 
Similar to the experiments performed employing phosphate buffer described in 
subchapter 4.2, the salt type was considered as a variable in the citrate buffer 
composition. To this purpose, the same salts (NaCl and MgCl2) were added 
separately to a 50 mM citrate buffer solution at pH 4.2, as described in Figure 1b. 
Blank injections were performed in order to establish the UV baseline level, followed 
by sample injections. An amount of 2 µg of mAb2 and 0.6 µg of mAb3 were 
separated by HF5-UV in citrate buffers and the elution profiles are reported in 
Figures 14. 
 
 
Figure 14 – HF5 separation profiles at 280 nm of (a) mAb2 and (b) mAb3 in phosphate buffer 
solutions supplemented with different salts. The mAb2 fragments are marked as “f” 
 
Figures 14 show how the presence of MgCl2 in the citrate buffer improves the 
monomer peak symmetry, unfortunately at the expense of sample recovery, while 
other separation parameters like the resolution between species and band 
broadening (separation efficiency) remain unaltered. 
 
These experiments show once again the importance of choosing the appropriate salt to add to 
the buffer/carrier solution. Both NaCl and MgCl2 provide a good separation performance, 
while the presence of NaCl is better at assuring a high sample recovery of both mAb2 and 
mAb3. 
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Increasing amounts of mAb3 were separated by HF5-UV employing a carrier 
solution which consisted in 50 mM citrate buffer supplemented with 50 mM MgCl2 in 
order to establish whether the sample incomplete recovery was caused by the 
experimental conditions or by an autosampler error. The separation profiles are 
reported in Figure 15. 
The mAb3 total recovery increased when progressively higher sample amounts were 
injected, established by calculating the area under the peak in each case. The results 
are reported in Table 6. Since the sample recovery was actually improved when 
injecting higher amounts, these results exclude a systematic incomplete sample 
recovery. 
 
Figure 15 – HF5 separation profiles of mAb3at 280 nm. Increasing amounts of mAb3, separated in 
50 mM citrate buffer supplemented with 50 mM MgCl2, pH 4.2 
 
Table 6 – m Ab2 sample recovery calculations based on area under the peak at 280 nm values 
Sample 
amount (µg) 
Area under the peak 
(mAU*s) 
Sample relative 
recovery (%) 
Sample recovery 
increase (%) 
0.6 160 100  
1.2 330 103.1 3.1 
2.4 706 110.3 10.3 
3.6 1110 115.7 15.7 
5.0 1597 119.8 19.8 
 
The phenomenon of nonspecific protein adsobtion to the hollow fiber inner wall, 
leading incomplete sample recovery, abnormal elution position, loss of peak 
symmetry and poor resolution is an issue which HF5 (FFF) and SEC have in 
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common. The sample interaction with the column matrix is a known SEC limitation. 
However, this issue can be addressed by performing a series of injections of the same 
sample known as make-up runs, which is a common practice in SEC and 
recommended by SEC columns manufacturers. The purpose of these make-up runs, 
which are usually not described in journal articles, is to let the sample adhere to the 
column matrix until the sample recovery gradually starts to improve, indicating that 
the non-specific interactions have been diminished because the active “sticky” sites 
have been saturated. 
Since it is a proven method to overcome sample loss, this practice was adopted in 
FFF (HF5). Usually 10-20 µg of sample (or a standard protein, such as BSA) are 
injected repeatedly and separated by HF5, letting the protein adhere until it saturates 
the hollow fiber inner wall (HF5).  
The downside of this procedure is that, if it is performed with an unstable protein 
(which might be the case of a protein during formulation development), it might lead 
to progressive sample accumulation on the hollow fiber wall causing the depletion of 
the fiber. 
 
These experiments served to demonstrate how sample recovery can be improved by 
performing a hollow fiber make-up procedure, which is a practice adopted from SEC. 
Therefore, mAb3 separation could be performed in the carrier solution which proved to be 
optimal from all points of view (separation performance and sample recovery) and the sample 
recovery was improved by approximately 20%. 
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F. CARRIER SOLUTION IONIC STRENGTH (II) – PHOSPHATE / CITRATE BUFFER 
 
Finally, the last set of experiments was performed employing a mixture of phosphate 
and citrate buffer as carrier solution, at pH 5.0 and supplemented with different 
amounts of NaCl. This phosphate/citrate combination is very similar to the mAb3 
formulation buffer and its preparation is depicted in Figure 1c. The exact carrier 
solutions composition is reported in Table 7. 
 
Table 7 – Composition of phosphate/citrate buffer carrier solutions, different ionic strength (pH 
5.0) 
Carrier Composition Ionic strength (mM) 
J 
14.1 mM phosphate buffer + 7.8 citrate buffer 
+ 75 mM NaCl 
141 
K 
14.1 mM phosphate buffer + 7.8 citrate buffer 
+ 150 mM NaCl 
216 
 
Blank injections were performed to establish the UV baseline level, followed by 
sample injections. An amount of 2 µg of mAb2 and 0.6 µg of mAb3 were separated 
by HF5-UV employing the formulation buffer-like carrier solutions and the elution 
profiles are displayed in Figure 15. 
 
 
Figure 16 - Separation profiles at 280 nm of (a) mAb2 and (b) mAb3 in phosphate/citrate buffer 
solutions supplemented with different amounts of NaCl.  
 
Figure 15a, corresponding to the separation profiles of mAb2, shows the presence of 
fragments and aggregates peaks only in carrier K, with the highest ionic strength 
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value. On the other hand, the separation profiles of mAb3 depicted in Figure 15b 
show a poor separation in both cases, as well as false UV peaks probably caused by 
the phosphate/NaCl salts combination. This carrier solution, even though very 
similar to the mAb3 formulation buffer, is not suitable for the separation of mAb3.   
 
These experiments demonstrated the possibility to perform separations in carrier solutions 
whose composition is similar to the formulation buffer of therapeutic proteins. However, 
separating in such buffers, although guaranteeing less stress on the sample stability, did not 
lead to good separation results. Sample recovery as well as low abundant mAb species 
detection and separation may be compromised due to insufficient ionic strength.   
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4.1.5. HF5 – FLD METHOD OPTIMIZATION FOR THE 
QUANTIFICATION OF AGGREGATE LEVELS IN PROTEIN 
FORMULATIONS. 
INTRINSIC FLUORESCENCE-BASED DETECTION OF ANTIBODY 
AGGREGATES: LOD AND LOQ ESTIMATION. 
ADVANTAGES OF MINIATURIZATION: UV DETECTION 
SENSITIVITY BOOST EMPLOYING A SMALLER INNER DIAMETER 
HOLLOW FIBER. 
 
 
 
 
This sub-chapter summarizes the exploratory study aimed to demonstrate the 
advantages of miniaturization of the separation device, online coupled with high 
sensitivity detection systems, for the detection and quantification of protein 
aggregates that may be present in antibody formulations. The advantages of using a 
miniaturized separation device consist not only in a reduced sample dilution during 
the separation, but also in employing lower flow rates, which – according to Lambert 
Beer law applied to flow systems (Equation 2, discussed in sub-chapter 3.2.1.1, 
Chapter 3) – lead to increased detection sensitivity.  
Furthermore, the maximum separation efficiency is determined by the analytes 
biophysical and chemical properties, in particular, by their detectability and tendency 
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towards overloading, a key aspect regarding HF5 applications (Equation 13, discussed 
in sub-chapter 2.2.2, Chapter 2). 
 
The first part of this study describes the method development process of an HF5 
method that employs the intrinsic fluorescence of antibodies (in this case, an IgG1 
type antibody) as detection method. Once the HF5 method was optimized, the 
detection sensitivity was evaluated by means of Limit of Detection (LoD) and Limit 
of Quantification (LoQ) estimation.  
The second part of this study explores other methods of increasing HF5 detection 
sensibility, which consisted in employing a hollow fiber with a smaller internal 
diameter and the peptide bond absorption of antibodies as detection method. This 
study showed that a 4-fold increase in sensitivity as well as a 2-fold increase in 
efficiency was achieved, even when the antibody aggregates were present at trace 
levels, when compared to the separation performance obtained with the standard 
(commercial) hollow fiber membrane.  
The definitions and formulas of all analytical parameters employed in this study 
were previously discussed in sub-chapter 2.4 (Chapter 2). 
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4.1.5.1. EXPERIMENTAL SETUP 
 
HF5 analyses were performed using an Agilent 1200 HPLC system (Agilent 
Technologies, Santa Clara, CA, USA) consisting in a degasser, an isocratic pump, an 
auto sampler, a variable wavelength UV detector and a fluorescence detector, 
combined with an Eclipse® DUALTEC prototype separation system (Wyatt 
Technology Europe, Dernbach, Germany). The ChemStation version B.04.02 (Agilent 
Technologies) data system for Agilent instrumentation was used to set and control 
the instrumentation and for the computation of various separation parameters. The 
software package Wyatt Eclipse @ ChemStation version 3.5.02 (Wyatt Technology 
Europe) was used to set and control the FFF separation system. The fluorescence 
detector (FLD) was set at an excitation wavelength of 280 nm (specific for proteins) 
and an emission wavelength of 340 nm, which was the specific fluorescence emission 
maximum of tryptophan, Trp (therefore for proteins containing this amino acid, such 
as antibodies).  
The hollow-fiber was a 17 cm long polyether-sulfone (PES) fiber, type FUS 0181 
available from Microdyn-Nadir (Wiesbaden, Germany) with the following 
characteristics: 0.8 mm ID, 1.3 mm OD and a molecular weight cut-off of 10 kDa, 
corresponding to an average pore size of 5 nm. The HF5 separation device was 
already described in the previous chapters. A hollow fiber membrane with a smaller 
inner diameter, type FUS 0353 in PES material with 0.5 mm ID and a MWCO of 30 
kDa was employed in the last part of this study. 
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4.1.5.2. SAMPLES AND REAGENTS 
 
The first sample was an IgG1 antibody, for simplicity named mAb3, at a 
concentration of 40 mg/mL (stock solution). The sample was initially diluted 1:80 in 
the mobile phase and a sample volume of 10 µL containing 5 µg of mAb3 was 
injected at all times during the HF5 method development phase of this study. During 
the second part of this study – the estimation of LoD and LoQ of the mAb3 aggregate 
levels – the sample was diluted subsequently until the desired final concentration 
was achieved. Previous studies on mAb3, discussed in sub-chapter 4.1.4, showed that 
approximately 10% of the sample was represented by the dimer form of the 
antibody. 
In the third part of this study, where a hollow fiber with a smaller ID was employed 
to increase detection sensitivity, a different IgG1 type antibody was used, for 
simplicity named mAb2, at a concentration of 2 mg/mL. Antibody mAb2 was diluted 
at a final concentration of 0.5 mg/mL to suit the requirements for this study. During 
previous studies, reported in Chapter 4.1.4, mAb2 showed very low aggregates levels 
(1-2%). 
The carrier solution/mobile phase employed for the separation of mAb3 was 50 mM 
citrate buffer supplemented with 50 mM MgCl2, pH 4.2. A different carrier solution, 
consisting in 50 mM phosphate buffer supplemented with 150 mM NaCl (pH 7.2) 
was employed for the separation of mAb2. These carrier solutions were found 
optimal the separation of mAb2 and mAb3, respectively, according to the study 
conducted in sub-chapter 4.1.4.  The carrier solutions were prepared using MilliQ 
water purified by an Elix 3 UV Water Purification System (Millipore, Billerica, USA) 
and filtered through 0.2 µm pore membrane sterile filter units (Millipore), at all 
times. 
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4.1.5.3. HF5 – (UV) – FLD METHOD DEVELOPMENT FOR mAb3 
 
A. ESTABLISHING THE SIGNAL/NOISE RATIO FOR  
FLUORESCENCE EMISSION AT 340 nm 
 
First, a previously tested HF5 method was employed for the separation of mAb3, 
which represented the starting point for the method development. An amount of 5 
µg of mAb3 was injected during the focus-inject step, performed at 0.85 ml/mL focus 
flow rate for 4 min. When the focus step was completed, the sample was eluted at a 
channel flow rate of 0.35 mL/min, under the effect of a constant cross-flow rate of 
0.35 mL/min for 15 min. The fluorescence emission at 340 nm and the absorbance at 
280 nm were recorded simultaneously and the separation profiles are reported in 
Figure 1. 
 
 
Figure 1 – HD5 separation profiles of mAb3: (a) fluorescence emission at 340 nm and (b) UV 
absorbance at 280 nm (b) recorded during the same sample run  
 
Previous studies (sub-chapters 4.1.3 and 4.1.4) have confirmed that the UV signal is 
not only affected by pressure variations during a normal FFF run, in particular when 
switching between operational modes (such as the signal variations shown in the red 
circles in Figure 1), but also requires a long period of time to stabilize before a sample 
run can be performed (usually 45-60 min, called “system conditioning”). This is 
because many salts in the mobile phase composition (such as phosphates, but also 
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acetate and citrate) have an UV absorbance of their own [Aitken and Learmonth 
2002].  It is a known fact that, even though protein absorbance at 210 or 215 nm of the 
peptide bonds is very intense, it is rarely used because of possible impurities 
interference (such as the previously mentioned mobile phase salts).  
Figure 1b shows how the UV baseline is affected by the pressure changes during 
mAb3 separation performed in citrate buffer. The red arrow indicates a signal 
variation which could be easily mistaken for the presence of mAb3 fragments. 
Fortunately, Figure 1a confirms that mAb3 does not contain any fragments; 
therefore, the UV signal variation should be attributed to other factors. The lack of 
specific sample signal represents an important issue, especially when the sample 
composition is unknown or during the quantification of low protein aggregates 
levels. This is where the fluorescence detection comes into play. Figure 1a shows that 
not only the system conditioning is not required (since the mobile phase salts do not 
fluoresce at 340 nm), but also the baseline remains stable during the entire HF5 
sample run. 
 
Once the sample run is completed, the next one can be performed right away, 
without the need to wait for the baseline to stabilize again. The areas highlighted by 
the red circles in Figure 1a and 1b show the signal variation when the cross-flow is 
annulled (also called “field release”), allowing the sample components which were not 
separated to exit the system before the next injection. This “M” shaped signal 
variation is very common and is known as “system peak”. If the separation system 
and the online coupled detectors are clean, the height of this peak is constant and is 
identical even during blank runs (Figure 2a and 2b), therefore, serves as indicator. 
Next, the fluorescence emission and the UV absorbance were registered during a 
blank run in order to establish the signal/noise ratios (S/N) and the profiles are 
reported in Figure 2. 
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Figure 2 – (a) Fluorescence emission at 340 nm and (b) UV absorption at 280 nm during the same 
blank run; (c) estimation of the noise level of the fluorescence baseline 
 
The blank run in Figure 2b reflects, once more, the UV signal baseline variations 
caused by the pressure changes which occur during the normal operation of an FFF 
system. And, once again, Figure 2a shows that the fluorescence signal is not affected 
by the pressure changes. The fluorescence signal baseline was examined more closely 
in Figure 2c and the noise level was established at 0.0021 LU, as the signal random 
variations above and below the “zero line” in green.  
 
B. HF5 – FLD METHOD OPTIMIZATION FOR mAb3 
 
The first HF5 parameter that was optimized was the focus time. The same mAb3 
amount (5 µg) was injected during the focus-inject step at 0.85 mL/min of focus flow 
rate, while the focus-inject duration was increased over subsequent runs. The sample 
was eluted at a channel flow rate of 0.35 mL/min, under the effect of a constant cross-
flow rate of 0.35 mL/min. The separation profiles are reported in Figure 3. 
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Figure 3 – HF5 separations of mAb3 with different focus-inject durations (a) real scale and (b) 
peaks overlaid on the monomer retention time at 6 min focus-inject 
 
The mAb3 monomer peak height increases proportionally to the focus – inject 
duration. Figure 4a shows the importance of the sample relaxation process (sample 
focus step), which may lead to incomplete separation or even incomplete sample 
recovery. Figure 4b shows that, as the focus-inject time duration increases, the band 
broadening is reduced and the peaks become narrower. Moreover, the separation 
between the two peaks improves, shown by the progressive decrease of the valley 
height between the peaks.  
Table 1 reports the effects of the sample focus time on the separation through 
parameters like area under the peak, peak height and peak width at half height (w1/2), 
retention times, and peak symmetry.  
 
Table 1 – Sample focus-inject time variation effects on the separation performance 
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Increasing the focus time up to 4 min, an improvement in both sample recovery 
(estimated as total area under the peak) and monomer-dimer resolution is observed. 
Between 4 min and 6 min, the resolution is constant and only the sample recovery 
improved slightly. A 4 min focus time was considered optimal and used in the 
following experiments. 
Next, the cross—flow rate was chosen as a variable and all other separation 
parameters were kept constant. The same mAb3 amount (5 µg) was injected during 
the focus-inject step at 0.85 mL/min of focus flow rate for 4 min. The sample was 
eluted at a channel flow rate of 0.35 mL/min, under the effect of different, but 
constant cross-flow rates. The elution profiles are reported in Figure 4. 
  
Figure 4 – HF5 separation profiles of mAb3 under the effect of different cross-flow rates (a) real 
scale and (b) peaks overlaid on the monomer retention time at 0.65 mL/min cross-flow rate and (c) 
table reporting the separation performance parameters 
 
As the cross-flow rates increases, the resolution between the peaks improves 
noticeably up to a certain point (0.5 mL/min of cross-flow rate value). The sample 
recovery decreases slightly as the cross-flow value is increased. Since the sample 
spends more time inside the hollow fiber, while being retained by progressively 
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stronger fields, it was expected that the peaks became progressively broader because 
of the longitudinal diffusion effect (a.k.a. band broadening). The strength of the field 
(the flow rate) causes the peaks to become increasingly more asymmetrical (tailed). 
Finally, the effect of a field that is too strong for the separation of mAb3 (0.65 
mL/min) causes an effect which resembles very much to the sample overloading 
effect. This is the reason why the monomer peak looks “split” and the separation 
actually worsens. A cross-flow rate of 0.5 mL/min was considered optimal and used 
in the following experiments. 
Next, the channel (detector) flow rate was chosen as a variable and all other separation 
parameters were kept constant. The same mAb3 amount (5 µg) was injected during 
the focus-inject step at 0.85 mL/min of focus flow rate for 4 min. The sample was 
eluted at different channel flow rates, under the effect of a constant cross-flow rate of 
0.5 mL/min. The elution profiles are reported in Figure 5. 
 
Figure 5 – HF5 separation profiles of mAb3 under the effect of different  channel flow rates (a) real 
scale and (b) peaks overlaid on the monomer retention time at 0.35 mL/min channel flow rate and 
(c) table reporting the separation performance parameters 
 
As the channel flow rate is increased, the band broadening diminishes (the faster 
channel flow counteracts the sample longitudinal dispersion). The peaks resolution 
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remains constant, as well as the valley height between the monomer and dimer. Since 
the signal intensity increases inversely to the flow rate, a slower channel rate can be 
used to enhance detection. However, in this study a channel flow rate of 0.5 mL/min 
was considered optimal and used in the following experiments.  
Summarizing, the optimal HF5-FLD method consisted in injecting the mAb sample 
during focus, performed at 0.85 mL/min for 4 min. Once the focus step was complete, 
the sample was eluted at 0.5 mL/min (initially 0.35 mL/min), under the effect of a 
constant cross-flow rate of 0.5 mL/min (initially 0.35 mL/min). 
The comparison between the elution profiles of mAb3, obtained applying the initial 
HF5 method and the optimized method is reported in Figure 6. 
 
 
Figure 6 – HF5 separation profiles of mAb3: (a) initial HF5 method; (b) optimized HF5 method, (c) 
table reporting the separation performance parameters 
 
Since the ratio between the channel flow rate and the cross-flow rate did not change 
(=1), the optimized method allows the separation of mAb3 monomer and dimer in 
approximately 14 min of analysis time, while the separation performance is 
improved. This optimized method was employed at all times from this point 
forward. 
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4.1.5.4. STUDY FOR THE DETERMINATION OF THE LIMIT OF DETECTION (LOD) 
AND THE LIMIT OF QUANTIFICATION (LOQ) OF AGGREGATE LEVELS PRESENT IN 
mAb3 FORMULATION. 
 
A. ASCERTAINING THE LINEARITY INTERVAL FOR THE mAb3 FLUORESCENCE 
EMISSION AT 340 nm 
 
Signal to Noise Ratio (S/N) is a dimensionless measure of the relative strength of an 
analytical signal (S) to the average strength of the background instrumental noise (N) 
for a particular sample and is closely related to the detection level. The ratio is useful 
for determining the effect of the noise on the relative error of a measurement [Skoog 
and Leary 1992].  
Limit of Blank (LoB), Limit of Detection (LoD), and Limit of Quantification (LoQ) are 
terms used to describe the smallest concentration of an analyte that can be reliably 
measured by an analytical procedure.  
LoD is a feature of limit assays, usually expressed as %, ppm or ppb and defined by 
the ICH guidelines as “the lowest amount of analyte in a sample that can be detected, but 
not necessarily quantitated under the stated experimental conditions”. There are two 
approaches for the determination of LoD. The first consists in comparing signals 
from samples with known levels of impurities with blank signals (the LoD is then 
established at a ratio of 2:1 or 3:1),while the second approach consists in estimating 
the LoD from the standard deviation of the signal and the slope of the calibration 
curve (LoD=3σ/s) [Guidelines 2014]. 
On the other hand, LoQ is a feature of quantitative assays for low levels of analytes 
in sample matrices and is defined by the ICH guidelines as “the concentration of the 
related substance in the sample that will give a S/N ratio of 10:1”. Impurities in bulk drug 
substance, as well as degradation products in final therapeutic protein formulations 
are characterized by means of LoQ. LoQ of an analytical method is influenced by 
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detector sensitivity, as well as sample preparation procedure at low levels of 
impurities [Guidelines 2014]. 
 
The Limit of Blank can be calculated from:  LoB = meanblank + 1.645 (STDEVblank).  
In this study, five blank injections were performed for the determination of LoB and 
a value of 0.00229 was found (meanblank = 0.00202 L.U. and STDEVblank = 0.000164 L.U.). 
 
In general, the fluorescence detection cannot be used to quantify (there are a few 
exceptions, and even so the method for quantifying cannot be validated) because, 
although directly correlated to the protein amount, an increase in the fluorescence 
signal can also indicate changes in the protein conformation, therefore not able to 
distinguish between the two. However, the intrinsic fluorescence signal is highly 
valuable in determining whether certain experimental conditions change the protein 
molecular conformation or whether the changes occur in the proximity of a 
fluorophore (observed as a shift in the emission wavelength or change in 
fluorescence intensity). Therefore, in general, fluorescence detection only provides 
qualitative information [Zölls et al. 2012]. 
Despite all these reasons, since this study did not involve drastic changes in the 
experimental conditions which would result in conformational modifications, the 
intrinsic Trp fluorescence is proposed as sensitive method of detection for the 
quantification of mAb3 aggregates levels.  
 
In order to ascertain of the linear relationship between the fluorescence signal intensity 
and the sample amount, in the concentration range of interest (which was as low as 
possible, since LoD and LoQ were to be determined), a series of six different sample 
amounts was injected and each of them was replicated 3 times, each time injecting 
the same sample volume. The mAb3 dilutions are reported in Table 2. 
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Table 2 – Sample dilutions of mAb3 in mobile phase 
Initial 
concentration of 
the stock solution 
Dilution 
Final 
concentration 
(mg/mL) 
Injected amount 
(constant Vinj=10 
µL) 
40 mg/mL 1:80 from 40 mg/mL 0.5 5.000 
 1:1.25 from 0.5 mg/mL 0.4 4.000 
 1: 2 from 0.5 mg/mL 0.25 2.500 
 1:2 from 0.25 mg/mL 0.125 1.250 
 1:5 from 0.5 mg/mL 0.1 1.000 
 1:3 from 0.1 mg/mL 0.0334 0.334 
 
The elution profiles of the different mAb3 sample amounts are reported in Figure 6. 
As the sample amount is diminished, the peaks become more symmetric (below 2.5 
µg) and the ratio between the monomer and the dimer peak height increases (from 7 
to 12.5).  
 
 
Figure 7 – HF5-FLD separation profiles of different amounts of mAb3, (a) above 1µg and (b) below 
1µg 
 
Figure 6b reports the separation profiles of sample amounts below 1 µg of mAb3 
sample. The dimer peak cannot be discriminated from the baseline if the injected 
mAb3 amount is too low (below 0.16 µg). 
The calibration curve, which correlates the intensity of the fluorescence signal and the 
sample concentration, was traced by plotting the mAb3 dimer peak height against 
the corresponding injected (total) sample amount and is reported in Figure 7, along 
with the separation performance parameters.  
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Figure 8 – (a) Calibration curve for the mAb3 dimer peak and (b) separation performance 
parameters, including the dimer peak height values used for the calibration curve 
 
Once the linear relationship was established, the LoD and LoQ for the mAb3 dimer 
were calculated and the results are reported in Table 3. 
 
Table 3 - LoD and LoQ determination of mAb3 aggregates 
Equation x1 (µg) x2 (µg) 
LoD = y1 = 0.0266 x1 – 0.0039 0.404  
LoQ = y2 = 0.0266 x2 – 0.0039  1.007 
Where: 
LoD = 3 × LoB = 0.006871 L.U. (y1) 
LoQ = 10 × LoB = 0.022903 L.U. (y2) 
 
The LoQ and LoD values reported in Table 3 refer to the mAb3 injected amount 
required for the dimer to the distinguished from the instrumental noise (0.404 µg) 
and the mAb3 amount required for the dimer to be quantified (1.007µg). When 1 µg 
of mAb3 was injected, the dimer represented 13.16% of the total amount (Table in 
Figure 7b), therefore, the smallest quantifiable dimer amount was 132 ng.  
Following the same procedure, the smallest dimer amount that can be detected by 
the FLD detector was found to be 47.86 ng, representing 11.82% of the mAb3 injected 
amount. 
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4.1.5.5. ADVANTAGES OF MINIATURIZATION: UV SIGNAL SENSIBILITY BOOST 
WHEN EMPLOYING A HOLLOW FIBER WITH A SMALLER INNER DIAMETER 
HF5 – UV METHOD FOR THE SEPARATION OF mAb2  
STUDY PERFORMED IN COLLABORATION WITH WYATT TECHNOLOGY EUROPE 
(DERNBACH, GERMANY) 
 
As discussed in sub-chapter 3.2.1.1, the Lambert-Beer law applied to flow systems 
(Equation 2) shows how the sample absorbance (A) is inversely related to the 
volumetric flow rate value (F). This linear relationship can be affected by sample 
recovery. The area under the peak for each analyte at a specific wavelength is 
correlated to the sample recovery through the extinction coefficient (at the same 
wavelength) and, therefore, inversely proportional to the flow rate at which the 
analyte is eluted through the UV detection system. Especially when dealing with 
trace levels of protein aggregates, we can make the most of this relationship by 
decreasing as much as possible the channel (detector) flow rate. However, we need 
take into consideration the implications of a slower channel flow rate on band 
broadening, as reported in the mAb3 method development part of this study. 
A relatively simple solution which could resolve the band broadening issue, even at 
very low channel flow rates, is further miniaturization of the separation device. In 
theory, this solution can be implemented by simply replacing the standard hollow 
fiber membrane (PES, ID 800 µm) with a hollow fiber of the same material having a 
smaller inner diameter.  
A variety of hollow fiber materials, pore sizes corresponding to different MWCOs are 
available from Microdyn Nadir (the supplier for the hollow fibers which are 
compatible with the HF5 cartridge commercialized by Wyatt Technology Europe), 
suitable for different fields of application (environment, metal, textile, paper, food, 
pharmaceutical/biotechnology and chemical). However, the choice in terms of 
hollow fiber inner diameter (ID) is restricted to a narrow range, from 0.5 to 1.0 mm.  
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Therefore, the hollow fiber of choice for this sensibility study was the one with the 
smallest ID, with the following characteristics: type FUS 0353, PES material, ID 0.5 
mm, pore size corresponding to a MWCO of 30 kDa and 17 cm of length. One of the 
main concerns in replacing the standard hollow fiber membrane (with a larger ID, 0.8 
mm) was the efficacy of the sealing system. Fortunately, there were no visible leaks 
when the smaller ID hollow fiber replaced the standard one, therefore we proceeded 
with the study.  
The protein chosen for this study was a different IgG1 type antibody, mAb2. During 
previous studies on this particular antibody (described in Chapter 4.1.4), the 
monomeric form was very stable and only a very small percentage of this mAb2 was 
found as dimer (roughly 1.5%), also very stable under various environmental 
changes. Therefore, mAb2 was considered the optimal sample type for this study 
because it contained only trace amounts of aggregates and they were stable. 
A very low amount of mAb2 (0.15 µg, 0.3 µL of a 0.5 mg/mL mAb2 solution) was 
injected at all times and the separations were performed employing 50 mM 
phosphate buffer supplemented with 150 mM NaCl (ionic strength: 300 m) at a final 
pH of 7.2 as mobile phase. A UV/Vis variable wavelength detector set at 205 nm was 
coupled online with the HF5 module on the Eclipse® DUALTECTM FFF separation 
system as a concentration detector and to monitor the separation process.  
While the UV signal at 280 nm is specific for the proteins amino acidic side chains (in 
particular, only three of them are chromophores: tyrosine, phenylalanine and 
especially tryptophan) and can be employed to identify a particular protein and 
discriminate between proteins, in the far UV region (between 190 and 230 nm) the 
protein chains have a very low absorbance compared to the peptide bond. Therefore, 
the peptide bond absorbance at 205 nm can be considered an absolute means to 
determine the protein presence in a sample and, even though the protein absorbance 
maximum intensity is at 190 nm (at 205 nm is only half the value obtained at 190 nm), 
the 205 nm is the wavelength of choice because there is no oxygen absorbance 
interference [Aitken and Learmonth 2002]. 
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The HF5 method was adjusted accordingly to suit the new hollow fiber membrane 
characteristics: the sample runs were performed by injecting the same amount of 
sample (0.15 µg of mAb2) during focus, performed at 0.22 mL/min for 6 min (to 
compensate for the very low flow rate). After the completion of the focus step, the 
sample was eluted at a channel flow rate of 0.22 mL/min under the effect of different 
cross-flow rates (different filed strengths). The elution profiles obtained under 
different cross-flow rates are reported in Figure 8. 
 
 
Figure 9 – HF5 separation profiles of mAb2 at 205 nm, employing a hollow fiber with an ID of 0.5 
mm (a – f) and the separation performance parameters table (g) 
 
All separation profiles show that the dimer is not completely separated from the 
monomer. However, this is not a reflection on the performance, but rather a 
consequence of the proportion between the two mAb2 species. Since the monomer is 
present in a very large amount (98.5% of the sample), its peak is very broad 
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compared to the dimer peak. Consequently, the tail of the monomer peak partly 
covers the dimer peak. 
Applying an increasingly stronger field, the dimer peak is better resolved, shown by 
Figures 8b through 8f. The separation efficiency for the monomer increases 
proportionally with the cross-flow rate, while the efficiency for the dimer has an 
opposite trend. This can be explained by the fact that the dimer peak width increases 
proportionally with the field strength, but so does the retention level (evaluated 
through the retention time value, tR). An opposite trend was observed for the 
monomer peak width (Table g in Figure 8). 
As the cross-flow rate increases, the monomer peak remains symmetric, while the 
dimer peak becomes tailed under the effect of stronger fields. The peak symmetry 
was calculated only when the flow conditions allowed the separation of the dimer 
peak (Figures 8d – 8f). 
There were no noticeable trends of the resolution as the cross-flow rate was 
increased. The monomer-dimer resolution had an acceptable value at all times (1.25 = 
baseline separation > RS > 1 = acceptable). 
 
4.1.5.6. CONCLUSIONS 
 
This study provided proof that, when a miniaturized separation device like a very 
small ID hollow fiber (membrane) is coupled online with a very sensitive detection 
method, such as UV detection at 205 nm, trace amounts of aggregate levels can be 
successfully detected and quantified. When injecting only 150 ng of mAb2, an 
amount as low as 2.25 ng of dimer can be quantified, corresponding to 1.5% of the 
total protein amount.  
The proposed HF5-UV method is not only time-efficient, allowing the mAb2 
separation under 13 min, but the use of a smaller ID hollow fiber as separation device 
also enhances considerably the detection sensitivity.  
Chapter 4, Part 1, 4.1.5. Advantages of miniaturization: sensitivity boost by HF5-FLD online coupling and HF5 
separation device with smaller inner diameter  
189 
 
 
In Figure 9, a comparison between the separation performance of the commercial 
hollow fiber membrane and the smaller ID hollow fiber is reported. The fluorescence 
detection at 340 nm was used as detection method, based on the optimistic results 
described previously in this sub-chapter, when the sample of choice was mAb3 
(which contained a larger amount of dimer).  
 
Figure 10 – HF5 separation profiles of mAb2. Comparison between hollow fiber separation devices: 
standard membrane (ID 0.8 mm, black) and smaller ID membrane (ID 0.5 mm, red). Advantages of 
miniaturization: sensitivity and separation efficiency 
 
From the dimer peak height ratio obtained under the flow conditions (corresponding 
to the two hollow fiber devices), we obtain a 4-fold sensitivity increase when the 
hollow fiber ID is smaller. Similarly, for the same hollow fiber smaller ID, we observe 
a 2-fold efficiency increase, thanks to the more advantageous retention time/peak 
width ratio. These results are in agreement with the conclusions drawn from Equation 
13 in sub-chapter 2.2.2 (Chapter 2). 
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4.1.6. HF5 – MALS AND SEC – MALS PERFORMANCE 
COMPARISON FOR THE SEPARATION OF IMMUNOGLOBULINS 
(IgGs).  
FFF SELECTIVITY FEATURE 
 
 
 
 
In this sub-chapter, the advantages of HF5 in terms of versatility (carrier solution 
composition, even similar to the antibody formulation buffer), lower sample dilution 
and FFF selectivity are the features which make it an ideal candidate as SEC 
orthogonal method for therapeutic proteins formulation characterization. 
The miniaturization of the separation device – thus requiring lower volumetric flow 
rates – allows less sample dilution during the separation, as well as enhanced 
detection, according to Lambert-Beer law applied to flow systems (Equation 2, sub-
chapter 3.2.1.1, Chapter 3). In addition, the gentle HF5 separation mechanism should 
be less disruptive of large protein aggregates held together by weak, non-covalent 
forces.  
Thanks to the virtually unlimited chromatographic space for the separation of 
protein aggregates, when coupled with an appropriate detection system, HF5 should 
be able to allow the separation of a wide range (sizes and MW) of antibody 
aggregates, therefore able to quantify them reliably. As shown in the previous sub-
chapter 4.1.5, LoD and LoQ for antibody high MW species are in the nanograms 
range when the peptide bond absorption in the far UV is employed as detection 
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method. 
Although from many points of view a very robust system, SEC presents some 
drawbacks, including (a) the trade-off between the dynamic range of analysis (size 
and MW) and the species resolution, (b) the potential loss of large aggregates 
(physically filtered out, or by adsorption/interaction to the column matrix), (c) the 
potential disruption of large or “sticky” aggregates and even (d) the formation of new 
aggregates during the separation [Arakawa et al. 2010]. Moreover, protein samples 
are often diluted into a buffer which is usually different from the final formulation 
buffer, therefore may experience instability issues during separation [Lowe et al. 
2011].  
The performance of HF5 online coupled with UV and MALS detection is discussed in 
comparison with SEC for the separation of the same antibody formulation. The 
definitions and formulas of all analytical parameters employed for the method 
validation tentative in this sub-chapter were previously discussed in sub-chapter 2.4 
(Chapter 2). Furthermore, the sample recovery and the reversibility of the self-
association process were monitored over time by UV detection, like discussed in sub-
chapter 4.1.3, showing the sample evolution and the metastable equilibrium between 
antibody species. 
HF5 high selectivity allowed the separation and identification of more antibody 
species than SEC, which is a fundamental feature for the characterization of complex 
protein mixtures.  
Last, but not least, HF5 versatility is highlighted when employing a carrier solution 
with very low ionic strength and a carrier solution whose composition is similar to 
the antibody formulation. 
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4.1.6.1. EXPERIMENTAL SETUP 
 
SEC and HF5 analyses were performed using an Agilent 1200 HPLC system (Agilent 
Technologies, Santa Clara, CA, USA) consisting in a degasser, an isocratic pump, an 
auto sampler and a variable wavelength UV detector, combined with an Eclipse® 
DUALTEC prototype separation system (Wyatt Technology Europe, Dernbach, 
Germany). The ChemStation version B.04.02 (Agilent Technologies) data system for 
Agilent instrumentation was used to set and control the instrumentation and for the 
computation of various separation parameters. The software package Wyatt Eclipse 
@ ChemStation version 3.5.02 (Wyatt Technology Europe) was used to set and 
control the FFF separation system. An Agilent 1100 UV-Vis variable wavelength 
detector operating at a wavelength of 280 nm was used as a concentration detector at 
all times. 
An 18-angle MALS detector model DAWN® HELEOSTM light scattering detector 
(Wyatt Technology Corporation, Santa Barbara, CA, USA), employing a laser 
operating at a wavelength of 658 nm, was used in all experiments. 
ASTRA® software version 5.3.2.14 (Wyatt Technology Corporation) was used to 
handle signals from the detectors (MALS and UV) and to compute the proteins 
absolute MW and concentration values.  
The SEC columns were a WTC-0305S (Wyatt SEC protein column for MALS, 5µm 
coated silica beads 300Å, size 7.8x300mm), operating in the MW range from 5.000 to 
1.250.000 Da (g/mol), and a Mab PAC SEC-1 (Thermo Scientific Dionex, 5µm coated 
silica beads 300Å, size 4.0x300 mm), operating in a MW range from 10.000 to 
1.000.000 Da. 
The hollow-fiber was a 17 cm long polyether-sulfone (PES) fiber, type FUS 0181 
available from Microdyn-Nadir (Wiesbaden, Germany) with the following 
characteristics: 0.8 mm ID, 1.3 mm OD and a molecular weight cut-off of 10 kDa, 
corresponding to an average pore size of 5 nm. 
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4.1.6.2. MATERIALS AND METHODS 
 
The carrier solution/mobile phase was phosphate buffered saline (PBS) prepared at 
three concentrations, with different ionic strength values. Their exact compositions 
are reported in Table 1. 
 
Table 1 – The carrier solutions compositions employed in this study 
Carrier Composition Comment 
A 
50 mM phosphate buffer + 300 mM NaCl, 
pH 6.8 (IS 450 mM) 
Typical high IS buffer for the separation 
of proteins, recommended for Dionex 
SEC column by the manufacturer 
B 
50 mM phosphate buffer + 50 mM NaCl, 
pH 6.8 (IS 200 mM) 
Typical buffer recommended for Wyatt 
SEC column by the manufacturer 
C 
10 mM phosphate buffer + 150 mM NaCl, 
pH 7.0 (IS 180 mM) 
low IS eluent for mAbs recommended 
or Dionex SEC column by the 
manufacturer 
C 
10 mM phosphate buffer + 25 mM NaCl,  
pH 7.0 (IS 55 mM) 
Employed only in HF5 
D 
42 mM phosphate buffer + 24 mM citrate 
buffer + 105.5 mM NaCl, pH 5.0 (IS 171.5 mM) 
Employed only in HF5 
 
The carrier solutions were prepared using MilliQ water purified by an Elix 3 UV 
Water Purification System (Millipore, Billerica, USA) and filtered through 0.2 µm 
pore membrane sterile filter units (Millipore), at all times. 
The sample employed in this study was an IgG2 type antibody, for simplicity called 
mAb4, prepared at a concentration of 0.329 mg/mL. An amount of 2 µg of mAb4 was 
injected at all times. 
When the Dionex SEC column was employed, the separations were performed at 0.2 
mL/min flow rate and when the WTC SEC column was used, mAb4 was eluted at 0.5 
mL/min flow rate. 
When the separations took place in HF5, mAb4 was injected during focus, performed 
at 0.85 mL/min focus flow rate for 4.5 min. The sample was focused at a distance of 
approximately 15% fiber length from the channel inlet and eluted afterwards at a 
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channel flow rate of 0.35 mL/min under the effect of a constant cross-flow rate of 0.35 
mL/min for 20 min. 
 
4.1.6.3. RESULTS 
 
Sample mAb4 was separated by SEC employing two different columns (Dionex SEC 
and WTC SEC) and the recommended carrier solutions for each SEC column. HF5 
separations were performed afterwards under identical separation conditions 
(employing the same buffers) and the separation performance of the two techniques 
was compared. The separation was monitored by UV detection at 280 nm 
(concentration detector) at all times and, by coupling online the Eclipse® 
DUALTECTM separation system with a DAWN® HELEOSTM (MALS) detector, the 
absolute molecular weight (MW) of all eluting species was calculated. A mAbs 
specific value of      
                   was used in all MW calculations. 
 
A. SEC AND HF5-UV-MALS  
IN VERY HIGH IONIC STRENGTH MOBILE PHASE (450 mM) 
 
First, mAb4 was injected in HF5 and the Dionex SEC column and separated 
employing the carrier A reported in Table 1 (IS =450 mM), which was also the 
recommended elution buffer for the SEC column. The separation profiles at 280 nm 
of mAb4, as well as the MW value corresponding to each eluting peak, are reported 
in Figure 1, (a) the SEC separation and (b) the HF5 separation. Figure 1a depicts the 
SEC-UV-MALS elution profile of mAb4 in carrier A. The UV absorption at 280 nm 
allows the detection of four peaks and their assignment is reported in Table 2, while 
an additional peak is observed only by light scattering. Since the protein 
concentration signal is lacking in correspondence of the peak marked as “HMWS” 
(high MW species), it is not possible to confirm that this peak actually corresponds to 
protein aggregates.   
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Figure 1 – UV-MALS separation profiles of mAb4 in carrier A employing (a) Dionex SEC column 
and (b) HF5 channel. 
 
Table 2 – Peak assignment for the SEC separation profile reported in Figure 1a. Absolute MW 
values derived from MALS measurements. 
Peak # MW (g/mol) MWHMWS/MW1mer  Peak assignment 
HMWS > 108  Polydisperse population 
1 850.000 5.8 Hexamer 
2 599.200 4.1 Tetramer 
3 304.500 2.1 Dimer 
4 146.400 1.0 Monomer 
 
Figure 1b shows the HF5-UV-MALS elution profile of mAb4. In this case, the UV 
signal at 280 detects six eluting species, whose assignment is reported in Table 3.  
 
Table 3 - Peak assignment for the HF5 separation profile reported in Figure 1b. Absolute MW 
values derived from MALS measurements 
Peak # MW (g/mol) MWHMWS/MW1mer Peak assignment 
1 143.500 1.0 Monomer 
2 244.500 1.7 Dimer 
3 397.800 2.8 Trimer 
4 587.300 4.1 Tetramer 
5 1.188.000 8.3 Octamer 
6 2.561.000  Polydisperse population 
 
Aside from the opposite elution order, several observations can be drawn from the 
comparison between SEC and HF5 results. The most obvious one is that HF5 allows 
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the separation of two additional mAb4 species (oligomers) that were not separated 
by SEC: the trimer and the octamer, while the mAb4 hexamer is only present in the 
SEC elution profile. Since mAb4 is a highly self-associated antibody, most likely 
induced by the storage conditions, it is possible that the dynamic dissociation of the 
HMWS into smaller MW species is so fast that its composition changed between the 
SEC and HF5 analysis. In addition, as demonstrated in sub-chapter 4.1.2 (Chapter 4), 
it is also very likely that SEC is not selective enough and the trimer as well as the 
octamer co-elute with other species.  
Selectivity is a fundamental parameter in the analyses of mixtures, because it is 
important for the separation technique to allow the separation and detection of all 
species present in the protein formulation. If selectivity is not high enough, the 
presence of several species can be overlooked, in which case the separation profile 
would not reflect the true sample composition. 
Just like for the protein mixture in sub-chapter 4.1.2, the SEC and HF5 selectivity the 
separation of mAb4 in carrier A was calculated as the MW-based selectivity (SMW), 
defined as the slope of the log (tR) against the corresponding log (MW) plot, where 
the retention times, as well as MW values, were derived from the experimental data. 
The slopes were calculated on the first four eluting species, where the relationship 
between the two logarithms is linear, and the selectivity plots are reported in Figure 
2, (a) for the SEC separation and (b) for the HF5 separation. 
 
 
Figure 2 – Selectivity plots obtained in carrier A for (a) SEC and (b) HF5. The numbers near the data 
points represent the peak numbers in their elution order. 
As expected, the HF5 selectivity for the separation of mAb4 is higher compared to 
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SEC, meaning that, at equal MW values, the difference in retention time is higher in 
HF5 when compared to SEC. This finding confirms the fact that SEC does not allow 
the separation / detection of mAb4 trimer and octamer resulting in them co-eluting 
with other species with similar MW value.  
For a more in-depth comparison between SEC and HF5, several specific separation 
parameters were calculated, like separation efficiency (N, number of plates) specific 
resolution (Rsp), HF5 retention level (RL) and its equivalent in SEC, the capacity factor 
(k), as well as selectivity (SMW) and their values are reported in Table 4. HMWS peak 
(SEC) was excluded from the calculations because it corresponds to a polydisperse 
population (non resolved species, whose protein nature was not confirmed). 
 
Table 4 - Separation performance parameters for SEC Dionex and HF5 separations in carrier A 
Device 
Peak 
# 
tR 
(min) 
Retention 
MW 
(g/mol) 
Efficiency 
(N) 
Resolution 
RS 
Specific 
resolution 
(Rsp) 
Selectivity 
SMW 
   k       
SEC 1 9.6 0.49 850.000 3542   
0.15 
 2 10.0 0.47 599.200 1964 0.48 3.2 
 3 10.9 0.42 304.500 2975 1.08 3.7 
 4 12.5 0.34 146.400 4649 2.05 6.4 
   RL       
HF5 1 8.3 21.8 143.500 556   
0.38 
 2 11.3 29.7 244.500 695 1.89 8.2 
 3 13.0 34.2 397.800 1184 1.09 5.2 
 4 14.2 37.4 587.300 1785 0.82 4.8 
 5 15.1 39.7 1.188.000 1878 0.67 2.2 
 6 16.0 42.1 2.561.000 2108 0.65 1.9 
 
The dead volume of the SEC column was calculated as the volume of the equivalent 
cylinder (4.0x300 mm) and was found to be 3.77 mL. The dead time (t0) at 0.2 mL/min 
flow rate was 18.85 min. The t0 was related to the retention time through the capacity 
factor, k (also called chromatographic partition coefficient) for the analytes separated 
by SEC, instead of the retention level, RL calculated for the analytes separated by 
HF5. The SEC capacity factors are in the expected range (0 < k < 1) and the HF5 
retention levels are in the range recommended by [Wahlund 2013] and [Litzen et al. 
Chapter 4, Part 1, 4.1.6: HF5-MALS and SEC-MALS performance comparison (Immunoglobulins, IgGs) 
 
200 
 
1993] (RL<50). 
As expected, efficiency is always higher for SEC because the band broadening in HF5 
(FFF in general) is higher. The specific resolution values (Rsp), which take into 
consideration the MW of the resolved species, are similar. Baseline resolution (Rs > 
1.25)  is achieved only for the first two peaks in HF5 and the last two peaks in SEC, 
while acceptable resolution is obtained between peaks 2 and 3 (Rs > 1), in both SEC 
and HF5. 
A net distinction in the favor of HF5 is made by selectivity: the selectivity of both 
small and large mAb4 oligomers is always higher for HF5. The SEC analysis is more 
time-efficient, but the downside is the reduced chromatographic space available for 
the separation of all mAb4 oligomers. Altogether, these observations illustrate the net 
advantages of employing the HF5 separation device for an accurate characterization 
of mAb4 instead of the SEC Dionex column. 
 
B. SEC AND HF5-UV-MALS  
IN MODERATE IONIC STRENGTH MOBILE PHASE (200 mM) 
 
Next, mAb4 was injected in HF5 and the WTC SEC column and separated employing 
the carrier B reported in Table 1 (IS =200 mM), which was also the recommended 
elution buffer for the SEC column. The separation profiles at 280 nm of mAb4, as 
well as the MW value corresponding to each eluting peak, are reported in Figure 3, 
(a) the SEC separation and (b) the HF5 separation. 
Figure 3a depicts the SEC-UV-MALS elution profile of mAb4 in carrier B: the UV 
absorption at 280 nm allows the detection of four peaks and their identification is 
reported in Table 5, while an additional peak is observed only by light scattering, 
similar to the one reported in Figure 1a. Not even in this case is possible to confirm 
that this peak actually corresponds to protein aggregates due to the lack of UV signal 
in this chromatographic region.   
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Figure 3 – UV-MALS separation profiles of mAb4 in carrier B employing (a) Dionex SEC column 
and (b) HF5 channel. 
 
Table 5 – Peak assignment for the SEC separation profile reported in Figure 3a. Absolute MW 
values derived from MALS measurements. 
Peak # MW (g/mol) MWHMWS/MW1mer Peak assignment 
HMWS > 107  Polydisperse population 
1 2.100.589 13.9 Polydisperse population 
2 856.500 5.7 Hexamer 
3 352.700 2.3 Dimer 
4 151.500 1.0 Monomer 
 
Figure 3b shows the HF5-UV-MALS elution profile of mAb4: in this case, the UV 
signal at 280 detects four eluting species, just like in SEC, whose assignment is 
reported in Table 6.  
 
Table 6 - Peak assignment for the HF5 separation profile reported in Figure 3b. Absolute MW 
values derived from MALS measurements 
Peak # MW (g/mol) MWHMWS/MW1mer Peak assignment 
1 138.500 1.0 Monomer 
2 282.300 2.0 Dimer 
3 492.600 3.6 Tetramer 
4 2.500.000 18.1 Polydisperse population 
 
Both SEC and HF5 allow the separation and detection of four eluting peaks, but the 
MW values derived from experimental data show that, based on the 
MWHMWS/MW1mer ratios, SEC and HF5 do not separate exactly the same species. This 
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is a known issue when comparing results obtained with techniques which employ 
different principles (in this case the separation mechanism) or when complementary 
tests are preformed on the same sample: there is no way of knowing which one 
provides the true sample composition. Nonetheless, due to the reversibility of the 
antibody self-association, it is conceivable that the sample composition may have 
changed between the SEC and HF5 analyses or that the SEC and HF5 profiles simply 
show different stages of the mAb4 oligomers dissociation process.  
Moreover, when the sample recovery is incomplete, due to preferential adsorbtion of 
aggregates, it leads to questionable accuracy on aggregate levels [Carpenter et al. 
2010]. For instance, in a recent publication [Gabrielson et al. 2007], where FFF and 
SV-AUC were proposed as orthogonal techniques when SEC failed to detect the 
HMWS of mAbs present at trace levels, all three techniques provided different 
results. SEC not only underestimated the aggregates levels, but modified the 
aggregates distribution. Moreover, certain oligomers have shown preferential 
adsorbtion to the SEC column matrix. 
Since it was not possible to determine which technique led to erroneous results, the 
separation performance of SEC and HF5 was compared using the values derived 
from experimental data. First, the MW-based selectivity of SEC and HF5 for the 
separation of mAb4 in carrier B was calculated from the experimental retention time 
and MW values. The slopes were calculated on the first three eluting species, where 
the relationship between the two logarithms is linear, and the selectivity plots are 
reported in Figure 4, (a) for the SEC separation and (b) for the HF5 separation. 
As expected, even in this case, the HF5 selectivity for the separation of mAb4 is 
higher compared to SEC, meaning that, at equal MW values, the difference in 
retention time is higher in HF5 when compared to SEC. In order to compare the SEC 
and HF5 performance, the same specific separation parameters were calculated as for 
mAb4 separation by SEC and HF5 in carrier A and their values are reported in Table 
7. HMWS peak (SEC) was excluded from the calculations because of the polydisperse 
nature of the population (non resolved species).  
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Figure 4 – Selectivity plots obtained in carrier B for (a) SEC and (b) HF5. The numbers near the data 
points represent the peak numbers in their elution order. 
 
Table 7 – Separation performance parameters for SEC WTC and HF5 separations in carrier B 
Device 
Peak 
# 
tR 
(min) 
Retention 
MW 
(g/mol) 
Efficiency 
(N) 
Resolution 
RS 
Specific 
resolution 
(Rsp) 
Selectivity 
SMW 
   k       
SEC 1 12.6 0.56 2.100.589 5474   
0.13 
 2 13.0 0.55 856.500 3084 0.53 1.4 
 3 14.1 0.51 352.700 4661 1.23 3.2 
 4 16.2 0.43 151.500 7293 2.67 7.3 
   RL       
HF5 1 8.5 22.4 138.500 401   
0.34 
 2 11.3 29.7 282.300 615 1.60 5.2 
 3 13.0 34.2 492.600 1025 1.03 4.3 
 4 14.2 37.4 2.500.000 1302 0.74 1.0 
 
The dead volume of the SEC column was calculated as the volume of the equivalent 
cylinder (7.8x300 mm) and was found to be 14.33 mL. The calculated dead time (t0) at 
0.5 mL/min flow rate was 28.67 min. The t0 was related to the retention time through 
the capacity factor, k for the analytes separated by SEC, instead of the retention level, 
RL calculated for the analytes separated by HF5. 
The SEC WTC column offers higher analytes retention compared to the Dionex 
column (k factor in Tables 4 and 7). The retention levels obtained in HF5 in carrier B 
are similar to the values obtained in carrier A (Table 4) and are always in the 
recommended range (< 50).  
As expected, the efficiency in SEC is higher than in HF5 and the SEC WTC column 
offers an even higher efficiency compared to the Dionex column (Table 4) for the 
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separation on mAb4. The SEC WTC column is a little more selective than the Dionex 
column, as well (b closer to 0.1, b = 0.13 for WTC vs. b = 0.15 for Dionex).  
As in the previous case (carrier A), reported in section A of this sub-chapter, the 
specific resolution in SEC and HF5 is similar and the resolution is obtained at 
baseline (Rs > 1.25) for the first two peaks in HF5 and the last two peaks in SEC, while 
an acceptable resolution is obtained for peaks 2 and 3 in both SEC and HF5. 
Even in this case, selectivity is higher in HF5, which means that HF5 has a higher 
ability to distinguish mAb4 species with similar MW values. Since both SEC and HF5 
analyses require almost then same amount of time (20 min) and taking into 
consideration all the observations made on the performance parameters, there is a 
clear advantage into employing the HF5 device instead of the SEC WTC column. 
 
C. SEC AND HF5-UV-MALS 
 IN LOWER IONIC STRENGTH MOBILE PHASE (180 MM) 
 
Lastly, mAb4 was injected in HF5 and both SEC columns and separated employing 
carrier C reported in Table 1 (IS = 180 mM), which was also the recommended low IS 
elution buffer for the SEC Dionex column. The separation profiles at 280 nm of 
mAb4, as well as the MW value corresponding to each eluting peak, are reported in 
Figure 5, (a) the SEC separation employing the Dionex column, (b) SEC separation 
employing the WTC column and (b) the HF5 separation. 
All separation profiles depicted in Figure 5 show only three peaks detected by UV 
absorbance at 280 nm, while MALS detection allows the detection of additional 
HMWS, whose presence would have otherwise been neglected. However, in the 
absence of UV signal in correspondence of the light scattering peak, the protein 
nature of these aggregates cannot be confirmed. 
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Figure 5 - UV-MALS separation profiles of mAb4 in carrier C employing (a) Dionex SEC column, 
(b) WTC SEC column and (c) HF5 
 
The peaks assignments, based on the MW values calculated for each peak are 
reported in Table 8. The MW values derived from experimental data show that based 
on the MWHMWS/MW1mer ratios, SEC and HF5 do not separate exactly the same 
species.  
 
Table 8 – Peak assignment for the separation profiles reported in Figure 5. Absolute MW values 
derived from MALS measurements. 
Device Peak # MW (g/mol) MWHMWS/MW1mer Peak assignment 
SEC Dionex HMWS > 106  Polydisperse population 
(Figure 5a) 
1 370.300 2.3 Dimer 
2 158.200 1.0 Monomer 
SEC WTC HMWS > 106  Polydisperse population 
(Figure 5b) 
1 950.400 5.9 Hexamer 
2 459.400 2.8 Trimer 
3 262.600 1.7 Dimer 
4 159.400 1.0 Monomer 
HF5 1 149.800 1.0 Monomer 
(Figure 5c) 
2 353.900 2.4 Dimer 
3 752.400 5.0 Pentamer 
4 4.024.589 26.9 Polydisperse population 
Chapter 4, Part 1, 4.1.6: HF5-MALS and SEC-MALS performance comparison (Immunoglobulins, IgGs) 
 
206 
 
Since this issue was already discussed in sections A and B, it can be interpreted like: 
(a) changes in the mAb4 composition caused by the dynamic and spontaneous 
dissociation of HMWS into species with smaller MW or (b) the SEC separation 
changing the oligomers distribution by disrupting the aggregates (interactions with 
the column matrix), documented in literature or (c) both.  
Since it is not possible to determine the real cause of SEC and HF5 detecting different 
mAb4 species only based on UV-MALS data, it was considered appropriate to 
continue this study using the experimentally-derived value as such. Therefore, the 
MW-based selectivity of SEC and HF5 for the separation of mAb4 in carrier C was 
calculated from the experimental retention time and absolute MW values. The slope 
values corresponding to HF5 and SEC WTC were calculated on the first three eluting 
species, where the relationship between the two logarithms is linear and using only 
two points available for the SEC Dionex column. The selectivity plots are reported in 
Figure 6, (a) for the HF5 separation and (b) for the SEC separations. 
 
 
Figure 6 – Selectivity plots obtained in carrier C for (a) HF5 and (b) SEC. The numbers near the data 
points represent the peak numbers in their elution order. 
 
As expected, once more, the HF5 selectivity for the separation of mAb4 is higher 
compared to both SEC Dionex and SEC WTC corresponding values, indicating that 
HF5 can separate mAb4 species with smaller differences in MW. Small MW 
differences correspond to significant differences in retention time. In order to 
compare the SEC and HF5 performance, the same specific separation parameters 
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discussed in section A and B were calculated and their values are reported in Table 7.  
The dead volumes of the SEC columns were calculated in sections A and B:  a dead 
volume of 14.3 mL and a t0 of 28.7 min for the SEC WTC column and a dead volume 
of 3.8 mL and a t0 of 18.9 min for the SEC Dionex column. The t0 was related 
afterwards to the retention time through the capacity factor, k for the analytes 
separated by SEC, instead of the retention level, RL calculated for the analytes 
separated by HF5. 
Table 9 – Separation performance parameters for SEC WTC and HF5 separations in carrier C 
Device 
Peak 
# 
tR 
(min) 
Retention 
MW 
(g/mol) 
Efficiency 
(N) 
Resolution 
RS 
Specific 
resolution 
(Rsp) 
Selectivity 
SMW 
   k       
SEC 
Dionex 
1 10.8 0.43 370.300 4808   
0.16 
2 12.4 0.34 158.200 1682 0.55 1.5 
   k      
SEC  
WTC 
1 12.6 0.56 950.400 5327   
0.21 
2 13.0 0.55 459.400 3261 0.56 1.8 
3 14.1 0.51 262.600 4770 1.25 5.1 
4 16.2 0.43 159.400 7822 2.69 12.4 
   RL      
HF5 
1 8.3 21.8 149.800 406   
0.25 
2 10.8 28.4 353.900 840 1.56 4.2 
3 12.5 32.9 752.400 958 1.10 3.4 
4 13.6 35.8 4.024.589 616 0.60 0.8 
 
Even at low ionic strength, the SEC WTC column offers higher analytes retention 
compared to the Dionex column and the RL obtained in HF5 employing carrier C are 
similar to the values obtained in other carriers  (carrier A, Table 4 and carrier B, Table 
7), always in the recommended range (< 50). 
As expected, the efficiency in SEC is higher than in HF5 and the SEC WTC column 
offers, once more, an even higher efficiency compared to the Dionex column for the 
separation on mAb4.   
As already observe din sections A and B, the Rsp in SEC and HF5 is similar and the 
resolution is obtained at baseline (Rs > 1.25) for the first two peaks in HF5 and the 
last three peaks in SEC, while the resolution in SEC Dionex is very low. 
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Once again, selectivity is higher in HF5 compared to SEC, which means that HF5 has 
a higher ability to distinguish mAb4 species with close MW values. Considering that 
both SEC WTE and HF5 analyses require almost then same amount of time (20 min) 
and taking into consideration all the observations made on the performance 
parameters, there is a net advantage into employing the HF5 device instead any of 
the SEC columns for the separation of mAb4. The selectivity of the SEC Dionex 
column does not change significantly when decreasing the ionic strength of the 
carrier (b = 0.16 at low IS vs. b = 0.15 at very high IS), thus demonstrating the 
robustness of the Dionex SEC column, while the SEC WTC column is the least 
selective among all separation devices (b = 0.21 at low IS vs. b = 0.13 at very high IS) 
in the low ionic strength buffer. 
 
D. SAMPLE RECOVERY AND mAb4 SELF – DISSOCIATION  
DURING THE STUDY 
 
The mAb4 recovery was calculated as the total area under peak for each 
experimental condition (carrier solutions A, B and C) and separating device (HF5, 
SEC WTC and SEC Dionex) and the results are reported in Figure 7. The highest area 
under the peak was associated to a complete (100%) sample recovery and all the 
other recovery values were calculated as relative to it. 
The self-dissociation of mAb4 HMWS was monitored over 8 working days, which 
corresponded to the duration of the study presented in this sub-chapter, by 
calculating the under each eluting peak. In addition, the disaggregation phenomenon 
is displayed as % distribution of the mAb4 species over time (color coded in Figure 
7).  
As expected, the highest sample recovery is obtained employing the SEC Dionex 
column in carrier A, since it contains the highest amount of salt (NaCl). Nonetheless, 
even at low IS (carrier C), the SEC Dionex column offers the highest mAb4 recovery. 
Under all experimental conditions and employing different separation devices, the 
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mAb4 recovery is always above 93%. 
 
 
Figure 7 – Sample recovery and mAb4 species distribution (%) by SEC and HF5 
 
The self-dissociation of mAb4 is a spontaneous phenomenon (dynamic), as seen for 
mAb1 in sub-chapter 4.1.3 (Chapter 4). It can be somewhat slowed down by storing 
the sample at 4°C, but not entirely stopped. Figure 7 shows that mAb4 oligomers co-
exist with the monomer and, at room temperature, the trend of their dynamic 
equilibrium is shifted towards their dissociation into monomer.  
The mAb4 conversion was monitored even after the SEC-HF5 comparison study was 
completed, by injecting the same mAb4 amount and separating by HF5 for the next 
few days and employing carrier solutions D and E. The mAb4 oligomers conversion 
into smaller MW species (usually monomer) is reported din Figure 8. 
 
Figure 8 shows the tendency of the oligomers to dissociate into monomer as an 
increase in the monomer % (Area 1) and a simultaneous decrease in the % of the 
higher order oligomers (Areas 2-6). This conversion is faster in the beginning and 
slows down as the time passes. Figure 8 also shows the fact that HF5 at 97.5 hours 
allows the separation of more species than the previous SEC separation (SEC WTC at 
96.0 hours), confirming the gentle separation mechanism of FFF. It is very likely that 
the SEC separation changed the aggregates % by disrupting high order oligomeric 
species through interactions with the column matrix. 
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Figure 8 - mAb4 oligomers conversion into smaller MW species over 7 days. Carrier solutions 
indicated by letters A – E. 
 
   E. HF5-UV-MALS IN LOWER IONIC STRENGTH MOBILE PHASES:  
CARRIER D (55 MM) AND CARRIER E (171.5 MM) 
 
Lastly, after the SEC-HF5 comparison was completed, HF5 was employed for the 
separation of mAb4 in low (E) and very low (D) ionic strength carrier solutions, to 
demonstrate the versatility of the technique residing in the wide choice of carrier 
solutions.  
The exact composition of the mobile phases was reported in Table 1. The mAb4 
sample was the same one used during the SEC-HF5 comparison study, therefore in 
an advanced stage of self-dissociation of the high order oligomers.   
The HF5 separation profiles at 280 nm of mAb4, as well as the MW value 
corresponding to each eluting peak, are reported in Figure 9, (a) in carrier D and (b) 
in carrier E. 
 
 
Figure 9 – HF5-UV-MALS separation profiles of mAb4 in (a) carrier D and (b) carrier E. 
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As expected, the separation profiles in Figure 9a and 9b show the separation of only 
3 and, respectively 2 mAb4 species. The exact MW values, as well as the peaks 
assignment are reported in Table 10. The values reported in Table 10 confirm that 
peaks 1 and 2 in Figures 9 correspond to mAb4 monomer and respectively, mAb4 
dimer.   
A third peak, corresponding to a polydisperse population of mAb4, with an average 
MW between the trimer and the tetramer is observed only in Figure 9a. It is 
conceivable that, during the separation reported in Figure 9b, these HMWS have 
already dissociated into monomer, therefore they are no longer present at the time of 
the analysis. This explanation is supported by the oligomers % distribution in Figure 
8, which shows the increased levels of monomer when carrier E is employed (time: 
168.5 h) compared to the previous monomer % value obtained in carrier D (time: 
163.0 h). 
 
Table 10 – Peak assignment for the separation profiles reported in Figure 9. Absolute MW values 
derived from MALS measurements. 
Carrier Peak # MW (g/mol) MWHMWS/MW1mer Peak assignment 
D 1 153.400 1.0 Monomer 
(Figure 9a) 
2 315.300 2.1 Dimer 
3 534.000 3.5 Polydisperse population 
E 1 149.500 1.0 Monomer 
(Figure 9b) 2 355.600 2.4 Dimer / polydisperse  
 
Next, the MW-based HF5 selectivity for the separation of mAb4 in carrier D and E 
was calculated from the experimental retention time and MW values. The slopes 
were calculated on the all the available experimental points and the selectivity plots 
are reported in Figure 10. 
The selectivity values are very similar to the ones obtained in higher ionic strength, 
(reported in Tables 4, 7 and 9), therefore, a direct correlation between the ionic 
strength of the mobile phase and the HF5 selectivity could not be established based 
on this data. The HF5 selectivity remains high (around 0.3) and appears not to be 
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influenced by ionic strength.  
 
Figure 10 – HF5 selectivity plots obtained in carrier D and carrier E. The numbers near the data 
points represent the peak numbers in their elution order 
 
The same specific separation parameters discussed in section A, B and C were 
calculated for the HF5 separations in carriers D and E and their values are reported 
in Table 11. The void time, t0 was related to the retention time through the retention 
level, RL. 
Table 11 – Separation performance parameters for HF5 separations in carriers D and E 
Carrier 
Peak 
# 
tR 
(min) 
Retention 
MW 
(g/mol) 
Efficiency 
(N) 
Resolution 
RS 
Specific 
resolution 
(Rsp) 
Selectivity 
SMW 
   RL       
D 
1 7.1 17.8 153.400 471   
0.31 
2 8.9 22.3 315.300 994 1.42 4.5 
3 10.5 26.3 534.000 471 0.94 4.1  
   RL      
E 
1 6.9 17.3 149.500 930   
0.27 
2 8.8 21.9 355.600 480 1.46 3.9 
 
The retention levels, RL, as well as specific resolution values, Rsp obtained in HF5 in 
carriers D and E are similar to the values obtained in other carriers (carrier A, Table 4 
and carrier B, Table 7 and carrier C, Table 9), with RL always in the recommended 
range (< 50). Baseline or at least acceptable resolution among mAb4 species is always 
obtained in carriers D and E. 
As mentioned previously in this section, the selectivity values are high (around 0.3) 
and apparently not influenced by the carrier solution ionic strength. Efficiency values 
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are even higher than the ones previously reported for carriers A – C. 
 
4.1.6.4. CONCLUSIONS 
 
HF5 has proven to be a highly selective (average SMW = 0.3) separation tool for the 
characterization of mAb4, a representative protein formulation which contained high 
order oligomers in dynamic equilibrium with the monomer. As the time passed, this 
equilibrium shifted towards the monomer, therefore the oligomers dissociated into 
smaller MW species. Thanks to the gentle separation mechanism, HF5 online coupled 
with MALS detection was able to detect and quantify these changes in the mAb4 
composition more accurately than SEC. 
Even though the SEC separation is slightly faster, allowing the mAb4 separation in a 
short analysis time, it is very likely that some mAb4 species co-eluted with other 
species with similar MW value, therefore their presence was not detected. It is also 
very likely that, during the SEC separation, the loosely bound oligomers were 
disrupted, hence, the results obtained by SEC did not reflect the true mAb4 
composition.  
These two SEC issues (insufficient selectivity and changes in the sample composition 
caused by the separation mechanism / interactions with the column matrix) were 
overcome when HF5 was employed, thanks to the gentle separation mechanism 
(since the retention is achieved by applying an external field a not by the sample 
passing through a sieving matrix) and to the high HF5 selectivity, which allowed the 
separation and detection of HMWS present at trace levels.  
Both SEC and HF5 provided a good sample recovery and the mAb4 oligomers 
dynamic dissociation was monitored over 7 days, providing valuable information 
regarding the spontaneous changes in the sample composition which were not 
necessarily related to the separation technique. Any separation technique 
intrinsically changes the sample composition, but the fact that we were able to 
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monitor these changes reflects the transient nature of these aggregates and the fact 
that these aggregates are, most likely, metastable higher order oligomeric species, as 
described by [Philo 2006, Philo and Arakawa 2009]. 
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4.1.7. HIGH REPRODUCIBILITY AND LOW DETECTION LIMIT 
HF5 – MALS METHOD FOR THE CHARACTERIZATION OF 
AGGREGATES IN PROTEIN FORMULATIONS. CASE STUDY: 
AVIDINOX® 
 
 
 
In sub-chapter, the short-term accelerated stability study of a modified protein, 
stored in lyophilized form (AvidinOX®), was conducted by HF5 online coupled with 
UV and MALS detection.  
The rapid development of protein-based pharmaceuticals highlights the need for 
robust analytical methods to ensure their quality (purity and stability). Monoclonal 
antibodies and large proteins that have an increasing role in biopharmaceutical 
applications for their highly specific action and are often modified to enhance or 
modulate their activity or stability when used as drugs. Their biological activity and 
the stability are closely related to the preservation of their complex structure, which 
is often subjected to stresses (external factors), which can cause their degradation 
and/or lead to aggregation. 
Due to its ability to easily aggregate in solution, AvidinOX® is a model sample that 
gives the opportunity to demonstrate the various HF5 advantages (described in sub-
chapters 4.1.1 – 4.1.6) for the of study the aggregation process, for the size and MW 
characterization and for the quantification of the various type of aggregates during 
several storage conditions in a relatively short time. 
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The detailed description of the HF5 method development is discussed in the first 
part of this study, where the design of experiments approach (a 2x2 factorial design) 
was employed and a simple algorithm was built to help choose the optimal 
combination of flow conditions for AvidinOX® formulation separation. Criteria like 
resolution, peak symmetry and valley height between species are employed for the 
construction of the algorithm. 
The protein aggregates, present at trace levels, were successfully quantified and their 
MW values were calculated by MALS. This study also highlighted the 
miniaturization advantages regarding the decreased limit of detection of AvidinOX® 
(protein) aggregates and the HF5 versatility regarding the carrier solution 
composition (the possibility of working in denaturing vs. native mobile phase) that 
made possible the distinction and quantification of different types of protein 
aggregates (covalent vs. non-covalent). 
The self-association process between units of an oxidized protein (AvidinOX®, each 
64 kDa unit is actually a very stable tetramer, therefore made of 4x16 kDa sub-units), 
which have (most likely) suffered a conformational change due to chemical 
instability, and/or promoted by the presence of degradation products, was 
monitored by HF5-UV-MALS. 
The definitions and formulas of all analytical parameters employed in this study 
were previously discussed in sub-chapter 2.4 (Chapter2). 
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4.1.7.1. EXPERIMENTAL SETUP 
 
HF5 was performed using an Agilent 1200 HPLC system (Agilent Technologies, 
Santa Clara, CA, USA) consisting in a degasser, an isocratic pump, an auto sampler 
and a variable wavelength UV detector, combined with an Eclipse® DUALTECTM 
FFF separation system (Wyatt Technology Europe, Dernbach, Germany). The 
ChemStation version B.04.03 [87] software for Agilent instrumentation (Agilent 
Technologies) was used to set and control the instrumentation and for the 
computation of various separation parameters. The software package Wyatt Eclipse 
@ ChemStation version 4.02 (Wyatt Technology Europe) was used to manage the FFF 
separation system. 
The hollow fiber was a 17 cm long polyether-sulfone (PES) fiber, type FUS 0181 
available from Microdyn-Nadir (Wiesbaden, Germany) with the following 
characteristics: 0.8 mm ID, 1.3 mm OD, and 10 kDa MWCO, corresponding to an 
average pore diameter of 5 nm.  
An 18-angle multi angle light scattering (MALS) detector model DAWN® HELEOSTM 
(Wyatt Technology Corporation, Santa Barbara, CA, USA) operating at a wavelength 
of 658 nm was used to measure the absolute MW of proteins in solution. An UV 
detector operating at 280 nm was used as concentration detector. ASTRA® software 
version 5.3.2.14 (Wyatt Technology Corporation) was used to handle signals from the 
detectors (MALS, and UV), to compute the protein MW values and to quantify the 
aggregate levels. 
 
4.1.7.2. SAMPLES AND REAGENTS 
 
AvidinOX®  (produced by Sigma Tau) is an oxidized form of avidin and indicated 
by its manufacturer as a ”pre-targeting receptor” for drug delivery in cancer, widely 
used in vitro for its capacity to bind biotin. However, due to its short residence in  
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blood and tissues, in vivo use of avidin is limited to therapeutic treatments where the 
radiolabelled biotin or its derivatives must be rapidly eliminated from the 
circulation. AvidinOX® is obtained by 4-hydroxyazobenzene-2′-carboxylic acid-
assisted sodium periodate oxidation. Its synthesis method generates aldehyde 
groups from avidin carbohydrates, sparing biotin-binding sites from inactivation 
[Reschiglian et al. 2013].  
AvidinOX® binds cellular and interstitial protein amino groups through Schiff bases, 
in both normal and neoplastic tissues, resulting in a tissue half-life of 2weeks, 
compared with 2 h of native avidin. AvidinOX® preserves the native structure of 
avidin, consisting in four identical subunits (homotetramer) of 16 kDa and high 
affinity and specificity for biotin. Nonetheless, as a consequence of the chemical 
modifications that lead to Schiff base formations, in solution at neutral pH, the 
protein easily tends to aggregate, thus it is stored in lyophilized conditions [Santis et 
al. 2010, Petronzelli et al. 2011]. 
 
Sodium chloride (NaCl), sodium acetate and urea were acquired from Sigma Aldrich 
Co. (St. Luis, MO, USA).  Lyophilized AvidinOX® vials, supplied by Sigma-Tau, were 
reconstituted with ultrapure water to a final concentration of 3 mg/mL of protein in 
formulation buffer (mannitol 3 mg/mL, 0.067 M Sodium Acetate, pH 5.3). On one 
occasion, AvidinOX® was reconstituted in 4 M urea solution to the same final 
concentration, 3 mg/mL. Samples were injected immediately after preparation and 
after 3 h of storage at room temperature and 4°C or after 24 hours of storage at room 
temperature and 4°C.  
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4.1.7.3. RESULTS AND DISCUSSION 
 
A. DESIGN OF EXPERIMENTS (DOE) APPLIED TO HF5 METHOD DEVELOPMENT. 
SIMPLE ALGORITHM PROPOSED TO DETERMINE THE OPTIMAL SEPARATION 
METHOD, UNDER DIFFERENT EXPERIMENTAL CONDITIONS. CASE STUDY: 
AVIDINOX® FORMULATION. 
 
A 2x2 factorial design was employed during the HF5 method development. Two of 
the most important parameters that have great implications on the separation 
mechanism were considered as factors in the factorial design: the channel flow rate, vc 
and the cross-flow rate, vx. Each of them had two levels: a high value (+) and a low 
value (-), resulting in a total of 4 initial combinations. The flow rate values used for 
the 4 combinations are reported in Table 1.  
Table 1 - Factorial design for the HF5 method development, part 1 
Area vc 
(mL/min) 
Variable 
1 
vx 
(mL/min) 
Variable 
2 
Combination 
A 0.2 - 0.35 - - -  
B 0.2 - 0.85 + - + 
C 0.4 + 0.35 - + - 
D 0.4 + 0.85 + + +  
 
Taking into account the manufacturer’s (Wyatt Technology Europe) 
recommendations regarding the flow rates that can be achieved during a typical HF5 
run under optimal conditions with Eclipse® DUALTECTM (0.1 – 1.0 mL/min for the 
cross flow rate and 0.1 – 0.5 mL/min for the channel flow rate), the instrumental 
operational range was divided into 4 initial areas and a combination between the two 
factors was placed inside of each one (see Figure 1). 
Figure 1 depicts the approach used for the HF5 method development of AvidinOX®, 
considering also the MW of the protein (64 kDa): the instrument operational range 
was sliced into 4 sections and a flow rates combination was chosen inside each one. 
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Figure 1 – HF5 operational limits and flow rate combinations for the experimental design 
 
The experiments were performed following the order illustrated in Table 1. For each 
experiment, an amount of 9 µg of AvidinOX® was injected (3 µL of a 3 mg/mL 
solution) and separated in a carrier solution very similar to the protein’s formulation 
buffer: 50 mM acetate buffer supplemented with 100 mM NaCl (total ionic strength 
150 mM), at pH 5.3. A second mobile phase was employed to separate AvidinOX®, 
whose composition was identical to the first one, but supplemented with 4M urea, 
from this point forward called “denaturing carrier solution”. 
The focus flow rate (0.85 mL/min) and the focus time (3 min) were set constant for all 
experiments within the Eclipse method. The total elution time was set at 22 min 
(considered sufficient for all the species of interest to elute), followed by a 2 minutes 
field release to avoid possible sample carry over. 
The HF5 elution profiles at 280 nm are reported in Figure 2, for both non-denaturing 
and denaturing separation conditions. Each flow rates combination (A-D) allows the 
separations of at least two AvidinOX® oligomers. As expected, the retention times of 
the same species increase when the separation is performed under denaturing 
conditions, because of the urea 4 M solution viscosity (η/η0 = 1.2, therefore     
tR,urea/tR,water = 1.2). 
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Figure 2 – HF5 separation profiles at 280 nm obtained under non-denaturing and denaturing 
conditions applying flow conditions A, B, C and D. 
 
The separation was monitored by UV detection at 280 nm and the following 
separation parameters were calculated in order to choose the best out of the 4 
combinations: resolution, peak symmetry and valley height between peaks (expressed as % 
of the smallest separated peak) and the values are reported in Table 2. 
 
Table 2 – Separation performance parameters: resolution, peak symmetry and valley height 
between first and second peak (part 1) 
Mobile phase Area Resolution 
Monomer 
symmetry 
Valley height as % of the 
smallest peak 
Non denaturing A (- -) 0.94 1.02 58.8 
 B (- +) 0.82 1.77 58.8 
 C (+ - ) 0.85 1.03 94.4 
 D (+ +) 0.79 2.19 56.2 
Denaturing A (- -) 1.07 1.18 35.2 
 B (- +) 0.89 1.52 50.0 
 C (+ - ) 0.89 1.07 66.6 
 D (+ +) 0.97 1.91 43.4 
 
The best combination was found to be A, for both denaturing and non-denaturing 
separation conditions, not only based on the values corresponding to these 
separation parameters, but after careful observation of the UV elution profiles and 
after making sure that the values actually reflected the best separation conditions.  
Flow rates combination A was further explored to narrow down to the most suitable 
Chapter 4, Part1, 4.1.7. HF5-UV-MALS for the characterization of aggregates in protein formulations  
Case study: AvidinOX®  
223 
 
separation method for the AvidinOX® samples. The same 2x2 factorial design 
approach was used, but with different flow rate values (reported in Table 3) – at the 
border with the other areas (Figure 1). The same sample amount and volume were 
separated and the same carrier solutions were employed. 
 
Table 3 - Factorial design for the HF5 method development, part 2 
Area vc 
(mL/min) 
Variable 
1 
vx 
(mL/min) 
Variable 
2 
Combination 
A 0.2 - 0.35 - - -  
A1 0.2 - 0.55 + - + 
A2 0.35 + 0.35 - + - 
A3 0.35 + 0.55 + + +  
 
The separation parameters values obtained from experiments involving areas A, A1, 
A2 and A3 are summarized in Table 4.  
 
Table 4 – HF5 performance parameters: resolution, peak symmetry and valley height between first 
and second peak (part 2) 
Mobile phase Area Resolution 
Monomer 
symmetry 
Valley height as % of the 
smallest peak 
Non denaturing A (- -) 0.94 1.02 58.8 
 A1 (- +) 1.15 1.36 31.5 
 A2 (+ -) 1.11 1.5 33.3 
 A3 (+ +) 0.89 1.22 55.5 
Denaturing A (- -) 1.07 1.18 35.2 
 A1 (- +) 1.28 1.37 33.3 
 A2 (+ -) 1.24 1.63 26.3 
 A3 (+ +) 1.14 1.25 37.5 
 
In order to facilitate data interpretation, the monomer symmetry value was plotted 
against the corresponding monomer-dimer resolution for each flow condition, under 
both non-denaturing (Figure 3a) and denaturing separation conditions (Figure 3b). 
In Figure 3, the acceptable resolution value (1) and peak symmetry optimal value (1) 
are highlighted as red lines. These are the same values which will be used in the 
objective approach to choosing the optimal separation flow rates combination of 
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AvidinOX®. 
 
 
Figure 3 – HF5 performance under (a) non-denaturing and (b) denaturing conditions. Symmetry 
plotted against corresponding resolution for each flow rates combination. The (resolution; 
symmetry) values are displayed under each flow condition 
 
 
Based on the computed separation parameters obtained with DOE approach, a 
simple algorithm is proposed in order help choose the optimal flow rates 
combination for the separation under both non-denaturing (Figure 4) and denaturing 
(Figure 5) separation conditions, represented as red dots in Figure 3. 
The first decisional block of the algorithm represents the resolution. A score is 
calculated for each flow rates combinations, represented by the difference between 
the calculated resolution (Rs) and 1, which corresponds to an acceblable separation 
(when 2% of peak ares overlapse).  
The positive resolution scores are tested according to the second decisional block, 
represented by the peak symmetry value, 1 representing a gausssian (symmetric 
peak). Negative values correspond to tailed peaks, while postive values correspond 
to fronted peaks.   
The negative resolution scores are tested again, and the ones that match the criteria 
(0.9<Rs<1) arrive to the symmetry decisional block, and tested following the above 
described procedure. 
A total score, represented by the sum between resolution score and symmetry score, is 
calculated for each value which passed the symmetry decisional block. The two 
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values closest to zero arrive to the third decisional block, which is represented by the 
valley height between the separated species and the other values are discarded. The 
flow rates combination with the smallest % is chosen as the optimal method. 
 
 
Figure 4 – Simple algorithm used to determine the optimal flow rates combination for the 
separation of AvidinOX® formulation under non-denaturing conditions 
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Figure 5 – Simple algorithm used to determine the optimal flow rates combination for the 
separation of AvidinOX® formulation under denaturing conditions 
 
The factorial experiment approach (2x2 in this case, but it could be extended to other 
factors/variables or levels) provides a simple and quick, yet effective way to “scan” 
the whole instrumental range in search for most suitable separation method for the 
sample of interest. The number of experiments depends on the considered factors 
and on the number of levels for each one.  
There are a few software meant for the design of experiments already commercially 
available that are able not only to generate the combinations (which becomes more 
difficult as the factors and/or the levels are more than 2) and to plan the order of 
experiments through randomization (to eliminate the succession of experiments as 
another variable to take into consideration), but are also able to calculate and 
represent visually the correlations between factors. 
Since one of the major drawbacks of FFF in general is having to take into 
consideration too many parameters when developing a method, without knowing 
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exactly how and if one parameter could influence another (or more), the factorial 
design approach could prove itself very useful to study the correlations between 
separation variables and their impact on the separation parameters.  
This approach could simplify immensely the method development step aimed for the 
separation of protein from their oligomeric species (i.e: antibodies), rendering FFF as 
separation method more “user-friendly”, not to mention time-saving, all the while 
remaining versatile. 
However, careful interpretation of the results is required, because the parameters 
values alone can be deceiving and could lead to an erroneous interpretation, if they 
are not supported by the confirmation from elution profiles.  
 
B. HF5 – MALS METHOD FOR THE STUDY OF AVIDINOX® FORMULATION 
STABILITY AND AS MEANS OF INVESTIGATING THE NATURE OF AVIDINOX® HIGH 
MOLECULAR WEIGHT SPECIES (HMWS) 
 
The HF5 methods that proved to be optimal for the separation of the AvidinOX® 
formulations were chosen applying the algorithms described in the previous section 
(marked with red dots in Figure 3) and are reported in Table 5. 
 
Table 5 – HF5 methods for the AvidinOX® stability study 
Mobile phase 
vc 
(mL/min) 
vfocus 
(mL/min) 
Focus time 
(min) 
vx 
(mL/min) 
Non-denaturing 0.2 
0.85 3 
0.55 
Denaturing 0.2 0.35 
 
AvidinOX® formulation’s stability was monitored over a series of injections at 
specific time intervals. More specifically, the variation of the protein oligomers levels 
was monitored by UV-MALS detection, immediately after the reconstitution (t0), after 
3h, at room temperature (t1) and after 24h, at 4°C (t2).  
AvidinOX® stability was investigated under both native and denaturing conditions, 
in order to determine the true nature of the protein aggregates. For each experiment, 
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an amount of 9 µg of AvidinOX® was injected (3 µL of a 3 mg/mL solution) and 
separated in a carrier solution very similar to the protein’s formulation buffer: 50 mM 
acetate buffer supplemented with 100 mM NaCl (total ionic strength 150 mM), at pH 
5.3.  
A denaturing mobile phase was also employed to separate AvidinOX®, which had a 
composition identical to the first one, but supplemented with 4M urea. Urea, as 
denaturant, has the ability to disrupt protein aggregates bound by weak interactions, 
such as hydrogen bonds or hydrophobic interactions.  
The HF5 elution profiles, as well as the oligomers levels are reported in Figure 6. The 
blue traces correspond to separation performed under native (non-denaturing) 
conditions, while the red traces were obtained under denaturing conditions. 
 
 
Figure 6 – HF5 separation profiles of AvidinOX® at 280 nm during the stability study (a) injected 
immediately after reconstitution; (b) injected after 3h of reconstitution and storage at room 
temperature and (c) injected after 24h of reconstitution and storage at 4°C 
 
Each HF5 separation method allows the elution of three bands of AvidinOX®. The 
retention time difference between the red and the blue traces at each time point can 
be explained by the different viscosity of the mobile phase. When 4 M urea was 
added to the mobile phase, a retention time delay was to be expected: since    
ηurea/ηwater = 1.2, the corresponding retention time delay will be directly related to the 
viscosity ratio according to HF5 retention theory (Equations 11 and 12 discussed in 
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sub-chapter 2.2.2, Chapter 2).  
From the retention time values, the peaks were assigned as follows: (1) AvidinOX® 
monomer, (2) AvidinOX® dimer and (3) AvidinOX® trimer. The oligomers levels 
have different trends under denaturing and non-denaturing separation conditions. 
Under native conditions, the trimer levels slightly increase over time, regardless of 
the storage temperature. Under denaturing conditions, the trimer levels decrease 
after 3h at room temperature, but increase when kept for 24h at 4°C. The dimer 
levels, under both non-denaturing and denaturing conditions, slightly decrease after 
3h of storage at room temperature, but increase after 24h at 4°C.  
The absolute MW values of the three elution bands were determined by online 
coupling Eclipse® DUALTECTM (HF5) with a DAWN® HELEOSTM (MALS detector) 
and using a UV concentration detector set at 280 nm. 
For each experiment, an amount of 9 µg of AvidinOX® was injected (3 µL of a 3 
mg/mL solution) and the aggregate levels, as well as their absolute MW was 
monitored as follows: at t0 (immediately after reconstitution) after 2h (kept at RT), 3h 
(kept at RT and at 4°C) and after 24h ( kept at 4°C). 
The elution profiles and the MW values corresponding to the three elution bands of 
AvidinOX® formulation kept at 4°C are reported in Figure 7 (a) separated in non-
denaturing mobile phase and (b) separated in denaturing mobile phase. 
 
 
Figure 7 - HF5-MALS elution profiles and MW corresponding to the three elution bands of 
AvidinOX® kept at 4°C after reconstitution 
With the passing of time, the elution bands tend to lose symmetry and the retention 
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times increase. The balance between the oligomers levels shifts slightly, as described 
before. The MW values were averaged over a series of 5 injections for each condition 
(5 x non-denaturing and 5 x denaturing) and the ratios MW oligomer/MW monomer were 
found as follows: MW peak 2/MW peak 1 = 2.04 ± 0.06 and MW peak 3/MW peak 1 = 4.37 ± 0.08. 
These absolute MW values prove that the third peak was erroneously assigned (from 
the retention time value) to the AvidinOX® trimer, when, in fact, its MW value 
corresponds to the tetramer. 
The elution profiles and the MW values corresponding to the three elution bands of 
AvidinOX® formulation stored at room temperature are reported in Figure 8 (a) 
separated in non-denaturing mobile phase and (b) separated in denaturing mobile 
phase. 
 
Figure 8 – HF5-UV-MALS elution profiles and MW corresponding to the three elution bands of 
AvidinOX® stored at room temperature after reconstitution 
 
When stored at room temperature after reconstitution, AvidinOX® elution bands 
have highly reproducible retention times up to 3h since sample reconstitution. The 
MW oligomer/MW monomer ratios are very similar to the ones already reported in the 
previous paragraph. 
The aggregates levels for all experimental conditions are reported in Table 6. The 
tetramer levels decrease when the separations are performed in denaturing mobile 
phase. This finding suggests the presence of two types of AvidinOX® aggregates: 
non-covalent, which dissociate into smaller units when urea 4 M is present and 
covalent, which are not disrupted by urea. The two types of aggregate levels are 
reported in Table 7. 
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Table 6 – Aggregates levels during the stability study of AvidinOX® formulation 
Time t (°C) Mobile phase Monomer (%) Dimer (%) Tetramer (%) 
reconstitution any Non denaturing 88.9 7.9 3.0 
  Denaturing 85.0 11.0 2.6 
2h RT Non denaturing 86.1 8.9 4.4 
  Denaturing 86.5 10.1 3.8 
3h RT Non denaturing 87.8 8.6 3.4 
  Denaturing 86.5 10.9 2.1 
3h 4°C Non denaturing 86.4 9.1 3.9 
  Denaturing 85.3 10.9 2.8 
24h 4°C Non denaturing 84.5 10.7 4.2 
  Denaturing 82.2 13.1 3.6 
 
The amount of covalent aggregates was calculated as the difference between the 
aggregate levels detected in non-denaturing and denaturing carrier solution and they 
are reported as % relative to the aggregates levels under non-denaturing conditions 
(100%). The dimer is the only oligomer whose levels increase under denaturing 
conditions. 
 
Table 7 – True nature of AvidinOX® hMWs 
Time t°C 
Tetramer 
covalent 
aggregates (%) 
Tetramer non-
covalent 
aggregates (%) 
Dimer % increase 
under denaturing 
conditions 
reconstitution any 86.7 13.3 28.2 
2h RT 86.4 13.6 11.9 
3h RT 61.8 38.2 21.1 
3h 4°C 71.8 28.2 16.5 
24h 4°C 85.7 14.3 18.3 
  
Table 7 reports that most of the aggregates in tetramer form are preserved under 
denaturing conditions, therefore stable to urea denaturation (most likely covalent), 
and the highest decrease occurs when the sample is stored at RT for 3h. The highest 
conversion rate occurs immediately after sample reconstitution, when 13.3% of 
tetramer dissociates into dimer units. The same phenomenon is observed in reverse, 
as a monomer dynamic association into dimer, occurring simultaneously with the 
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tetramer dissociation (4.4% of monomer converts into dimer).  
The same trend, though less obvious, of dynamic association (monomer into dimer) / 
dissociation (tetramer into dimer) can be noticed along all the time points. This 
suggests that all oligomers tend towards the dimer form, which appears to be the 
most stable of all oligomers, but this process can be slowed down over time, by 
keeping the sample at 4°C.  
In order to test the effectiveness of urea as denaturant and to understand whether the 
time that the denaturant spends in contact with the protein influences the aggregates 
levels, an AvidinOX® sample was reconstituted in 4M urea solution, separated 
under non-denaturing conditions after 3h and its elution profile was compared to the 
sample reconstituted in water. The comparison is reported in Figure 9. 
 
 
Figure 9 – AvidinOX® aggregates levels after 3h since sample reconstitution, storage at room 
temperature 
 
Figure 9 shows that the AvidinOX® oligomers levels do not change significantly 
when the sample reconstitution is performed in 4 M urea and the 2% decrease in 
monomer levels appears to be directly related to the increase in the dimer levels. This 
finding suggests that the presence of urea causes the denaturation of the monomeric 
units leading to the aggregation of conformationally-altered monomers into dimers 
(probably according to aggregation mechanism 2, sub-chapter 4.1). 
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C. LIMIT OF QUANTIFICATION (LOQ) AND LIMIT OF DETECTION (LOD) 
ESTIMATION FOR HIGH MW AGGREGATES IN AVIDINOX® FORMULATION             
BY HF5 – UV.  
 
The reproducibility of the HF5-UV method was tested under both native (non-
denaturing) and denaturing conditions, at different time intervals from sample 
reconstitution and at different sample storage temperatures. In particular, the 
reconstituted sample was separated at t0, after 3h (t1) stored at RT and after 24h (t2) 
stored at 4°C. Each separation was performed three times and the method 
repeatability was tested on the retention times of the three main bands. The retention 
time mean (average) value and the relative standard deviation (RSD%) calculated 
over three repeated runs are reported in Table 8.  
No significant differences can be observed between the retention time values of the 
same species, repeated under the same experimental conditions. The HF5 method is 
therefore highly repeatable (first level of precision is met).  
Table 8 – Average retention time values and standard deviation (n=3) for the three main elution 
bands in native (non-denaturing) and denaturing conditions. 
 Non denaturing Denaturing 
 
# Peak 
Average 
tR (min) 
RSD% # Peak 
Average 
tR (min) 
RSD% 
t0 1 8.7 4.6 1 10.6 7.5 
 2 11.8 5.1 2 14.0 19.3 
 3 14.2 5.6 3 16.3 7.4 
3h (t1), RT 1 8.8 8.0 1 10.6 0.9 
 2 11.7 7.7 2 14.0 11.4 
 3 13.9 4.3 3 17.0 4.7 
24h (t2), 4°C 1 9.0 2.2 1 10.2 2.9 
 2 12.0 5.8 2 13.5 3.7 
 3 14.3 11.9 3 15.9 3.1 
 
Next, the reliability on the detection method was evaluated. For this purpose, the 
signal from a fluorescence detector was included in the study, along with the UV 
signal which was always recorded. The fluorescence detector was set on an excitation 
wavelength of 280 nm and an emission wavelength of 340 nm, specific for proteins. 
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The UV signal was set, as usual, to record an absorbance wavelength of 280 nm. 
Since both detectors were coupled online with the Eclipse® DUALTECTM FFF 
separation system, their signals were recorded simultaneously. 
Aliquots of the same AvidinOX® sample were placed in three different vials and the 
same sample amount (9 µg) was injected in sequence. Figure 10 reports the elution 
profiles of AvidinOX® injected immediately after reconstitution (a and c) and after 
3h, samples stored at room temperature (b and d). 
 
 
Figure 10 – HF5 elution profiles of different aliquots of AvidinOX®, fluorescence emission at 340 
nm (a and b) and UV absorbance at 280 nm(c and d).  
 
Figures 10a and 10b show the variation of the monomer peak height and the table 
below shows the same significant variations in the area under the peak (either total 
or monomer) when the fluorescence signal is used to monitor AvidinOX® 
separation. Figures 10c and 10d show that the elution profiles are identical under 
either separation conditions and the table below confirms the repeatability of the 
measurements, since the RSD is only 2%. This findings confirm that the UV 
absorbance signal in much more reliable for the quantification of the aggregates 
levels in AvidinOX® formulation than the fluorescence emission signal (as discussed 
in sub-chapters 3.2.1.2 and 4.1.5., the fluorescence signal might also reflect changes in 
the molecular conformation of AvidinOX®, which disturb the linear relationship 
between protein concentration and fluorescence emission).  
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Next, the Limit of Blank (LOB = meanblank + 1.645×STDEVblank) was determined over 10 
blank injections and was found to be 0.019 mAU. 
The limit of detection (LoD) and of quantification (LoQ) for dimer and tetramer were 
determined from the corresponding calibration curves obtained by injecting different 
amounts of AvidinOX® and separating by HF5-UV under non-denaturing conditions. 
LoD and LoQ were determined on samples injected immediately after the 
reconstitution, when the aggregates level was the lowest.  
The calibration curves were determined as dimer and tetramer height (expressed in 
mAU) plotted against the corresponding dimer and tetramer injected amount 
(expressed in µg). Since the sample recovery was considered complete and the 
injected amount was known at all times, the dimer amounts used in the calibration 
curves were estimated as % of the (total) injected amount.  The calibration curves and 
their equations are reported in Figure 11. 
 
 
Figure 11 – Calibration curves for the calculation of LoD and LoQ of AvidinOX® aggregates 
 
The limit of detection (LOD = 3 × LoB) and quantification (LoQ = 10 × LoB) are 
reported in Table 9, for both dimer and tetramer. 
The following oligomers distribution was determined at t0 under non-denaturing 
conditions: monomer (88.9%), dimer (7.9%) and tetramer (3.0%), previously reported 
in Table 6. Correlating this distribution with LoD and LoQ values from Table 9, the 
lowest AvidinOX® amount which needs to be injected in order for the dimer to be 
detected is 215 ng and 524.9 ng in order for the dimer to be quantified and, 
respectively, the lowest AvidinOX® amount which needs to be injected in order for 
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the tetramer to be detected is 489.7 ng and 1723.6 ng in order for the tetramer to be 
quantified. 
Table 9 – LoD and LoQ determination of AvidinOX® aggregates 
Aggregate type Equation x1 (ng) x2 (ng) 
Dimer LoD = y1 = 5,4046 x1 - 0,0351 16.99  
 LoQ = y2 = 5,4046 x2 - 0,0351  41.46 
Tetramer LoD = y1 = 3,5739 x1 + 0,0042 14.69  
 LoQ = y2 = 3,5739 x2 + 0,0042  51.71 
Where: 
LoD = 3 × LoB = 0.0567 mAU (y1) 
LoQ = 10 × LoB = 0.189 mAU (y2) 
 
 
4.1.7.4. CONCLUSIONS 
 
Since one of the major drawbacks of FFF, in general, is having to take into 
consideration too many parameters when developing a method, design of 
experiments (DOE) approach could simplify immensely the method development 
process aimed at the separation of (therapeutic) protein self-associated species 
(monomers and their oligomeric species, rendering FFF more “user-friendly”, not to 
mention time-saving and sample- customizable. A simple algorithm was successfully 
applied, which provided the optimal flow rates combination for the separation of 
AvidinOX® under both denaturing and non-denaturing conditions. 
The versatility of HF5 allowed the use of a denaturing mobile phase containing a 
high urea concentration and the online coupling of HF5 with MALS provided the 
accurate MW of AvidinOX® elution bands. The stability of the AvidinOX® 
formulation was monitored over time and under different sample storage conditions. 
Employing denaturing and non-denaturing carrier solutions, the true nature of the 
aggregates was established and most of the high MW aggregates were found to be 
urea-insoluble, therefore considered covalent.  
Lastly, the repeatability of the HF5 results was confirmed, meeting the first level of 
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precision and – after ascertaining the UV signal’s reliability as detection method – the 
LoD, as well as LoQ values, were determined for both dimer and tetramer. The 
developed HF5-UV-(MALS) methods are highly sensitive, able to detect and quantify 
trace levels of AvidinOX® aggregates and it is proven that they provide repeatable 
results.  
This study proves how, thanks to (a) the wide size range of separation and (b) the 
virtually infinite chromatographic space for the elution of aggregates, (c) the ability 
to analyze protein formulation under a variety of storage conditions and 
formulations and (d) the great versatility toward the choice of separation conditions 
(mobile phase composition, pH, additives) without loss of efficiency, HF5-UV-MALS 
could become the method of choice for the analysis of proteins formulations, where it 
can be invaluable in quantifying trace levels of high MW protein aggregates 
 
Note: parts B and C of this sub-chapter were published as [Reschiglian et al. 2013] 
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INTRODUCTION 
 
 SYNOPSIS: SENESCENCE 
 
Senescence (from the Latin word: “senescere”, meaning “to grow old”) or biological 
aging represents an intrinsic process occurring in all living organisms that consists in 
the age-related progressive deterioration of all physiological functions, loss of 
viability, increased vulnerability towards pathogens, reflecting changes at molecular 
and cellular level and ultimately leading to death. At both organism and cellular 
level, the ability to respond to stressors declines and the homeostatic imbalance, as 
well as the risk of aging-associated diseases increase – all hallmarks or aging. 
The factors that cause the development of cancer, neurodegenerative and 
cardiovascular diseases are all rooted in the natural biological aging process. 
Consequently, understanding the molecular mechanisms underlying aging is 
fundamental to understand many disease processes. For instance, the oxidation and 
nitration of intracellular proteins leading to the formation and accumulation of 
protein aggregates are suspected to be the culprits behind the loss of cellular function 
and the reduced ability of senescent animals to fight against physiological stresses 
[Squier 2001, Cannizzo et al. 2011] (and references therein).  
Since oxidatively modified proteins are thermodynamically unstable and assume 
partially unfolded tertiary structures prone to form aggregates, it is very likely that 
oxidized proteins are intermediates in the formation if amyloid fibrils. Therefore, 
identifying oxidatively sensitive protein targets, which may play a protective role (by 
to down-regulating the energy metabolism and, consequently, reducing the 
generation of reactive oxygen species, ROS) is of particular interest.  
Accordingly, regulating the rate of ROS generation, may enhance cellular 
maintenance and repair functions, which, in turn, have proven to enhance life-span 
and  diminish a host of age-related diseases [Squier 2001] (and reference therein). 
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SYNOPSIS: OXIDATIVE STRESS 
 
Inside any living organism, damaged cells are constantly being replaced and the 
proteins degraded to constituting AA and re-synthesized. The reactive oxygen species 
(ROS), such as hydrogen (H*), hydroxyl radical (OH*), transition metals (copper and 
iron), oxygen (O*and RO*), diatomic oxygen (O2*,HO2*, RO2*), and its superoxide 
(O2*-) [Cannizzo et al. 2011], highly reactive chemical species, are formed as a natural 
by-product of the normal metabolism of oxygen [Mirzaei and Regnier 2008] (and 
references therein). ROS are employed by the organism to fight against pathogens or 
to dispose of damaged cell components, thus, have important roles in cell signaling, 
homeostasis (maintaining the equilibrium inside the living organisms) and 
programmed cell death. Under normal circumstances, cells defend themselves from 
the damage caused by ROS through antioxidants like glutathione, vitamins A, C, and 
E, and flavonoids and enzymatic scavengers of ROS such as superoxide dismutase 
(SOD), catalase, and glutathione peroxide [Aiken et al. 2011] (and references therein), 
whose role is to prevent the unnecessary formation of ROS or to dispose of them 
before they can damage vital components of cells. ROS are present at very low levels 
and their damage is constantly repaired. Therefore, under normal circumstances, 
there is equilibrium between antioxidants and ROS levels, which makes it possible 
for the cells to be continuously renewed and disposed of [Bandyopadhyay et al. 1999] 
(and references therein).  
Nonetheless, following natural aging/senescence, the body gradually loses its ability 
to repair itself, due to the loss of equilibrium between the oxidizing species (ROS) 
and antioxidants, which is believed to be the main cause of biological aging [Imlay 
2003] (and references therein). This imbalance between the over-production (and 
action) of ROS and the reduced ability of the organism to readily dispose of the 
reactive intermediates or to repair the resulting damage is a condition called oxidative 
stress. The consequences of oxidative stress in the living organisms include toxicity 
induced by the production of peroxides and free radicals which damage cellular 
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components (proteins, lipids, and DNA). In addition, oxidative stress may disturb 
normal mechanisms of cellular signaling, since some ROS act as cellular messengers 
in redox signaling [Dare et al. 2014] (and references therein).  
Oxidative stress is believed to be the root cause of a plethora of pathologies, 
including cancer, Parkinson's disease, Alzheimer's disease, Huntington’s disease, 
atherosclerosis, heart failure, myocardial infarction, fragile X syndrome, Sickle Cell 
Disease, autism, and chronic fatigue syndrome [Rubinsztein et al. 2005, Patel and 
Chu 2011] (and references therein). 
Associated with an increased production of ROS and/or significantly less efficacious 
antioxidant defenses, the effects of oxidative stress depend upon the entity of these 
changes. For instance, cells are able to overcome small perturbations and regain their 
function, nonetheless, even moderate oxidation can trigger apoptosis (programmed 
cell death), while more intense stresses may cause necrosis and severe oxidative 
stress can cause cell death [Imlay 2003] (and references therein). 
 
A. REACTIVE OXYGEN SPECIES (ROS), OXIDATIVE STRESS AND 
SENESCENCE 
 
The ROS are employed by the immune system as lethal weapons against pathogens, 
therefore, the production of ROS (and reactive nitrogen species) is a central part of 
this mechanism of pathogens disposal. The non-specific action of these highly 
reactive oxidants is advantageous because it targets and damages the entire cell, 
therefore impeding the pathogen to escape [Imlay 2003] (and references therein). 
However, the production of ROS is a particularly destructive aspect of oxidative 
stress because, for instance, when reactive oxygen and nitrogen species overwhelm 
cellular antioxidants, it leads to oxidative damage to cellular proteins (and 
aggregation thereof) and impaired homeostasis. Furthermore, protein aggregation 
contributes to the formation of amyloid deposits that accumulate during biological 
aging [Squier 2001] (and references therein). 
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Due to their non-specific action, ROS (inescapable side-products of oxidative 
metabolism) can damage lipids, nucleic acids and proteins. More specifically, ROS-
mediated protein oxidation causes tertiary structural alterations (therefore loss or 
impairment of biological function) that promote protein aggregation and amyloid 
formation. The production of ROS roughly correlates with the life-span of living 
organisms, and is believed to represent a major determinant for the rate of aging and 
the development of numerous age-related diseases [Squier 2001] (and references 
therein). 
Although, even under normal conditions, the efficiency of antioxidant and repair 
mechanisms cannot avoid completely the oxidation reaction mediated by ROS, 
during aging, the cellular homeostatic machinery becomes progressively impaired, 
which, in turn, increases the vulnerability towards oxidative damage. Oxidative 
processes cause reversible or irreversible changes/damage to macromolecules and 
their accumulation is associated to senescence [Valle 2011] (and references therein). 
 
B. OXIDATIVE STRESS, SENESCENCE AND PROTEIN DAMAGE 
 
PROTEIN POST-TRANSLATIONAL MODIFICATIONS  
 
Protein oxidative modifications that occur during aging consist in post-translational 
modifications, which lead to altered stability and decreased function, observed in a 
variety of proteins isolated from senescent animals. Following oxidation, these 
proteins become conformationally unstable and prone to aggregation. Furthermore, 
it is highly probable that these oxidized proteins act as nucleation sites/intermediates 
in amyloid formation. The balance between protein oxidation and misfolding 
(leading to aggregation) and their degradation and repair (re-synthesis) will decide 
the aggregation extent. Thus, a decreased repair rate of damaged proteins and a 
consequent extended half-life of oxidized proteins in the cell, will promote 
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aggregation and amyloid fibril formation [Squier 2001] (and references therein).  
Oxidative stress-mediated protein modifications that occur during senescence 
include direct amino acid (AA) modifications by hydroxylation and formation of 
carbonyl derivatives (aldehyde and ketonic groups on AA side chains), protein 
nitrosylation, or indirect AA modifications by addition of peroxidated lipids or 
products from glycation and glycoxidation. Among these modifications, protein 
carbonylation is the most frequent and a true biomarker of aging (or oxidative stress 
presence, in general). More specifically, AA like lysine, arginine, threonine and proline 
residues undergo aging-related carbonylation more frequent than others [Kopito 
2000, Lindner and Demarez 2009, Scharf et al. 2013] (and references therein).  
Other post-translation modifications include (a) nitration, which occurs at tyrosine 
residues (several nitro-tyrosines have been detected in aging proteins, as well as in 
proteins implicated in neurodegenerative diseases) or by cystein-s-thiolation, which 
has also been implicated as a post-translational protein modification occurring in 
aging (induces loss or gain of function in different proteins) and (b) sulfoxidation of 
several AA and, among them, methionine is particularly susceptible to this 
modification resulting in loss of biological function and conformational alterations.  
Protein fragmentation, sub-unit dissociation, unfolding, and exposure of 
hydrophobic residues and aggregation, with an overall loss of function represent 
other consequences of protein degradation by oxidation during aging [David et al. 
2010] (and references therein).   
Therefore, protein aggregates are seen as an inherent part of aging and evidence 
points towards the primary AA sequence and the overall protein structure to play an 
important role in the tendency of the protein to form aggregates [Bandyopadhyay et 
al. 1999, Cannizzo et al. 2012] (and references therein). 
 
 
 
 
Chapter 4, Part 2: Study of oxidative-stress related protein aggregation phenomena during biological aging 
247 
 
CLEARANCE OF OXIDIZED PROTEINS AND FORMATION MECHANISM OF 
PROTEIN AGGREGATES: WHY DAMAGED PROTEINS AND AGGREGATES 
ACCUMULATE 
 
Senescence-related AA substitutions or post-translational modifications of specific 
AA and/or decreases in the function of chaperones or proteases can result in an 
increase in the fraction of misfolded and damaged proteins, a process associated with 
the formation of protein aggregates. Consequently, protein aggregates interfere with 
the biological activity of native proteins by disrupting cellular functions and act as 
nuclei for the aggregation of other unrelated proteins, overloading chaperones and 
proteases in a way that progressively increases the fraction of misfolded proteins in 
the cell [Squier 2001] (and references therein). 
The extent of production of oxidized species, and the level of oxidation are the two 
determinant factors for the clearance of oxidized proteins. When the oxidative 
damage is too extensive and irreversible, proteins are targeted for degradation [Kiffin 
et al. 2004] (and references therein). The main requirement for proteins to enter the 
narrow proteasome catalytic chamber is the proteasome protein unfolding capability. 
For instance, since a low oxidation extent still allows protein unfolding, mildly 
oxidized proteins are almost completely degraded by the proteasome system, while 
extensively oxidized proteins (often entangled in misfolded aggregates) cannot be 
unfolded for proteasome degradation [Kiffin et al. 2004] (and references therein). In 
this case, extensively damaged proteins will form an “inclusion-like” body named 
“aggresome”, which actively seizes insoluble proteins, will be transported to the late 
endosomes and lysosomes by macroautophagy [Kopito 2000]. 
Moreover, extracellular aggregates and aggregates from cells which were 
programmed to die (apoptotic) are engulfed by tissue resident macrophages 
(phagocytes) and dendritic cells. Normally, damaged biomolecules are degraded to 
their constitutive AA inside the endosomal tract by a series of acidic hydrolases. 
Nonetheless, when the proteins suffer extensive damage, oxidized protein, together 
with carbohydrates and lipids often form entangled aggregates, which polymerize as 
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lipofuscin-like aggregates, which are resistant to endosomal degradation. These 
endosomal-resistant aggregates can increase progressively over time by the addition 
of newly damaged molecules, and induce cytotoxic cell death [Kiffin et al. 2004, Patel 
and Chu 2011, Cannizzo et al. 2012] (and references therein). 
Amyloid fibrils formation occurs when protein aggregates form ordered filaments, 
and the underlying cause of a range of age-related disease (such as Alzheimer). 
Furthermore, amyloid fibrils are protease-resistant structures, therefore their 
formation is irreversible once initiated, behaving like nuclei for further aggregation 
[Squier 2001, Rubinsztein et al. 2005, Nixon 2013] (and references therein). 
Recent advances in the understanding of proteasome structure and mechanism of 
action during oxidative stress were discussed  by [Aiken et al. 2011], along with a 
visual description of how cells cope with oxidative stress through proteasome-
mediated degradation pathways. The oxidative stress-triggered cellular response is 
summarized as a flowchart, reported in Figure 1([Aiken et al. 2011]): 
 
 
Figure 1 – Oxidative stress-triggered cellular response. The flow chart details the production of ROS and the 
consequent cellular response: either the restoration of normal cellular homeostasis or apoptotic/necrotic cell 
death [Aiken et al. 2011] 
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One common feature of oxidative stress-induced protein aggregates is that they are 
supposed to have a higher MW and size than the individual protein components of 
which they are composed. Furthermore, protein fragmentation is another effect of 
ROS damage and it was shown that protein fragments also have aggregation 
propensity [Mirzaei and Regnier 2008] (and references therein). 
 
C. IMMUNOSENESCENCE, OXIDATIVE STRESS, PROTEIN 
DAMAGE AND ACCUMULATION OF PROTEIN AGGREGATES 
 
Immunosenescence represents the progressive deterioration of the immune system as 
a consequence of natural aging. It manifests through a reduced capacity to respond 
to pathogens, as well as reduced vaccination efficacy (declining long-term immune 
memory) and is believed to be a function of age of the living organism relative to 
their life expectancy [Scharf et al. 2013] (and references therein).   
There are two main biochemical mechanisms which relate immunosenescence to 
oxidative stress: (1) a decline in cellular functions consequent to protein, lipid and 
carbohydrate oxidative damage, and (2) cellular death subsequent to the progressive 
accumulation of oxidatively-damaged protein aggregates. As for any other aging 
cells inside the living organism, an increased amount of free radicals (ROS) was 
observed in the cells of the immune system. Consequently, innate immune responses 
(phagocytosis – dendritic cells, ROS production, and Toll Like Receptor functions) 
are generally compromised, as well as adaptive immune responses which are hampered 
by a decrease in the variety of the B and T immune cell repertoires,as well as their 
ability to clonally expand (proliferate from a common ancestor) following antigen 
stimulation. Furthermore, it was believed that endosomal accumulation of 
oxidatively-damaged proteins hinders the efficient processing of antigens and the 
macroautophagy-delivered degradation of proteins [Cannizzo et al. 2011] (and 
references therein).  
An aspect of immunosenescence which was unknown until not so long ago was 
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whether the aging-related oxidative stress compromised the biological function of dendritic 
cells (major players in the innate immune system). In this regard, [Cannizzo et al. 
2012] showed in a recent study the causality between the accumulation of oxidized 
products (damaged proteins and their aggregates) and the lack of efficacy of the  
immune response from dendritic cells, as well as an improvement in the adaptive 
immune system in recognizing antigens upon oxidative stress decrease, aspects 
which were not yet confirmed. 
Moreover, the study showed the accumulation of oxidatively damaged proteins in the 
dendritic cells from aging lymphatic organs. The accumulation of oxidatively-damaged 
proteins in the endosomes of aging dendritic cells was investigated, showing that 
accumulation of such protein aggregates was not possible due to the short life span 
of dendritic cells. Large protein aggregates accumulate only in non-dividing cells 
endosomal compartments (neurons, cardiomyocytes and endothelial cells) [Cannizzo 
et al. 2012] (and references therein). 
 
OXIDATIVE STRESS DAMAGE: PROTEIN CARBONYLATION 
 
As previously stated, protein carbonylation of AA residues is as hallmark and a true 
biomarker for the age-related protein post-translational modifications. Protein 
carbonyls result from the oxidation of AA residues, the most frequent targeted being 
arginine, lysine and proline. Protein carbonyls can also arise from reactions of the AA 
like lysine, cysteine, or histidine with unsaturated aldehydes, which develop during 
the peroxidation of polyunsaturated fatty acids or from the oxidation of advanced 
glycation end (AGE) products [Cannizzo et al. 2011] (and references therein).  
Typical post-translational protein modification associated with oxidative stress 
consists in the addition of carbonyl groups (aldehydes or ketones) to AA side chains. 
Semialdehyde carbonyls are mainly present on lysine, arginine and proline and 
represent the most abundant carbonyls observed in aging cells, while ketone 
carbonyls are mainly seen on histidine, proline, threonine and tryptophan residues 
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[Bandyopadhyay et al. 1999, Butterﬁeld et al. 2012] (and references therein). 
Another post-translational oxidative modification, introduced by either α-amidation 
or following oxidation of the glutamyl side chain, is the oxidative AA side-chain 
cleavage. In addition, some of the degradation products of lipid oxidation can directly 
bind AA side chains (mainly cysteine, lysine and histidine) through a Michael 
addition or Schiff base formation. Glycation, the non enzymatic addition of sugar to 
AA side chains, is also increased during oxidative stress conditions, while glycation 
additions to amine groups are collectively referred to as Maillard reactions. 
Advanced End Glycation products (AGE) are generated through aldose groups of a 
mono or polysaccharide binding to the amine groups on proteins, mainly on a lysine 
side chain. Most AGE products are rather unstable and promote further 
rearrangements, referred to as Amadori reactions [Imlay 2003, Cannizzo et al. 2011, 
Grune et al. 2013] (and references therein). 
Another common modification following ROS-induced protein oxidation is cross-
linking. The two most common cross-linking reactions are: (1) the formation of 
disulfide bonds between two oxidized cysteins and (2) Schiff base formation between 
carbonyl groups on different AA [Ishii et al. 2007, Butterﬁeld et al. 2012]. 
Protein carbonylation is an irreversible ROS-induced oxidative modification, which often 
leads loss of protein activity and irreversible modification/damage promoted protein 
aggregation, followed by increased susceptibility to proteolysis. Consequently, 
protein carbonylation is considered a true read-out of oxidative stress. Moreover, 
carbonylated proteins are present in many aging-related inflammatory and 
neurodegenerative diseases [Aiken et al. 2011, Cannizzo et al. 2011, Cannizzo et al. 
2012].  
In the case of neurological diseases like Alzheimer’s and Parkinson’s disease, protein 
aggregates are generally composed of a single protein. Another consequence of 
carbonyl formation is the protein conformation alteration (these neurodegenerative 
disorders are also known as protein misfolding diseases), which, in turn, can increase 
protein hydrophobicity and enhance nonspecific protein–protein interactions, and 
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subsequent compromised cell viability and impaired protein turnover [Mirzaei and 
Regnier 2008] (and references therein).  
 
IN VITRO AND IN VIVO EXPERIMENTAL MODELS FOR THE SIMULATION 
OF AGING EFFECTS: PARAQUAT – INDUCED OXIDATIVE STRESS 
 
Paraquat is the commercial name for N,N′-dimethyl-4,4′-bipyridinium dichloride, a 
quaternary ammonium bipyridyl compound and one of the most widely used 
herbicides in the world. Paraquat has long been known to participate in cyclic 
reduction-oxidation reactions in biological systems, where it readily undergoes a 
single electron reduction in tissues, forming a free radical. Paraquat is often used in 
science as catalyst for the formation of ROS and more specifically, for the formation 
of the superoxide free radical [Takizawa et al. 2007]. In vivo, Paraquat is reduced by 
an electron donor such as NADPH, before being oxidized by an electron receptor 
such as dioxygen to produce the superoxide, a major ROS [Bus and Gibson 1984] 
(Figure 2). 
 
Figure 2 – Example of oxidative stress-induces (irreversible) protein carbonylation reaction, 
adapted from [Aslan et al. 2008] and [Bus and Gibson 1984] 
 
Paraquat is used in murine models for the study of neurodegeneration [Manning-
Bog et al. 2002, McCormack et al. 2002, McCarthy et al. 2004, Yang and Tiffany-
Chapter 4, Part 2: Study of oxidative-stress related protein aggregation phenomena during biological aging 
253 
 
Castiglioni 2007] and leads to a reduced motor activity and, finally, cell death. 
Furthermore, the efficacy of Paraquat for oxidative stress generation purposes was 
reported in other types of cells. For example, used at low concentrations, Paraquat is 
able to induce protein aggregation in very short time, simulating the effects of aging  
both in vitro and in vivo [Scharf et al. 2013]. For in vitro studies of aging, solutions of 
known concentration of PQ are directly added to the cells in culture. 
In this dissertation, Paraquat was employed to simulate the effects of aging in vitro as well as 
in vivo. Dendritic cells (Jaws II cell line culture) were treated with increasing molarities of 
Paraquat (in vitro) and mice were injected intra-peritoneally with Paraquat (in vivo). The 
efficacy of the Paraquat treatment, as well as the oxidatively-damaged proteins aggregates 
formation, isolation, characterization and quantification by HF5-(UV)-MALS are discussed 
in sub-chapters 4.2.1.4.B and C. The Paraquat controlled protein aggregation model was 
setup and served for the HF5 method development.  
 
D. CURRENT PROTEOMIC TECHNOLOGIES AND THEIR 
LIMITATIONS 
 
Proteomics technologies show certain limitations that are mostly related to the 
detection sensitivity of the analytical techniques employed for the study of difficult 
protein classes, such as low abundant, hydrophobic and basic proteins. 
First of all, the selection of the proteomic methodology highly depends on the sample 
to be analyzed and the aim of the study. In general, the “standard” approach is the 
use of 2D gel/MALDI-TOF-MS and, since certain protein classes cannot be detected 
by these technologies, subsequent 2D LC–MS or tandem MS are necessary. However, 
it appears that the second approach is, generally, more effective. Moreover, as a rule 
of thumb, the complexity of the sample analysis protocol is directly related to the 
chemical integrity of the sample and analysis reproducibility, as well as the sample 
recovery [Garbis et al. 2005] (and references therein).   
Basically, the limitations in a proteomic analysis can be classified as: (1) limitations 
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related to the complexity (the composition) of the proteome to be analyzed, the major 
issue being protein expression levels (which appear in all proteomics analyses), and 
(2) limitations of the analytical methods [Reschiglian and Moon 2008]. Consequently, 
the field of proteomics concentrates on both increasing the quantity of the low 
abundant proteins, to enable an efficient detection, and to applying the proper 
analytical methods to visualize all proteins in the mixture. 
For instance, due to the vast protein diversity in terms of molecular sizes, charge 
state, hydrophobicity, protein conformational states, post-translational modifications 
or complex formation with other bio-macromolecules, it would be unfeasible to use a 
single sample preparation protocol, all the while capturing effectively the entire 
proteome. Since proteins are not expressed in equal amounts, there are large 
differences in the protein levels in all proteomes [Garbis et al. 2005] (and references 
therein). 
A wide variety of analytical methods are applied to achieve the isolation and 
characterization of low-abundant proteins, which usually require enrichment of the 
low-abundant fraction and/or the depletion of highly abundant proteins that may 
interfere with the detection. For instance, in order to increase the probability to detect 
low abundant proteins, the original protein mixture (proteome) is separated into less 
complex fractions, where each of them contains a lower number of total proteins in 
comparison with the starting material [Garbis et al. 2005] (and references therein).  
In a recent review, [Reschiglian and Moon 2008] discussed the pre-fractionation 
methods currently employed in proteomics, indicating the emerging role and gentle 
separation mechanism of Field Flow Fractionation (FFF) that allows proteins to 
maintain intact their biophysical properties (conformation included). In particular, 
the advantages brought by its miniaturized version, HF5, in terms of detection 
sensitivity, efficiency, solvent biocompatibility, as well as the possibility of on-line 
coupling with mass spectrometry (MS) are appealing features for proteomics.  
Many publications support their findings in the field of proteomics:[Reschiglian et al. 
2004, Reschiglian et al. 2005, Kang and Moon 2006, Reschiglian et al. 2006, Roda et al. 
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2006, Rambaldi et al. 2007, Kim et al. 2008, Lee et al. 2010, Reschiglian et al. 2011].    
 
In this dissertation, HF5 was employed as a pre-fractionation method in a proteomic study. 
Since the aim of the study was to purify, characterize and quantify oxidatively-damaged 
protein aggregates present at trace levels, the complexity of the proteome (originating from 
different types of cells and different stages of aging) was reduced. Fractions were pooled from 
subsequent HF5 fractionations of the same sample, dialyzed and lyophilized to enrich the high 
MW aggregates fraction, discussed in sub-chapter 4.2.1.4.B and C. 
 
E. IDENTIFICATION, ISOLATION AND PROTEOMIC ANALYSIS 
OF OXIDIZED PROTEINS AND PROTEIN AGGREGATES 
 
OXIDATIVE STRESS DETECTION 
 
The presence of oxidative stress can be achieved by fluorescent means, for instance, 
employing fluorogenic probes that can be used for measuring cellular oxidative 
stress in both live and fixed cell imaging. A highly efficient novel fluorogenic probe 
is CellROX® Deep Red Reagent (Life TechnologiesTM), with absorption/emission 
maxima at ~644/665 nm. This dye is cell-permeant and is non-fluorescent in a 
reduced state, meanwhile, upon oxidation by reactive oxygen species (ROS), it 
exhibits bright fluorescence.  
In this dissertation, the effectiveness of the in vivo Paraquat treatment, whose aim was to 
induce oxidative stress (and simulate in a brief time the effects of aging), was evaluated by 
fluorescent means, employing CellROX® Deep Red Reagent (Life TechnologiesTM).The test, 
discussed in sub-chapter 4.2.1.4.C, showed highly increased fluorescence intensity in the 
Paraquat-treated mouse.  
Recent developments in the field of functional proteomics have highlighted the 
selectivity of particular antibodies towards recognizing post-translational oxidative 
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modifications that occur following oxidative stress, therefore have provided the 
means for the detection, as well as affinity purification of aging-related oxidatively 
damaged entities. Coupled with proteomics and mass spectrometry, this selective 
purification has led the way towards mapping the oxidized proteins, and towards 
the identification of different types of oxidative modifications. [Cannizzo et al. 2011] 
(and references therein). 
 
IDENTIFICATION AND ANALYSIS OF CARBONYLATED PROTEINS 
 
The presence of carbonyl groups on oxidized proteins can be identified and 
quantified by derivatization with 2,4-dinitrophenylhydrazine (DNPH), which leads 
to the formation of hydrazones (Figure 3). When DNPH reacts with protein 
carbonyls, the  amount of protein-hydrazone complex produced can also be 
measured spectrophotometrically at 375 nm and quantified against a calibration 
curve with a standard protein (such as BSA).  
 
Figure 3 – Principle of carbonyl groups derivatization with DNPH [Aslan et al. 2008] 
 
In this dissertation, the quantification of oxidative-stress induced carbonyl modifications was 
performed on two sets of samples, both treated with the pesticide Paraquat to induce oxidative 
stress: (a) in vitro Paraquat-treated Jaws II dendritic cell lysate samples and (b) in vivo 
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Paraquat-treated spleen cell lysate samples originating from mice. The protein carbonyl 
spectrophotometric assay discussed in sub-chapters 4.2.1.4.B (in vitro) and 4.2.1.4.C (in vivo) 
showed increased amounts of carbonyl in the Paraquat-treated samples as compared to control 
(non treated samples). 
The DNPH-induced protein hydrazones can also be immunologically detected, using 
an anti-DNPH antibody that gives a precise indication on the amount of total protein 
carbonyls in a given sample. Furthermore, the advantage of having a DNPH specific 
antibody is that carbonylated proteins can be either immunoprecipitated or detected 
by SDS-PAGE or 2-D Fluorescence Difference Gel Electrophoresis (2-D DIGE), as 
preparative methods before mass spectrometry. 
Following this procedure, reported schematically in Figure 4, [Cannizzo et al. 2012] 
showed that spleen and lymph node cells from aging mice accumulate oxidatively 
damaged proteins that presented hallmarks like carbonylated AA side-chains, AGE 
products and lipid peroxidation.  
 
 
Figure 4 – Experimental procedure designed to identify the presence of oxidative stress-related 
protein modifications in dendritic cells, followed by the identification (mapping) of the 
modifications at biochemical level [Cannizzo et al. 2012] 
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SDS-PAGE performed on immunolabeled damaged proteins and protein aggregates 
showed an age-related progressively increased amount of high MW species (left in 
the stacking gel). Subsequent MS analyses performed on proteins excised from the 
stacking gel, as well as the resolved gel, allowed mapping the post-translational 
modifications suffered by proteins during aging. Moreover, the fact that damaged 
proteins and aggregates were found in dendritic cells derived from bone marrow 
(BM) CD34+ precursors indicates that these precursors are already compromised and 
is expected that they have a reduced biological function. 
In this dissertation, HF5-(UV)-MALS analytical platform was employed for the size-
separation, characterization (size and MW) and quantification of age-related protein 
aggregates in BM CD34+ precursor cells, discussed in sub-chapter 4.2.1.4.D. The results 
confirmed the previous finding by [Cannizzo et al. 2012].Furthermore, the offline MS 
analyses allowed the identification of age-related post-translational modifications and their 
extent. 
Previous attempts by [Cannizzo et al. 2012] to isolate and characterize protein 
aggregates in CD34+ precursor cells are schematically reported in Figure 5. Their 
approach consisted in employing as first dimension of separation Fast Protein Liquid 
Chromatography (FPLC), a preparative separation technique routinely used in 
proteomics  
Although FPLC was successfully employed by [Scharf et al. 2013] for the estimation 
of the oxidative post-translational modifications extent in structural proteins of 
intervertebral discs (IVDs) isolated from aging mice, where increased protein 
carbonylation was associated with protein fragmentation and aggregation, the study 
conducted by [Cannizzo et al. 2012] showed only the presence of age-related micro-
aggregates of carbonylated proteins (1-3×106 Da, Figure 5), separated employing FPLC. 
However, FPLC fractions did not show the presence of large aggregates, concluding 
that DCs endosomal compartments do not accumulate such aggregates due to their 
short turn-over. 
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Figure 5 – Experimental procedure designed to for the isolation of oxidative stress-related protein 
aggregates in dendritic cells, followed by the Western blot performed on FPLC fractions [Cannizzo 
et al. 2012] 
 
In this dissertation, FPLC was employed as first dimension of separation for the purifications 
of protein aggregates in oxidatively modified Jaws II dendritic cells (treated with Paraquat to 
induce oxidative stress and simulate the effects of aging in a short period of time). 
Nonetheless, FPLC proved not to be effective enough to resolve high MW protein aggregates, 
discussed in sub-chapter 4.2.1.4.B.  
On the other hand, since HF5 is based on a different separation principle, allowing proteins 
(and protein aggregates) elution in increasing MW and size order (opposed to FPLC order of 
elution), provided enough separation space even for very high MW protein aggregates 
(>3×106 Da). Moreover, thanks to HF5 versatility in terms of carrier solution composition, 
separations performed in denaturing carrier solution (containing different concentrations of 
urea), allowed the discrimination and quantification of urea-resistant covalent/irreversible 
protein aggregates, discussed in sub-chapters 4.2.1.4.B through 4.2.1.4.D.   
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Size exclusion chromatography (SEC) is another separation technique employed 
during proteomic procedures, recently used for the purification of oxidative stress-
modified proteins and complexes in a study by [Mirzaei and Regnier 2008]. The 
effects of oxidative stress-induced protein aggregation were studied employing 
standard proteins and yeast cells. Oxidized standard proteins, at increasing ROS 
concentrations, were fractionated by SEC and displayed different elution profiles, 
indicating that protein aggregation occurs in stages and that protein fragments 
(result of ROS damage) also give rise to aggregates. Moreover, several carbonylated 
proteins and proteins known to form complexes with higher MW protein complexes 
were identified by MS on SEC fractions of oxidatively stressed yeast cells. In 
addition, these proteins were found to be part of the proteome known as the 
aggresome [Mirzaei and Regnier 2008] (and references therein). 
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4.2.1. NOVEL METHODOLOGY BASED ON HF5 – MALS FOR 
THE SIZE-SEPARATION, CHARACTERIZATION AND 
QUANTIFICATION OF OXIDATIVE STRESS-RELATED PROTEIN 
AGGREGATES LEVELS IN WHOLE CELL LYSATES 
STUDY IN COLLABORATION WITH THE PATHOLOGY, IMMUNOLOGY AND MICROBIOLOGY 
LABORATORY OF A. EINSTEIN COLLEGE OF MEDICINE (YESHIVA UNIVERSITY, NY, USA) 
 
 
 
Protein aggregation is a common biological phenomenon, often occurring during 
pathological conditions, which can induce impaired proteostasis (proteostasis, 
“protein”+”homeostasis” is a concept which regards the plethora of competing and 
integrated biological pathways within cells that control the biogenesis, folding, 
trafficking and degradation of proteins present within and outside the cell).  
An analytical platform, such as HF5-UV-MALS, capable of separating protein 
aggregates based on their biophysical properties, integrated as a functional proteomics 
methodology, would allow further understanding of the correlation between the 
protein sequence/structure and their tendency to aggregate, how different post-
translational modifications affect unfolding and aggregation and the proteomic 
machinery associated with aggregates formation and degradation. 
In this sub-chapter, a methodology which employs HF5 online coupled with UV and 
MALS detection was developed for the hydrodynamic size-based separation, 
characterization (MW, rms radius and molecular conformation) and quantification of 
protein aggregates from complex protein samples. Developed on an experimental 
model based on a set of dendritic cells line (Jaws II) samples, treated with 
progressively increasing concentrations of the pesticide Paraquat to induce oxidative 
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stress (and simulate the effects of aging in a short period of time), the HF5-(UV)-
MALS method and was then applied on an in vivo Paraquat-treated murine model. 
The presence of high MW aggregates was observed in spleen and brain cells, as 
compared to control (non-treated) samples. The aggregates were isolated, 
characterized and quantified by HF5-(UV)-MALS and fractions were collected for 
complementary analyses. 
Finally, the same HF5-(UV)-MALS method was and applied successfully to oxidative 
stress-related (damaged) protein aggregates present in aging samples, more in 
particular, bone marrow CD34+ precursor cells. The wide size and MW range of HF5 
allowed the separation of highly complex samples (cell lysates) in a single-step 
analysis and in a relatively short time, therefore employed as the first dimension of 
separation in a functional proteomics study.  
The HF5 method was, therefore, applied successfully to cell lysates containing in 
vitro and in vivo oxidative stress-induced aggregates, as well as to cell lysates 
containing aging-related protein aggregates.   
Data processing allowed the analysis of the aggregates amount, absolute MW and 
size (rh and rms radius).  HF5 versatility allowed the samples separation under native 
conditions, as well as under different degrees of denaturing conditions (2 and/or 4 M 
Urea).  
Offline native PAGE analyses conducted on protein fractions separated by HF5 
corroborated the results obtained by HF5-(UV)-MALS: the separation occurred by 
molecular weight (MW), as well as by hydrodynamic size and the presence of 
aggregates above 5.0×106 Da only was observed only in conditions of oxidative stress. 
Offline mass spectrometric (MS) analysis, performed on high MW protein 
(aggregates) fractions separated by HF5, confirmed the presence of several proteins 
previously reported to be insoluble or aggregation-prone and allowed the 
identification of post-translational modifications associated with increased 
unfolding, aggregation and targeting by proteasome and autophagic/endosomal 
degradation.  
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4.2.1.1. INSTRUMENTAL SETUP 
 
All HF5 separations were performed employing an Agilent 1100 HPLC system 
(Agilent Technologies, Santa Clara, CA, USA) consisting in a degasser, a quaternary 
pump, an auto sampler and a diode array UV-Vis detector coupled with an Eclipse® 
DUALTECTM flow FFF separation system (kindly provided by Superon GmbH, 
Dernbach, Germany).  
The HF5 separation device was a 34 cm long cartridge assembled from two 
commercial (17 cm long) cartridges connected with a union piece, therefore called 
“double length” HF5 cartridge. Since a longer cartridge was employed successfully for 
the separation of a standard protein mixture in sub-chapter 4.1.2 (Chapter 2) without 
any downsides, on the contrary, allowing for a scale-up of the injected amount and 
complete sample recovery, the “double length” HF5 cartridge was considered the 
best solution for this study, able to provide enough protein per fraction for 
subsequent offline electrophoresis, MS analysis and other complementary assays.  
The HF5 channel was equipped with a 34 cm long  polyether-sulfone (PES) fiber, 
type FUS 0181 (Microdyn-Nadir, Wiesbaden, Germany) with the following 
characteristics: 0.8 mm inner diameter, 1.3 mm outer diameter and 10 kDa MWCO, 
corresponding to an average pore diameter of 5 nm. Its assembly and the modes of 
operation of the Eclipse® DUALTEC system have already been described in recent 
literature [Johann et al. 2010].  
The ChemStation version B.04.03 (Agilent Technologies) software for Agilent was 
used to set and control the HPLC components and the software package Wyatt 
Eclipse @ ChemStation version 4.02 (Wyatt Technology Europe) was used to manage 
the Eclipse® DUALTEC separation system.  
An 18-angle MALS detector model DAWN® EOSTM light scattering detector 
(provided by Wyatt Technology Corporation, Santa Barbara, CA, USA), employing a 
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laser operating at a wavelength of 658 nm, was used in all experiments.  
An Agilent 1100 UV-Vis diode array detector operating at a wavelength of 280 nm 
was used as a concentration detector at all times. A second UV signal at 260 nm was 
registered to assess the DNA presence in the samples. 
ASTRA® software version 6.0.6 (Wyatt Technology Corporation) was used to handle 
signals from the detectors (MALS and UV), for the determination of the molecular 
weight (MW) of proteins in solution and their size (rms radius). 
 
4.2.1.2. SAMPLES 
 
A mixture of native protein markers, NativeMarkTM Unstained Protein Standard, 
(Novex®, Life TechnologiesTM), employed as a sample model, was separated 
employing a native carrier solution in order to evaluate the performance of the HF5 
method under optimal separation conditions.  
 
MICE 
C57BL/6J mice (3, 12 and 22 month old) were purchased from Harlam as part of the 
age-controlled NIH mouse colony program. All animal procedures were carried out 
according to a protocol approved by the Institutional Animal Care of Albert Einstein 
College of Medicine.  
 
SAMPLE PREPARATIONS – performed by the Laboratory of Pathology, Immunology and 
Microbiology of A. Einstein College of Medicine (Yeshiva University, NY, USA) 
 
 BONE MARROW cells were flushed from the femur and tibia of 3, 12 and 22 
months old mice. Cells were centrifuged at 1500 rpm for 10 minutes, and 
CD34+ bone marrow precursors were purified by magnetic beads 
immunoselection (Miltenyi Biotec), following the manufacturer’s instructions.    
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After positive immunoselection cells were washed with cold PBS three times 
and immediately lysed in 1% NP40,  50 mM Tris/HCl, 150 mM NaCl, 5mM 
EDTA and 10 mM DTT,  supplemented with 1X  protease inhibitor cocktail for 
30 minutes on ice. Lysates were spun at 8,000 rpm and the supernatant 
collected for total protein determination using Bradford assay (Biorad). 
 SPLEEN cells were harvested from C57Bl6 mice, and digested for 30 minutes at 
37°C with 4000 U/ml of collagenase type II (Invitrogen) in sterile Hanks’ 
balanced saline solution (HBSS) with Ca2+ and Mg2+ (Life Technologies).  Cells 
were collected through a 70 
and the cell pellet resuspended in red blood cell lysis buffer (8.3 g/L 
ammonium chloride in 0.01 M Tris-HCl buffer from Sigma, Aldrich).   
Following 5 minutes incubation at room temperature, complete media was 
added to stop the lysis reaction and the cells were pelleted at 1500 rpm for 10 
min and further processed for HF5 separation or FACS analysis.   
 BRAIN cells from control and Paraquat-treated mice were harvested and 
dissected on ice to separate their cortex regions. Upon pooling the cortex 
regions of three mice they were minced and immediately homogenated in 
0.25M sucrose using a motorized homogenator with Teflon pestle (8 strokes at 
maximal speed).  Protein concentration was estimated using Bradford assay 
(Biorad) and samples were stored frozen until use. 
 
INDUCTION OF OXIDATIVE STRESS AND CELL LYSIS – performed by the Laboratory of 
Pathology, Immunology and Microbiology of A. Einstein College of Medicine (Yeshiva 
University, NY, USA) 
 
 IN VITRO: Jaws II cells (CLR-11904; American Type Culture Collection), a DCs 
cell line established from C57Bl6 bone marrow were grown in complete media 
HyClone DMEM/High glucose (Thermo Scientific) supplemented with 10% 
FBS and 1% Hepes Buffer (Fisher Scientific), MEM Non-essential amino acids, 
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1mM sodium pyruvate, 10 U/ml penicillin and 100 μg/ml streptomycin all 
from Sigma.  N,N′-dimethyl-4,4′-bipyridinium dichloride (Paraquat, PQ) was 
used to induce oxidative stress.  
Three final concentrations of the drug, 0.25 mM, 5 mM and 10 mM were used. 
Control cells remained untreated.  Twenty million cells for each condition 
were incubated at 37°C and 5% CO2 for 6 hours, then collected, centrifuged at 
1500 rmp for 5 minutes and washed twice with sterile PBS.  Pellets were lysed 
in 150 mM Nacl, 50 mM Tris-HCl, 1% nonidet p-40 , 10 mM DTT, 5 mM EDTA 
supplemented with 1X of protease inhibitor cocktail (Sigma, St. Louis) and 
Bradford assay was performed to determine protein concentrations against a 
standard curve. The total carbonyl content from total cell lysates and from 
each HF5 collected fraction was determined spectrophotometrically with the 
OxiSelect Protein Carbonyl Spectrophotometric Assay kit (Cell Biolabs, CA).  
The absorbance of the DNPH-derivatized carbonyl groups was read at 375 
nm.  Results were normalized to the amount of total protein in each sample 
fraction. 
 IN VIVO: Oxidative stress was induced in C57BL/6 mice by i.p injection with 
PQ-saline solution (2.5mg/25g body weight) on two consecutive days.  Twenty 
four hours prior to the experiment, animals were fasted to minimize the 
potential background. Before imaging all animals were intravenously injected 
with Cell-ROX Deep Red (2.5mM, excitation 640 nm/emission 664 nm, 
Molecular Probes, CA) for in vivo fluorescent imaging using the IVIS (In-Vivo 
F PRO imaging system (Bruker BioSpin Molecular Imaging, CT) system.  
Whole animals were imaged 30 minutes post injection and images were 
captured at an excitation 610 nm/emission 700 nm using a built-in cooled 
closed-caption device camera.  Images were threshold with respect to 
background intensity and different levels of fluorescence intensity were 
displayed using pseudo rainbow color scheme analyzed using built-in 
Carestream Molecular Imaging Software.   
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4.2.1.3. MATERIALS AND METHODS 
 
REAGENTS 
Trifluoroacetic acid, acetonitrile, acetic acid, formic acid, iodacetamide and methanol 
were purchased from Fisher Scientific (Pittsburgh, PA).  Urea, thiourea, 
octylglucoside, dithiothreitol (DTT), iodoacetamide, ammonium bicarbonate, 
Coomassie Brilliant Blue R-250, KCl, KH2PO4, H3PO4 and Na2CO3 were purchased 
from SIGMA (St. Louis, MO, USA). Complete Proteinase inhibitor cocktail was also 
purchased from Sigma.  Porcine trypsin (20 µg, specific activity > 5,000 units/mg seq. 
grade modified) and Lys-C (sequencing grade, 10µg) were purchased from Promega 
(Madison, WI). 
Tris-HCl 1M and pH 8.0 was supplied by Teknova, while NaCl and urea were 
supplied by Sigma. All carrier solutions employed during this study were prepared 
using MilliQ water purified by an Elix 3 UV Water Purification System (Millipore, 
Billerica, USA) and filtered through 0.2 µm pore membrane sterile filter units 
(SteritopTM, Millipore). 
 
HF5 METHOD 
Lysates were run in either native carrier solution buffer (50 mM Tris-HCl 
supplemented with 150 mM NaCl and proteases inhibitors, pH 7.4) or denaturing 
carrier solution, with a composition similar to the cells lysis buffer (50 mM Tris-HCl, 
supplemented with 150 mM NaCl, 2 or 4 M urea and proteases inhibitors, pH 8.0). 
Cell lysates were injected during the focusing step, performed at 0.5 mL/min of focus 
flow rate for 5 minutes, after which each sample was eluted at 0.5 mL/min of 
longitudinal flow rate under a field gradient decreasing from 0.4 mL/min to 0.1 
mL/min over 70 minutes.  
Protein fractions were collected after HF5 separation. Samples separated under the 
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same conditions (either native or denaturing) and using the same flow rates were 
pooled (3-5 runs) for further analysis.  To remove the high salt concentration (NaCl 
and urea), the fractions were dialyzed overnight against 10 mM Tris-Cl solution at 
pH 8.0 using Side – a – lyzer® cassettes (MWCO: 3500 Da, 3 – 15 mL, Pierce) or Snake 
Skin pleated dialysis tubing (MWCO: 3500 Da, capacity of 3.7 mL/cm, Pierce) for 
larger volumes. All fractions were lyophilized immediately after the dialysis was 
completed. 
 
ASTRA® COMPUTATIONS  
The Astra® software (version 6.0.6, Wyatt Technology Corporation) was used to 
calculate the MW ranges for all lysate samples. The light scattering intensity 
registered by detectors 2 through 18 and the concentration signal from the UV 
detector (280 nm) were correlated through a 1st degree Zimm model, thus providing 
the MW values. An average value of 1.0 (mL/mg×cm) for the extinction coefficient at 
280 nm (280nm0.1%) was used in all MW calculations. The ExPASy ProtParam free 
bioinformatics tool (http://www.expasy.org/) was used to compute the specific 
280nm0.1% for all protein standards in the mixture (Novex®, Life TechnologiesTM), used 
as a model sample.  
The angular dependency of the scattered light was correlated through a 1st degree 
Zimm model, thus providing the rms radius values. The sample recovery, as well as 
the protein aggregates amounts, calculated as % of the total protein amount in the 
lysates, were also quantified by Astra. 
Astra software was also employed to determine the molecular conformation of the 
protein aggregates. The correlation plots (conformation plots) were generated from 
experimental data, by plotting the rms radius values against the corresponding MW 
values (both in logarithmic scale). The plots were fitted linearly and the slope values 
were assigned to known conformation types. A slope value of 1.0 corresponds to a 
rod conformation, a slope value of 0.5 – 0.6 corresponds to a random coil conformation 
and a slope value of 0.33 corresponds to a sphere conformation. The trend (slope 
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and/or change of the slope) of the molecular conformations was determined for rms 
radius values above 10 nm (due to DAWN EOS® instrumental range limitation), with 
corresponding MW values usually above 1×106 g/mol. 
 
HYDRODYNAMIC RADIUS (rH) CALCULATIONS 
The Eclipse ISIS simulation software (Superon GmbH, Germany) was employed to 
predict the retention time (tR), hydrodynamic radius (rH) and diffusion coefficient (D) 
of each native marker in the mixture (Novex®, Life TechnologiesTM), by inputting the 
HF5 method flow rates and the known MW values (declared by the manufacturer).   
The same software was employed for the calculation of the rH range for each cell 
lysate (reported in each graph as a secondary x axis), but based on the experimental 
tR values instead of the ones predicted from the MW values.  
The viscosity values for the carrier solutions were extrapolated from data found in 
literature [Kawahara and Tanford 1966] (ηwater,25°C = 10-3 N·s/m2 for Tris-HCl buffer; 
1.0909× ηwater,25°C for Tris-HCl + 2M urea and 1.2215× ηwater,25°C for Tris-HCl + 4M urea). 
 
PROTEIN CARBONYL SPECTROPHOTOMETRIC ASSAY – performed by the Laboratory of 
Pathology, Immunology and Microbiology of A. Einstein College of Medicine (Yeshiva 
University, NY, USA) 
The quantification of the protein carbonyl modifications was performed using the 
OxiSelect™ Protein Carbonyl Spectrophotometric Assay Kit supplied by Cell Biolabs, 
Inc. First, the protein carbonyls in BSA standards (1-10 mg/mL) were derivatized 
with DNPH. When DNPH reacts with protein carbonyls, the amount of protein-
hydrozone produced can also be measured spectrophotometrically at 375 nm. 
Proteins were then precipitated following the TCA (trichloroacetic acid) precipitation 
protocol and free DNPH was removed by washing the protein pellet. After 
dissolving the protein pellet in GuHCl, the absorbance of protein-hydrozone was 
measured at 375 nm, and the protein carbonyl was calculated.  
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ELECTROPHORESIS – performed by the Laboratory of Pathology, Immunology and 
Microbiology of A. Einstein College of Medicine (Yeshiva University, NY, USA) 
 SDS-PAGE was performed on whole cells lysates (before fractionation) in 
order to determine qualitatively the presence of HMW protein aggregates. 
Each cell lysate sample, containing approximately 20 µg of protein (previously 
quantified by BCA assay) were diluted in the recommended sample buffer 
62.5 mM Tris-Cl, pH 6.8, 2% SDS, 25% glycerol, 0.01 % bromphenol blue), 
supplemented with 2-mercaptoethanol and incubated for 5 min at 110°C. 
After the protein denaturation was completed, a sample volume of 15µL was 
loaded in each well of a Mini-PROTEAN® TGXTM Gel (4 -15%), supplied by 
BioRad and recommended for the MW range of 20–250 kD.  
The electrophoretic run was performed in the recommended Tris/Glycine/SDS 
running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3) and was 
considered complete after approximately 1.5 hours. The gel was re-
equilibrated in water for 5 min and stained employing the Pierce Color Silver 
Stain Kit (supplied by Pierce), following the manufacturer’s instructions. 
 
 NATIVE PAGE. The HF5 fractions were desalted by dialysis and concentrated 
by lyophilization. After lyophilization the powdered proteins were 
resuspended in a total volume of 100 µL of Milli-Q water. Aliquots of  25 µL of 
samples, either diluted in water or not, were  further resuspended in a precast 
Native PAGE Sample Buffer (4X) and Cathode Buffer Additive (Invitrogen) 
and loaded in a NativePAGETM Novex® Bis-Tris Gel System (3%-12%) 
supplied by Invitrogen and recommended in the MW range from 30 to 10.000 
kDa. The same protein amount was loaded in each gel, based on previous 
protein quantification by BCA assay.  
The run was performed at 150 Volts for 110 minutes following the supplier’s 
instructions. After the run was completed, the gel was re-equilibrated in water 
Chapter 4, Part 2, 4.2.1. Novel HF5-(UV)-MALS methodology for the size-separation, characterization and 
quantification of oxidative stress-related protein aggregates in whole cell lysates  
274 
 
for 5 min and stained employing the Pierce Color Silver Stain Kit (supplied by 
Pierce), following the manufacturer’s instructions. 
 
FPLC SIZE-EXCLUSION CHROMATOGRAPHY – performed by the Laboratory of Pathology, 
Immunology and Microbiology of A. Einstein College of Medicine (Yeshiva University, NY, 
USA) 
 
An amount of 800 µg of total cell lysate, from untreated and Paraquat-treated 
samples, was loaded on a Superdex 200 column (HiLoad 16/60, prep grade, GE 
Healthcare Life Sciences) operated by a Biorad Biologic Duo Flow medium-pressure 
chromatographic system.  PBS or 50 mM Tris-Cl were used as mobile phase, eluted at 
an isocratic flow rate of 1/mL minute.  Protein elution was monitored at 280 nm.  
 
FACS ANALYSIS – performed by the Laboratory of Pathology, Immunology and Microbiology 
of A. Einstein College of Medicine (Yeshiva University, NY, USA) 
 
C57Bl6 spleen cells were harvested from control and PQ-treated mice, previously 
injected with Cell-ROX Deep Red. Spleens were digested for 30 minutes at 37°C with 
collagenase (4000 U/ml collagenase type II from Invitrogen) in sterile Hanks’ 
balanced saline solution (HBSS) with Ca2+ and Mg2+ (Life Technologies).  Cells were 
then collected using a 70 mm sieve, centrifuged at 1500 rpm for 10 minutes and the 
cell pellet resuspended in red blood cells lysis buffer for 5 min at RT (Sigma).  Cells 
were then washed at 1500 rpm for 10 minutes and the pellet resuspended in FACS 
buffer (PBS supplemented with 4% FBS and 0.2% sodium azide). The following FITC 
labeled antibody were used for staining: CD3, CD19, CD11b, CD11c and GR-1 
(Pharmingen).  Finally, cells were analyzed by flow cytometry (Becton Dickinson, 
N.J, USA) 
 
. 
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PROTEOMIC ANALYSIS OF HF5 PURIFIED AGGREGATES - performed by the Laboratory of 
Pathology, Immunology and Microbiology of A. Einstein College of Medicine (Yeshiva 
University, NY, USA) 
 
Protein aggregates purified by HF5 (with the highest MW) were incubated in 0.1 M 
ammonium bicarbonate buffer with 4M urea and sonicated for 15 minutes at RT.  The 
samples were further reduced with 10 mM TCEP-HCl in 0.1 M ammonium 
bicarbonate buffer, pH 8.9, for 30 minutes, at RT.  The reduction was followed 
immediately by alkylation with 55 mM iodacetamide solution in 0.1 M ammonium 
bicarbonate, at RT, in the dark for 45 minutes.   
Proteins were digested with trypsin and Lys-C (sequencing grade, Promega) at 37°C 
for 12 hours.  Following digestion, the samples were subjected to desalting using 
ZipTip (C18) reversed-phase system (Millipore, Billerica, MA) and submitted for 
MS/MS peptide sequencing.   
LTQ-MS/MS sequencing was performed using a Nanospray LC-MS/MS on a LTQ 
linear ion trap mass spectrometer (LTQ Thermo Scientific, San Jose, CA, USA) 
interfaced with a TriVersa NanoMate nanoelectrospray ion source (Advion 
BioSciences, Ithaca, NY, USA). The 15 most abundant ions were selected for MS/MS. 
Raw data files were converted to .mgf files using Proteome Discoverer 1.3 (Thermo 
Fisher Scientific). 
All .mgf files were searched against the house mouse (Mus musculus; 16,230 
sequences) in SwissProt 57.15 (515,203 total sequences; 181,334,896 total residues) 
using Mascot, in-house, (Matrix Science, London, UK; version 2.3.02). The following 
parameters were used for all searches: trypsin; 1 missed cleavage; fixed modification 
of carbamidomethylation (for Cys) and variable modifications: deamidation (Asn 
and Gln), oxidation (Met, Pro, Lys, Arg); monoisotopic masses: peptide precursor 
mass tolerance of 1.5 Da; and product ion mass tolerance of 0.5 Da.   
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A false discovery rate (FDR) for peptide identification was assessed by decoy 
database searching and was finally adjusted to less than 1.0% for proteins and 
peptides.  Proteins were considered identified having at least one bold red (BR) 
significant peptide with an ion score cut-off of 40 or greater (corresponding to p≤0.05 
and a FDR proteins ≤1.0%). 
 
PATHWAYS ANALYSIS – performed by the Laboratory of Pathology, Immunology and 
Microbiology of A. Einstein College of Medicine (Yeshiva University, NY, USA) 
 
The putative interactions among the identified proteins in the high MW aggregates, 
fractionated from 3 and 22 months old spleen and bone marrow, were analyzed 
using the functional networks interactive pathways analysis (IPA). The ArrayTrack™ 
(http://www.fda.gov) bioinformatics tool from the FDA web site was used to 
generate the heat map corresponding to the major up- and down-regulated pathways 
by importing the -log (p) values associated with each pathway as provided by IPA 
analysis.   
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4.2.1.4. RESULTS AND DISCUSSION 
A. NATIVE PROTEINS MIXTURE 
 
The developed HF5 method was simulated first, employing the ISIS simulation 
software (Superon GmbH), on a native proteins mixture (NativeMarkTM Unstained 
Protein Standard, Novex®, Life TechnologiesTM) used as a sample model, to check the 
correlations between retention time (tR), hydrodynamic size (rh), diffusion coefficient 
(D) and MW under ideal separation conditions (Figure 1).  
 
 
Figure 1 – Native markers: (a) relationship between hydrodynamic radius and retention time; (b) 
relationship between MW and retention time and (c) relationship between MW and D. 
 
The Eclipse ISIS simulation software was employed to predict the (theoretical) tR, rH 
and D of each native marker, by inputting the HF5 method flow rates and the known 
MW values (declared by Life TechnologiesTM in the product sheet). Figure 1a shows 
how the protein size influences the tR, therefore how the separation occurs according 
to size. Figure 1b shows how the protein MW influences the tR, therefore how the 
separation occurs according to MW.  
The slope of this plot (0.4) represents the value of parameter b, reported in Equation 
14 (sub-chapter 2.2.2 of Chapter 2). A slope value of 0.4 indicates molecular 
conformations between hard sphere (0.33) and random coil (0.5-0.6). Figure 1c shows 
how the diffusion coefficient, D (which determines the size, shape and surface 
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properties of proteins) is correlated to the proteins MW. The mathematical 
expression which represents D as a function of MW is reported in Equation 14. 
In FPLC-UV or SEC-UV, the MW value of an unknown protein/protein aggregate in 
a complex sample like a cell lysate, is determined by interpolation using the 
calibration curve, which is built by plotting known MWs of standard proteins against 
their experimental retention time (tR).  This procedure assumes constant molecular 
conformations, usually globular (rigid sphere). The same approximation was made 
by the ISIS simulation software. Since the MW value assignment is based on a 
specific tR, a slight change in the latter may lead to erroneous MW assignments, 
making this procedure faulty. 
Indeed, when the HF5 method was applied experimentally to the same native 
markers mixture,  discrepancies between the theoretical (Figure 1a) and experimental 
tR (Figure 2) were observed, most likely caused by proteins shape deviation from 
rigid sphere (globular conformation), especially at high MW values.  
 
 
Figure 2 – HF5-UV-MALS separation profile of the standard protein mixture. The peak assignment 
was based on the absolute MW values computed by Astra® 
 
Shifts in the tR are very likely due to molecular conformational changes (like the ones 
caused by carbonylation of proteins side-chains, under the effect of oxidative stress 
or by protein denaturation, under the effect of urea), but also by specific/non-specific 
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interactions between the lysate components and the column matrix in FPLC and SEC.  
On the other hand, the MW determined by multi-angle light scattering (MALS) 
measurements is absolute (does not require calibration with molecular standard, nor 
makes approximations on the shape of the protein).  
Based on differences in hydrodynamic size, proteins with the same MW may have 
different tR, indicating molecular conformation differences. Indeed, the native 
proteins MW values derived from MALS measurements matched the ones declared 
by the manufacturer (Life TechnologiesTM), even though there was a discrepancy 
between the experimental (Figure 2) and the predicted tR values (Figure 1a).  
The peaks were identified based on the absolute MW values, as follows: (1) soybean 
trypsin inhibitor, 20 kDa; (2) bovine serum albumin, 66 kDa; (3) lactate 
dehydrogenase, 146 kDa; (4) β-phycoerythrin, 242 kDa; (5) apoferritin band 1, 480 
kDa; (6) apoferritin band 2, 720 kDa; (7) IgM pentamer, 1048 kDa and (8) IgM 
hexamer, 1236 kDa.  
 
Given these satisfactory results, the next step consisted in applying the HF5-(UV)-
MALS method to the cell lysate samples.  
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B. HF5-UV-MALS OF PROTEIN AGGREGATES GENERATED IN VITRO 
 
To evaluate the capabilities of HF5 to separate over a wide MW range of proteins and 
complex protein aggregates, as present in a total cell lysate, an experimental culture 
of control cells and cells treated with different concentrations of Paraquat was setup. 
Paraquat is known to induce oxidative stress, a condition known to induce protein 
(irreversible) damage and promote protein aggregation. The Paraquat – induced 
oxidative stress is known to lead to the oxidation of the proteins side chains and the 
most frequent consequences are the carbonyl modifications, therefore considered 
markers of oxidative stress.  
The Carbonyl spectrophotometric assay was performed on total cell lysates in order 
to determine the extent of the carbonyl modifications suffered upon Paraquat 
treatment, therefore to validate the efficacy of the Paraquat treatment and the results 
are reported in Figure 3a. The same samples were run on SDS-PAGE and the gel is 
reported in Figure 3b. 
 
 
Figure 3 – Tests performed on whole cell lysates, following in vitro treatment with Paraquat: (a) 
protein carbonyl assay and (b) Silver staining of an SDS-PAGE. Performed and kindly provided by the 
Laboratory of Pathology, Immunology and Microbiology of A. Einstein College of Medicine (Yeshiva University, 
NY, USA) 
 
Figure 3a demonstrates the efficacy of the Paraquat treatment, since an increased 
amount of total protein carbonylation was observed, directly proportional to the 
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molarities of Paraquat treatment. Figure 3b shows an increased amount of SDS-
insoluble aggregates, as compared to untreated cells, also proportional to the amount 
of Paraquat added to the cell cultures. Moreover, Figure 3b shows an increased 
amount of low MW proteins/fragments in the Paraquat-treated cells, associated with 
oxidative cleavage. 
 
Analysis of the samples by gel filtration (FPLC) employing a Superdex S 200 column 
confirmed high MW aggregates in the PQ treated samples, as well as presence of low 
MW cleavage products (Figure 4).  However, the very high MW aggregates (MW > 
1x106 Da) did elute in the void volume with the dextran blue (MW = 2x106 g/mol).   
Running the samples on a Sephadex column with increased porosity (S300) did not 
separate with enough resolution aggregates above 2x106 g/mol (data not shown).   
 
 
Figure 4 – FPLC separation profile at 280 nm of protein lysates from control cells and cells treated 
with 5 mM Paraquat.  Dextran blue 2×106 MW elutes with the void volume. Performed and kindly 
provided by the Laboratory of Pathology, Immunology and Microbiology of A. Einstein College of Medicine 
(Yeshiva University, NY, USA) 
 
Next, control and Paraquat-treated cell lysates were separated by HF5 under native 
conditions and the elution profiles, as well as the corresponding MW ranges are 
reported in Figure 5a. Figure 5a also reports the elution of the native protein markers 
(the same as reported in Figure 1) and the elution of Blue Dextran (MW: 2000 kDa). 
The rms radius ranges, derived from the MALS measurements and computed by 
Astra® are reported in Figure 5b. 
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Figure 5 – HF5-UV-MALS elution profiles of the control and Paraquat-treated cell lysates, 
separated under native conditions, reporting: (a) MW range calculated by Astra; (b) rms radius 
range calculated by Astra and (c) lysate fractions collected for further characterization 
 
Increased protein aggregation and the presence of HMW aggregates could be 
observed in Paraquat-treated samples, as compared to the untreated cells. All 
samples contain a common MW range of proteins and protein aggregates with MWs 
up to 3.3×106 g/mol. All Paraquat treated samples also show the presence of HMWs 
which are not present in the control sample, reported in Figure 5a and 6a. An 
increase in the protein aggregates upper MW limit with increasing Paraquat molarity 
is also observed in Figure 6a and the exact values are reported in Table 1. 
Aggregates of the same MW value showed reduced rH and rms radius values in the 
Paraquat treated samples when compared to the control, suggesting changes in the 
aggregate molecular conformation following carbonylation. 
Conformational differences among the aggregates in the control and the treated 
samples were observed in the correlation plot reported in Figure 6b, obtained by 
plotting the log (rms radius) against the corresponding log (MW) values. The 
molecular conformation state (sphere, random coil or rod) was assigned based on the 
slope value of the correlation plot, as described in the Astra® Computations sub-
section of Materials and Methods. 
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Figure 6 – Control and Paraquat treated samples (a) MW ranges of the Paraquat-treated samples 
compared to the control and (b) conformation plots, the number below the assigned molecular 
conformation represents the slope derived from experimental data 
Figure 6b shows the conformation trend of the protein aggregates present in the Jaws 
II cell lysate samples separated under native conditions and how the increase in the 
Paraquat concentration progressively modifies the overall conformation trend of the 
protein aggregates. 
The Paraquat treatment had two distinct effects on the proteins/protein aggregates 
and their HF5 elution behavior in native carrier solution:  
(A) Conformation /shape effect: this led to observing different slope values in the 
correlation plot for the samples under examination. The protein aggregates are more 
compact in the treated samples and their compactness increases with the Paraquat 
concentration. Consequently, proteins aggregates with the same MW value have 
progressively anticipated retention times in the Paraquat-treated samples;  
(B) Density effect: at equal MW value, protein aggregates in the treated samples have 
smaller rms radii compared to the control sample and the rms radius decreases with 
the Paraquat concentration. A smaller rms radius indicates that the scattering points 
are found closer to the mass center, leading to the same MW being concentrated in a 
smaller space. This implies that aggregates with the same MW have higher densities 
in the treated samples. 
Moreover, the Paraquat has an overall effect on the elution behavior of all aggregates 
present in the treated samples, therefore even on aggregates whose formation was 
not mediated by the Paraquat treatment with MWs between 1.0×106 and 3.3×106 Da. It 
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is very likely that the Paraquat led to the carbonylation of the side chains causing a 
conformational change, but did not lead to further aggregation. The amount of the 
Paraquat – induced protein aggregates shows an increase with the Paraquat 
concentration and the values are reported in Table 1, along with the corresponding 
MW ranges and the elution times. 
 
The next step consisted in determining whether HF5 runs employing a denaturing 
carrier solution could help establish the biophysical properties of the protein 
aggregates. Lysates from control sample and sample treated with the highest amount 
of Paraquat (10 mM) were separated under mild denaturing conditions (2 M urea) 
and the elution profiles, as well as the corresponding MW ranges are reported in 
Figure 7a. The rms radius ranges, derived from the MALS measurements and 
computed by Astra® are reported in Figure 7b. 
 
Figure 7 – HF5-UV-MALS elution profiles of the control and Paraquat-treated cell lysates, 
separated under denaturing conditions (2 M urea), reporting: (a) molecular weight range calculated 
by Astra; (b) rms radius range calculated by Astra and (c) lysate fractions collected for further 
characterization 
Analysis of the rH and rms radius showed that protein aggregates with the same MW 
eluted at different tR, suggesting a reduced hydrodynamic size (for the aggregates 
with anticipated tR). Moreover, aggregates with the same MW had similar rms radius 
values, even though eluted at different tR. The results are reported in Table 2. 
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A drastic decrease in the percentage of the Paraquat-induced protein aggregates was 
observed (approximately 92%), indicating that many of the aggregates observed 
under native conditions are non-covalent. Nonetheless, Paraquat-induced aggregates 
representing 1.9% of the whole lysate, are present in the sample under denaturing 
condition (Table 1), therefore urea-resistant.  
Indeed, at low concentration (2M) urea acts by disrupting the hydrogen bonds in the 
protein secondary structure thus disrupting non-covalent aggregates. As expected 
under denaturing conditions, the presence of new protein aggregates with MW 
above 1.7×107 g/mol, was also observed (Figure 7a, Tables 1 and 2). 
Table 1 – Separation of Jaws II cell lysates under native and denaturing conditions 
Jaws II cell lysates 
Native conditions – Figure 5a 
Sample CTR 0.25 mM PQ 5 mM PQ 10 mM PQ 
Common MW range (g/mol) 1.5×104 – 3.3×106 
Hydrodynamic radius range (nm)  2 – 115  2 – 74  2 – 61  2 – 45  
MW range of Paraquat – induced 
aggregates (g/mol) 
- 
3.3×106  
5.5×106 
3.3×106  
6.2×106 
3.3×106  
1.7×107 
Hydrodynamic radius range (nm) of 
Paraquat – induced aggregates 
- 74 – 115  61 – 115  45 – 115  
Amount of Paraquat – induced 
aggregates 
- 12.5% 17.9% 25.1% 
Denaturing conditions – Figure 7a 
Sample CTR 10 PQ 
Common MW range (g/mol) 1.5×104 – 3.3×106 
Hydrodynamic radius range (nm)  2 – 30  2 – 22  
MW range of Paraquat – induced 
aggregates (g/mol) 
- 3.3×106 – 1.7×107 
Hydrodynamic radius range (nm) of 
Paraquat – induced aggregates 
- 22 – 37  
Amount of Paraquat – induced 
aggregates 
- 1.9% 
MW range of new aggregates 
(denaturing conditions) 
3.3×106 – 1.7×107 1.7×107 – 4.3×107 
Hydrodynamic radius range 
(nm) of new aggregates 
30 – 58  37 – 58  
Amount of new aggregates 
(denaturing conditions) 
8% 0.9% 
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The detailed fraction-by-fraction characterization by HF5-UV-MALS, containing the 
MW ranges, rms radius and hydrodynamic radius (rH) ranges for each lysate fraction 
reported in Figures 5c (native) and 7c (denaturing), is reported in Table 2. 
Table 2 - Fractions of Jaws II cell lysates separated under native and denaturing conditions. MW, 
rms radius and hydrodynamic radius (rh) ranges. 
Jaws II cell lysates fractions  
MW range (g/mol) – Figure 5a, fractions: Figure 5c 
Fractions 1 2 3 4 5 6 
Control 
4.4×104 
1.5×105 
1.5×105 
2.8×105 
2.8×105 
6.5×105 
6.5×105 
2.2×106 
2.2×106 
3.0×106 
3.0×106 
3.3×106 
rh range (nm) 5 – 10   10 – 18  18 – 26  26 – 48  48 – 76  76 – 115  
Treated (10PQ) 
1.6×104 
1.6×105 
1.6×105 
4.8×105 
4.8×105 
1.2×106 
1.2×106 
7.2×106 
7.2×106 
1.7×107 
1.7×107 
1.7×107 
rh range (nm) 5 – 10   10 – 18  18 – 26  26 – 48  48 – 76  76 – 115  
Rms radius range (nm) – Figure 5b, fractions below figure 
Fractions 1 2 3 4 5 6 
Control N/A N/A N/A 20.9 – 46.6 46.6 – 71.0 71.0 – 108.6 
Treated (10PQ) N/A N/A N/A 18.0 – 52.6 52.6 – 88.5 88.5 – 126.4 
MW range (g/mol) – Figure 7a, fractions: Figure 7c 
Fractions 1 2 3 4 5 6 
Control 
7.1×103 
3.4×104 
3.4×104 
1.4×105 
1.4×105 
3.1×105 
3.1×105 
3.1×106 
3.1×106 
3.3×106 
 
New aggregates 
(denaturing 
conditions) 
    
3.3×106 
9.1×106 
9.1×106 
1.7×107 
rh range (nm) 5 – 8  8 – 14  14 – 19  19 – 32  32 – 43  43 – 58  
Treated (10PQ) 
6.2×103 
3.9×104 
3.9×104 
1.2×105 
1.2×105 
6.8×105 
6.8×105 
1.0×107 
1.0×107 
1.7×107 
 
New aggregates 
(denaturing 
conditions) 
    
1.7×107 
3.9×107 
3.9×107 
4.3×107 
rh range (nm) 5 – 8  8 – 14  14 – 19  19 – 32  32 – 43  43 – 58  
Rms radius range (nm) – Figure 7b, fractions below figure 
Fractions 1 2 3 4 5 6 
Control N/A N/A N/A N/A 16.0 – 27.6  
New aggregates 
(denaturing 
conditions) 
    
16.2 – 27.6 27.6 – 38.9 
Treated (10PQ) N/A N/A N/A 7.5 – 23.6 23.6 – 26.1  
New aggregates 
(denaturing 
conditions) 
    
26.1 – 36.8 36.8 – 49.9 
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Under native conditions, the size of the aggregates progressively decreased as the 
Paraquat molarity increased. Moreover, under both denaturing and non denaturing 
conditions, aggregates of the same MW showed reduced rH and rms radius values in 
the Paraquat treated samples when compared to the control, suggesting molecular 
conformation changes induced by the Paraquat treatment.  
 
Figure 8 reports the correlation plots for the Jaws II cell lysates samples during the 
separation in denaturing buffer; the change in the slope value indicating the different 
molecular conformation trends, suggests overall modified conformations caused by 
the Paraquat treatment.  
 
Figure 8 – Conformation plots of control and Paraquat treated sample separated under denaturing 
conditions (2 M urea); the number below the assigned molecular conformation represents the slope 
derived from experimental data 
When separated under mild denaturing conditions, the aggregates in both control 
and treated samples tend to become more compact when compared to native 
conditions: their rms radius values decrease drastically (Table 2). Both samples 
contain protein aggregates with random-coil conformations in the common MW range 
(1.0×106 – 3.3×106 Da). In correspondence of the Paraquat-induced covalent 
aggregates (MWs above 3.3×106 Da), we observe a slope change towards even more 
compact, sphere-like, molecular conformations.  
 
To confirm the suitability of the HF5 method to separate protein aggregates of 
different MWs, protein fractions were collected from control and Paraquat-treated 
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samples separated under native conditions (Figure 5c) and run on a native gel. The 
results are reported in Figure 9. 
 
Figure 9 – Native-PAGE performed on the HF5 fractions form control and Paraquat-treated lysate 
samples. The fractions were dialyzed and lyophilized prior to electrophoresis. Performed and kindly 
provided by the Laboratory of Pathology, Immunology and Microbiology of A. Einstein College of Medicine 
(Yeshiva University, NY, USA) 
 
 
The gel confirmed protein separation by HF5, detected as the increment in MW in 
progressive fractions from 1x105 to over 2.5x106. Additionally, fraction 6 collected 
after the elution of dextran blue (2x106 Da) indicated the presence of protein 
aggregates in the Paraquat-treated cells, but not control ones (Table 2).  
 
Altogether, the results confirm the capability of HF5 to separate proteins and protein 
aggregates according to their MW, as well as hydrodynamic size, from a complex 
mixture of proteins as present in total cell lysate. 
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C. HF5-UV-MALS OF PROTEIN AGGREGATES GENERATED IN VIVO 
 
Next, the HF5 capabilities were evaluated during the separation of protein 
aggregates formed in vivo and in primary cells, during conditions of increased 
oxidative stress.  To this goal, mice were injected intraperitoneally with Paraquat 
(2.5mg/25g body weight) for two consecutive days. On day three mice were injected 
intravenously with the CellRox probe that fluoresces upon binding to reactive 
oxygen species and the results are displayed in Figure 10.    
 
 
Figure 10 – (a) In vivo Detection of Oxidative Stress in control (CTR) and Paraquat (PQ) treated 
mice. The in vivo detection of fluorescence was performed using the In-Vivo Imaging System FX 
PRO (Carestream); (b) FACS analysis of spleen cell subpopulations isolated ex vivo, following 
CellROX injection. Performed and kindly provided by the Laboratory of Pathology, Immunology and 
Microbiology of A. Einstein College of Medicine (Yeshiva University, NY, USA) 
 
Increased fluorescence was observed in parenchyma organs in Paraquat-treated mice 
(Figure 10a).  Similarly, increased ROS-generated fluorescence was also observed on 
ex vivo purified spleen cell subpopulations, as analyzed by FACS and reported in 
Figure 10b.   
Next, total spleen lysates from control and Paraquat treated mice were run by HF5 
and the elution profiles, as well as the corresponding MW ranges are reported in 
Figure 11. 
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Figure 11 – HF5-UV-MALS elution profiles of the control and Paraquat-treated spleen cell lysates, 
separated under (a) native conditions and (b) denaturing conditions (2 M urea), both reporting the 
molecular weight range calculated by Astra, and (c) lysate fractions collected for further 
characterization 
When separated under native conditions, both control and Paraquat-treated spleen 
cell lysate samples show a common MW range of proteins and protein aggregates, 
with MWs up to 1.2×106 g/mol. However, the treated sample also shows the presence 
of protein aggregates that are not present in the control sample (Figure 11a). The 
Paraquat–induced aggregates amounted to 21.4% of the total protein lysates of the 
treated sample, as reported in Table 3. 
The biophysical nature of the Paraquat-induced aggregates was investigated further, 
by separating the same samples under mild denaturing conditions (2 M urea). The 
HMWs observed only in the treated sample were still present (Figure 11b), but their 
amount decreased significantly.  
As reported previously for the in vitro Paraquat-induced aggregates (Table 1), the 
results indicate that most Paraquat-induced aggregates (approximately 74%) are non-
covalent. The aggregates amounts along with the corresponding MW ranges and the 
elution times are reported in Table 3.  
Once again, upon Paraquat treatment, aggregates having the same MW value 
showed reduced rH values when compared to the control sample suggesting more 
compact aggregates following protein carbonylation. This observation is valid for 
separations under native and mild denaturing conditions.  
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Table 3 – Separation of spleen cell lysates (control and treated sample) under native and 
denaturing conditions 
Native conditions – Figure 11a 
Sample CTR PQ 
Common MW range (g/mol) 5.0×105 – 1.2×106 
Hydrodynamic radius range (nm)  2 – 55  2 – 23  
MW range of Paraquat – induced 
aggregates (g/mol) 
- 1.2×106 – 2.6×106 
Hydrodynamic radius range (nm) 
of Paraquat – induced aggregates 
- 23 – 55  
Amount of Paraquat – induced 
aggregates 
- 21.4% 
Denaturing conditions – Figure 11b 
Sample CTR PQ 
Common MW range (g/mol) 5.0×105 – 1.2×106 
Hydrodynamic radius range (nm)  2 – 40  2 – 26  
MW range of Paraquat – induced 
aggregates (g/mol) 
-  1.2×106 – 2.6×106 
Hydrodynamic radius range (nm) 
of Paraquat – induced aggregates 
- 26 – 40  
Amount of Paraquat – induced 
aggregates 
- 5.5%  
 
Importantly, the quantification of protein carbonylation, as a measure of oxidative 
stress, showed an increase in the amount of carbonyl groups in each fraction of the 
Paraquat-treated cell lysate separated by HF5 (Figure 11c), but most predominantly 
in the high MW fractions of the spleen cell lysate. The results are reported in Figure 
12.  
 
 
Figure 12 – Protein carbonyl assay performed of different fractions, collected from control and 
Paraquat spleen samples (Figure 11c). Performed and kindly provided by the Laboratory of Pathology, 
Immunology and Microbiology of A. Einstein College of Medicine (Yeshiva University, NY, USA) 
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Next, brain lysates from control and Paraquat-treated mice were analyzed by HF5-
(UV)-MALS. Their elution profiles, as well as corresponding MW ranges are reported 
in Figure 13a (native) and 13b (denaturing, 2M urea). The rms radius ranges, derived 
from the MALS measurements and computed by Astra® are reported in Figure 13b. 
 
 
Figure 13 – HF5-UV-MALS elution profiles of the control and Paraquat-treated brain cell lysates, 
(a) separated under native conditions, reporting the MW ranges  calculated by Astra and  (b) rms 
radius ranges calculated by Astra and (c) separated under denaturing conditions (2 M urea), 
reporting MW ranges calculated by Astra 
 
A common MW range of proteins and protein aggregates, with MWs up to 7.5×106 
g/mol is observed for both control and treated sample, reported in Table 4. Once 
again, the brain sample from Paraquat-treated mice showed the presence of high MW 
aggregates, with MW above 7.5×106 g/mol, which were not detected in the control 
sample (Figure 13a).  These aggregates amounted to up to the 26.1% of total proteins 
in the treated sample, reported in Table 4.  
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Table 4 – Separation of brain cell lysates (control and treated sample) under native and denaturing 
conditions 
Native conditions – Figure 13a 
Sample CTR PQ 
Common MW range (g/mol) 1.0×105 – 7.5×106 
Hydrodynamic radius range (nm)  4 – 203  4 – 100  
MW range of Paraquat – induced 
aggregates (g/mol) 
- 7.5×106 – 3.9×107 
Hydrodynamic radius range (nm) 
of Paraquat – induced aggregates 
- 100 – 200  
Amount of Paraquat – induced 
aggregates 
- 26.1% 
Denaturing conditions – Figure 13c 
Sample CTR PQ 
Common MW range (g/mol) 1.0×105 – 7.5×106 
Hydrodynamic radius range (nm)  0 – 116  0 – 68  
MW range of Paraquat – induced 
aggregates (g/mol) 
- 7.5×106 – 3.9×107 
Hydrodynamic radius range (nm) 
of Paraquat – induced aggregates 
- 68 – 115  
Amount of Paraquat – induced 
aggregates 
- 14.8% 
MW range of new aggregates 
(denaturing conditions) 
7.5×106 – 2.0×107 3.9×107 – 8.0×107 
Hydrodynamic radius range (nm) 
of new aggregates 
116 – 177  115 – 177  
Amount of new aggregates 
(denaturing conditions) 
12% 10%  
 
Once again, upon Paraquat treatment, aggregates having the same MW value 
showed reduced rH values (anticipated tR) when compared to the control sample, 
suggesting more compact aggregates following protein carbonylation. Figure 13b 
shows a broad size range of proteins and protein aggregates for both lysates (control 
and treated sample) and, once again, at equal MW, the aggregates in the treated 
sample show reduced rms radius.  
However, the Paraquat-induced aggregates, eluting from 31.5 to 55 min, are larger 
than previously observed in the control sample, arriving up to 120 nm of rms radius. 
These findings support the protein molecular conformational changes caused by 
carbonylation, already reported for the Jaws II cell lysates (Figures 6b and 8).  
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Once the samples were separated under denaturing conditions (4 M urea, Figure 
13c), a decrease in their amount was observed, but less significantly of what observed 
in the spleen samples (Table 3), indicating that most Paraquat-induced aggregates in 
the brain samples are covalent (urea-resistant). As expected, under denaturing 
conditions, the presence of new protein aggregates was also observed and reported 
in Table 4 
 
Altogether the data indicate MW and size-based HF5 separation of protein 
aggregates formed in vivo in primary cells. Additionally, it indicates that the majority 
of proteins modified by carbonylation, a post-translational modification typically 
observed in condition of oxidative stress, are predominantly observed in the HMW 
fractions.  
 
D. HF5-UV-MALS OF AGING – RELATED PROTEIN AGGREGATES  
 
The increasing protein tendency to aggregate with aging is a generally 
acknowledged fact. Indeed, increased amounts of protein post-translational 
modifications including glycation, carbonylation and lipoxidation in aging bone 
marrow lysates were previously reported by [Cannizzo et al. 2011, Cannizzo et al. 
2012]. These modifications are normally associated with increased protein 
aggregation.   
 
Thus, as next step we set to determine whether the proposed methodology could be 
successfully applied to protein aggregates as occurring in aging bone marrow 
precursors cell.   CD34+ cells were purified from the total bone marrow of 3, 12 and 22 
months old mice and the lysates were run on an SDS-PAGE to confirm presence of 
protein aggregation. The results are reported in Figure 14 (Figure 4a). Indeed, a 
progressively increased amount of high MW aggregates was observed with aging. 
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Figure 14 - Silver staining of an SDS-PAGE gel of total bone marrow cell lysate from 3, 12 and 22 
months old mice. Performed and kindly provided by the Laboratory of Pathology, Immunology and 
Microbiology of A. Einstein College of Medicine (Yeshiva University, NY, USA) 
 
Next, the same lysates were separated and characterized by HF5-(UV)-MALS using 
either native or denaturing carrier solutions. The elution profiles, as well as 
corresponding MW ranges are reported in Figure 15. 
 
Figure 15 – HF5-UV-MALS elution profiles of bone marrow cell lysates from aging samples (mice 
of 3, 12 and 22 months), reporting the MW ranges calculated by Astra separated under: (a) native 
conditions, (b) mild denaturing conditions, 2 M urea and (c) denaturing conditions, 4 M urea; (d) 
protein fractions collected for further characterization. 
 
Figure 15a shows that all three aging samples contained a common MW range of 
proteins and protein aggregates with MWs up to 4.4×106 g/mol, reported in Table 5.  
Additionally, the 22 months old bone marrow cell lysate also contained higher MWs 
that were not present in the samples from 3 and 12 months old mice, representing 
approximately 15.9% of the 22 months sample (Table 5).  
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Next, the samples were fractionated under denaturing conditions (2M and 4 M urea). 
Figures 15b and 15c show that the majority of aging-related protein aggregates, 
observed under native conditions, were still present in the 22 months sample. 
Indeed, their amount decreased only slightly as the urea concentration increased, 
indicating that many of the age-related aggregates presented covalent bonds (Table 
5). 
Importantly, aggregates, with the same MW, but collected from different ages, eluted 
at different retention times due to differences in the hydrodynamic sizes (rh), also 
reported in Table 5.  These rh differences, between protein aggregates with the same 
MW value (but of different age), are due to changes in the aggregate molecular 
conformation, as previously reported for the Paraquat-treated cell lysates (Figure 6b 
and Figure 8). As expected under denaturing conditions, the formation of new 
aggregates was observed and reported in Table 5.  
 
The rms radius ranges, derived from the MALS measurements and computed by 
Astra® are reported in Figure 16a; whereas Figure 16b reports the conformation 
trends of the covalent aggregates present in bone marrow cell lysates from aging 
samples (mice of 3, 12 and 22 months)  
 
 
Figure 16 – HF5-UV-MALS elution profiles of the bone marrow aging (mice of 3, 12 and 22 months) 
cell lysates separated under mild denaturing conditions (2 M urea), reporting the (b) rms radius 
ranges calculated by Astra and (b) conformation plots; the number below the assigned molecular 
conformation represents the slope derived from experimental data 
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Table 5 – Separation of bone marrow cell lysates (3, 12 and 22 months under native and denaturing 
conditions 
Bone marrow cell lysates 
Native conditions – Figure 15a 
Sample 3 months 12 months 22 months 
Common MW range (g/mol) 5.0×104 – 4.4×106 
Hydrodynamic radius range (nm)  3 – 111  3 – 111  3 – 53  
MW range of aging – induced 
aggregates (g/mol) 
- - 4.4×10
6 – 1.3×107 
Hydrodynamic radius range (nm) of 
aging – induced aggregates 
- - 53 – 111  
Amount of aging – induced 
aggregates 
- - 15.9% 
Mild denaturing conditions (2 M urea) – Figure 15b 
Sample 3 months 12 months 22 months 
Common MW range (g/mol) 1.0×10
5 – 4.4×106 
Hydrodynamic radius range (nm)  4 – 90  4 – 89  4 – 66  
MW range of aging – induced 
aggregates (g/mol) 
- - 4.4×106 – 1.3×107 
Hydrodynamic radius range (nm) of 
aging – induced aggregates 
- - 66 – 97 
Amount of aging – induced 
aggregates 
- - 11.5% 
MW range of new aggregates 
(denaturing conditions) 
4.4×10
6
 – 1.2×107 4.4×106 – 1.2×107 1.3×107 – 2.1×107 
Hydrodynamic radius range 
(nm) of new aggregates 
90 – 113  89 – 113  97 – 113  
Amount of new aggregates 
(denaturing conditions) 
2% 3% 12% 
Denaturing conditions (4 M urea) – Figure 15c 
Sample 3 months 12 months 22 months 
Common MW range (g/mol) 1.0×10
5 – 4.4×106 
Hydrodynamic radius range (nm)  3 – 7  3 – 7  3 – 9  
MW range of aging – induced 
aggregates (g/mol) 
- - 4.4×106 – 1.3×107 
Hydrodynamic radius range (nm) of 
aging – induced aggregates 
- - 9 – 18  
Amount of aging – induced 
aggregates 
- - 11%
 
MW range of new aggregates 
(denaturing conditions) 
4.4×10
6
 – 3.0×107 4.4×106 – 3.0×107 4.4×106 – 1.5×107 
Hydrodynamic radius range 
(nm) of new aggregates 
7 – 51  7 – 51  18 – 51  
Amount of new aggregates 
(denaturing conditions) 
49% 56% 7% 
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Figure 16a shows the presence of very large protein aggregates in the 22 months 
sample that are not present in the younger ones.  Figure 16b shows the differences in 
the conformation trends, indicated by the slope values and how the overall 
molecular conformations change due to modifications (mostly carbonylation, but 
also lipoxidation and glycation) caused by oxidative stress during the aging process. 
Indeed, the aging-related protein aggregates in the 22 months sample presented 
sphere-like, highly compact conformations, whereas aggregates found in younger 
bone marrow present a relaxed rod-like conformation (Figure 4e).   
 
Additionally, the correlation plot reported in Figure 16b indicates different 
compactness degrees: the younger samples (3 and 12 months) show a very small rms 
radius increase over time, suggesting protein aggregates of very high density when 
compared to the oldest sample (22 months).  
Moreover, correlating Figures 16a and 16b, is shown that the age-related aggregates 
that are present only in the oldest sample not only have higher MW values (as 
reported in Table 5), but have a much larger size and a more compact conformation 
when compared to the non age-related aggregates.  
 
Analysis of the rH and rms radius showed how protein aggregates with the same MW 
eluted at different tR, suggesting a reduced hydrodynamic size for the aggregates 
with anticipated tR, as already reported for other cell lysate samples. The detailed 
fraction-by-fraction characterization by HF5-UV-MALS, containing the MW ranges, 
rms radius and hydrodynamic radius (rH) ranges for each lysate fraction depicted in 
Figures 15d and 16c is reported in Table 6. 
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Table 6 – Fractions of aging bone marrow cell lysates (3, 12 and 22 months old mice) separated 
under native and denaturing conditions. MW, rms radius and hydrodynamic radius (rh) ranges. 
Bone marrow cell lysates separated under mild denaturing conditions (2 M urea) 
Fractions 1 2 3 4 5 
Hydrodynamic radius 
range (nm) 
27 – 41  41 – 52  52 – 69  69 – 91  91 – 116  
Mass 
fraction 
3 months 8.3% 8.9% 6.1% 3.8% 1.7% 
12 months 11.4% 12.0% 8.2% 5.2% 2.5% 
22 months 12.1% 15.0% 11.5% 7.8% 4.5% 
MW range 
(g/mol) 
3 months 
2.322×105 
7.902×105 
7.902×105 
1.434×106 
1.434×106 
2.139×106 
2.139×106 
4.033×106 
4.033×106 
1.194×107 
12 months 
2.722×105 
8.655×105 
8.655×105 
1.321×106 
1.321×106 
2.323×106 
2.323×106 
4.129×106 
4.129×106 
1.244×107 
22 months 
1.254×106 
1.568×106 
1.568×106 
2.454×106 
2.454×106 
4.640×106 
4.640×106 
9.033×106 
9.033×106 
2.103×107 
Rms radius 
range (nm) 
3 months N/A 41.6 – 47.4 47.4 – 58.5 58.5 – 71.9 71.9 – 94.4 
12 months N/A 26.2 – 41.6 41.6 – 67.8 67.8 – 84.5 84.5 – 99.2 
22 months N/A 155.9 – 171.4 171.4 – 208.7 208.7 – 232.1 232.1 – 264.8 
 
Altogether the data demonstrate that H5F-MALS can separate age-related aggregates 
from total cell lysates and characterize their MW, hydrodynamic radius and 
conformation. 
 
E. MASS SPECTROMETRIC ANALYSIS OF AGING-RELATED PROTEIN AGGREGATES.  
PERFORMED BY THE LABORATORY OF PATHOLOGY, IMMUNOLOGY AND MICROBIOLOGY OF A. 
EINSTEIN COLLEGE OF MEDICINE (YESHIVA UNIVERSITY, NY, USA) 
 
It has been recently reported that, during physiological aging, several 
hundred proteins tend to become more insoluble and aggregate (metastable 
proteins). Proteomic analysis of these proteins identified communality in biochemical 
and biological properties, including amino acids primary sequence, increased beta-
sheets and grouping in specific biological pathways [Cannizzo et al. 2012].   
To determine whether HF5-purified protein aggregates shared similarities with what 
was previously published, samples collected from the highest molecular weight 
fractions were digested using a combination of Lys-C and trypsin in 0.1 M 
bicarbonate buffer and 4M urea and peptide fragments analyzed by mass 
Chapter 4, Part 2, 4.2.1. Novel HF5-(UV)-MALS methodology for the size-separation, characterization and 
quantification of oxidative stress-related protein aggregates in whole cell lysates  
300 
 
spectrometry (Table 7).   
In total bone marrow and spleen samples, 65% and 55% respectively of the proteins 
found in the high MW aggregate (MW>107) corresponded to proteins known to 
increase their tendency to aggregate in aging. Among those, several enzymes, 
histones and signaling molecules were found and reported in Figure 17 and Table 7.   
 
Figure 17 – (a) Pie charts of the aggregate proteome from 3 and 22 months old total bone marrow; b) 
Pie charts of the aggregate proteome from 3 and 22 months old spleen lysate. Proteins were 
identified by mass spectrometry and analyzed by scaffold analysis. Kindly provided by the Laboratory 
of Pathology, Immunology and Microbiology of A. Einstein College of Medicine (Yeshiva University, NY, USA) 
The other 35% and 45% (bone marrow and spleen respectively) were proteins known 
to have a tendency to aggregate and being insoluble regardless the aging process. 
This category comprised several matrix proteins and cytoskeleton proteins.  
 
Ingenuity pathway analysis of the urea collected high MW aggregates (MW>107) 
indicated grouping into few major pathways including cell growth, cellular 
respiration, metabolism, cytoskeleton and mobility and oxidative stress (Figure 18b).  
 
Figure 18a shows the proteins distribution in the CD34+ bone marrow cell lysates 
aggregates from 3, 12, 22 months old mice. 171 proteins common proteins were 
identified for all three ages, several common proteins for each pair (3 – 12; 3 – 22 and 
12 – 22 months), as well as age-specific proteins (13 proteins for the 3 months old, 14 
for the 12 months old and 2 proteins for the 22 months old mice). 
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Figure 18 – (a) Scaffold analysis for proteins distribution in the CD34+ bone marrow cell lysates 
aggregates and (b) heat map of the major functional pathways represented in the aggregate 
proteome fractionated from bone marrow cells collected from 3, and 22 months old mice. Kindly 
provided by the Laboratory of Pathology, Immunology and Microbiology of A. Einstein College of Medicine 
(Yeshiva University, NY, USA 
 
Table 7 – Mass spectrometry analysis of protein aggregates in bone marrow and spleen cell lysates. 
Bone marrow 
Identified Proteins Accession Number 3months 22 months 
Protein Kinase A 
anchor protein 
gi|6753026 26% 38% 
Aldehyde 
dehydrogenase II 
gi|191804 0 41% 
B-cell scaffold protein  1 gi|110835719 29% 0 
Beta actin gi|4501885 100% 100% 
Protein kinase 2, beta gi|148687716 28% 40% 
Cathepsin C gi|45219895 0 91% 
Cathepsin G gi|6681083 0 100% 
Collagen IV alpha-2 gi|556299 86% 90% 
Peroxidase gi|145966840 100% 100% 
Ribonuclease A family, 
member 6 
gi|21426871 0 91% 
Ferritin light chain 1 gi|114326466 0 98% 
Fibrillin 1 gi|118197277 100% 91% 
Fibronectin 1 gi|148667849 99% 100% 
High mobility group 1 
protein 
gi|600761 0 100 
High mobility group 
protein B2 
gi|11527222 0 47% 
Histone 1, H1e gi|13430890 86% 100% 
Inhibitor of CDK 
interacting with cyclin 
A1 
gi|47523979 0 38% 
Myeloperoxidase gi|226823250 0 91% 
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Rotamase gi|118091 0 45% 
Plectin-1 gi|122065897 55% 53% 
Potassium voltage-
gated channel A4 
gi|3023498 0 35% 
Cystatin-related protein 
1 
gi|82886009 0 41% 
Collagen IV alpha 1 gi|148690109 86% 91% 
Collagen XIX alpha 1 gi|111600306 0 53% 
Prosaposin gi|1381582 0 0 
Protease, serine, 1 gi|16716569 78% 89% 
Protein kinase C, beta 1 gi|148685332 0 44% 
Proteoglycan 2 gi|6679457 98% 98% 
Calgranulin B gi|6677837 86% 100% 
THAP domain 
containing 11 
gi|10946934 0 37% 
WD repeat domain 42A gi|148707088 0 41% 
Spleen 
Identified Proteins Accession Number 3 months 22 months 
Actin, gamma, 
cytoplasmic 1 
gi|123298587 100% 100% 
AHNAK nucleoprotein 
isoform 1 
gi|61743961 100% 100% 
Annexin A1 gi|124517663 86% 78% 
Beta tubulin gi|12846758 0 78% 
Proteoglycan 2 gi|6679457 100% 100% 
Collagen XIX, alpha 1 gi|111600306 65% 66% 
Cytochrome P450 gi|148666702 31% 25% 
DEAD box polypeptide  
50 
gi|60551791 0 0 
Dpep1 protein gi|13097534 0 34% 
Peroxidase gi|145966840 100% 100% 
Ribonuclease A family, 
member 6 
gi|21426871 0 78% 
Fca/m receptor gi|11071950 0 20% 
Fibronectin 1 gi|148667849 97% 100% 
Hist1h3e protein gi|119850953 33% 24% 
Igh-1 a protein similar gi|1334091 0 100% 
Major vault protein gi|13879460 100% 100% 
Myosin light chain 
kinase 
gi|126157499 33% 0 
Myosin-9 isoform gi|114326446 100% 100% 
Proline rich 12 gi|153791304 0 20% 
Protein kinase C, beta 1 gi|148685332 0 18% 
Chapter 4, Part 2, 4.2.1. Novel HF5-(UV)-MALS methodology for the size-separation, characterization and 
quantification of oxidative stress-related protein aggregates in whole cell lysates  
303 
 
Myeloperoxidase gi|129826 0 100% 
P(4,5)P2 3-kinase alpha gi|1171954 0 30% 
Plectin-1 gi|122065897 39% 40% 
Ribosomal L15 60S gi|12846287 98% 97% 
Ribosomal protein L27 
60S 
gi|6708474 79% 78% 
Spastin isoform 1 gi|244790106 0 20% 
    
Protein marked in red are equally expressed in aggregates from 3 and 22 months old mice 
 
 
4.2.1.5. CONCLUSIONS 
 
The work presented in this chapter showed the importance of developing a 
methodology that allows separation of protein aggregates based on their size and 
biophysical properties, providing insight on the different type of aggregates. Further 
analyses on the isolated protein aggregates may provide insight upon their formation 
and disposal under different stress conditions, altogether furthering our knowledge 
on the mechanisms controlling cellular proteostasis. 
 
Field-flow fractionation (FFF) and its miniaturized variant (HF5) was previously 
employed successfully for the separation of serum proteins including IgGs, albumin, 
hemoglobin and phospholipids in high-density and low-density lipoproteins from 
human plasma [Reschiglian et al. 2003, Kang and Moon 2006, Zattoni et al. 2007].  
Herein, by online coupling HF5 and MALS we were able to separate for the first time 
protein aggregates, based on their size, molecular weight and biophysical properties, 
from a total cell lysate [Reschiglian et al. 2004, Reschiglian et al. 2006, Reschiglian et 
al. 2013]. Data processing allowed analysis of the aggregates amount, molecular 
weight and size (rH and rms radius).  Samples were run under non denaturing 
conditions using PBS or Tris-Buffer and under different degrees of denaturing 
conditions (2 and/or 4 M Urea).  Further analysis of the collected fractions on native 
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gels confirmed separation by molecular weight and the presence of aggregates above 
5.0×106 Da only in conditions of oxidative stress.     
Additionally, proteomic analysis performed on the highest molecular weight 
aggregates (MW>107) confirmed the presence of several proteins previously reported 
to be insoluble or with increased tendency to aggregate during aging.  The proteomic 
analysis on the purified aggregates presented here confirmed the presence of an 
aggregate proteome which share several proteins previously reported to be 
associated with age-related aggregation [David et al. 2010]. 
 
Altogether, several information could be gathered by HF5 purification that would 
have not be possible to obtain with traditional methods employed to separate protein 
aggregates, including filter assay, ultracentrifugation, agarose gels and size-exclusion 
chromatography (FPLC).  
Firstly, and more importantly, we determined that HF5 does indeed separate 
proteins and protein aggregates over a wide range of sizes and molecular weights 
from complex protein mixtures such as the total cell lysates proteome, in a single step 
analysis.  
Secondly, we observed how protein aggregates of the same MW eluted at different tR 
because of different hydrodynamic sizes, which directly relate to their molecular 
conformation. Indeed, HF5-MALS online coupling allowed the determination of the 
molecular conformation of all protein aggregates, and showed that the oxidative 
stress-induced ones had a more compact conformation, following the protein 
modifications (carbonylation) caused by either Paraquat treatment or by the aging 
process. Thirdly, the ability to separate lysates under both physiological and 
denaturing conditions allowed establishing the biophysical nature of the aggregates. 
Schiff-base covalent bound protein aggregates that could not be disrupted by high 
molar urea were discriminated from the aggregates that were purely based on 
hydrophobic or electrostatic interactions and hydrogen bonds. In this respect, it is 
important to notice that samples obtained from mice, where oxidative stress was 
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induced for a short period of time, protein aggregates were indeed formed, but were 
readily solubilized in urea. However, we were able to report the percentages of the 
two types of oxidative stress-related aggregates. On the other hand, lysates from 
aging bone marrow presented high MW aggregates, as compared to the same 
specimens from younger mice, which could be fractionated in non-denaturing 
conditions and were poorly solubilized in high molar urea. This data indicates the 
suitability of HF5 (method and technique, in general) to separate aggregates with 
different biophysical properties.  
Last, but not least, the subsequent offline MS analysis on the HF5 high MW fractions 
of bone marrow cell lysates from aging mice confirmed the presence of several 
proteins previously reported to be insoluble or with increased tendency to aggregate 
during aging. 
 
Understanding the biophysical properties of the different species of protein 
aggregates can be highly relevant to predict their biological consequences. For 
instance, the compactness of the aggregates was shown recently to determine their 
ability to be cleared up by autophagy.  The autophagic machinery required for the 
sequestration of the aggregates and delivery to lysosomes can only assembly in the 
surface of compact aggregates, whereas those showing active disassembly by 
chaperones cannot be targeted to this pathway [Wong et al. 2012].  Additionally, 
soluble or insoluble protein aggregates have different consequences on cellular 
toxicity [Kopito 2000]. Thus, being able to correlate the aggregates biophysical 
properties with their clearance and their overall effect on cellular proteostasis is 
highly significant. 
 
In conclusion, this work shows for the first time that HF5 can be used to separate 
oxidative-stress and age-related protein aggregates from total cell lysates. By online 
coupling HF5 and MALS, important biophysical information on the separated 
aggregates can be gathered. The results provided by HF5-MALS were corroborated 
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by both native gel and proteomic analysis of the high molecular weight aggregates.  
In the future, the method could be applied for the separation of aggregates formed 
under different pathological conditions to better characterize their biochemical and 
biophysical properties and gain further insight into protein aggregation under 
different stressors. 
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